{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import pandas as pd\n",
    "import json\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_drugbank_page(drug_name):\n",
    "    \"\"\"\n",
    "    Toy function. Just navigates to the Drugbank page of the drug 'drug_name'. Used to check that we get to the right page.\n",
    "    \"\"\"\n",
    "    search_url = f\"https://www.drugbank.ca/unearth/q?query={drug_name}&searcher=drugs\" # URL for DrugBank search\n",
    "    response = requests.get(search_url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        soup = BeautifulSoup(response.text, 'html.parser')\n",
    "        # Find the first link in the search results\n",
    "        return soup\n",
    "    return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_drug_info(drug_name):\n",
    "    \"\"\"\n",
    "    Get information on the drug. The returned object is a dictionary that contains all the sections on the drug info from the first (main) card\n",
    "    in drugbank.\n",
    "    \"\"\"\n",
    "    url = f\"https://www.drugbank.ca/unearth/q?query={drug_name}&searcher=drugs\"\n",
    "    response = requests.get(url)\n",
    "    if response.status_code != 200:\n",
    "        return \"Failed to retrieve the page\"\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    drug_info = {}\n",
    "\n",
    "    headers = soup.find_all('h2')  # Find the main headers (h2 elements)\n",
    "    for header in headers:\n",
    "        header_title = header.get_text().strip()\n",
    "        next_element = header.find_next_sibling()\n",
    "        \n",
    "        drug_info[header_title] = {} # Used to store the info for a particular section\n",
    "\n",
    "        while next_element and next_element.name != 'h2':\n",
    "            if next_element.name == 'dl':\n",
    "                for dt, dd in zip(next_element.find_all('dt'), next_element.find_all('dd')):\n",
    "                    subtitle = dt.get_text().strip()\n",
    "                    content = dd.get_text().strip()\n",
    "                    drug_info[header_title][subtitle] = content\n",
    "            next_element = next_element.find_next_sibling()\n",
    "\n",
    "    return drug_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Identification': {'Summary': 'Aspirin is a salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events.',\n",
       "  'Brand Names': \"Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala\",\n",
       "  'Generic Name': 'Acetylsalicylic acidCommonly known or available as Aspirin',\n",
       "  'DrugBank Accession Number': 'DB00945',\n",
       "  'Background': 'Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) Label. \\nInterestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer 15. Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor 11,14 and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others 19. \\nAcetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants Label.',\n",
       "  'Type': 'Small Molecule',\n",
       "  'Groups': 'Approved, Vet approved',\n",
       "  'Structure': '3DDownload MOLSDF3D-SDFPDBSMILESInChI\\n\\n\\n Similar StructuresStructure for Acetylsalicylic acid (DB00945)× Close',\n",
       "  'Weight': 'Average: 180.1574 Monoisotopic: 180.042258744',\n",
       "  'Chemical Formula': 'C9H8O4',\n",
       "  'Synonyms': '2-Acetoxybenzenecarboxylic acid2-Acetoxybenzoic acidAcetylsalicylateAcetylsalicylsäureacide 2-(acétyloxy)benzoïqueAcide acétylsalicyliqueácido acetilsalicílicoAcidum acetylsalicylicumASAAspirinAspirinaAzetylsalizylsäureo-acetoxybenzoic acidO-acetylsalicylic acido-carboxyphenyl acetatePolopirynaSalicylic acid acetate',\n",
       "  'External IDs': 'BAY1019036\\nNSC-27223\\nNSC-406186'},\n",
       " 'Pharmacology': {'Indication': 'Pain, fever, and inflammation\\nAcetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures Label. \\nThe extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)Label.\\nOther indications\\nASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: \\nReducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) Label. \\nReducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction Label.\\nFor reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) Label.\\nFor the prevention of thromboembolism after hip replacement surgery Label. \\nFor decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) Label.\\nUsed for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site Label. \\nImportant note regarding use of the extended-release formulation 21\\nIn the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action Label,21. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA 21.\\nReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See how',\n",
       "  'Associated Conditions': 'Acute Coronary Syndrome (ACS)\\nAnxiety\\nAtherothrombotic cerebral infarction\\nCardiovascular Disease (CVD)\\nCardiovascular Events\\nCardiovascular Mortality\\nColorectal Adenomas\\nColorectal Cancer\\nCommon Cold\\nCoronary artery reocclusion\\nDeath\\nDyspeptic signs and symptoms\\nFever\\nFlu caused by Influenza\\nHeadache\\nHeterozygous Familial Hypercholesterolemia (HeFH)\\nInflammation\\nJuvenile Idiopathic Arthritis (JIA)\\nMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)\\nMenstrual Pain\\nMigraine\\nMorbidity\\nMucocutaneous Lymph Node Syndrome\\nMuscle Contraction\\nMyalgia\\nMyocardial Infarction\\nMyocardial Infarction (MI), first occurrence\\nNeuropathic Pain\\nPain\\nPain caused by Common Cold\\nPain caused by Rheumatism\\nPericarditis\\nPolycythemia Vera (PV)\\nPre-Eclampsia\\nRheumatism\\nRheumatoid Arthritis\\nRhino Sinusitis\\nSevere Pain\\nSpondyloarthropathies\\nStroke\\nSystemic Lupus Erythematosus\\nTension Headache\\nThromboembolism\\nThrombosis\\nToothache\\nTransient Ischemic Attack\\nVascular Death\\nVenous Thromboembolism\\nAcute Inflammation\\nArticular inflammation\\nAtherothrombotic events\\nDeath caused by Myocardial Infarction\\nFever or influenza-like illness\\nModerate Pain\\nRecurrent Ischemic Stroke',\n",
       "  'Associated Therapies': 'Anti-platelet Therapy\\nHemodialysis Treatment\\nSecondary Prevention',\n",
       "  'Contraindications & Blackbox Warnings': 'Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events with our Clinical APILearn more',\n",
       "  'Pharmacodynamics': 'Effects on pain and fever\\nAcetylsalicylic acid disrupts the production of prostaglandins throughout the body by targeting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) 9,10,11. Prostaglandins are potent, irritating substances that have been shown to cause headaches and pain upon injection into humans. Prostaglandins increase the sensitivity of pain receptors and substances such as histamine and bradykinin. Through the disruption of the production and prevention of release of prostaglandins in inflammation, this drug may stop their action at pain receptors, preventing symptoms of pain. Acetylsalicylic acid is considered an antipyretic agent because of its ability to interfere with the production of brain prostaglandin E1. Prostaglandin E1 is known to be an extremely powerful fever-inducing agent Label. \\nEffects on platelet aggregation\\nThe inhibition of platelet aggregation by ASA occurs because of its interference with thromboxane A2 in platelets, caused by COX-1 inhibition. Thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to clot formation and future risk of heart attack or stroke Label. \\nA note on cancer prevention\\nASA has been studied in recent years to determine its effect on the prevention of various malignancies 15. In general, acetylsalicylic acid is involved in the interference of various cancer signaling pathways, sometimes inducing or upregulating tumor suppressor genes 15,17. Results of various studies suggest that there are beneficial effects of long-term ASA use in the prevention of several types of cancer, including stomach, colorectal, pancreatic, and liver cancers 16. Research is ongoing.',\n",
       "  'Mechanism of action': \"Acetylsalicylic acid (ASA) blocks prostaglandin synthesis. It is non-selective for COX-1 and COX-2 enzymes 9,10,11. Inhibition of COX-1 results in the inhibition of platelet aggregation for about 7-10 days (average platelet lifespan). The acetyl group of acetylsalicylic acid binds with a serine residue of the cyclooxygenase-1 (COX-1) enzyme, leading to irreversible inhibition. This prevents the production of pain-causing prostaglandins. This process also stops the conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent inducer of platelet aggregation Label. Platelet aggregation can result in clots and harmful venous and arterial thromboembolism, leading to conditions such as pulmonary embolism and stroke. \\nIt is important to note that there is 60% homology between the protein structures of COX-1 and COX-2. ASA binds to serine 516 residue on the active site of COX-2 in the same fashion as its binding to the serine 530 residue located on the active site of COX-1. The active site of COX-2 is, however, slightly larger than the active site of COX-1, so that arachidonic acid (which later becomes prostaglandins) manages to bypass the aspirin molecule inactivating COX-2 11,12. ASA, therefore, exerts more action on the COX-1 receptor rather than on the COX-2 receptor 14. A higher dose of acetylsalicylic acid is required for COX-2 inhibition 15. \\nTargetActionsOrganismAProstaglandin G/H synthase 1inhibitorHumansAProstaglandin G/H synthase 2inhibitorHumansUAldo-keto reductase family 1 member C1inhibitorHumansU5'-AMP-activated protein kinaseactivatorHumansUEndothelin-1 receptorinhibitorHumansUCellular tumor antigen p53inducerHumansU78 kDa glucose-regulated proteininhibitorbinderHumansURibosomal protein S6 kinase alpha-3inhibitorHumansUNF-kappa-B inhibitor alphainhibitorHumansUTumor necrosis factor-inducible gene 6 proteininhibitordownregulatorHumansUCaspase-1inhibitordownregulatorHumansUCaspase-3inhibitordownregulatorHumansUInhibitor of nuclear factor kappa-B kinase subunit betaNot AvailableHumansUExtracellular signal-regulated kinase (ERK)Not AvailableHumansUG1/S-specific cyclin-D1downregulatorHumansUMyc proto-oncogene proteindownregulatorHumansUProliferating cell nuclear antigendownregulatorHumansUCyclin AdownregulatorUSialidase-1inhibitorHumans\",\n",
       "  'Absorption': 'Absorption is generally rapid and complete following oral administration but absorption may be variable depending on the route, dosage form, and other factors including but not limited to the rate of tablet dissolution, gastric contents, gastric emptying time, and gastric pH Label.\\nDetailed absorption information\\nWhen ingested orally, acetylsalicylic acid is rapidly absorbed in both the stomach and proximal small intestine. The non-ionized acetylsalicylic acid passes through the stomach lining by passive diffusion. Ideal absorption of salicylate in the stomach occurs in the pH range of 2.15 - 4.10. Intestinal absorption of acetylsalicylic acid occurs at a much faster rate. At least half of the ingested dose is hydrolyzed to salicylic acid in the first-hour post-ingestion by esterases found in the gastrointestinal tract. Peak plasma salicylate concentrations occur between 1-2 hours post-administration Label.',\n",
       "  'Volume of distribution': 'This drug is distributed to body tissues shortly after administration. It is known to cross the placenta. The plasma contains high levels of salicylate, as well as tissues such as spinal, peritoneal and synovial fluids, saliva and milk. The kidney, liver, heart, and lungs are also found to be rich in salicylate concentration after dosing. Low concentrations of salicylate are usually low, and minimal concentrations are found in feces, bile, and sweat Label.',\n",
       "  'Protein binding': '50% to 90% of a normal therapeutic concentration salicylate (a main metabolite of acetylsalicylic acid Label) binds plasma proteins, particularly albumin, while acetylsalicylic acid itself binds negligibly Label. Acetylsalicylic acid has the ability to bind to and acetylate many proteins, hormones, DNA, platelets, and hemoglobin Label.',\n",
       "  'Metabolism': 'Acetylsalicylic acid is hydrolyzed in the plasma to salicylic acid. Plasma concentrations of aspirin following after administration of the extended-release form are mostly undetectable 4-8 hours after ingestion of a single dose. Salicylic acid was measured at 24 hours following a single dose of extended-release acetylsalicylic acid 21.\\nSalicylate is mainly metabolized in the liver, although other tissues may also be involved in this process Label. The major metabolites of acetylsalicylic acid are salicylic acid, salicyluric acid, the ether or phenolic glucuronide and the ester or acyl glucuronide. A small portion is converted to gentisic acid and other hydroxybenzoic acids Label.\\nHover over products below to view reaction partnersAcetylsalicylic acid\\n\\n\\nPhenolic glucuronide + Salicylic acid acyl glucuronide\\n\\n\\nSalicylic acid\\n\\n\\nGentisic acid\\n\\n\\nSalicyluric acid',\n",
       "  'Route of elimination': 'Excretion of salicylates occurs mainly through the kidney, by the processes of glomerular filtration and tubular excretion, in the form of free salicylic acid, salicyluric acid, and, additionally, phenolic and acyl glucuronides Label. \\nSalicylate can be found in the urine soon after administration, however, the entire dose takes about 48 hours to be completely eliminated. The rate of salicylate is often variable, ranging from 10% to 85% in the urine, and heavily depends on urinary pH. Acidic urine generally aids in reabsorption of salicylate by the renal tubules, while alkaline urine increases excretion Label.\\nAfter the administration of a typical 325mg dose, the elimination of ASA is found to follow first order kinetics in a linear fashion. At high concentrations, the elimination half-life increases Label.',\n",
       "  'Half-life': 'The half-life of ASA in the circulation ranges from 13 - 19 minutes. Blood concentrations drop rapidly after complete absorption. The half-life of the salicylate ranges between 3.5 and 4.5 hours Label.',\n",
       "  'Clearance': 'The clearance rate of acetylsalicylic acid is extremely variable, depending on several factors 6. Dosage adjustments may be required in patients with renal impairment Label. The extended-release tablet should not be administered to patients with eGFR of less than 10 mL/min 21.',\n",
       "  'Adverse Effects': 'Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!See the data  Improve decision support & research outcomes with our structured adverse effects data.See a data sample',\n",
       "  'Toxicity': 'Lethal doses\\nAcute oral LD50 values have been reported as over 1.0 g/kg in humans, cats, and dogs, 0.92 g/kg - 1.48 g/kg in albino rats, 1.19 g/kg in guinea pigs, 1.1 g/kg in mice, and 1.8 g/kg in rabbit models Label.\\nAcute toxicity\\nSalicylate toxicity is a problem that may develop with both acute and chronic salicylate exposure 7.\\nMultiple organ systems may be affected by salicylate toxicity, including the central nervous system, the pulmonary system, and the gastrointestinal system. Severe bleeding may occur. In the majority of cases, patients suffering from salicylate toxicity are volume-depleted at the time of presentation for medical attention. Fluid resuscitation should occur immediately and volume status should be monitored closely. Disruptions in acid-base balance are frequent in ASA toxicity 7. \\nThe acute toxicity of acetylsalicylic in animals has been widely studied. The signs of poisoning in rats from lethal doses are mild to severe gastroenteritis, hepatitis, nephritis, pulmonary edema, encephalopathy, shock and some toxic effects on other organs and tissues. Mortality has been observed following convulsions or cardiovascular shock. An important differentiating property between various animal species is the ability to vomit toxic doses. Humans, cats and dogs have this ability, but rodents or rabbits do not Label. \\nChronic toxicity and carcinogenesis\\nChronic ASA toxicity is frequently accompanied by atypical clinical presentations that may be similar to diabetic ketoacidosis, delirium, cerebrovascular accident (CVA), myocardial infarction (MI) or cardiac failure. Plasma salicylate concentrations should be measured if salicylate intoxication is suspected, even if there no documentation available to suggest ASA was ingested. In older age, nephrotoxicity from salicylates increases, and the risk of upper gastrointestinal hemorrhage is increased, with higher rates of mortality 8. It is also important to note that ASA toxicity may occur even with close to normal serum concentrations. Prevention of chronic ASA includes the administration of smallest possible doses, avoidance of concurrent use of salicylate drugs, and therapeutic drug monitoring. Renal function should be regularly monitored and screening for gastrointestinal bleeding should be done at regular intervals 8. \\nChronic toxicity studies were performed in rodents. ASA was administered at doses measured to be 2 to 20 times the maximum tolerated clinical dose to mice for up to one year. Negative dose-related effects were seen. These include decreased mean survival time, decreased number of births and progeny reaching an appropriate age for weaning. No evidence of carcinogenesis was found in 1-year studies Label. At daily doses of 0.24 g/kg/day given for 100 days to albino rats, ASA led to signs to excessive thirst, aciduria, diuresis, drowsiness, hyperreflexia, piloerection, changes in respiration, tachycardia, followed by soft stools, epistaxis, sialorrhea, dacryorrhea and mortality during hypothermic coma in the second study month Label.\\nUse in pregnancy and lactation\\nWhile teratogenic effects were observed in animals nearly lethal doses, no evidence suggests that this drug is teratogenic in humans Label. It is advisable, however, to avoid ASA use the first and second trimester of pregnancy, unless it is clearly required. If acetylsalicylic acid containing drugs are ingested by a patient attempting to conceive, or during the first and second trimester of pregnancy, the lowest possible dose at the shortest possible duration should be taken Label. This drug is contraindicated in the 3rd trimester of pregnancy Label.',\n",
       "  'Pathways': 'PathwayCategoryAcetylsalicylic Acid Action PathwayDrug action',\n",
       "  'Pharmacogenomic Effects/ADRs': 'Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetailsCytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of acetylsalicylic acid.DetailsLeukotriene C4 synthase---(A;C) / (C;C)C alleleADR Directly StudiedThe presence of this genotype in LTC4S may indicate an increased risk of chronic urticaria when treated with acetylsalicylic acid.DetailsIntegrin beta-3GPIIIa PlA2(C;C) / (C;T)T > CEffect Directly StudiedPatients with this genotype have increased resistance to the anti-thrombotic effects of aspirin.DetailsCytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C\\xa0 … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetailsCytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails'},\n",
       " 'Interactions': {'Drug Interactions': 'This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. ApprovedVet approvedNutraceuticalIllicitWithdrawnInvestigationalExperimentalAll DrugsDrugInteractionIntegrate drug-drug interactions in your software\\n\\n\\nAbacavirAcetylsalicylic acid may decrease the excretion rate of Abacavir which could result in a higher serum level.AbataceptThe metabolism of Acetylsalicylic acid can be increased when combined with Abatacept.AbciximabAcetylsalicylic acid may increase the antiplatelet activities of Abciximab.AbrocitinibThe risk or severity of bleeding and thrombocytopenia can be increased when Acetylsalicylic acid is combined with Abrocitinib.AcamprosateThe excretion of Acamprosate can be decreased when combined with Acetylsalicylic acid.AcarboseThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Acarbose.AcebutololAcetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.AceclofenacThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aceclofenac.AcemetacinThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Acemetacin.AcenocoumarolAcetylsalicylic acid may increase the anticoagulant activities of Acenocoumarol.Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more',\n",
       "  'Food Interactions': 'Avoid alcohol. Alcohol increases the risk of gastrointestinal bleeding.\\nAvoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.\\nTake after a meal. This reduces irritating gastrointestinal effects.\\nTake with a full glass of water.'},\n",
       " 'Products': {'': 'Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access now  Access drug product information from over 10 global regions.Access now',\n",
       "  'Product Ingredients': 'IngredientUNIICASInChI KeyLysine acetylsalicylate2JJ274J14562952-06-1JJBCTCGUOQYZHK-UHFFFAOYSA-N',\n",
       "  'Product Images': 'PreviousNext',\n",
       "  'International/Other Brands': 'Acenterine / Acetophen (Merck) / Adiro / Aspergum / Aspro / Easprin / Empirin / Nu-seals / Rhodine / Rhonal / Solprin / Solprin acid / St. Joseph Aspirin for Adults / Tasprin',\n",
       "  'Brand Name Prescription Products': 'NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImageDurlazaCapsule, extended release162.5 mg/1OralNew Haven Pharmaceuticals, Inc.2015-09-25Not applicableUS',\n",
       "  'Over the Counter Products': 'NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage365 Everyday Value AspirinTablet, film coated325 mg/1OralWhole Foods Market, Inc.2018-08-23Not applicableUS365 Everyday Value AspirinTablet, film coated325 mg/1OralWhole Foods Market, Inc.2021-06-08Not applicableUS7 Select Adult Chewable AspirinTablet, chewable81 mg/1Oral7 Eleven2014-08-052017-08-09US7 Select AspirinTablet, film coated325 mg/1Oral7-Eleven2014-08-052021-03-31US81 mg Low Dose AspirinTablet81 mg/1OralBig Lots Stores, Inc.2008-02-122013-06-25USA.N.TTablet325 mgOralบริษัท บี.เอม.ฟาร์มาซี จำกัด1991-08-21Not applicableThailandA.S.A.Tablet325 mgOralD.C. Labs Limited2001-05-282005-07-19CanadaA.S.A.Tablet500 mgOralD.C. Labs Limited2001-12-222005-07-19CanadaA.S.A. (acetylsalicylic Acid) Tab 325mg USPTablet325 mgOralAccurex Health Care Manufacturing Inc.1996-12-312003-01-28CanadaA.S.A. 325 Mg TabletTablet325 mgOralJamp Pharma Corporation2003-10-16Not applicableCanada',\n",
       "  'Mixture Products': 'NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage10 Person ANSIAcetylsalicylic acid (325 mg/1) + Acetaminophen (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalGenuine First Aid2010-04-24Not applicableUS217Acetylsalicylic acid (325 mg / tab) + Caffeine citrate (30 mg / tab)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1910-12-311998-04-21Canada217 Strong TabAcetylsalicylic acid (500 mg / tab) + Caffeine citrate (30 mg / tab)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1973-12-311998-04-21Canada222 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (8 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1951-12-312015-08-17Canada25 Person ANSIAcetylsalicylic acid (325 mg/1) + Acetaminophen (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; TopicalGenuine First Aid2010-04-25Not applicableUS282 Mep TabAcetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg) + Meprobamate (200 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-311998-08-14Canada282 TabAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-04-21Canada282 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg)TabletOralPendopharm Division Of Pharmascience Inc1998-11-012021-05-11Canada292 TabAcetylsalicylic acid (375 mg) + Caffeine citrate (30 mg) + Codeine phosphate (30 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311998-08-14Canada292 TabletsAcetylsalicylic acid (375 mg) + Caffeine citrate (15 mg) + Codeine phosphate (30 mg)TabletOralPendopharm Division Of Pharmascience Inc1998-10-012021-04-29Canada',\n",
       "  'Unapproved/Other Products': 'NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage4032 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)Inhalant; Kit; Liquid; Ointment; Spray; TabletOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4134 First Aid KitAcetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL)Cream; Kit; Liquid; TabletOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4139 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g)KitOral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4142 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Benzalkonium chloride (1.3 mg/1mL) + Benzethonium chloride (0.2 g/100g) + Benzocaine (10 g/100g) + Lidocaine hydrochloride (2 g/100g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4154 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g)KitOral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4196 First Aid KitAcetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)Cream; Kit; Liquid; Ointment; Swab; TabletOphthalmic; Oral; TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4209 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzethonium chloride (0.2 g/100g) + Benzocaine (20 g/100g) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4211 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzethonium chloride (0.2 g/100g) + Benzocaine (20 g/100g) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4213 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Benzalkonium chloride (0.13 g/100mL) + Isopropyl alcohol (0.7 mL/1mL) + Povidone-iodine (10 mg/1mL)KitOral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS4214 First Aid KitAcetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Benzalkonium chloride (1.3 mg/1mL) + Benzalkonium chloride (0.13 g/100mL) + Water (98.6 mL/100mL)Inhalant; Kit; Liquid; Spray; TabletOphthalmic; Oral; Respiratory (inhalation); TopicalHoneywell Safety Products USA, Inc2018-10-18Not applicableUS'},\n",
       " 'Categories': {'ATC Codes': 'B01AC06 — Acetylsalicylic acidB01AC — Platelet aggregation inhibitors excl. heparinB01A — ANTITHROMBOTIC AGENTSB01 — ANTITHROMBOTIC AGENTSB — BLOOD AND BLOOD FORMING ORGANSC07FX04 — Bisoprolol and acetylsalicylic acidC07FX — Beta blocking agents, other combinationsC07F — BETA BLOCKING AGENTS, OTHER COMBINATIONSC07 — BETA BLOCKING AGENTSC — CARDIOVASCULAR SYSTEMC10BX04 — Simvastatin, acetylsalicylic acid and ramiprilC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMM01BA03 — Acetylsalicylic acid and corticosteroidsM01BA — Antiinflammatory/antirheumatic agents in combination with corticosteroidsM01B — ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATIONM01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTSM — MUSCULO-SKELETAL SYSTEMN02BA71 — Acetylsalicylic acid, combinations with psycholepticsN02BA — Salicylic acid and derivativesN02B — OTHER ANALGESICS AND ANTIPYRETICSN02 — ANALGESICSN — NERVOUS SYSTEMC10BX02 — Pravastatin and acetylsalicylic acidC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMB01AC56 — Acetylsalicylic acid, combinations with proton pump inhibitorsB01AC — Platelet aggregation inhibitors excl. heparinB01A — ANTITHROMBOTIC AGENTSB01 — ANTITHROMBOTIC AGENTSB — BLOOD AND BLOOD FORMING ORGANSN02AJ07 — Codeine and acetylsalicylic acidN02AJ — Opioids in combination with non-opioid analgesicsN02A — OPIOIDSN02 — ANALGESICSN — NERVOUS SYSTEMN02AJ02 — Dihydrocodeine and acetylsalicylic acidN02AJ — Opioids in combination with non-opioid analgesicsN02A — OPIOIDSN02 — ANALGESICSN — NERVOUS SYSTEMN02BA01 — Acetylsalicylic acidN02BA — Salicylic acid and derivativesN02B — OTHER ANALGESICS AND ANTIPYRETICSN02 — ANALGESICSN — NERVOUS SYSTEMC10BX05 — Rosuvastatin and acetylsalicylic acidC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMN02BA51 — Acetylsalicylic acid, combinations excl. psycholepticsN02BA — Salicylic acid and derivativesN02B — OTHER ANALGESICS AND ANTIPYRETICSN02 — ANALGESICSN — NERVOUS SYSTEMA01AD05 — Acetylsalicylic acidA01AD — Other agents for local oral treatmentA01A — STOMATOLOGICAL PREPARATIONSA01 — STOMATOLOGICAL PREPARATIONSA — ALIMENTARY TRACT AND METABOLISMC10BX01 — Simvastatin and acetylsalicylic acidC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMC07FX03 — Metoprolol and acetylsalicylic acidC07FX — Beta blocking agents, other combinationsC07F — BETA BLOCKING AGENTS, OTHER COMBINATIONSC07 — BETA BLOCKING AGENTSC — CARDIOVASCULAR SYSTEMN02AJ18 — Oxycodone and acetylsalicylic acidN02AJ — Opioids in combination with non-opioid analgesicsN02A — OPIOIDSN02 — ANALGESICSN — NERVOUS SYSTEMC10BX12 — Atorvastatin, acetylsalicylic acid and perindoprilC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMC10BX08 — Atorvastatin and acetylsalicylic acidC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMC10BX06 — Atorvastatin, acetylsalicylic acid and ramiprilC10BX — Lipid modifying agents in combination with other drugsC10B — LIPID MODIFYING AGENTS, COMBINATIONSC10 — LIPID MODIFYING AGENTSC — CARDIOVASCULAR SYSTEMC07FX02 — Sotalol and acetylsalicylic acidC07FX — Beta blocking agents, other combinationsC07F — BETA BLOCKING AGENTS, OTHER COMBINATIONSC07 — BETA BLOCKING AGENTSC — CARDIOVASCULAR SYSTEM',\n",
       "  'Drug Categories': 'Acids, Carbocyclic\\nAgents causing angioedema\\nAgents causing hyperkalemia\\nAgents that produce hypertension\\nAlimentary Tract and Metabolism\\nAnalgesics\\nAnalgesics, Non-Narcotic\\nAnti-Inflammatory Agents\\nAnti-Inflammatory Agents, Non-Steroidal\\nAnti-Inflammatory Agents, Non-Steroidal (Non-Selective)\\nAntiinflammatory and Antirheumatic Products\\nAntiplatelet agents\\nAntipyretics\\nBenzene Derivatives\\nBlood and Blood Forming Organs\\nCardiovascular Agents\\nCyclooxygenase Inhibitors\\nCytochrome P-450 CYP2C19 Inducers\\nCytochrome P-450 CYP2C19 Inducers (strength unknown)\\nCytochrome P-450 CYP2C9 Substrates\\nCytochrome P-450 Enzyme Inducers\\nCytochrome P-450 Substrates\\nDecreased Platelet Aggregation\\nDecreased Prostaglandin Production\\nDrugs that are Mainly Renally Excreted\\nHematologic Agents\\nHydroxybenzoates\\nMusculo-Skeletal System\\nNephrotoxic agents\\nNon COX-2 selective NSAIDS\\nOAT1/SLC22A6 inhibitors\\nOAT3/SLC22A8 Inhibitors\\nP-glycoprotein inducers\\nP-glycoprotein substrates\\nPeripheral Nervous System Agents\\nPlatelet Aggregation Inhibitors Excl. Heparin\\nSalicylates\\nSalicylic Acid and Derivatives\\nSensory System Agents\\nStomatological Preparations\\nUGT1A6 substrate',\n",
       "  'Chemical TaxonomyProvided by Classyfire': 'DescriptionThis compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.KingdomOrganic compoundsSuper ClassBenzenoidsClassBenzene and substituted derivativesSub ClassBenzoic acids and derivativesDirect ParentAcylsalicylic acidsAlternative ParentsPhenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Carboxylic acid esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compoundsSubstituentsAcylsalicylic acid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Hydrocarbon derivativeMolecular FrameworkAromatic homomonocyclic compoundsExternal Descriptorssalicylates, acetate ester, benzoic acids (CHEBI:15365)',\n",
       "  'Description': 'This compound belongs to the class of organic compounds known as acylsalicylic acids. These are o-acylated derivatives of salicylic acid.',\n",
       "  'Kingdom': 'Organic compounds',\n",
       "  'Super Class': 'Benzenoids',\n",
       "  'Class': 'Benzene and substituted derivatives',\n",
       "  'Sub Class': 'Benzoic acids and derivatives',\n",
       "  'Direct Parent': 'Acylsalicylic acids',\n",
       "  'Alternative Parents': 'Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Carboxylic acid esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds',\n",
       "  'Substituents': 'Acylsalicylic acid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Hydrocarbon derivative',\n",
       "  'Molecular Framework': 'Aromatic homomonocyclic compounds',\n",
       "  'External Descriptors': 'salicylates, acetate ester, benzoic acids (CHEBI:15365)',\n",
       "  'Affected organisms': 'Humans and other mammals'},\n",
       " 'Chemical Identifiers': {'UNII': 'R16CO5Y76E',\n",
       "  'CAS number': '50-78-2',\n",
       "  'InChI Key': 'BSYNRYMUTXBXSQ-UHFFFAOYSA-N',\n",
       "  'InChI': 'InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)',\n",
       "  'IUPAC Name': '2-(acetyloxy)benzoic acid',\n",
       "  'SMILES': 'CC(=O)OC1=CC=CC=C1C(O)=O'},\n",
       " 'References': {'Synthesis Reference': 'Marino Gobetti, Guido Vandoni, \"Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them.\" U.S. Patent US4563443, issued March, 1981.\\nUS4563443',\n",
       "  'General References': 'Macdonald S: Aspirin use to be banned in under 16 year olds. BMJ. 2002 Nov 2;325(7371):988. [Article] Sneader W: The discovery of aspirin: a reappraisal. BMJ. 2000 Dec 23-30;321(7276):1591-4. [Article] Aukerman G, Knutson D, Miser WF: Management of the acute migraine headache. Am Fam Physician. 2002 Dec 1;66(11):2123-30. [Article] Authors unspecified: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988 Aug 13;2(8607):349-60. [Article] Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS: Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007 May;41(5):737-41. Epub 2007 Apr 24. [Article] Levy G: Clinical pharmacokinetics of aspirin. Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):867-72. [Article] Authors unspecified: Guidance document: management priorities in salicylate toxicity. J Med Toxicol. 2015 Mar;11(1):149-52. doi: 10.1007/s13181-013-0362-3. [Article] Durnas C, Cusack BJ: Salicylate intoxication in the elderly. Recognition and recommendations on how to prevent it. Drugs Aging. 1992 Jan-Feb;2(1):20-34. [Article] Flower R: What are all the things that aspirin does? BMJ. 2003 Sep 13;327(7415):572-3. doi: 10.1136/bmj.327.7415.572. [Article] Hall MN, Campos H, Li H, Sesso HD, Stampfer MJ, Willett WC, Ma J: Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):314-21. [Article] Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8. [Article] Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120. doi: 10.1146/annurev.pharmtox.38.1.97. [Article] Varga Z, Sabzwari SRA, Vargova V: Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017 Apr 8;9(4):e1144. doi: 10.7759/cureus.1144. [Article] Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S: Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017 Jun;36(2):289-303. doi: 10.1007/s10555-017-9675-z. [Article] Alfonso L, Ai G, Spitale RC, Bhat GJ: Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014 Jul 8;111(1):61-7. doi: 10.1038/bjc.2014.271. Epub 2014 May 29. [Article] Tsoi KKF, Ho JMW, Chan FCH, Sung JJY: Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. Int J Cancer. 2018 Dec 21. doi: 10.1002/ijc.32083. [Article] Li D, Wang P, Yu Y, Huang B, Zhang X, Xu C, Zhao X, Yin Z, He Z, Jin M, Liu C: Tumor-preventing activity of aspirin in multiple cancers based on bioinformatic analyses. PeerJ. 2018 Sep 26;6:e5667. doi: 10.7717/peerj.5667. eCollection 2018. [Article] Hasan Arif; Sandeep Aggarwal (2018). Salicylic Acid (Aspirin): StatPearls. StatPearls Publishing. Mayo Clinic website: Salicylate [Link] Health Canada Product Monograph: Aspirin (acetylsalicylic acid) for oral administration [Link] Durlaza FDA label [File]',\n",
       "  'External Links': 'Human Metabolome DatabaseHMDB0001879KEGG DrugD00109KEGG CompoundC01405PubChem Compound2244PubChem Substance46505803ChemSpider2157BindingDB22360RxNav1191ChEBI15365ChEMBLCHEMBL25ZINCZINC000000000053Therapeutic Targets DatabaseDAP000843PharmGKBPA448497Guide to PharmacologyGtP Drug PagePDBe LigandAINRxListRxList Drug PageDrugs.comDrugs.com Drug PagePDRhealthPDRhealth Drug PageWikipediaAspirin',\n",
       "  'Human Metabolome Database': 'HMDB0001879',\n",
       "  'KEGG Drug': 'D00109',\n",
       "  'KEGG Compound': 'C01405',\n",
       "  'PubChem Compound': '2244',\n",
       "  'PubChem Substance': '46505803',\n",
       "  'ChemSpider': '2157',\n",
       "  'BindingDB': '22360',\n",
       "  'RxNav': '1191',\n",
       "  'ChEBI': '15365',\n",
       "  'ChEMBL': 'CHEMBL25',\n",
       "  'ZINC': 'ZINC000000000053',\n",
       "  'Therapeutic Targets Database': 'DAP000843',\n",
       "  'PharmGKB': 'PA448497',\n",
       "  'Guide to Pharmacology': 'GtP Drug Page',\n",
       "  'PDBe Ligand': 'AIN',\n",
       "  'RxList': 'RxList Drug Page',\n",
       "  'Drugs.com': 'Drugs.com Drug Page',\n",
       "  'PDRhealth': 'PDRhealth Drug Page',\n",
       "  'Wikipedia': 'Aspirin',\n",
       "  'PDB Entries': '1oxr / 1tgm / 2qqt / 3gcl / 3iaz / 4nsb / 6mqf / 8j3w',\n",
       "  'FDA label': 'Download (399 KB)',\n",
       "  'MSDS': 'Download (24.2 KB)'},\n",
       " 'Clinical Trials': {'Clinical Trials': 'PhaseStatusPurposeConditionsCount4Active Not RecruitingBasic SciencePlatelet Function14Active Not RecruitingPreventionAtrial Fibrillation / Stroke14Active Not RecruitingPreventionCancer14Active Not RecruitingPreventionDiabetes Mellitus14Active Not RecruitingTreatmentAcute Coronary Syndrome (ACS)14Active Not RecruitingTreatmentAcute Coronary Syndrome (ACS) / Coronary Artery Disease (CAD) / Diabetes Mellitus / Obesity14Active Not RecruitingTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Coronary Heart Disease (CHD)14CompletedNot AvailableChronic Stable Angina Pectoris / Coronary Heart Disease (CHD)14CompletedNot AvailableDuodenal Ulcer14CompletedBasic ScienceAcute Coronary Syndrome (ACS) / Atrial Fibrillation1'},\n",
       " 'Pharmacoeconomics': {'Manufacturers': 'Bayer healthcare llc',\n",
       "  'Packagers': 'A-S Medication Solutions LLC\\nBASF Corp.\\nExcellium Pharmaceutical Inc.\\nHarvest Pharmaceuticals Inc.\\nKaiser Foundation Hospital\\nMajor Pharmaceuticals\\nMckesson Corp.\\nPar Pharmaceuticals\\nPrepak Systems Inc.\\nRosedale Therapeutics\\nTime-Cap Labs\\nUnited Research Laboratories Inc.',\n",
       "  'Dosage Forms': 'FormRouteStrengthTabletOralInhalant; kit; liquid; ointment; spray; tabletOphthalmic; Oral; Respiratory (inhalation); TopicalCream; kit; liquid; tabletOphthalmic; Oral; TopicalCream; kit; liquid; ointment; swab; tabletOphthalmic; Oral; TopicalKitOphthalmic; Oral; Respiratory (inhalation); TopicalInhalant; kit; liquid; spray; tabletOphthalmic; Oral; Respiratory (inhalation); TopicalCream; inhalant; kit; swab; tabletOral; Respiratory (inhalation); TopicalKitOral; Respiratory (inhalation); TopicalInhalant; kit; liquid; ointment; spray; swab; tabletOphthalmic; Oral; Respiratory (inhalation); TopicalCream; kit; liquid; ointment; spray; tabletOphthalmic; Oral; TopicalCream; kit; liquid; ointment; swab; tabletOral; TopicalKit; liquid; ointment; swab; tabletOphthalmic; Oral; TopicalKit; liquid; ointment; swab; tabletOral; TopicalKit; liquid; ointment; spray; tabletOphthalmic; Oral; TopicalKitIrrigation; Oral; Respiratory (inhalation); TopicalKitIrrigation; Ophthalmic; Oral; Respiratory (inhalation); TopicalTabletOral250 MGTabletOral500.000 mgTablet; tablet, film coatedOralTabletOral325 mg / tabInjection, powder, for solutionPowder, for solutionOralGranule, effervescentOral9.88 gKit; tablet, delayed release; tablet, extended releaseOralTablet, delayed releaseOral81 mg/1TabletOral325 1/1KitOral; TopicalKitTopicalCapsuleOral25.000 MGCapsule, extended releaseOralTablet, effervescentOral324 mgGranule, effervescentOralTablet, effervescentOral325 mg/1Tablet, effervescentOralTabletOral324 mgCapsule, coated pellets160 mgTabletOral300.00 mgTabletOral100.000 mgTablet, delayed releaseOral975 mg / tabTablet, delayed releaseOral600 mg / tabTablet, delayed releaseOral650 mg / tabSuppositoryRectal150 mgSuppositoryRectal650 mgCapsule, extended releaseOralTablet, chewableOral80 mgTablet, delayed releaseOral162 mgTablet, delayed releaseOral100 mgCapsule, delayed releaseOralTablet, film coatedOral500 mg/1TabletOral300 mgTablet, delayed releaseOral81 mgGum, chewingOral325 mg / gumTablet, film coatedOralSuppositoryRectal300 mg/1SuppositoryRectal600 mg/1TabletOral325 mg/1TabletOral325 g/1Tablet, coatedOral325 ng/1Tablet, coatedOral325 mg/1Tablet, extended releaseOral81 mg/1Tablet, film coatedOral325 mg/1TabletOral80 mg / tabTablet, coatedOral100 mgTablet, chewableOral500 mgTabletOralTablet, delayed release; tablet, extended releaseOral325 mg / tabTablet, delayed release; tablet, extended releaseOral500 mg / tabTablet, delayed releaseOral81 mg/811GranuleOral500 mgTablet, coatedOral81 mg/1Tablet, delayed releaseOral325 mg / ectGranuleOral500 mg / pckTablet, coatedOral500 mg/5001TabletOral500 mg / tabGranuleOral500 mg / sachetTabletOral81 mg/1Tablet, film coatedOral81 mg/1Tablet, chewableOral81 mg/1Tablet, film coatedOral100 mgPowderOral325 mg/1GranuleOralSuppositoryRectalTabletOral100 MGTablet, effervescentOral400 MGTablet, effervescentOral400 MGTabletOral0.5 gPillGranule, effervescentOral500 mgGranuleOral500.00 mgGranule, for suspensionOral30 MGTablet, effervescentOral500 mgTablet, coatedOral500 mgTablet, coatedOralCapsuleOralTablet, effervescentOralTabletOral320 mgTablet, delayed releaseOral75 MGTablet, film coatedOral30 mgTabletOral75 MGGranule, for suspensionOralTablet, delayed releaseOral325 mg / tabCapsuleAerosol, metered; injection; kit; tablet; tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; SublingualTabletOral500 mg/1PowderOral500 mg/1Tablet, coatedOral500 mg/1SprayOral6 mg/0.1mLLozengeOralCapsuleOral100.00 mgGranule, effervescentOral0.65 gCapsuleOralTablet, orally disintegratingOralCapsule, coatedOral100 mgPowder, for solutionOral100 MGPowder, for solutionOral160 MGPowder, for solutionOral300 MGPowder, for solutionOral75 MGTablet, delayed releaseOral80 mg / tabTablet, chewableOralTablet, film coatedOral100 mgGranuleOral300.000 mgAerosol, metered; injection; kit; solution; tablet; tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; SublingualTabletOral300.000 mgPasteDentalCapsule, extended releaseOral162.5 mg/1Tablet, coatedOral150 mgTablet, delayed releaseOral150 mgTablet, delayed releaseOral325 mgTablet, delayed releaseOral500 mgCapsule, coatedOral324 mgCapsule, coatedOral150 mgCapsule, coatedOral300 mgCapsule, coatedOral500 mgTablet, delayed releaseOral325 mg/3251Tablet, delayed releaseOral650 mgTablet, chewableOral81 mgTablet, delayed releaseOral975 mgTablet, chewableOral325 mgKit; tablet, film coatedOralCapsule, gelatin coatedOralTablet, orally disintegratingOral81 mg/1TabletOral50 MGKitOphthalmic; Oral; TopicalCapsule, coatedOralTablet, coatedOral162 mg/1621Tablet, coatedOral81 mg/811Tablet, film coatedTopicalPowderOralTabletOral300 mg / tabTablet, delayed releaseOral50 mgTabletOral500.00 mgTabletOral100.00 mgTablet, coatedOralInjection, powder, for solutionIntramuscular; Intravenous1000 mgInjection, powder, for solutionIntramuscular; Intravenous500 mgInjection, powder, for solutionIntravenous; Parenteral1 g/5mlInjection, powder, for solutionIntravenous; Parenteral500 mg/2.5mlPowder, for solutionOral1000 mgPowder, for solutionOral200 mgPowder, for solutionOral500 mgSuppositoryRectal0.6 gSuppositoryRectal1.3 gSuppositoryRectal1300 mgSuppositoryRectal600 mgKitOral325 mg/1TabletOral324 mgTablet, chewableBuccal500 mgTablet, delayed releaseOralTabletOral450 mgTablet, multilayerOralTablet, film coatedOralKit; tablet; tablet, delayed releaseOralTabletOral81 mgTablet, delayed releaseOral80 mgTabletOral100.0 mgKitOralTabletTabletOral300.000 mgTablet, delayed releaseOral325 mg/1TabletOral80 mgStripOral81 mg/1PowderOral600 mgPowderOralTablet, film coatedOral50 mgTablet, film coatedOral75 mgTablet, delayed releaseOralTablet, solubleOral300 mgTabletOral81 mg/81mgTabletOral325 mg/325mgCapsuleOral325 mg/325mgCapsuleOral81 mg/81mgTablet, effervescentOral350 mgTablet, delayed releaseOral60 mgPowderOral650 mg/1sachetPowder, for solutionOral162 mg/1sachetPowderOral162 mg/1sachetTabletOral325 mgTabletOral162 mgTabletOral500 mgTablet, film coatedOral300 mgTablet, film coatedOral500 mgTablet, delayed releaseOral300 mg',\n",
       "  'Prices': 'Unit descriptionCostUnitEntrophen 10 650 mg Enteric-Coated Tablet0.09USD tablet  DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.',\n",
       "  'Patents': 'Patent NumberPediatric ExtensionApprovedExpires (estimated)RegionUS5972916No1999-10-262017-07-14USUS6015577No2000-01-182017-01-18USUS6926907No2005-08-092023-02-28USUS9101637No2015-08-112022-03-23USUS9226892No2016-01-052032-09-29USUS8865187No2014-10-212022-03-23USUS9216150No2015-12-222032-09-29USUS9351984No2016-05-312021-12-19USUS9539214No2017-01-102033-03-13USUS9364439No2016-06-142022-05-31USUS8206741No2012-06-262023-02-28USUS9987231No2018-06-052033-01-02USUS10786444No2020-09-292032-09-29USUS10646431No2020-05-122032-09-29US'},\n",
       " 'Properties': {'State': 'Solid',\n",
       "  'Experimental Properties': 'PropertyValueSourcemelting point (°C)138-140http://www.rsc.org/learn-chemistry/content/filerepository/CMP/00/000/045/Aspirin.pdfboiling point (°C)140 °Chttp://www.chemicalland21.com/lifescience/phar/ACETYLSALICYLIC%20ACID.htmwater solubility10 mg/mLhttps://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=USlogP1.18https://www.fip.org/files/fip/BPS/BCS/Monographs/AcetylsalicylicAcid.pdfpKa3.5https://www.fip.org/files/fip/BPS/BCS/Monographs/AcetylsalicylicAcid.pdf',\n",
       "  'Predicted Properties': \"PropertyValueSourcelogP1.24ChemaxonpKa (Strongest Acidic)3.41ChemaxonpKa (Strongest Basic)-7.1ChemaxonPhysiological Charge-1ChemaxonHydrogen Acceptor Count3ChemaxonHydrogen Donor Count1ChemaxonPolar Surface Area63.6 Å2ChemaxonRotatable Bond Count3ChemaxonRefractivity44.45 m3·mol-1ChemaxonPolarizability17.1 Å3ChemaxonNumber of Rings1ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxon\",\n",
       "  'Predicted ADMET Features': 'PropertyValueProbabilityHuman Intestinal Absorption+0.9645Blood Brain Barrier+0.9376Caco-2 permeable-0.6607P-glycoprotein substrateNon-substrate0.685P-glycoprotein inhibitor INon-inhibitor0.9118P-glycoprotein inhibitor IINon-inhibitor0.9615Renal organic cation transporterNon-inhibitor0.914CYP450 2C9 substrateNon-substrate0.7518CYP450 2D6 substrateNon-substrate0.9116CYP450 3A4 substrateNon-substrate0.7225CYP450 1A2 substrateNon-inhibitor0.9046CYP450 2C9 inhibitorNon-inhibitor0.9071CYP450 2D6 inhibitorNon-inhibitor0.9576CYP450 2C19 inhibitorNon-inhibitor0.9445CYP450 3A4 inhibitorNon-inhibitor0.9611CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9557Ames testNon AMES toxic0.9326CarcinogenicityNon-carcinogens0.8356BiodegradationReady biodegradable0.9067Rat acute toxicity2.6386 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.9433hERG inhibition (predictor II)Non-inhibitor0.9799  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)'},\n",
       " 'Spectra': {'Mass Spec (NIST)': 'Download (8.27 KB)',\n",
       "  'Spectra': 'SpectrumSpectrum TypeSplash KeyGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-014l-2960000000-ffcb8d28ab7e460b0da8GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-006w-2910000000-910e8ce2493a05870b33Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot AvailableGC-MS Spectrum - EI-BGC-MSsplash10-00dl-9400000000-64327d3bef0063cf4fe1GC-MS Spectrum - CI-BGC-MSsplash10-00di-0900000000-113943b65024522c1712GC-MS Spectrum - EI-BGC-MSsplash10-014i-1590000000-7890c99ca2b0e2c4ff19GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014l-2960000000-ffcb8d28ab7e460b0da8GC-MS Spectrum - GC-MSGC-MSsplash10-006w-2910000000-910e8ce2493a05870b33GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-006w-2900000000-253eb678a85f77d4ba61Mass Spectrum (Electron Ionization)MSsplash10-00dl-6900000000-74f8a29aa18d0c3afe98MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-00kr-6900000000-324f46e8def1652ed4bfMS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-000i-9000000000-cdf64eaf75083da6f355MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-000i-9000000000-ee75806b6fb8a38fd697MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-00dl-9400000000-64327d3bef0063cf4fe1MS/MS Spectrum - CI-B (Unknown) , PositiveLC-MS/MSsplash10-00di-0900000000-113943b65024522c1712Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableLC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-bc50013edb10656e0aa4LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-2900000000-8c55c1f8d7cb7f247a5dLC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000l-9700000000-d475fd0478daf18a419aLC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9100000000-3daaf3c8697e17e67869LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-ee876bcdd1a5c7c229a0LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-cd4e1f8fe0a2bbc869f9LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-4dca49851b5b9fd03d1aLC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-9000000000-4611655c6aff89d706ebLC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-9000000000-4d636e2d7318b857528dLC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-1256ca04e4244fbc4a64LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-2cae7e19320bfa1a03a0LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-42f69c49b256900b7524LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-0900000000-4860d5cbeeb9c31311ecLC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-3900000000-cc185048e2a1bcc52124LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ba-9700000000-ec436cb71e803899f611LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9100000000-75f611f9e761b63033d9LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-02tc-9000000000-15b9abe0f191aedd9620LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ik9-9000000000-644d508a79eb48c24ec31H NMR Spectrum1D NMRNot Applicable1H NMR Spectrum1D NMRNot Applicable13C NMR Spectrum1D NMRNot Applicable[1H,13C] 2D NMR Spectrum2D NMRNot Applicable'},\n",
       " 'Interested in using DrugBank in a commercial product or application?': {},\n",
       " 'Stay up-to-date with the latest from DrugBank!': {},\n",
       " 'Thank you for subscribing!': {}}"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "info = get_drug_info(\"Aspirin\")\n",
    "info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_additional_info(drug_name):\n",
    "    \"\"\"\n",
    "    Get information on the target(s). The returned object is a dictionary that contains all the sections on the drug info from the second card\n",
    "    in drugbank.\n",
    "    \"\"\"\n",
    "    url = f\"https://www.drugbank.ca/unearth/q?query={drug_name}&searcher=drugs\"\n",
    "    response = requests.get(url)\n",
    "    if response.status_code != 200:\n",
    "        return \"Failed to retrieve the page\"\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    additional_info = {}\n",
    "\n",
    "    containers = soup.find_all('div', class_='bond-list-container') # Find all containers with class 'bond-list-container', this is how the target information is usually found\n",
    "    for container in containers:\n",
    "        container_id = container.get('id')\n",
    "        if container_id:\n",
    "            additional_info[container_id] = []\n",
    "\n",
    "            cards = container.find_all('div', class_='bond card') # The number of extra information cards may vary so find everything that you can\n",
    "            for card in cards:\n",
    "                card_data = {}\n",
    "\n",
    "                card_header = card.find('div', class_='card-header')\n",
    "                if card_header:\n",
    "                    label_tag = card_header.find('strong')\n",
    "                    if label_tag and label_tag.find('a'):\n",
    "                        label = label_tag.find('a').get_text().strip()\n",
    "                        card_data['Label'] = label\n",
    "\n",
    "                dl_elements = card.find_all('dl') # Extract other data from the card body\n",
    "                for dl in dl_elements:\n",
    "                    for dt, dd in zip(dl.find_all('dt'), dl.find_all('dd')):\n",
    "                        dt_text = dt.get_text().strip()\n",
    "                        dd_text = dd.get_text().strip()\n",
    "                        card_data[dt_text] = dd_text\n",
    "\n",
    "                additional_info[container_id].append(card_data)\n",
    "\n",
    "    return additional_info\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Additional Information': {'targets': [{'Label': '5-hydroxytryptamine receptor 3A',\n",
       "    'Kind': 'Protein',\n",
       "    'Organism': 'Humans',\n",
       "    'Pharmacological action': 'Yes',\n",
       "    'Actions': 'Antagonist',\n",
       "    'General Function': 'Voltage-gated potassium channel activity',\n",
       "    'Specific Function': 'This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...',\n",
       "    'Gene Name': 'HTR3A',\n",
       "    'Uniprot ID': 'P46098',\n",
       "    'Uniprot Name': '5-hydroxytryptamine receptor 3A',\n",
       "    'Molecular Weight': '55279.835 Da'}],\n",
       "  'enzymes': [{'Label': 'Cytochrome P450 2C9',\n",
       "    'Kind': 'Protein',\n",
       "    'Organism': 'Humans',\n",
       "    'Pharmacological action': 'Unknown',\n",
       "    'Actions': 'Substrate',\n",
       "    'General Function': 'Steroid hydroxylase activity',\n",
       "    'Specific Function': 'Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...',\n",
       "    'Gene Name': 'CYP2C9',\n",
       "    'Uniprot ID': 'P11712',\n",
       "    'Uniprot Name': 'Cytochrome P450 2C9',\n",
       "    'Molecular Weight': '55627.365 Da'},\n",
       "   {'Label': 'Cytochrome P450 3A4',\n",
       "    'Kind': 'Protein',\n",
       "    'Organism': 'Humans',\n",
       "    'Pharmacological action': 'Unknown',\n",
       "    'Actions': 'Substrate',\n",
       "    'General Function': 'Vitamin d3 25-hydroxylase activity',\n",
       "    'Specific Function': 'Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...',\n",
       "    'Gene Name': 'CYP3A4',\n",
       "    'Uniprot ID': 'P08684',\n",
       "    'Uniprot Name': 'Cytochrome P450 3A4',\n",
       "    'Molecular Weight': '57342.67 Da'},\n",
       "   {'Label': 'Cytochrome P450 2D6',\n",
       "    'Kind': 'Protein',\n",
       "    'Organism': 'Humans',\n",
       "    'Pharmacological action': 'Unknown',\n",
       "    'Actions': 'Substrate',\n",
       "    'General Function': 'Steroid hydroxylase activity',\n",
       "    'Specific Function': 'Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...',\n",
       "    'Gene Name': 'CYP2D6',\n",
       "    'Uniprot ID': 'P10635',\n",
       "    'Uniprot Name': 'Cytochrome P450 2D6',\n",
       "    'Molecular Weight': '55768.94 Da'}]}}"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_additional_info(\"ANZEMET\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_link(url_suffix):\n",
    "    \"\"\" \n",
    "    Helper function to go to the function under the headers in the additional info section (secondary cards) in Drugbank.\n",
    "    \"\"\"\n",
    "    base_url = \"https://go.drugbank.com\"\n",
    "    detailed_url = f\"{base_url}{url_suffix}\"\n",
    "    response = requests.get(detailed_url)\n",
    "\n",
    "    if response.status_code != 200:\n",
    "        return None\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    detailed_info = {}\n",
    "\n",
    "    dl_elements = soup.find_all('dl') # The structure of detailed pages can be different, this is a general approach\n",
    "    for dl in dl_elements:\n",
    "        for dt, dd in zip(dl.find_all('dt'), dl.find_all('dd')):\n",
    "            dt_text = dt.get_text().strip()\n",
    "            dd_text = dd.get_text().strip()\n",
    "            detailed_info[dt_text] = dd_text\n",
    "\n",
    "    return detailed_info\n",
    "\n",
    "def get_additional_info_detailed(drug_name):\n",
    "    \"\"\"\n",
    "    More detailed version of the get_additional_info function. In the previous function we read all the information form the Drugbank page of the drug.\n",
    "    Here, we go to the Drugbank page of the considered extra information piece (target, enzyme, trasportation, etc.) and read the information from there.\n",
    "    This information is generally more detailed.\n",
    "    \"\"\"\n",
    "    url = f\"https://www.drugbank.ca/unearth/q?query={drug_name}&searcher=drugs\"\n",
    "    response = requests.get(url)\n",
    "    if response.status_code != 200:\n",
    "        return \"Failed to retrieve the page\"\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    additional_info = {}\n",
    "\n",
    "    containers = soup.find_all('div', class_='bond-list-container') # Find all containers with class 'bond-list-container'\n",
    "    for container in containers:\n",
    "        container_id = container.get('id')\n",
    "        if container_id:\n",
    "            additional_info[container_id] = []\n",
    "\n",
    "            cards = container.find_all('div', class_='bond card') # Find all individual cards within the container as we don't know how many there're in total\n",
    "            for card in cards:\n",
    "                card_data = {}\n",
    "\n",
    "                card_header = card.find('div', class_='card-header') # Extract the label from the card header\n",
    "                if card_header:\n",
    "                    label_tag = card_header.find('strong')\n",
    "                    if label_tag and label_tag.find('a'):\n",
    "                        label = label_tag.find('a').get_text().strip()\n",
    "                        card_data['Label'] = label\n",
    "\n",
    "                    detail_link = card_header.find('a', class_='bond-details-link') # Find the detail link and fetch detailed info\n",
    "                    if detail_link:\n",
    "                        link_suffix = detail_link['href']\n",
    "                        detailed_info = search_link(link_suffix)\n",
    "                        if detailed_info:\n",
    "                            card_data['Detailed Info'] = detailed_info\n",
    "\n",
    "                additional_info[container_id].append(card_data)\n",
    "\n",
    "    return additional_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'targets': [{'Label': 'Prostaglandin G/H synthase 1',\n",
       "   'Detailed Info': {'Name': 'Prostaglandin G/H synthase 1',\n",
       "    'Synonyms': '1.14.99.1\\nCOX-1\\nCOX1\\nCyclooxygenase-1\\nPGH synthase 1\\nPGHS-1\\nPHS 1\\nProstaglandin H2 synthase 1\\nProstaglandin-endoperoxide synthase 1',\n",
       "    'Gene Name': 'PTGS1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0036935|Prostaglandin G/H synthase 1\\nMSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR\\nTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS\\nNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF\\nLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ\\nYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY\\nATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF\\nDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA\\nLVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL\\nVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS\\nPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL',\n",
       "    'Number of residues': '599',\n",
       "    'Molecular Weight': '68685.82',\n",
       "    'Theoretical pI': '7.39',\n",
       "    'GO Classification': 'Functionsdioxygenase activity / heme binding / lipid binding / metal ion binding / peroxidase activity / prostaglandin-endoperoxide synthase activityProcessesaging / arachidonic acid metabolic process / cyclooxygenase pathway / inflammatory response / learning / lipid metabolic process / maintenance of blood-brain barrier / memory / negative regulation of epinephrine secretion / negative regulation of norepinephrine secretion / positive regulation of smooth muscle contraction / positive regulation of vasoconstriction / prostaglandin biosynthetic process / regulation of blood pressure / regulation of cell proliferation / response to corticosterone / response to fatty acid / response to organonitrogen compound / response to oxidative stress / sensory perception of pain / small molecule metabolic process / xenobiotic metabolic processComponentscytoplasm / endoplasmic reticulum membrane / extracellular exosome / Golgi apparatus / intracellular membrane-bounded organelle / nuclear envelope / nucleus / photoreceptor outer segment',\n",
       "    'General Function': 'Prostaglandin-endoperoxide synthase activity',\n",
       "    'Specific Function': 'Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.',\n",
       "    'Pfam Domain Function': 'An_peroxidase (PF03098)\\nEGF (PF00008)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Microsome membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0021254|Prostaglandin G/H synthase 1 (PTGS1)\\nATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCGCTCCCC\\nGTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC\\nCAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC\\nACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA\\nCTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG\\nTTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCGCCTGGTACTCACAGTGCGCTCC\\nAACCTTATCCCCAGTCCCCCCACCTACAACTCAGCACATGACTACATCAGCTGGGAGTCT\\nTTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA\\nCCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC\\nCTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT\\nGCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC\\nAAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG\\nTATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG\\nTACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC\\nCAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT\\nGCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC\\nACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC\\nAAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT\\nGACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCATGGAGTTC\\nAACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG\\nTACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC\\nCTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC\\nCACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG\\nCCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC\\nGTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG\\nGAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT\\nATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT\\nCCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG\\nGCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT\\nGTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA',\n",
       "    'Chromosome Location': '9',\n",
       "    'Locus': '9q32-q33.3',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP23219UniProtKB Entry NamePGH1_HUMANGenBank Protein ID387018GenBank Gene IDM31822GenAtlas IDPTGS1HGNC IDHGNC:9604',\n",
       "    'General References': 'Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989 Dec 15;165(2):888-94. [Article] Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991 Jun;5(9):2304-12. [Article] Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A: Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun. 1992 Jan 31;182(2):433-8. [Article] Diaz A, Reginato AM, Jimenez SA: Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. J Biol Chem. 1992 May 25;267(15):10816-22. [Article] Qin N, Zhang SP, Reitz TL, Mei JM, Flores CM: Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305. Epub 2005 Sep 1. [Article] Scott BT, Hasstedt SJ, Bovill EG, Callas PW, Valliere JE, Wang L, Wu KK, Long GL: Characterization of the human prostaglandin H synthase 1 gene (PTGS1): exclusion by genetic linkage analysis as a second modifier gene in familial thrombosis. Blood Coagul Fibrinolysis. 2002 Sep;13(6):519-31. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H, Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y, Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW, Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA, French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JG, Glison C, Grafham DV, Gribble S, Griffiths C, Griffiths-Jones S, Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ES, Hart EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ, Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J, Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE, McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV, Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S, Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L, Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T, Jackson MJ, Bentley DR, Beck S, Rogers J, Dunham I: DNA sequence and analysis of human chromosome 9. Nature. 2004 May 27;429(6990):369-74. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-82. [Article] Sostres C, Gargallo CJ, Lanas A: Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. doi: 10.4292/wjgpt.v5.i1.40. [Article] Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L, Bairoch A, Van Dorsselaer A, Carapito C: N-terminome analysis of the human mitochondrial proteome. Proteomics. 2015 Jul;15(14):2519-24. doi: 10.1002/pmic.201400617. Epub 2015 Jun 8. [Article] Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004 Dec;25(12):2467-72. Epub 2004 Aug 12. [Article]',\n",
       "    'Drug Relations': \"DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00244MesalazineapprovedyesinhibitorDetailsDB00316AcetaminophenapprovedyesinhibitorDetailsDB00328Indomethacinapproved, investigationalunknowninhibitorDetailsDB00461NabumetoneapprovedunknowninhibitorDetailsDB00465KetorolacapprovedunknowninhibitorDetailsDB00469TenoxicamapprovedunknowninhibitorDetailsDB00500TolmetinapprovedunknowninhibitorDetailsDB00554Piroxicamapproved, investigationalunknowninhibitorDetailsDB00573FenoprofenapprovedunknowninhibitorDetailsDB00586Diclofenacapproved, vet_approvedyesinhibitorDetailsDB00749Etodolacapproved, investigational, vet_approvedunknowninhibitorDetailsDB00788Naproxenapproved, vet_approvedyesinhibitorDetailsDB00861Diflunisalapproved, investigationalunknowninhibitorDetailsDB00870Suprofenapproved, withdrawnyesinhibitorDetailsDB00939Meclofenamic acidapproved, vet_approvedyesinhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedyesinhibitorDetailsDB00963Bromfenacapproved, withdrawnunknowninhibitorDetailsDB01009Ketoprofenapproved, vet_approvedunknowninhibitorDetailsDB01014Balsalazideapproved, investigationalyesinhibitorDetailsDB01050IbuprofenapprovedyesinhibitorDetailsDB00154Dihomo-gamma-linolenic acidinvestigational, nutraceuticalyesinhibitorDetailsDB00159Icosapentapproved, nutraceuticalyesinhibitorDetailsDB00712Flurbiprofenapproved, investigationalunknowninhibitorDetailsDB00784Mefenamic acidapprovedunknowninhibitorDetailsDB01399SalsalateapprovedyesinhibitorDetailsDB00350Minoxidilapproved, investigationalunknowninducerDetailsDB00605Sulindacapproved, investigationalunknowninhibitorDetailsDB00936Salicylic acidapproved, investigational, vet_approvedyesinhibitorDetailsDB01283Lumiracoxibapproved, investigationalyesinhibitorDetailsDB01837O-acetyl-L-serineexperimentalunknownDetailsDB02110Protoporphyrin Ix Containing CoexperimentalunknownDetailsDB021982-Bromoacetyl GroupexperimentalunknownDetailsDB03753Flurbiprofen Methyl EsterexperimentalunknownDetailsDB02379Beta-D-GlucoseexperimentalunknownDetailsDB04557Arachidonic AcidexperimentalunknownDetailsDB04817Metamizoleapproved, investigational, withdrawnunknownDetailsDB03783PhenacetinwithdrawnunknownDetailsDB01892HyperforinnutraceuticalunknowninhibitorDetailsDB02709ResveratrolinvestigationalunknowninhibitorDetailsDB12445NitroaspirininvestigationalunknowninhibitorDetailsDB00814Meloxicamapproved, vet_approvedunknowninhibitorDetailsDB02266Flufenamic acidapprovedunknownDetailsDB00991OxaprozinapprovedyesinhibitorDetailsDB01600Tiaprofenic acidapprovedyesinhibitorDetailsDB01397Magnesium salicylateexperimentalyesinhibitorDetailsDB00250Dapsoneapproved, investigationalunknownsubstrateDetailsDB01041Thalidomideapproved, investigational, withdrawnnosubstrateDetailsDB00711Diethylcarbamazineapproved, investigational, vet_approvedunknowninhibitorDetailsDB06725Lornoxicamapproved, investigationalyesinhibitorDetailsDB00821Carprofenapproved, vet_approved, withdrawnunknowninhibitorDetailsDB00796Candesartan cilexetilapprovedunknownsubstrateDetailsDB01029Irbesartanapproved, investigationalunknownsubstrateDetailsDB01181IfosfamideapprovedunknownsubstrateDetailsDB05109Trabectedinapproved, investigationalunknownsubstrateDetailsDB00313Valproic acidapproved, investigationalunknownsubstrateDetailsDB00857Terbinafineapproved, investigational, vet_approvedunknownsubstrateDetailsDB00582VoriconazoleapprovedunknownsubstrateDetailsDB01075Diphenhydramineapproved, investigationalunknownsubstrateDetailsDB00216Eletriptanapproved, investigationalunknownsubstrateDetailsDB01355HexobarbitalexperimentalunknownsubstrateDetailsDB00829Diazepamapproved, illicit, investigational, vet_approvedunknownsubstrateDetailsDB00470Dronabinolapproved, illicitnoinhibitorDetailsDB01198ZopicloneapprovedunknownsubstrateDetailsDB00471MontelukastapprovedunknownsubstrateDetailsDB00549Zafirlukastapproved, investigationalunknownsubstrateDetailsDB00744Zileutonapproved, investigational, withdrawnunknownsubstrateDetailsDB00533Rofecoxibapproved, investigational, withdrawnunknownsubstrateDetailsDB00412Rosiglitazoneapproved, investigationalunknownsubstrateDetailsDB01221Ketamineapproved, vet_approvedunknownsubstrateDetailsDB00672Chlorpropamideapproved, investigationalunknownsubstrateDetailsDB00731Nateglinideapproved, investigationalunknownsubstrateDetailsDB06737ZaltoprofenexperimentalunknownsubstrateDetailsDB06739SeratrodastexperimentalunknownsubstrateDetailsDB06738KetobemidoneinvestigationalunknownsubstrateDetailsDB00812Phenylbutazoneapproved, vet_approvedyesinhibitorDetailsDB02773(3-Chloro-4-Propoxy-Phenyl)-Acetic AcidexperimentalunknownDetailsDB02047(+)-2-(4-biphenyl)propionic acidexperimentalunknownDetailsDB079812-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1R)-1-(hydroxymethyl)propyl]acetamideexperimentalunknownDetailsDB079831-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACIDexperimentalunknownDetailsDB079842-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-n-[(1S)-1-(hydroxymethyl)propyl]acetamideexperimentalunknownDetailsDB03752P-(2'-Iodo-5'-Thenoyl)Hydrotropic AcidexperimentalunknownDetailsDB03667Acetic Acid Salicyloyl-Amino-EsterexperimentalunknownDetailsDB06802Nepafenacapproved, investigationalunknowninhibitorDetailsDB00795SulfasalazineapprovedyesinhibitorDetailsDB01435Antipyrineapproved, investigationalunknowninhibitorDetailsDB01419AntrafenineapprovedunknowninhibitorDetailsDB01401Choline magnesium trisalicylateapprovedunknowninhibitorDetailsDB08814Triflusalapproved, investigationalyesantagonistDetailsDB04552Niflumic acidexperimentalunknownDetailsDB00035DesmopressinapprovedunknowninducerDetailsDB00773EtoposideapprovedunknownsubstrateDetailsDB09213Dexibuprofenapproved, investigationalunknowninhibitorDetailsDB06736Aceclofenacapproved, investigationalyesinhibitorDetailsDB13919CandesartanexperimentalunknownsubstrateDetailsDB13783Acemetacinapproved, investigationalyesantagonistDetailsDB09215DroxicamwithdrawnyesinhibitorDetailsDB09212LoxoprofenapprovedyesantagonistDetailsDB09216Tolfenamic acidapproved, investigationalyesantagonistDetailsDB09214Dexketoprofenapproved, investigationalunknownantagonistDetailsDB09214Dexketoprofenapproved, investigationalunknowninhibitorDetailsDB09295TalniflumateexperimentalunknownantagonistDetailsDB09295TalniflumateexperimentalunknowninhibitorDetailsDB09288PropacetamolexperimentalyesantagonistDetailsDB11079Trolamine salicylateapprovedyesinhibitorDetailsDB11071Phenyl salicylateapprovedunknownantagonistDetailsDB13346Bufexamacapproved, withdrawnyesinhibitorDetailsDB11323Glycol salicylateapprovedyesantagonistDetailsDB11201Menthyl salicylateapprovedyesantagonistDetailsDB13501Bendazacapproved, withdrawnunknownDetailsDB09061Cannabidiolapproved, investigationalunknowninhibitorDetailsDB14011NabiximolsinvestigationalunknowninhibitorDetailsDB14009Medical Cannabisexperimental, investigationalunknowninhibitorDetailsDB13514Pranoprofenexperimental, investigationalyesinhibitorDetailsDB00328Indomethacinapproved, investigationalyesinhibitorDetailsDB01250OlsalazineapprovedyesinhibitorDetails\"}},\n",
       "  {'Label': 'Prostaglandin G/H synthase 2',\n",
       "   'Detailed Info': {'Name': 'Prostaglandin G/H synthase 2',\n",
       "    'Synonyms': '1.14.99.1\\nCOX-2\\nCOX2\\nCyclooxygenase-2\\nPGH synthase 2\\nPGHS-2\\nPHS II\\nProstaglandin H2 synthase 2\\nProstaglandin-endoperoxide synthase 2',\n",
       "    'Gene Name': 'PTGS2',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0021832|Prostaglandin G/H synthase 2\\nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\\nSTEL',\n",
       "    'Number of residues': '604',\n",
       "    'Molecular Weight': '68995.625',\n",
       "    'Theoretical pI': '7.41',\n",
       "    'GO Classification': 'Functionsarachidonate 15-lipoxygenase activity / enzyme binding / heme binding / lipid binding / metal ion binding / peroxidase activity / prostaglandin-endoperoxide synthase activityProcessesangiogenesis / arachidonic acid metabolic process / bone mineralization / brown fat cell differentiation / cellular response to ATP / cellular response to fluid shear stress / cellular response to hypoxia / cellular response to mechanical stimulus / cellular response to UV / cyclooxygenase pathway / decidualization / embryo implantation / hair cycle / inflammatory response / learning / lipoxygenase pathway / maintenance of blood-brain barrier / memory / movement of cell or subcellular component / NAD metabolic process / negative regulation of calcium ion transport / negative regulation of cell cycle / negative regulation of cell proliferation / negative regulation of smooth muscle contraction / negative regulation of synaptic transmission, dopaminergic / nicotinamide metabolic process / ovulation / positive regulation of apoptotic process / positive regulation of brown fat cell differentiation / positive regulation of cell migration involved in sprouting angiogenesis / positive regulation of fever generation / positive regulation of fibroblast growth factor production / positive regulation of NF-kappaB import into nucleus / positive regulation of nitric oxide biosynthetic process / positive regulation of platelet-derived growth factor production / positive regulation of prostaglandin biosynthetic process / positive regulation of smooth muscle cell proliferation / positive regulation of smooth muscle contraction / positive regulation of synaptic plasticity / positive regulation of synaptic transmission, glutamatergic / positive regulation of transforming growth factor beta production / positive regulation of vascular endothelial growth factor production / positive regulation of vasoconstriction / prostaglandin biosynthetic process / prostaglandin metabolic process / regulation of blood pressure / regulation of inflammatory response / response to drug / response to estradiol / response to fatty acid / response to fructose / response to glucocorticoid / response to lipopolysaccharide / response to lithium ion / response to manganese ion / response to oxidative stress / response to tumor necrosis factor / response to vitamin D / sensory perception of pain / small molecule metabolic process / vitamin metabolic process / water-soluble vitamin metabolic processComponentscaveola / cytoplasm / endoplasmic reticulum / endoplasmic reticulum lumen / endoplasmic reticulum membrane / neuron projection / nucleus / protein complex',\n",
       "    'General Function': 'Prostaglandin-endoperoxide synthase activity',\n",
       "    'Specific Function': 'Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.',\n",
       "    'Pfam Domain Function': 'An_peroxidase (PF03098)\\nEGF (PF00008)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Microsome membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)\\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG\\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\\nTCGACTGAACTGTAG',\n",
       "    'Chromosome Location': '1',\n",
       "    'Locus': '1q25.2-q25.3',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP35354UniProtKB Entry NamePGH2_HUMANGenBank Protein ID291988GenBank Gene IDL15326GenAtlas IDPTGS2HGNC IDHGNC:9605',\n",
       "    'General References': \"Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993 Apr 25;268(12):9049-54. [Article] Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8. [Article] Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994 May 1;221(3):889-97. [Article] Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T: Structure of the human cyclo-oxygenase-2 gene. Biochem J. 1994 Sep 15;302 ( Pt 3):723-7. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J, et al.: Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta. 1994 Nov 16;1209(1):130-9. [Article] Kim SF, Huri DA, Snyder SH: Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science. 2005 Dec 23;310(5756):1966-70. [Article] Sevigny MB, Li CF, Alas M, Hughes-Fulford M: Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett. 2006 Dec 11;580(28-29):6533-6. Epub 2006 Nov 9. [Article] Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis. 2004 Dec;25(12):2467-72. Epub 2004 Aug 12. [Article] Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-82. [Article] Sostres C, Gargallo CJ, Lanas A: Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. doi: 10.4292/wjgpt.v5.i1.40. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00154Dihomo-gamma-linolenic acidinvestigational, nutraceuticalyesDetailsDB00159Icosapentapproved, nutraceuticalyesinhibitorDetailsDB00480Lenalidomideapprovedunknownnegative modulatorDetailsDB00482Celecoxibapproved, investigationalyesinhibitorDetailsDB00533Rofecoxibapproved, investigational, withdrawnyesinhibitorDetailsDB00580Valdecoxibapproved, investigational, withdrawnyesinhibitorDetailsDB00605Sulindacapproved, investigationalyesinhibitorDetailsDB00712Flurbiprofenapproved, investigationalyesinhibitorDetailsDB00784Mefenamic acidapprovedyesinhibitorDetailsDB00812Phenylbutazoneapproved, vet_approvedyesinhibitorDetailsDB00821Carprofenapproved, vet_approved, withdrawnyesinhibitorDetailsDB00991OxaprozinapprovedyesinhibitorDetailsDB00244MesalazineapprovedyesinhibitorDetailsDB00316AcetaminophenapprovedyesinhibitorDetailsDB00328Indomethacinapproved, investigationalyesinhibitorDetailsDB00461NabumetoneapprovedyesinhibitorDetailsDB00465KetorolacapprovedyesinhibitorDetailsDB00469TenoxicamapprovedyesinhibitorDetailsDB00500TolmetinapprovedyesinhibitorDetailsDB00573FenoprofenapprovedyesinhibitorDetailsDB00586Diclofenacapproved, vet_approvedyesinhibitorDetailsDB00749Etodolacapproved, investigational, vet_approvedyesinhibitorDetailsDB00788Naproxenapproved, vet_approvedyesinhibitorDetailsDB00814Meloxicamapproved, vet_approvedyesinhibitorDetailsDB00861Diflunisalapproved, investigationalyesinhibitorDetailsDB00870Suprofenapproved, withdrawnyesinhibitorDetailsDB00939Meclofenamic acidapproved, vet_approvedyesinhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedyesinhibitorDetailsDB00963Bromfenacapproved, withdrawnyesinhibitorDetailsDB01009Ketoprofenapproved, vet_approvedyesinhibitorDetailsDB01014Balsalazideapproved, investigationalyesinhibitorDetailsDB01050IbuprofenapprovedyesinhibitorDetailsDB01283Lumiracoxibapproved, investigationalyesinhibitorDetailsDB01399SalsalateapprovedyesinhibitorDetailsDB00936Salicylic acidapproved, investigational, vet_approvedyesinhibitorDetailsDB01404Ginsenginvestigational, nutraceuticalunknowninhibitorDetailsDB01628Etoricoxibapproved, investigationalyesinhibitorDetailsDB01600Tiaprofenic acidapprovedyesinhibitorDetailsDB04743Nimesulideapproved, investigational, withdrawnyesinhibitorDetailsDB02709ResveratrolinvestigationalunknowninhibitorDetailsDB04725LicofeloneinvestigationalunknownDetailsDB05095CimicoxibinvestigationalunknownDetailsDB02266Flufenamic acidapprovedunknownDetailsDB00554Piroxicamapproved, investigationalyesinhibitorDetailsDB01397Magnesium salicylateexperimentalyesinhibitorDetailsDB00250Dapsoneapproved, investigationalunknownsubstrateDetailsDB01041Thalidomideapproved, investigational, withdrawnnosubstrateDetailsDB06725Lornoxicamapproved, investigationalyesinhibitorDetailsDB03866Prostaglandin G2experimentalunknownDetailsDB034771-Phenylsulfonamide-3-Trifluoromethyl-5-ParabromophenylpyrazoleexperimentalunknownDetailsDB06802Nepafenacapproved, investigationalunknowninhibitorDetailsDB00795SulfasalazineapprovedyesinhibitorDetailsDB04552Niflumic acidexperimentalyesinhibitorDetailsDB01435Antipyrineapproved, investigationalunknowninhibitorDetailsDB01419AntrafenineapprovedunknowninhibitorDetailsDB01401Choline magnesium trisalicylateapprovedunknowninhibitorDetailsDB00233Aminosalicylic acidapprovedunknowninhibitorDetailsDB00963Bromfenacapproved, withdrawnunknowninhibitorDetailsDB00887BumetanideapprovedunknowninducerDetailsDB06774CapsaicinapprovedunknowninhibitorDetailsDB00856Chlorphenesinapproved, experimentalunknowninhibitorDetailsDB05095CimicoxibinvestigationalunknowninhibitorDetailsDB00720Clodronic acidapproved, investigational, vet_approvedunknowninhibitorDetailsDB06195SeliciclibinvestigationalunknowninhibitorDetailsDB00035DesmopressinapprovedunknowninducerDetailsDB05804Prasterone sulfateinvestigationalunknowninducerDetailsDB01395DrospirenoneapprovedunknowninhibitorinducerDetailsDB06804Nonoxynol-9approved, withdrawnunknowninducerDetailsDB00515CisplatinapprovedunknowninhibitorDetailsDB00884Risedronic acidapproved, investigationalunknowninducerDetailsDB00360Sapropterinapproved, investigationalunknowninducerDetailsDB06436SemaxanibinvestigationalunknowninducerDetailsDB05875Sar9, Met (O2)11-Substance PinvestigationalunknowninducerDetailsDB00041AldesleukinapprovedunknowninducerDetailsDB00620Triamcinoloneapproved, vet_approvedunknowninhibitorDetailsDB08819TafluprostapprovedunknowninducerDetailsDB08910PomalidomideapprovedyesinhibitorDetailsDB00773EtoposideapprovedunknownsubstrateDetailsDB08439ParecoxibapprovedyesinhibitorDetailsDB09217Firocoxibexperimental, vet_approvedunknownDetailsDB13167Alclofenacapproved, withdrawnyesantagonistDetailsDB09213Dexibuprofenapproved, investigationalyesinhibitorDetailsDB11133Omega-3 fatty acidsapproved, nutraceuticalunknownsubstrateDetailsDB13168Omega-6 fatty acidsnutraceuticalunknownsubstrateDetailsDB06736Aceclofenacapproved, investigationalyesinhibitorDetailsDB13783Acemetacinapproved, investigationalyesantagonistDetailsDB09215DroxicamwithdrawnyesinhibitorDetailsDB09212LoxoprofenapprovedyesantagonistDetailsDB09216Tolfenamic acidapproved, investigationalyesantagonistDetailsDB09214Dexketoprofenapproved, investigationalunknownantagonistDetailsDB09214Dexketoprofenapproved, investigationalunknowninhibitorDetailsDB09295TalniflumateexperimentalunknownantagonistDetailsDB09295TalniflumateexperimentalunknowninhibitorDetailsDB09285MorniflumateexperimentalunknownDetailsDB09285MorniflumateexperimentalunknowninhibitorDetailsDB09288PropacetamolexperimentalyesantagonistDetailsDB11079Trolamine salicylateapprovedyesinhibitorDetailsDB11071Phenyl salicylateapprovedunknownantagonistDetailsDB13346Bufexamacapproved, withdrawnyesinhibitorDetailsDB11327DipyrithioneapprovedunknownDetailsDB13961Fish oilapproved, nutraceuticalyesinhibitorDetailsDB11323Glycol salicylateapprovedyesantagonistDetailsDB11201Menthyl salicylateapprovedyesantagonistDetailsDB13501Bendazacapproved, withdrawnunknownDetailsDB09061Cannabidiolapproved, investigationalunknowninhibitorDetailsDB14011NabiximolsinvestigationalunknowninhibitorDetailsDB14009Medical Cannabisexperimental, investigationalunknowninhibitorDetailsDB11752Bryostatin 1investigationalunknowninducerDetailsDB00482Celecoxibapproved, investigationalunknowninhibitorDetailsDB14060NS-398experimentalunknowninhibitorDetailsDB13514Pranoprofenexperimental, investigationalyesinhibitorDetailsDB00328Indomethacinapproved, investigationalyesinhibitorDetailsDB01250OlsalazineapprovedyesinhibitorDetails'}},\n",
       "  {'Label': 'Aldo-keto reductase family 1 member C1',\n",
       "   'Detailed Info': {'Name': 'Aldo-keto reductase family 1 member C1',\n",
       "    'Synonyms': '1.1.1.-\\n20-alpha-HSD\\n20-alpha-hydroxysteroid dehydrogenase\\nChlordecone reductase homolog HAKRC\\nDD1/DD2\\nDDH\\nDDH1\\nDihydrodiol dehydrogenase 1/2\\nHBAB\\nHigh-affinity hepatic bile acid-binding protein\\nIndanol dehydrogenase\\nTrans-1,2-dihydrobenzene-1,2-diol dehydrogenase',\n",
       "    'Gene Name': 'AKR1C1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0016017|Aldo-keto reductase family 1 member C1\\nMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQ\\nVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV\\nSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKP\\nGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV\\nLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN\\nRNVRYLTLDIFAGPPNYPFSDEY',\n",
       "    'Number of residues': '323',\n",
       "    'Molecular Weight': '36788.02',\n",
       "    'Theoretical pI': '7.99',\n",
       "    'GO Classification': 'Functions17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity / alditol / aldo-keto reductase (NADP) activity / androsterone dehydrogenase (B-specific) activity / bile acid binding / carboxylic acid binding / indanol dehydrogenase activity / ketosteroid monooxygenase activity / oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor / phenanthrene 9,10-monooxygenase activity / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activityProcessesbile acid and bile salt transport / bile acid metabolic process / cellular response to jasmonic acid stimulus / cholesterol homeostasis / daunorubicin metabolic process / digestion / doxorubicin metabolic process / epithelial cell differentiation / intestinal cholesterol absorption / oxidation-reduction process / phototransduction, visible light / progesterone metabolic process / protein homooligomerization / response to organophosphorus / retinal metabolic process / retinoid metabolic process / xenobiotic metabolic processComponentscytosol / extracellular exosome',\n",
       "    'General Function': 'Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity',\n",
       "    'Specific Function': 'Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. Has a low bile-binding ability. May play a role in myelin formation.',\n",
       "    'Pfam Domain Function': 'Aldo_ket_red (PF00248)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0016018|Aldo-keto reductase family 1 member C1 (AKR1C1)\\nATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGA\\nTTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTG\\nGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAG\\nGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTC\\nTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAA\\nAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTG\\nTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGAC\\nACAGTGGATCTCTGTGCCACATGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCC\\nAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCA\\nGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGA\\nAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGA\\nTCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTC\\nCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAG\\nCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAAC\\nGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAAC\\nAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCT\\nGATGAATATTAA',\n",
       "    'Chromosome Location': '10',\n",
       "    'Locus': '10p15-p14',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDQ04828UniProtKB Entry NameAK1C1_HUMANGenBank Protein ID181549GenBank Gene IDM86609GenAtlas IDAKR1C1HGNC IDHGNC:384',\n",
       "    'General References': 'Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE: cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J Biol Chem. 1993 May 15;268(14):10448-57. [Article] Lou H, Hammond L, Sharma V, Sparkes RS, Lusis AJ, Stolz A: Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding. J Biol Chem. 1994 Mar 18;269(11):8416-22. [Article] Ciaccio PJ, Jaiswal AK, Tew KD: Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. J Biol Chem. 1994 Jun 3;269(22):15558-62. [Article] Khanna M, Qin KN, Cheng KC: Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and molecular cloning of multiple cDNAs encoding structurally related proteins in humans. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):41-6. [Article] Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, Ito S: Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000 Feb;5(2):111-25. [Article] Zhang Y, Dufort I, Rheault P, Luu-The V: Characterization of a human 20alpha-hydroxysteroid dehydrogenase. J Mol Endocrinol. 2000 Oct;25(2):221-8. [Article] Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10. Nature. 2004 May 27;429(6990):375-81. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Qin KN, New MI, Cheng KC: Molecular cloning of multiple cDNAs encoding human enzymes structurally related to 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol. 1993 Dec;46(6):673-9. [Article] Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y, Ishida N: Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J. 1996 Jan 15;313 ( Pt 2):373-6. [Article] Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K, Hara A: Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J. 1994 Apr 15;299 ( Pt 2):545-52. [Article] Couture JF, Legrand P, Cantin L, Luu-The V, Labrie F, Breton R: Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol. 2003 Aug 15;331(3):593-604. [Article] El-Kabbani O, Dhagat U, Soda M, Endo S, Matsunaga T, Hara A: Probing the inhibitor selectivity pocket of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2564-7. doi: 10.1016/j.bmcl.2011.01.076. Epub 2011 Jan 22. [Article]',\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00157NADHapproved, nutraceuticalunknownDetailsDB03461Nicotinamide adenine dinucleotide phosphateexperimentalunknownDetailsDB046742-HYDROXY-3,5-DIIODOBENZOIC ACIDexperimentalunknownDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB00936Salicylic acidapproved, investigational, vet_approvedunknowninhibitorDetailsDB07768EpitestosteroneexperimentalunknownDetailsDB07931HexestrolwithdrawnunknownDetailsDB03467NaringeninexperimentalunknownantagonistDetailsDB00461NabumetoneapprovedunknownsubstrateDetailsDB01039FenofibrateapprovedunknownsubstrateDetailsDB00776OxcarbazepineapprovedunknownsubstrateDetailsDB06077Lumateperoneapproved, investigationalunknownsubstrateDetailsDB12612Ozanimodapproved, investigationalunknownsubstrateDetailsDB00959Methylprednisoloneapproved, vet_approvedunknownsubstrateDetailsDB06077Lumateperoneapproved, investigationalnosubstrateDetails'}},\n",
       "  {'Label': \"5'-AMP-activated protein kinase (Protein Group)\",\n",
       "   'Detailed Info': {'Name': \"5'-AMP-activated protein kinase\",\n",
       "    'Kind': 'protein group',\n",
       "    'Organism': 'Humans',\n",
       "    'Proteins': \"NameUniProt ID5'-AMP-activated protein kinase catalytic subunit alpha-1Q13131Details5'-AMP-activated protein kinase catalytic subunit alpha-2P54646Details5'-AMP-activated protein kinase subunit beta-1Q9Y478Details5'-AMP-activated protein kinase subunit beta-2O43741Details5'-AMP-activated protein kinase subunit gamma-1P54619Details5'-AMP-activated protein kinase subunit gamma-2Q9UGJ0Details5'-AMP-activated protein kinase subunit gamma-3Q9UGI9Details\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownactivatorDetailsDB12010Fostamatinibapproved, investigationalunknowninhibitorDetailsDB00273TopiramateapprovedunknowninducerDetailsDB00131Adenosine phosphateapproved, investigational, nutraceutical, withdrawnyesactivatorDetails'}},\n",
       "  {'Label': 'Endothelin-1 receptor',\n",
       "   'Detailed Info': {'Name': 'Endothelin-1 receptor',\n",
       "    'Synonyms': 'Endothelin A receptor\\nET-A\\nETA\\nETA-R\\nETRA\\nhET-AR',\n",
       "    'Gene Name': 'EDNRA',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0001040|Endothelin-1 receptor\\nMETLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVTTHQPTNLVLP\\nSNGSMHNYCPQQTKITSAFKYINTVISCTIFIVGMVGNATLLRIIYQNKCMRNGPNALIA\\nSLALGDLIYVVIDLPINVFKLLAGRWPFDHNDFGVFLCKLFPFLQKSSVGITVLNLCALS\\nVDRYRAVASWSRVQGIGIPLVTAIEIVSIWILSFILAIPEAIGFVMVPFEYRGEQHKTCM\\nLNATSKFMEFYQDVKDWWLFGFYFCMPLVCTAIFYTLMTCEMLNRRNGSLRIALSEHLKQ\\nRREVAKTVFCLVVIFALCWFPLHLSRILKKTVYNEMDKNRCELLSFLLLMDYIGINLATM\\nNSCINPIALYFVSKKFKNCFQSCLCCCCYQSKSLMTSVPMNGTSIQWKNHDQNNHNTDRS\\nSHKDSMN',\n",
       "    'Number of residues': '427',\n",
       "    'Molecular Weight': '48721.76',\n",
       "    'Theoretical pI': '8.41',\n",
       "    'GO Classification': 'Functionsendothelin receptor activity / phosphatidylinositol phospholipase C activityProcessesactivation of adenylate cyclase activity / activation of phospholipase C activity / artery smooth muscle contraction / cell proliferation / endothelin receptor signaling pathway / enteric nervous system development / G-protein coupled receptor signaling pathway / glucose transport / head development / heart development / in utero embryonic development / negative regulation of cAMP biosynthetic process / neural crest cell development / patterning of blood vessels / positive regulation of cytosolic calcium ion concentration / regulation of blood pressure / respiratory gaseous exchange / response to hypoxia / signal transduction / smooth muscle contraction / vasoconstrictionComponentscytosol / integral component of plasma membrane / plasma membrane',\n",
       "    'General Function': 'Phosphatidylinositol phospholipase c activity',\n",
       "    'Specific Function': 'Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.',\n",
       "    'Pfam Domain Function': '7tm_1 (PF00001)',\n",
       "    'Transmembrane Regions': '81-102\\n113-132\\n160-181\\n206-229\\n257-278\\n307-328\\n348-372',\n",
       "    'Cellular Location': 'Cell membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0010366|Endothelin-1 receptor (EDNRA)\\nATGGAAACCCTTTGCCTCAGGGCATCCTTTTGGCTGGCACTGGTTGGATGTGTAATCAGT\\nGATAATCCTGAGAGATACAGCACAAATCTAAGCAATCATGTGGATGATTTCACCACTTTT\\nCGTGGCACAGAGCTCAGCTTCCTGGTTACCACTCATCAACCCACTAATTTGGTCCTACCC\\nAGCAATGGCTCAATGCACAACTATTGCCCACAGCAGACTAAAATTACTTCAGCTTTCAAA\\nTACATTAACACTGTGATATCTTGTACTATTTTCATCGTGGGAATGGTGGGGAATGCAACT\\nCTGCTCAGGATCATTTACCAGAACAAATGTATGAGGAATGGCCCCAACGCGCTGATAGCC\\nAGTCTTGCCCTTGGAGACCTTATCTATGTGGTCATTGATCTCCCTATCAATGTATTTAAG\\nTTCTACCAAGATGTAAAGGACTGGTGGCTCTTCGGGTTCTATTTCTGTATGCCCTTGGTG\\nTGCACTGCGATCTTCTACACCCTCATGACTTGTGAGATGTTGAACAGAAGGAATGGCAGC\\nTTGAGAATTGCCCTCAGTGAACATCTTAAGCAGCGTCGAGAAGTGGCAAAAACAGTTTTC\\nTGCTTGGTTGTAATTTTTGCTCTTTGCTGGTTCCCTCTTCATTTAAGCCGTATATTGAAG\\nAAAACTGTGTATAACGAGATGGACAAGAACCGATGTGAATTACTTAGTTTCTTACTGCTC\\nATGGATTACATCGGTATTAACTTGGCAACCATGAATTCATGTATAAACCCCATAGCTCTG\\nTATTTTGTGAGCAAGAAATTTAAAAATTGTTTCCAGTCATGCCTCTGCTGCTGCTGTTAC\\nCAGTCCAAAAGTCTGATGACCTCGGTCCCCATGAACGGAACAAGCATCCAGTGGAAGAAC\\nCACGATCAAAACAACCACAACACAGACCGGAGCAGCCATAAGGACAGCATGAACTGA',\n",
       "    'Chromosome Location': '4',\n",
       "    'Locus': '4q31.23',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP25101UniProtKB Entry NameEDNRA_HUMANGenBank Protein ID238636GenBank Gene IDS63938GenAtlas IDEDNRAHGNC IDHGNC:3179',\n",
       "    'General References': \"Adachi M, Yang YY, Furuichi Y, Miyamoto C: Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1265-72. [Article] Cyr C, Huebner K, Druck T, Kris R: Cloning and chromosomal localization of a human endothelin ETA receptor. Biochem Biophys Res Commun. 1991 Nov 27;181(1):184-90. [Article] Hosoda K, Nakao K, Hiroshi-Arai, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S, Imura H: Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. 1991 Aug 5;287(1-2):23-6. [Article] Arai H, Nakao K, Hosoda K, Ogawa Y, Nakagawa O, Komatsu Y, Imura H: [Molecular cloning of human endothelin receptors and their expression in vascular endothelial cells and smooth muscle cells]. Jpn Circ J. 1992;56 Suppl 5:1303-7. [Article] Elshourbagy NA, Korman DR, Wu HL, Sylvester DR, Lee JA, Nuthalaganti P, Bergsma DJ, Kumar CS, Nambi P: Molecular characterization and regulation of the human endothelin receptors. J Biol Chem. 1993 Feb 25;268(6):3873-9. [Article] Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H: Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem. 1992 Sep 15;267(26):18797-804. [Article] Hayzer DJ, Rose PM, Lynch JS, Webb ML, Kienzle BK, Liu EC, Bogosian EA, Brinson E, Runge MS: Cloning and expression of a human endothelin receptor: subtype A. Am J Med Sci. 1992 Oct;304(4):231-8. [Article] Miyamoto Y, Yoshimasa T, Arai H, Takaya K, Ogawa Y, Itoh H, Nakao K: Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J. 1996 Feb 1;313 ( Pt 3):795-801. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Yang H, Tabuchi H, Furuichi Y, Miyamoto C: Molecular characterization of the 5'-flanking region of human genomic ETA gene. Biochem Biophys Res Commun. 1993 Jan 29;190(2):332-9. [Article] Bourgeois C, Robert B, Rebourcet R, Mondon F, Mignot TM, Duc-Goiran P, Ferre F: Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3. J Clin Endocrinol Metab. 1997 Sep;82(9):3116-23. [Article] Lee HJ, Chun M, Kandror KV: Tip60 and HDAC7 interact with the endothelin receptor a and may be involved in downstream signaling. J Biol Chem. 2001 May 18;276(20):16597-600. Epub 2001 Mar 21. [Article] Gordon CT, Weaver KN, Zechi-Ceide RM, Madsen EC, Tavares AL, Oufadem M, Kurihara Y, Adameyko I, Picard A, Breton S, Pierrot S, Biosse-Duplan M, Voisin N, Masson C, Bole-Feysot C, Nitschke P, Delrue MA, Lacombe D, Guion-Almeida ML, Moura PP, Garib DG, Munnich A, Ernfors P, Hufnagel RB, Hopkin RJ, Kurihara H, Saal HM, Weaver DD, Katsanis N, Lyonnet S, Golzio C, Clouthier DE, Amiel J: Mutations in the endothelin receptor type A cause mandibulofacial dysostosis with alopecia. Am J Hum Genet. 2015 Apr 2;96(4):519-31. doi: 10.1016/j.ajhg.2015.01.015. Epub 2015 Mar 12. [Article] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00559Bosentanapproved, investigationalyesantagonistDetailsDB04883DarusentaninvestigationalunknownDetailsDB12548Sparsentanapproved, investigationalyesantagonistDetailsDB05290SPP 301investigationalunknownDetailsDB05367Actelion-1investigationalunknownDetailsDB06403Ambrisentanapproved, investigationalyesantagonistDetailsDB06199AtrasentaninvestigationalunknownDetailsDB06558TezosentaninvestigationalunknownDetailsDB046742-HYDROXY-3,5-DIIODOBENZOIC ACIDexperimentalunknownDetailsDB06268Sitaxentanapproved, investigational, withdrawnyesantagonistDetailsDB08932MacitentanapprovedyesantagonistDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB06677ClazosentaninvestigationalunknownDetailsDB06460EnrasentaninvestigationalunknownDetails'}},\n",
       "  {'Label': 'Cellular tumor antigen p53',\n",
       "   'Detailed Info': {'Name': 'Cellular tumor antigen p53',\n",
       "    'Synonyms': 'Antigen NY-CO-13\\nP53\\nPhosphoprotein p53\\nTumor suppressor p53',\n",
       "    'Gene Name': 'TP53',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0006595|Cellular tumor antigen p53\\nMEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP\\nDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK\\nSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE\\nRCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS\\nSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP\\nPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG\\nGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD',\n",
       "    'Number of residues': '393',\n",
       "    'Molecular Weight': '43652.79',\n",
       "    'Theoretical pI': '6.78',\n",
       "    'GO Classification': 'FunctionsATP binding / chaperone binding / chromatin binding / copper ion binding / core promoter sequence-specific DNA binding / damaged DNA binding / DNA binding / double-stranded DNA binding / enzyme binding / histone acetyltransferase binding / histone deacetylase regulator activity / identical protein binding / p53 binding / protease binding / protein heterodimerization activity / protein kinase binding / protein N-terminus binding / protein phosphatase 2A binding / protein phosphatase binding / protein self-association / receptor tyrosine kinase binding / RNA polymerase II core promoter sequence-specific DNA binding / RNA polymerase II transcription factor activity, sequence-specific DNA binding / RNA polymerase II transcription factor binding / sequence-specific DNA binding / transcription factor activity, sequence-specific DNA binding / transcription factor binding / transcription regulatory region DNA binding / transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding / transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding / ubiquitin protein ligase binding / zinc ion bindingProcessesapoptotic process / B cell lineage commitment / base-excision repair / blood coagulation / cell aging / cell cycle arrest / cell differentiation / cell proliferation / cellular protein localization / cellular response to DNA damage stimulus / cellular response to drug / cellular response to glucose starvation / cellular response to hypoxia / cellular response to ionizing radiation / cellular response to UV / cellular response to UV-C / cerebellum development / chromatin assembly / chromosome breakage / circadian behavior / determination of adult lifespan / DNA damage response, signal transduction by p53 class mediator / DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest / DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator / DNA repair / DNA strand renaturation / double-strand break repair / embryonic organ development / entrainment of circadian clock by photoperiod / ER overload response / gastrulation / gene expression / in utero embryonic development / intrinsic apoptotic signaling pathway / intrinsic apoptotic signaling pathway by p53 class mediator / intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator / intrinsic apoptotic signaling pathway in response to hypoxia / mitochondrial DNA repair / mitotic cell cycle arrest / mitotic G1 DNA damage checkpoint / multicellular organism growth / multicellular organismal development / necroptotic process / negative regulation of apoptotic process / negative regulation of cell growth / negative regulation of cell proliferation / negative regulation of DNA replication / negative regulation of fibroblast proliferation / negative regulation of glucose catabolic process to lactate via pyruvate / negative regulation of helicase activity / negative regulation of macromitophagy / negative regulation of neuroblast proliferation / negative regulation of proteolysis / negative regulation of reactive oxygen species metabolic process / negative regulation of transcription from RNA polymerase II promoter / negative regulation of transcription, DNA-templated / negative regulation of transforming growth factor beta receptor signaling pathway / neuron apoptotic process / Notch signaling pathway / nucleotide-excision repair / oligodendrocyte apoptotic process / oxidative stress-induced premature senescence / positive regulation of apoptotic process / positive regulation of cardiac muscle cell apoptotic process / positive regulation of cell cycle arrest / positive regulation of execution phase of apoptosis / positive regulation of gene expression / positive regulation of histone deacetylation / positive regulation of intrinsic apoptotic signaling pathway / positive regulation of mitochondrial membrane permeability / positive regulation of neuron apoptotic process / positive regulation of peptidyl-tyrosine phosphorylation / positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway / positive regulation of protein oligomerization / positive regulation of reactive oxygen species metabolic process / positive regulation of release of cytochrome c from mitochondria / positive regulation of thymocyte apoptotic process / positive regulation of transcription from RNA polymerase II promoter / positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress / positive regulation of transcription from RNA polymerase II promoter in response to hypoxia / positive regulation of transcription, DNA-templated / programmed cell death / protein complex assembly / protein import into nucleus, translocation / protein localization / protein tetramerization / Ras protein signal transduction / regulation of apoptotic process / regulation of cellular senescence / regulation of fibroblast apoptotic process / regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter / regulation of intrinsic apoptotic signaling pathway by p53 class mediator / regulation of mitochondrial membrane permeability / regulation of mitochondrial membrane permeability involved in apoptotic process / regulation of tissue remodeling / regulation of transcription, DNA-templated / release of cytochrome c from mitochondria / replicative senescence / response to antibiotic / response to gamma radiation / response to ischemia / response to salt stress / response to X-ray / rRNA transcription / somitogenesis / T cell differentiation in thymus / T cell lineage commitment / T cell proliferation involved in immune response / transcription initiation from RNA polymerase II promoter / transforming growth factor beta receptor signaling pathway / viral processComponentscytoplasm / cytosol / endoplasmic reticulum / mitochondrial matrix / mitochondrion / nuclear chromatin / nuclear matrix / nucleolus / nucleoplasm / nucleus / PML body / protein complex / replication fork',\n",
       "    'General Function': 'Not Available',\n",
       "    'Specific Function': 'Not Available',\n",
       "    'Pfam Domain Function': 'P53 (PF00870)\\nP53_TAD (PF08563)\\nP53_tetramer (PF07710)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0021858|Cellular tumor antigen p53 (TP53)\\nATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCA\\nGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATG\\nGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCA\\nGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCCGTGGCCCCTGCACCAGCAGCTCCT\\nACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAG\\nAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAG\\nTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACC\\nTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATG\\nGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAG\\nCGCTGCTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAAT\\nTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTAT\\nGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGT\\nTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCC\\nAGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGA\\nGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCC\\nCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAG\\nAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATG\\nTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGG\\nGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCAT\\nAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA',\n",
       "    'Chromosome Location': 'Not Available',\n",
       "    'Locus': '17p13.1',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP04637UniProtKB Entry NameP53_HUMANGenBank Gene IDX02469GenAtlas IDTP53HGNC IDHGNC:11998',\n",
       "    'General References': \"Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M: Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 1985 May;4(5):1251-5. [Article] Lamb P, Crawford L: Characterization of the human p53 gene. Mol Cell Biol. 1986 May;6(5):1379-85. [Article] Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol. 1985 Jul;5(7):1601-10. [Article] Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 1986 Dec;6(12):4650-6. [Article] Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP: A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988 Oct 30;70(2):245-52. [Article] Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991 Oct;10(10):2879-87. [Article] Allalunis-Turner MJ, Barron GM, Day RS 3rd, Dobler KD, Mirzayans R: Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res. 1993 Jun;134(3):349-54. [Article] Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, Zevotek N: Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2001 Feb 2;276(5):3361-70. Epub 2000 Oct 31. [Article] Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005 Sep 15;19(18):2122-37. Epub 2005 Aug 30. [Article] Anderson CW, Allalunis-Turner MJ: Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. Radiat Res. 2000 Oct;154(4):473-6. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, Abouelleil A, Allen NR, Bi W, Bloom T, Borowsky ML, Bugalter BE, Butler J, Chang JL, Chen CK, Cook A, Corum B, Cuomo CA, de Jong PJ, DeCaprio D, Dewar K, FitzGerald M, Gilbert J, Gibson R, Gnerre S, Goldstein S, Grafham DV, Grocock R, Hafez N, Hagopian DS, Hart E, Norman CH, Humphray S, Jaffe DB, Jones M, Kamal M, Khodiyar VK, LaButti K, Laird G, Lehoczky J, Liu X, Lokyitsang T, Loveland J, Lui A, Macdonald P, Major JE, Matthews L, Mauceli E, McCarroll SA, Mihalev AH, Mudge J, Nguyen C, Nicol R, O'Leary SB, Osoegawa K, Schwartz DC, Shaw-Smith C, Stankiewicz P, Steward C, Swarbreck D, Venkataraman V, Whittaker CA, Yang X, Zimmer AR, Bradley A, Hubbard T, Birren BW, Rogers J, Lander ES, Nusbaum C: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 2006 Apr 20;440(7087):1045-9. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL: Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15836-41. Epub 2003 Dec 5. [Article] Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 1984 Dec 20;3(13):3257-62. [Article] Addison C, Jenkins JR, Sturzbecher HW: The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene. 1990 Mar;5(3):423-6. [Article] Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4766-70. [Article] Samad A, Carroll RB: The tumor suppressor p53 is bound to RNA by a stable covalent linkage. Mol Cell Biol. 1991 Mar;11(3):1598-606. [Article] Scheidtmann KH, Mumby MC, Rundell K, Walter G: Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen. Mol Cell Biol. 1991 Apr;11(4):1996-2003. [Article] Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T: The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene. 1996 Feb 15;12(4):813-8. [Article] Shaw P, Freeman J, Bovey R, Iggo R: Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene. 1996 Feb 15;12(4):921-30. [Article] Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C, Pan ZQ: p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol. 1997 Dec;17(12):7220-9. [Article] Schneider E, Montenarh M, Wagner P: Regulation of CAK kinase activity by p53. Oncogene. 1998 Nov 26;17(21):2733-41. [Article] Dumaz N, Milne DM, Meek DW: Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett. 1999 Dec 17;463(3):312-6. [Article] Liang SH, Clarke MF: A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem. 1999 Nov 12;274(46):32699-703. [Article] Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13777-82. [Article] Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000 Mar 24;275(12):8945-51. [Article] Abraham J, Kelly J, Thibault P, Benchimol S: Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. J Mol Biol. 2000 Jan 28;295(4):853-64. [Article] Luciani MG, Hutchins JR, Zheleva D, Hupp TR: The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol. 2000 Jul 14;300(3):503-18. [Article] Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP: The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000 Oct;2(10):730-6. [Article] Sandy P, Gostissa M, Fogal V, Cecco LD, Szalay K, Rooney RJ, Schneider C, Del Sal G: p53 is involved in the p120E4F-mediated growth arrest. Oncogene. 2000 Jan 13;19(2):188-99. [Article] Lopez-Borges S, Lazo PA: The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene. 2000 Jul 27;19(32):3656-64. [Article] Hainaut P, Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal. 2001 Aug;3(4):611-23. [Article] Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H: Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun. 2001 Sep 21;287(2):562-7. [Article] Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001 Oct 19;107(2):149-59. [Article] Hong TM, Chen JJ, Peck K, Yang PC, Wu CW: p53 amino acids 339-346 represent the minimal p53 repression domain. J Biol Chem. 2001 Jan 12;276(2):1510-5. [Article] Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M, Dai W: Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem. 2001 Sep 28;276(39):36194-9. Epub 2001 Jul 10. [Article] Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, Dai W: Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem. 2001 Nov 16;276(46):43305-12. Epub 2001 Sep 10. [Article] Rodriguez MS, Dargemont C, Hay RT: SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001 Apr 20;276(16):12654-9. Epub 2000 Dec 21. [Article] Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, Kito K, Ueda N, Shigemoto K, Hitsumoto Y, Nikawa J, Enomoto Y: Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem. 2001 Nov 23;276(47):44003-11. Epub 2001 Sep 6. [Article] Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H: A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell. 2001 Feb;7(2):283-92. [Article] Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE, Shi Y: Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2002 Dec 27;111(7):1041-54. [Article] Tsuji K, Mizumoto K, Yamochi T, Nishimoto I, Matsuoka M: Differential effect of ik3-1/cables on p53- and p73-induced cell death. J Biol Chem. 2002 Jan 25;277(4):2951-7. Epub 2001 Nov 12. [Article] Kim EJ, Park JS, Um SJ: Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem. 2002 Aug 30;277(35):32020-8. Epub 2002 Mar 29. [Article] Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML: Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002 Jan;4(1):1-10. [Article] D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002 Jan;4(1):11-9. [Article] Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC: p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003 May 15;63(10):2373-8. [Article] Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC: Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. J Biol Chem. 2003 Jul 11;278(28):25568-76. Epub 2003 Apr 30. [Article] Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y: The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem. 2003 Aug 29;278(35):33134-41. Epub 2003 Jun 16. [Article] Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL, Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem. 2003 Sep 26;278(39):37722-9. Epub 2003 Jul 7. [Article] O'Keefe K, Li H, Zhang Y: Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol. 2003 Sep;23(18):6396-405. [Article] Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A, Wakeham A, Tuan J, Saris C, Elliott G, Ma W, Benchimol S, Lowe SW, Mak TW, Thukral SK: Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5431-6. Epub 2003 Apr 17. [Article] Hasan MK, Yaguchi T, Minoda Y, Hirano T, Taira K, Wadhwa R, Kaul SC: Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Biochem J. 2004 Jun 15;380(Pt 3):605-10. [Article] An W, Kim J, Roeder RG: Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004 Jun 11;117(6):735-48. [Article] Kojic S, Medeot E, Guccione E, Krmac H, Zara I, Martinelli V, Valle G, Faulkner G: The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle. J Mol Biol. 2004 May 28;339(2):313-25. [Article] Li HH, Li AG, Sheppard HM, Liu X: Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell. 2004 Mar 26;13(6):867-78. [Article] Li M, Brooks CL, Kon N, Gu W: A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell. 2004 Mar 26;13(6):879-86. [Article] Ghosh A, Stewart D, Matlashewski G: Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004 Sep;24(18):7987-97. [Article] Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D: Regulation of p53 activity through lysine methylation. Nature. 2004 Nov 18;432(7015):353-60. Epub 2004 Nov 3. [Article] Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004 Jan;36(1):55-62. Epub 2003 Dec 14. [Article] Hublitz P, Kunowska N, Mayer UP, Muller JM, Heyne K, Yin N, Fritzsche C, Poli C, Miguet L, Schupp IW, van Grunsven LA, Potiers N, van Dorsselaer A, Metzger E, Roemer K, Schule R: NIR is a novel INHAT repressor that modulates the transcriptional activity of p53. Genes Dev. 2005 Dec 1;19(23):2912-24. [Article] Jalota A, Singh K, Pavithra L, Kaul-Ghanekar R, Jameel S, Chattopadhyay S: Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. J Biol Chem. 2005 Apr 22;280(16):16019-29. Epub 2005 Feb 8. [Article] Golubovskaya VM, Finch R, Cance WG: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem. 2005 Jul 1;280(26):25008-21. Epub 2005 Apr 25. [Article] Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q: WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem. 2005 Dec 30;280(52):43100-8. Epub 2005 Oct 11. [Article] Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005 Apr 29;18(3):283-93. [Article] Zeng PY, Berger SL: LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 2006 Nov 15;66(22):10701-8. [Article] Blanco S, Klimcakova L, Vega FM, Lazo PA: The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. FEBS J. 2006 Jun;273(11):2487-504. [Article] Gu YM, Jin YH, Choi JK, Baek KH, Yeo CY, Lee KY: Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. FEBS Lett. 2006 Jan 9;580(1):305-10. Epub 2005 Dec 19. [Article] Yoshida K, Liu H, Miki Y: Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem. 2006 Mar 3;281(9):5734-40. Epub 2005 Dec 23. [Article] Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL: Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006 Nov 30;444(7119):629-32. Epub 2006 Nov 15. [Article] Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X: Critical role for Daxx in regulating Mdm2. Nat Cell Biol. 2006 Aug;8(8):855-62. Epub 2006 Jul 16. [Article] Couture JF, Collazo E, Hauk G, Trievel RC: Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 2006 Feb;13(2):140-6. Epub 2006 Jan 15. [Article] Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR 3rd, Wright PE, Han J: PRAK is essential for ras-induced senescence and tumor suppression. Cell. 2007 Jan 26;128(2):295-308. [Article] Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, Lee SW: Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell. 2007 Aug 24;130(4):624-37. [Article] Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T: Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J. 2007 Jan 10;26(1):113-22. Epub 2006 Dec 14. [Article] Li HH, Cai X, Shouse GP, Piluso LG, Liu X: A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J. 2007 Jan 24;26(2):402-11. [Article] Zhou X, Yang G, Huang R, Chen X, Hu G: SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53. FEBS Lett. 2007 Oct 16;581(25):4943-8. Epub 2007 Sep 21. [Article] Arai S, Matsushita A, Du K, Yagi K, Okazaki Y, Kurokawa R: Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. FEBS Lett. 2007 Dec 11;581(29):5649-57. Epub 2007 Nov 20. [Article] Piskacek S, Gregor M, Nemethova M, Grabner M, Kovarik P, Piskacek M: Nine-amino-acid transactivation domain: establishment and prediction utilities. Genomics. 2007 Jun;89(6):756-68. Epub 2007 Apr 30. [Article] Yang W, Rozan LM, McDonald ER 3rd, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS: CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem. 2007 Feb 2;282(5):3273-81. Epub 2006 Nov 22. [Article] Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-Kurowska A, Reddi HV, Solomon A, Zeng MS, Kung A, Ma H, Gao Q, Dimri G, Stanculescu A, Miele L, Wu L, Griffin JD, Wazer DE, Band H, Band V: The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem. 2007 Apr 20;282(16):11969-81. Epub 2007 Feb 22. [Article] Lee JH, Kim HS, Lee SJ, Kim KT: Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci. 2007 Jul 1;120(Pt 13):2259-71. [Article] Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Zinn AR, Shime H, Inoue N: Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007 May;18(5):1701-9. Epub 2007 Mar 1. [Article] Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 2007 Mar 9;25(5):725-38. [Article] Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL: p53 is regulated by the lysine demethylase LSD1. Nature. 2007 Sep 6;449(7158):105-8. [Article] Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O: Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007 Aug 17;27(4):636-46. [Article] Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007 May 25;316(5828):1160-6. [Article] Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, Lee KY: Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 2008 Apr 11;368(3):690-5. doi: 10.1016/j.bbrc.2008.01.114. Epub 2008 Feb 4. [Article] Xie P, Tian C, An L, Nie J, Lu K, Xing G, Zhang L, He F: Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal. 2008 Sep;20(9):1671-8. doi: 10.1016/j.cellsig.2008.05.012. Epub 2008 Jun 27. [Article] Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD, Ilic D: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008 Jan 18;29(1):9-22. doi: 10.1016/j.molcel.2007.11.031. [Article] Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008 Jan;28(1):448-56. Epub 2007 Oct 29. [Article] Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article] Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, Ha NC, Lane DP, Song J: Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J. 2009 Jul 22;28(14):2100-13. doi: 10.1038/emboj.2009.164. Epub 2009 Jun 18. [Article] Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, Liu X: Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem. 2009 Jul 10;284(28):18588-92. doi: 10.1074/jbc.C109.001560. Epub 2009 May 27. [Article] Li DQ, Divijendra Natha Reddy S, Pakala SB, Wu X, Zhang Y, Rayala SK, Kumar R: MTA1 coregulator regulates p53 stability and function. J Biol Chem. 2009 Dec 11;284(50):34545-52. doi: 10.1074/jbc.M109.056499. Epub 2009 Oct 16. [Article] Hwang ES, Zhang Z, Cai H, Huang DY, Huong SM, Cha CY, Huang ES: Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol. 2009 Dec;83(23):12388-98. doi: 10.1128/JVI.00304-09. Epub 2009 Sep 23. [Article] Sun L, Shi L, Li W, Yu W, Liang J, Zhang H, Yang X, Wang Y, Li R, Yao X, Yi X, Shang Y: JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10195-200. doi: 10.1073/pnas.0901864106. Epub 2009 Jun 9. [Article] Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, Bergmann A, Johnson RL, Barton MC: Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11612-6. doi: 10.1073/pnas.0813177106. Epub 2009 Jun 25. [Article] Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16. [Article] Yuan J, Luo K, Zhang L, Cheville JC, Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010 Feb 5;140(3):384-96. doi: 10.1016/j.cell.2009.12.032. Epub 2010 Jan 21. [Article] Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL: A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010 Aug 6;142(3):409-19. doi: 10.1016/j.cell.2010.06.040. [Article] Venerando A, Marin O, Cozza G, Bustos VH, Sarno S, Pinna LA: Isoform specific phosphorylation of p53 by protein kinase CK1. Cell Mol Life Sci. 2010 Apr;67(7):1105-18. doi: 10.1007/s00018-009-0236-7. Epub 2009 Dec 30. [Article] Lim SO, Kim H, Jung G: p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. FEBS Lett. 2010 Jun 3;584(11):2231-6. doi: 10.1016/j.febslet.2010.04.006. Epub 2010 Apr 10. [Article] Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD: Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem. 2010 Jan 15;285(3):1743-53. doi: 10.1074/jbc.M109.064212. Epub 2009 Oct 30. [Article] Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, Reinberg D, Berger SL: G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010 Mar 26;285(13):9636-41. doi: 10.1074/jbc.M109.062588. Epub 2010 Jan 29. [Article] Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L: G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J Biol Chem. 2010 Apr 23;285(17):12823-30. doi: 10.1074/jbc.M109.094243. Epub 2010 Feb 2. [Article] Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, Kerkhoven R, Jonkers J, Voorhoeve PM, Agami R, Del Sal G: BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol. 2010 Apr;12(4):380-9. doi: 10.1038/ncb2038. Epub 2010 Mar 14. [Article] Fu X, Yucer N, Liu S, Li M, Yi P, Mu JJ, Yang T, Chu J, Jung SY, O'Malley BW, Gu W, Qin J, Wang Y: RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4579-84. doi: 10.1073/pnas.0912094107. Epub 2010 Feb 19. [Article] Burrows AE, Smogorzewska A, Elledge SJ: Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14280-5. doi: 10.1073/pnas.1009559107. Epub 2010 Jul 26. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Mori T, Ikeda DD, Fukushima T, Takenoshita S, Kochi H: NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle. 2011 Oct 1;10(19):3284-99. doi: 10.4161/cc.10.19.17176. Epub 2011 Oct 1. [Article] Wu L, Ma CA, Zhao Y, Jain A: Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression. J Biol Chem. 2011 Jan 21;286(3):2236-44. doi: 10.1074/jbc.M110.174755. Epub 2010 Oct 19. [Article] Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexo BA, Tjonneland A, Overvad K, Rudnai P, Gurzau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, Garcia-Prats MD, Sanambrosio E, Panadero A, De Juan A, Garcia A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, van Rossum MM, Cremers RG, van Oort IM, van Spronsen DJ, Schalken JA, Peters WH, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Moller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, O Neill BP, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadottir HT, Sigurdsson A, Steinthorsdottir V, Lindblom A, Sandler RS, Keku TO, Banasik K, Jorgensen T, Witte DR, Hansen T, Pedersen O, Jinga V, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeney LA, Kumar R, Mayordomo JI, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K: A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011 Sep 25;43(11):1098-103. doi: 10.1038/ng.926. [Article] Hou X, Liu JE, Liu W, Liu CY, Liu ZY, Sun ZY: A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene. 2011 Jun 30;30(26):2933-42. doi: 10.1038/onc.2011.19. Epub 2011 Feb 14. [Article] Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM: p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014. [Article] Bennett RL, Pan Y, Christian J, Hui T, May WS Jr: The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest. Cell Cycle. 2012 Jan 15;11(2):407-17. doi: 10.4161/cc.11.2.18999. Epub 2012 Jan 15. [Article] Iijima K, Yamada H, Miharu M, Imadome K, Miyagawa Y, Akimoto S, Kobayashi K, Okita H, Nakazawa A, Fujiwara S, Fujimoto J, Kiyokawa N: ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis. Eur J Immunol. 2012 Dec;42(12):3405-15. doi: 10.1002/eji.201242530. Epub 2012 Oct 16. [Article] Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, Bedford MT, Cheng JQ, Mer G: PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol. 2012 Sep;19(9):916-24. doi: 10.1038/nsmb.2353. Epub 2012 Aug 5. [Article] Miki T, Matsumoto T, Zhao Z, Lee CC: p53 regulates Period2 expression and the circadian clock. Nat Commun. 2013;4:2444. doi: 10.1038/ncomms3444. [Article] Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C: MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900. doi: 10.1073/pnas.1300490110. Epub 2013 Feb 19. [Article] Wimmer P, Berscheminski J, Blanchette P, Groitl P, Branton PE, Hay RT, Dobner T, Schreiner S: PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53. Oncogene. 2016 Jan 7;35(1):69-82. doi: 10.1038/onc.2015.63. Epub 2015 Mar 16. [Article] Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 1994 Jul 15;265(5170):386-91. [Article] Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH: Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol. 1994 Dec;1(12):877-90. [Article] McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ, Halazonetis TD: Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. 1997 Oct 15;16(20):6230-6. [Article] Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994 Jul 15;265(5170):346-55. [Article] Jeffrey PD, Gorina S, Pavletich NP: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995 Mar 10;267(5203):1498-502. [Article] Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996 Nov 8;274(5289):948-53. [Article] Gorina S, Pavletich NP: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 1996 Nov 8;274(5289):1001-5. [Article] Joerger AC, Allen MD, Fersht AR: Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem. 2004 Jan 9;279(2):1291-6. Epub 2003 Oct 8. [Article] Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z: Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006 Jun 23;22(6):741-53. [Article] Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, Frappier L: Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol. 2006 Mar;13(3):285-91. Epub 2006 Feb 12. [Article] Hu M, Gu L, Li M, Jeffrey PD, Gu W, Shi Y: Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol. 2006 Feb;4(2):e27. Epub 2006 Jan 17. [Article] West LE, Roy S, Lachmi-Weiner K, Hayashi R, Shi X, Appella E, Kutateladze TG, Gozani O: The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem. 2010 Nov 26;285(48):37725-32. doi: 10.1074/jbc.M110.139527. Epub 2010 Sep 24. [Article] Harris CC: p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980-1. [Article] Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49-53. [Article] De Vries EM, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS, Sommer SS: Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum Mutat. 1996;7(3):202-13. [Article] Joerger AC, Ang HC, Fersht AR: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15056-61. Epub 2006 Oct 2. [Article] Tu C, Tan YH, Shaw G, Zhou Z, Bai Y, Luo R, Ji X: Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr. 2008 May;64(Pt 5):471-7. doi: 10.1107/S0907444908003338. Epub 2008 Apr 19. [Article] Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR: Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5. doi: 10.1073/pnas.0805326105. Epub 2008 Jul 23. [Article] Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z: Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. [Article] Khoo KH, Joerger AC, Freund SM, Fersht AR: Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core. Protein Eng Des Sel. 2009 Jul;22(7):421-30. doi: 10.1093/protein/gzp018. Epub 2009 Jun 10. [Article] Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR: Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol. 2010 Jan 29;17(1):46-56. doi: 10.1016/j.chembiol.2009.12.011. [Article] Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z: Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol. 2010 Apr;17(4):423-9. doi: 10.1038/nsmb.1800. Epub 2010 Apr 4. [Article] Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G: Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet. 1991 Feb;86(4):369-70. [Article] Law JC, Strong LC, Chidambaram A, Ferrell RE: A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 1991 Dec 1;51(23 Pt 1):6385-7. [Article] Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30;250(4985):1233-8. [Article] Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990 Dec 20-27;348(6303):747-9. [Article] Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, et al.: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest. 1992 Feb;89(2):640-7. [Article] Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, et al.: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992 May 14;326(20):1309-15. [Article] Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990 Jun;5(6):893-9. [Article] Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9. [Article] Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61. [Article] Ishioka C, Sato T, Gamoh M, Suzuki T, Shibata H, Kanamaru R, Wakui A, Yamazaki T: Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. Biochem Biophys Res Commun. 1991 Jun 28;177(3):901-6. [Article] Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991 Aug 15;51(16):4495-9. [Article] Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991 Apr 4;350(6317):427-8. [Article] Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991 Apr 4;350(6317):429-31. [Article] Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res. 1992 Nov 1;52(21):5997-6000. [Article] Crook T, Vousden KH: Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 1992 Nov;11(11):3935-40. [Article] Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H, Tsuchida N: The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer. 1992 Dec 2;52(6):867-72. [Article] Bhatia K, Gutierrez MI, Magrath IT: A novel mutation in the p53 gene in a Burkitt's lymphoma cell line. Hum Mol Genet. 1992 Jun;1(3):207-8. [Article] Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E, May P: p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene. 1992 Nov;7(11):2161-7. [Article] Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT, Colburn NH: An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6516-20. [Article] Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol. 1993 Apr;142(4):1131-9. [Article] Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993 Oct 1;53(19):4477-80. [Article] Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G: Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene. 1993 Aug;8(8):2213-20. [Article] Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al.: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994 Mar 1;54(5):1298-304. [Article] Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB: A temperature-sensitive mutant of human p53. EMBO J. 1994 Jun 1;13(11):2535-44. [Article] Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, Li FP, Friend SH: Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995 Mar;56(3):608-15. [Article] Eeles RA: Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101-24. [Article] Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG: An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet. 1995 Dec;32(12):942-5. [Article] Audrezet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Hardy E, Bail JP, Volant A, Lozac'h P, Gouerou H, Ferec C: Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Hum Mutat. 1996;7(2):109-13. [Article] Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J: Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat. 1997;9(4):348-55. [Article] Miyaki M, Nishio J, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Nagato M, Chong JM, Koike M, Terada T, Kawahara Y, Fukutome A, Tomiyama J, Chuganji Y, Momoi M, Utsunomiya J: Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Oncogene. 1997 Dec 4;15(23):2877-81. [Article] van Rensburg EJ, Engelbrecht S, van Heerden WF, Kotze MJ, Raubenheimer EJ: Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample. Hum Mutat. 1998;11(1):39-44. [Article] Luca JW, Strong LC, Hansen MF: A germline missense mutation R337C in exon 10 of the human p53 gene. Hum Mutat. 1998;Suppl 1:S58-61. [Article] Guran S, Tunca Y, Imirzalioglu N: Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. Cancer Genet Cytogenet. 1999 Sep;113(2):145-51. [Article] Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137. [Article] Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R: An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5. [Article] Rutherford J, Chu CE, Duddy PM, Charlton RS, Chumas P, Taylor GR, Lu X, Barnes DM, Camplejohn RS: Investigations on a clinically and functionally unusual and novel germline p53 mutation. Br J Cancer. 2002 May 20;86(10):1592-6. [Article] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article] Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Borresen-Dale AL: Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res. 2007;9(1):R5. [Article] Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007 Jun;28(6):622-9. [Article] Qin B, Minter-Dykhouse K, Yu J, Zhang J, Liu T, Zhang H, Lee S, Kim J, Wang L, Lou Z: DBC1 functions as a tumor suppressor by regulating p53 stability. Cell Rep. 2015 Mar 3;10(8):1324-34. doi: 10.1016/j.celrep.2015.01.066. Epub 2015 Feb 26. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB05404AZD 3355investigationalunknownDetailsDB083631-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamineexperimentalunknownDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninducerDetailsDB01593Zincapproved, investigationalunknownDetailsDB03347Triethyl phosphateexperimentalunknownDetailsDB14487Zinc acetateapproved, investigationalunknownDetailsDB14533Zinc chlorideapproved, investigationalunknownchaperoneDetailsDB14548Zinc sulfate, unspecified formapproved, experimentalunknownchaperoneDetails'}},\n",
       "  {'Label': '78 kDa glucose-regulated protein',\n",
       "   'Detailed Info': {'Name': '78 kDa glucose-regulated protein',\n",
       "    'Synonyms': 'BiP\\nEndoplasmic reticulum lumenal Ca(2+)-binding protein grp78\\nGRP-78\\nGRP78\\nHeat shock 70 kDa protein 5\\nImmunoglobulin heavy chain-binding protein',\n",
       "    'Gene Name': 'HSPA5',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0019062|78 kDa glucose-regulated protein\\nMKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR\\nITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV\\nEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ\\nRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG\\nVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS\\nSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV\\nLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC\\nPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG\\nTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER\\nMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE\\nKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL',\n",
       "    'Number of residues': '654',\n",
       "    'Molecular Weight': '72332.425',\n",
       "    'Theoretical pI': '4.8',\n",
       "    'GO Classification': 'FunctionsATP binding / ATPase activity / calcium ion binding / chaperone binding / enzyme binding / glycoprotein binding / misfolded protein binding / protein domain specific binding / ribosome binding / ubiquitin protein ligase binding / unfolded protein bindingProcessesactivation of signaling protein activity involved in unfolded protein response / ATF6-mediated unfolded protein response / blood coagulation / cellular protein metabolic process / cellular response to antibiotic / cellular response to glucose starvation / cellular response to interleukin-4 / cerebellar Purkinje cell layer development / cerebellum structural organization / endoplasmic reticulum unfolded protein response / ER overload response / ER-associated ubiquitin-dependent protein catabolic process / IRE1-mediated unfolded protein response / maintenance of protein localization in endoplasmic reticulum / negative regulation of apoptotic process / negative regulation of protein homodimerization activity / negative regulation of transforming growth factor beta receptor signaling pathway / PERK-mediated unfolded protein response / platelet activation / platelet degranulation / positive regulation of cell migration / positive regulation of protein ubiquitination / positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress / protein folding in endoplasmic reticulum / regulation of ATF6-mediated unfolded protein response / regulation of IRE1-mediated unfolded protein response / regulation of PERK-mediated unfolded protein response / regulation of protein folding in endoplasmic reticulum / substantia nigra development / toxin transportComponentscell surface / endoplasmic reticulum / endoplasmic reticulum chaperone complex / endoplasmic reticulum lumen / endoplasmic reticulum membrane / endoplasmic reticulum-Golgi intermediate compartment / extracellular exosome / focal adhesion / integral component of endoplasmic reticulum membrane / melanosome / membrane / midbody / mitochondrion / myelin sheath / nucleus / plasma membrane / smooth endoplasmic reticulum',\n",
       "    'General Function': 'Unfolded protein binding',\n",
       "    'Specific Function': 'Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.',\n",
       "    'Pfam Domain Function': 'HSP70 (PF00012)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Endoplasmic reticulum lumen',\n",
       "    'Gene sequence': '>lcl|BSEQ0019063|78 kDa glucose-regulated protein (HSPA5)\\nATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG\\nGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCC\\nTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC\\nATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC\\nAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC\\nCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT\\nGAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT\\nGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT\\nTTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA\\nCGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC\\nGAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC\\nCTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT\\nGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG\\nCGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAA\\nGACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCT\\nTCTCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAG\\nACCCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAG\\nCCCGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTT\\nCTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAAT\\nGGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTC\\nCAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGT\\nCCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACTGATTCCAAGGAAC\\nACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACT\\nGTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGT\\nACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACC\\nTTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAAC\\nAAAAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGG\\nATGGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTCAAGGAGCGCATTGAT\\nACTAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAA\\nAAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAA\\nAAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAG\\nAAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCT\\nCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG',\n",
       "    'Chromosome Location': '9',\n",
       "    'Locus': '9q33-q34.1',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP11021UniProtKB Entry NameGRP78_HUMANGenBank Protein ID386758GenBank Gene IDM19645GenAtlas IDHSPA5HGNC IDHGNC:5238',\n",
       "    'General References': \"Ting J, Lee AS: Human gene encoding the 78,000-dalton glucose-regulated protein and its pseudogene: structure, conservation, and regulation. DNA. 1988 May;7(4):275-86. [Article] Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, Andrews TD, Searle S, Hunt SE, Scott CE, Jones MC, Ainscough R, Almeida JP, Ambrose KD, Ashwell RI, Babbage AK, Babbage S, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beasley H, Beasley O, Bird CP, Bray-Allen S, Brown AJ, Brown JY, Burford D, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Chen Y, Clarke G, Clark SY, Clee CM, Clegg S, Collier RE, Corby N, Crosier M, Cummings AT, Davies J, Dhami P, Dunn M, Dutta I, Dyer LW, Earthrowl ME, Faulkner L, Fleming CJ, Frankish A, Frankland JA, French L, Fricker DG, Garner P, Garnett J, Ghori J, Gilbert JG, Glison C, Grafham DV, Gribble S, Griffiths C, Griffiths-Jones S, Grocock R, Guy J, Hall RE, Hammond S, Harley JL, Harrison ES, Hart EA, Heath PD, Henderson CD, Hopkins BL, Howard PJ, Howden PJ, Huckle E, Johnson C, Johnson D, Joy AA, Kay M, Keenan S, Kershaw JK, Kimberley AM, King A, Knights A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd C, Lloyd DM, Lovell J, Martin S, Mashreghi-Mohammadi M, Matthews L, McLaren S, McLay KE, McMurray A, Milne S, Nickerson T, Nisbett J, Nordsiek G, Pearce AV, Peck AI, Porter KM, Pandian R, Pelan S, Phillimore B, Povey S, Ramsey Y, Rand V, Scharfe M, Sehra HK, Shownkeen R, Sims SK, Skuce CD, Smith M, Steward CA, Swarbreck D, Sycamore N, Tester J, Thorpe A, Tracey A, Tromans A, Thomas DW, Wall M, Wallis JM, West AP, Whitehead SL, Willey DL, Williams SA, Wilming L, Wray PW, Young L, Ashurst JL, Coulson A, Blocker H, Durbin R, Sulston JE, Hubbard T, Jackson MJ, Bentley DR, Beck S, Rogers J, Dunham I: DNA sequence and analysis of human chromosome 9. Nature. 2004 May 27;429(6990):369-74. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Chao CC, Lin-Chao S: A direct-repeat sequence of the human BiP gene is required for A23187-mediated inducibility and an inducible nuclear factor binding. Nucleic Acids Res. 1992 Dec 25;20(24):6481-5. [Article] Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE, van Eden W, van Der Zee R, Lanchbury JS, Panayi GS: The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol. 2001 Feb 1;166(3):1492-8. [Article] Rasmussen RK, Ji H, Eddes JS, Moritz RL, Reid GE, Simpson RJ, Dorow DS: Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2. Electrophoresis. 1997 Mar-Apr;18(3-4):588-98. [Article] Dana RC, Welch WJ, Deftos LJ: Heat shock proteins bind calcitonin. Endocrinology. 1990 Jan;126(1):672-4. [Article] Ji H, Reid GE, Moritz RL, Eddes JS, Burgess AW, Simpson RJ: A two-dimensional gel database of human colon carcinoma proteins. Electrophoresis. 1997 Mar-Apr;18(3-4):605-13. [Article] Cloutier P, Lavallee-Adam M, Faubert D, Blanchette M, Coulombe B: A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity. PLoS Genet. 2013;9(1):e1003210. doi: 10.1371/journal.pgen.1003210. Epub 2013 Jan 17. [Article] Meunier L, Usherwood YK, Chung KT, Hendershot LM: A subset of chaperones and folding enzymes form multiprotein complexes in endoplasmic reticulum to bind nascent proteins. Mol Biol Cell. 2002 Dec;13(12):4456-69. [Article] Purcell AW, Todd A, Kinoshita G, Lynch TA, Keech CL, Gething MJ, Gordon TP: Association of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity? Clin Exp Immunol. 2003 May;132(2):193-200. [Article] Cunnea PM, Miranda-Vizuete A, Bertoli G, Simmen T, Damdimopoulos AE, Hermann S, Leinonen S, Huikko MP, Gustafsson JA, Sitia R, Spyrou G: ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thioredoxin domains, is expressed in secretory cells or following ER stress. J Biol Chem. 2003 Jan 10;278(2):1059-66. Epub 2002 Oct 30. [Article] Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, Hearing VJ, Hunt DF, Appella E: Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res. 2003 Jan-Feb;2(1):69-79. [Article] Chi A, Valencia JC, Hu ZZ, Watabe H, Yamaguchi H, Mangini NJ, Huang H, Canfield VA, Cheng KC, Yang F, Abe R, Yamagishi S, Shabanowitz J, Hearing VJ, Wu C, Appella E, Hunt DF: Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res. 2006 Nov;5(11):3135-44. [Article] Hosokawa N, Wada I, Nagasawa K, Moriyama T, Okawa K, Nagata K: Human XTP3-B forms an endoplasmic reticulum quality control scaffold with the HRD1-SEL1L ubiquitin ligase complex and BiP. J Biol Chem. 2008 Jul 25;283(30):20914-24. doi: 10.1074/jbc.M709336200. Epub 2008 May 23. [Article] Christianson JC, Shaler TA, Tyler RE, Kopito RR: OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat Cell Biol. 2008 Mar;10(3):272-82. doi: 10.1038/ncb1689. Epub 2008 Feb 10. [Article] Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010 Jan 12;3(104):ra3. doi: 10.1126/scisignal.2000475. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Rosenow A, Noben JP, Jocken J, Kallendrusch S, Fischer-Posovszky P, Mariman EC, Renes J: Resveratrol-induced changes of the human adipocyte secretion profile. J Proteome Res. 2012 Sep 7;11(9):4733-43. doi: 10.1021/pr300539b. Epub 2012 Aug 27. [Article] Jakobsson ME, Moen A, Bousset L, Egge-Jacobsen W, Kernstock S, Melki R, Falnes PO: Identification and characterization of a novel human methyltransferase modulating Hsp70 protein function through lysine methylation. J Biol Chem. 2013 Sep 27;288(39):27752-63. doi: 10.1074/jbc.M113.483248. Epub 2013 Aug 6. [Article] Evensen NA, Kuscu C, Nguyen HL, Zarrabi K, Dufour A, Kadam P, Hu YJ, Pulkoski-Gross A, Bahou WF, Zucker S, Cao J: Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst. 2013 Sep 18;105(18):1402-16. doi: 10.1093/jnci/djt224. Epub 2013 Aug 29. [Article] Oka OB, Pringle MA, Schopp IM, Braakman I, Bulleid NJ: ERdj5 is the ER reductase that catalyzes the removal of non-native disulfides and correct folding of the LDL receptor. Mol Cell. 2013 Jun 27;50(6):793-804. doi: 10.1016/j.molcel.2013.05.014. Epub 2013 Jun 13. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Hendriks IA, D'Souza RC, Yang B, Verlaan-de Vries M, Mann M, Vertegaal AC: Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol. 2014 Oct;21(10):927-36. doi: 10.1038/nsmb.2890. Epub 2014 Sep 14. [Article] Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L, Bairoch A, Van Dorsselaer A, Carapito C: N-terminome analysis of the human mitochondrial proteome. Proteomics. 2015 Jul;15(14):2519-24. doi: 10.1002/pmic.201400617. Epub 2015 Jun 8. [Article] Wisniewska M, Karlberg T, Lehtio L, Johansson I, Kotenyova T, Moche M, Schuler H: Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78. PLoS One. 2010 Jan 11;5(1):e8625. doi: 10.1371/journal.pone.0008625. [Article] Macias AT, Williamson DS, Allen N, Borgognoni J, Clay A, Daniels Z, Dokurno P, Drysdale MJ, Francis GL, Graham CJ, Howes R, Matassova N, Murray JB, Parsons R, Shaw T, Surgenor AE, Terry L, Wang Y, Wood M, Massey AJ: Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity. J Med Chem. 2011 Jun 23;54(12):4034-41. doi: 10.1021/jm101625x. Epub 2011 May 20. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00025Antihemophilic factor, human recombinantapproved, investigationalunknownchaperoneDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorbinderDetailsDB09130Copperapproved, investigationalunknownDetailsDB13998Lonoctocog alfaapproved, investigationalunknownchaperoneDetailsDB13999Moroctocog alfaapprovedunknownchaperoneDetails'}},\n",
       "  {'Label': 'Ribosomal protein S6 kinase alpha-3',\n",
       "   'Detailed Info': {'Name': 'Ribosomal protein S6 kinase alpha-3',\n",
       "    'Synonyms': '2.7.11.1\\n90 kDa ribosomal protein S6 kinase 3\\nInsulin-stimulated protein kinase 1\\nISPK-1\\nISPK1\\nMAP kinase-activated protein kinase 1b\\nMAPK-activated protein kinase 1b\\nMAPKAP kinase 1b\\nMAPKAPK-1b\\nMAPKAPK1B\\np90-RSK 3\\np90RSK3\\npp90RSK2\\nRibosomal S6 kinase 2\\nRSK-2\\nRSK2\\nS6K-alpha-3',\n",
       "    'Gene Name': 'RPS6KA3',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0008668|Ribosomal protein S6 kinase alpha-3\\nMPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEINPQTEEVSIKEIAITHHVKEGH\\nEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERD\\nILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALA\\nLDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVV\\nNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLR\\nMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDPE\\nFTAKTPKDSPGIPPSANAHQLFRGFSFVAITSDDESQAMQTVGVHSIVQQLHRNSIQFTD\\nGYEVKEDIGVGSYSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLK\\nDVYDDGKYVYVVTELMKGGELLDKILRQKFFSEREASAVLFTITKTVEYLHAQGVVHRDL\\nKPSNILYVDESGNPESIRICDFGFAKQLRAENGLLMTPCYTANFVAPEVLKRQGYDAACD\\nIWSLGVLLYTMLTGYTPFANGPDDTPEEILARIGSGKFSLSGGYWNSVSDTAKDLVSKML\\nHVDPHQRLTAALVLRHPWIVHWDQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEP\\nVGRSTLAQRRGIKKITSTAL',\n",
       "    'Number of residues': '740',\n",
       "    'Molecular Weight': '83735.325',\n",
       "    'Theoretical pI': 'Not Available',\n",
       "    'GO Classification': 'FunctionsATP binding / cysteine-type endopeptidase inhibitor activity involved in apoptotic process / magnesium ion binding / protein kinase activity / protein serine/threonine kinase activity / ribosomal protein S6 kinase activityProcessesaxon guidance / cell cycle / central nervous system development / innate immune response / intracellular signal transduction / MyD88-dependent toll-like receptor signaling pathway / MyD88-independent toll-like receptor signaling pathway / negative regulation of apoptotic process / negative regulation of cysteine-type endopeptidase activity involved in apoptotic process / neurotrophin TRK receptor signaling pathway / positive regulation of cell differentiation / positive regulation of cell growth / positive regulation of transcription from RNA polymerase II promoter / protein phosphorylation / regulation of DNA-templated transcription in response to stress / regulation of translation in response to stress / response to lipopolysaccharide / signal transduction / skeletal system development / stress-activated MAPK cascade / synaptic transmission / toll-like receptor 10 signaling pathway / toll-like receptor 2 signaling pathway / toll-like receptor 3 signaling pathway / toll-like receptor 4 signaling pathway / toll-like receptor 5 signaling pathway / toll-like receptor 9 signaling pathway / toll-like receptor signaling pathway / toll-like receptor TLR1 / toll-like receptor TLR6 / TRIF-dependent toll-like receptor signaling pathwayComponentscytoplasm / cytosol / nucleoplasm',\n",
       "    'General Function': 'Ribosomal protein s6 kinase activity',\n",
       "    'Specific Function': \"Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1.\",\n",
       "    'Pfam Domain Function': 'Pkinase (PF00069)\\nPkinase_C (PF00433)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Nucleus',\n",
       "    'Gene sequence': '>lcl|BSEQ0013342|Ribosomal protein S6 kinase alpha-3 (RPS6KA3)\\nATGCCGCTGGCGCAGCTGGCGGACCCGTGGCAGAAGATGGCTGTGGAGAGCCCGTCCGAC\\nAGCGCTGAGAATGGACAGCAAATTATGGATGAACCTATGGGAGAGGAGGAGATTAACCCA\\nCAAACTGAAGAAGTCAGTATCAAAGAAATTGCAATCACACATCATGTAAAGGAAGGACAT\\nGAAAAGGCAGATCCTTCCCAGTTTGAACTTTTAAAAGTATTAGGGCAGGGATCATTTGGA\\nAAGGTTTTCTTAGTTAAAAAAATCTCAGGCTCTGATGCTAGGCAGCTTTATGCCATGAAG\\nGTATTGAAGAAGGCCACACTGAAAGTTCGAGACCGAGTTCGGACAAAAATGGAACGTGAT\\nATCTTGGTAGAGGTTAATCATCCTTTTATTGTCAAGTTGCATTATGCTTTTCAAACTGAA\\nGGGAAGTTGTATCTTATTTTGGATTTTCTCAGGGGAGGAGATTTGTTTACACGCTTATCC\\nAAAGAGGTGATGTTCACAGAAGAAGATGTCAAATTCTACTTGGCTGAACTTGCACTTGCT\\nTTAGACCATCTACATAGCCTGGGAATAATTTATAGAGACTTAAAACCAGAAAATATACTT\\nCTTGATGAAGAAGGTCACATCAAGTTAACAGATTTCGGCCTAAGTAAAGAGTCTATTGAC\\nCATGAAAAGAAGGCATATTCTTTTTGTGGAACTGTGGAGTATATGGCTCCAGAAGTAGTT\\nAATCGTCGAGGTCATACTCAGAGTGCTGACTGGTGGTCTTTTGGTGTGTTAATGTTTGAA\\nATGCTTACTGGTACACTCCCTTTCCAAGGAAAAGATCGAAAAGAAACAATGACTATGATT\\nCTTAAAGCCAAACTTGGAATGCCACAGTTTTTGAGTCCTGAAGCGCAGAGTCTTTTACGA\\nATGCTTTTCAAGCGAAATCCTGCAAACAGATTAGGTGCAGGACCAGATGGAGTTGAAGAA\\nATTAAAAGACATTCATTTTTCTCAACGATAGACTGGAATAAACTGTATAGAAGAGAAATT\\nCATCCGCCATTTAAACCTGCAACGGGCAGGCCTGAAGATACATTCTATTTTGATCCTGAG\\nTTTACTGCAAAAACTCCCAAAGATTCACCTGGCATTCCACCTAGTGCTAATGCACATCAG\\nCTTTTTCGGGGGTTTAGTTTTGTTGCTATTACCTCAGATGATGAAAGCCAAGCTATGCAG\\nACAGTTGGTGTACATTCAATTGTTCAGCAGTTACACAGGAACAGTATTCAGTTTACTGAT\\nGGATATGAAGTAAAAGAAGATATTGGAGTTGGCTCCTACTCTGTTTGCAAGAGATGTATA\\nCATAAAGCTACAAACATGGAGTTTGCAGTGAAGATTATTGATAAAAGCAAGAGAGACCCA\\nACAGAAGAAATTGAAATTCTTCTTCGTTATGGACAGCATCCAAACATTATCACTCTAAAG\\nGATGTATATGATGATGGAAAGTATGTGTATGTAGTAACAGAACTTATGAAAGGAGGTGAA\\nTTGCTGGATAAAATTCTTAGACAAAAATTTTTCTCTGAACGAGAGGCCAGTGCTGTCCTG\\nTTCACTATAACTAAAACCGTTGAATATCTTCACGCACAAGGGGTGGTTCATAGAGACTTG\\nAAACCTAGCAACATTCTTTATGTGGATGAATCTGGTAATCCGGAATCTATTCGAATTTGT\\nGATTTTGGCTTTGCAAAACAGCTGAGAGCGGAAAATGGTCTTCTCATGACTCCTTGTTAC\\nACTGCAAATTTTGTTGCACCAGAGGTTTTAAAAAGACAAGGCTATGATGCTGCTTGTGAT\\nATATGGAGTCTTGGTGTCCTACTCTATACAATGCTTACCGGTTACACTCCATTTGCAAAT\\nGGTCCTGATGATACACCAGAGGAAATATTGGCACGAATAGGTAGCGGAAAATTCTCACTC\\nAGTGGTGGTTACTGGAATTCTGTTTCAGACACAGCAAAGGACCTGGTGTCAAAGATGCTT\\nCATGTAGACCCTCATCAGAGACTGACTGCTGCTCTTGTGCTCAGACATCCTTGGATCGTC\\nCACTGGGACCAACTGCCACAATACCAACTAAACAGACAGGATGCACCACATCTAGTAAAG\\nGGTGCCATGGCAGCTACATATTCTGCTTTGAACCGTAATCAGTCACCAGTTTTGGAACCA\\nGTAGGCCGCTCTACTCTTGCTCAGCGGAGAGGTATTAAAAAAATCACCTCAACAGCCCTG\\nTGA',\n",
       "    'Chromosome Location': 'X',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP51812UniProtKB Entry NameKS6A3_HUMANHGNC IDHGNC:10432',\n",
       "    'General References': \"Bjorbaek C, Vik TA, Echwald SM, Yang PY, Vestergaard H, Wang JP, Webb GC, Richmond K, Hansen T, Erikson RL, et al.: Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients. Diabetes. 1995 Jan;44(1):90-7. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, Platzer M, Howell GR, Burrows C, Bird CP, Frankish A, Lovell FL, Howe KL, Ashurst JL, Fulton RS, Sudbrak R, Wen G, Jones MC, Hurles ME, Andrews TD, Scott CE, Searle S, Ramser J, Whittaker A, Deadman R, Carter NP, Hunt SE, Chen R, Cree A, Gunaratne P, Havlak P, Hodgson A, Metzker ML, Richards S, Scott G, Steffen D, Sodergren E, Wheeler DA, Worley KC, Ainscough R, Ambrose KD, Ansari-Lari MA, Aradhya S, Ashwell RI, Babbage AK, Bagguley CL, Ballabio A, Banerjee R, Barker GE, Barlow KF, Barrett IP, Bates KN, Beare DM, Beasley H, Beasley O, Beck A, Bethel G, Blechschmidt K, Brady N, Bray-Allen S, Bridgeman AM, Brown AJ, Brown MJ, Bonnin D, Bruford EA, Buhay C, Burch P, Burford D, Burgess J, Burrill W, Burton J, Bye JM, Carder C, Carrel L, Chako J, Chapman JC, Chavez D, Chen E, Chen G, Chen Y, Chen Z, Chinault C, Ciccodicola A, Clark SY, Clarke G, Clee CM, Clegg S, Clerc-Blankenburg K, Clifford K, Cobley V, Cole CG, Conquer JS, Corby N, Connor RE, David R, Davies J, Davis C, Davis J, Delgado O, Deshazo D, Dhami P, Ding Y, Dinh H, Dodsworth S, Draper H, Dugan-Rocha S, Dunham A, Dunn M, Durbin KJ, Dutta I, Eades T, Ellwood M, Emery-Cohen A, Errington H, Evans KL, Faulkner L, Francis F, Frankland J, Fraser AE, Galgoczy P, Gilbert J, Gill R, Glockner G, Gregory SG, Gribble S, Griffiths C, Grocock R, Gu Y, Gwilliam R, Hamilton C, Hart EA, Hawes A, Heath PD, Heitmann K, Hennig S, Hernandez J, Hinzmann B, Ho S, Hoffs M, Howden PJ, Huckle EJ, Hume J, Hunt PJ, Hunt AR, Isherwood J, Jacob L, Johnson D, Jones S, de Jong PJ, Joseph SS, Keenan S, Kelly S, Kershaw JK, Khan Z, Kioschis P, Klages S, Knights AJ, Kosiura A, Kovar-Smith C, Laird GK, Langford C, Lawlor S, Leversha M, Lewis L, Liu W, Lloyd C, Lloyd DM, Loulseged H, Loveland JE, Lovell JD, Lozado R, Lu J, Lyne R, Ma J, Maheshwari M, Matthews LH, McDowall J, McLaren S, McMurray A, Meidl P, Meitinger T, Milne S, Miner G, Mistry SL, Morgan M, Morris S, Muller I, Mullikin JC, Nguyen N, Nordsiek G, Nyakatura G, O'Dell CN, Okwuonu G, Palmer S, Pandian R, Parker D, Parrish J, Pasternak S, Patel D, Pearce AV, Pearson DM, Pelan SE, Perez L, Porter KM, Ramsey Y, Reichwald K, Rhodes S, Ridler KA, Schlessinger D, Schueler MG, Sehra HK, Shaw-Smith C, Shen H, Sheridan EM, Shownkeen R, Skuce CD, Smith ML, Sotheran EC, Steingruber HE, Steward CA, Storey R, Swann RM, Swarbreck D, Tabor PE, Taudien S, Taylor T, Teague B, Thomas K, Thorpe A, Timms K, Tracey A, Trevanion S, Tromans AC, d'Urso M, Verduzco D, Villasana D, Waldron L, Wall M, Wang Q, Warren J, Warry GL, Wei X, West A, Whitehead SL, Whiteley MN, Wilkinson JE, Willey DL, Williams G, Williams L, Williamson A, Williamson H, Wilming L, Woodmansey RL, Wray PW, Yen J, Zhang J, Zhou J, Zoghbi H, Zorilla S, Buck D, Reinhardt R, Poustka A, Rosenthal A, Lehrach H, Meindl A, Minx PJ, Hillier LW, Willard HF, Wilson RK, Waterston RH, Rice CM, Vaudin M, Coulson A, Nelson DL, Weinstock G, Sulston JE, Durbin R, Hubbard T, Gibbs RA, Beck S, Rogers J, Bentley DR: The DNA sequence of the human X chromosome. Nature. 2005 Mar 17;434(7031):325-37. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Moller DE, Xia CH, Tang W, Zhu AX, Jakubowski M: Human rsk isoforms: cloning and characterization of tissue-specific expression. Am J Physiol. 1994 Feb;266(2 Pt 1):C351-9. [Article] Kitano T, Schwarz C, Nickel B, Paabo S: Gene diversity patterns at 10 X-chromosomal loci in humans and chimpanzees. Mol Biol Evol. 2003 Aug;20(8):1281-9. Epub 2003 May 30. [Article] Sutherland C, Leighton IA, Cohen P: Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J. 1993 Nov 15;296 ( Pt 1):15-9. [Article] De Cesare D, Jacquot S, Hanauer A, Sassone-Corsi P: Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12202-7. [Article] Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L, Jacquot S, Hanauer A, Allis CD: Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science. 1999 Aug 6;285(5429):886-91. [Article] Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J: The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol. 2005 Oct 11;15(19):1762-7. [Article] Wingate AD, Campbell DG, Peggie M, Arthur JS: Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J. 2006 Feb 1;393(Pt 3):715-24. [Article] Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10. [Article] Cho YY, Yao K, Bode AM, Bergen HR 3rd, Madden BJ, Oh SM, Ermakova S, Kang BS, Choi HS, Shim JH, Dong Z: RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem. 2007 Mar 16;282(11):8380-92. Epub 2007 Jan 9. [Article] Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J: RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007 May 11;282(19):14056-64. Epub 2007 Mar 14. [Article] Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP: Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol. 2008 Sep 9;18(17):1269-77. doi: 10.1016/j.cub.2008.07.078. Epub 2008 Aug 21. [Article] Carriere A, Ray H, Blenis J, Roux PP: The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci. 2008 May 1;13:4258-75. [Article] Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48. doi: 10.1016/j.molcel.2008.07.007. [Article] Anjum R, Blenis J: The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008 Oct;9(10):747-58. doi: 10.1038/nrm2509. [Article] Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. doi: 10.1073/pnas.0805139105. Epub 2008 Jul 31. [Article] Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H: Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics. 2009 Jul;8(7):1751-64. doi: 10.1074/mcp.M800588-MCP200. Epub 2009 Apr 15. [Article] Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46. doi: 10.1126/scisignal.2000007. [Article] Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010 Jan 12;3(104):ra3. doi: 10.1126/scisignal.2000475. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, Kassem M, Mann M, Olsen JV, Blagoev B: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal. 2011 Mar 15;4(164):rs3. doi: 10.1126/scisignal.2001570. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Trivier E, De Cesare D, Jacquot S, Pannetier S, Zackai E, Young I, Mandel JL, Sassone-Corsi P, Hanauer A: Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature. 1996 Dec 12;384(6609):567-70. [Article] Jacquot S, Merienne K, De Cesare D, Pannetier S, Mandel JL, Sassone-Corsi P, Hanauer A: Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic heterogeneity and a high rate of de novo mutations. Am J Hum Genet. 1998 Dec;63(6):1631-40. [Article] Abidi F, Jacquot S, Lassiter C, Trivier E, Hanauer A, Schwartz CE: Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS). Eur J Hum Genet. 1999 Jan;7(1):20-6. [Article] Manouvrier-Hanu S, Amiel J, Jacquot S, Merienne K, Moerman A, Coeslier A, Labarriere F, Vallee L, Croquette MF, Hanauer A: Unreported RSK2 missense mutation in two male sibs with an unusually mild form of Coffin-Lowry syndrome. J Med Genet. 1999 Oct;36(10):775-8. [Article] Merienne K, Jacquot S, Pannetier S, Zeniou M, Bankier A, Gecz J, Mandel JL, Mulley J, Sassone-Corsi P, Hanauer A: A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental retardation. Nat Genet. 1999 May;22(1):13-4. [Article] Martinez-Garay I, Ballesta MJ, Oltra S, Orellana C, Palomeque A, Molto MD, Prieto F, Martinez F: Intronic L1 insertion and F268S, novel mutations in RPS6KA3 (RSK2) causing Coffin-Lowry syndrome. Clin Genet. 2003 Dec;64(6):491-6. [Article] Facher JJ, Regier EJ, Jacobs GH, Siwik E, Delaunoy JP, Robin NH: Cardiomyopathy in Coffin-Lowry syndrome. Am J Med Genet A. 2004 Jul 15;128A(2):176-8. [Article] Field M, Tarpey P, Boyle J, Edkins S, Goodship J, Luo Y, Moon J, Teague J, Stratton MR, Futreal PA, Wooster R, Raymond FL, Turner G: Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and nonsyndromic X-linked mental retardation. Clin Genet. 2006 Dec;70(6):509-15. [Article] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article] Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature. 2007 Mar 8;446(7132):153-8. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB12010Fostamatinibapproved, investigationalunknowninhibitorDetails'}},\n",
       "  {'Label': 'NF-kappa-B inhibitor alpha',\n",
       "   'Detailed Info': {'Name': 'NF-kappa-B inhibitor alpha',\n",
       "    'Synonyms': 'I-kappa-B-alpha\\nIkappaBalpha\\nIkB-alpha\\nIKBA\\nMAD3\\nMajor histocompatibility complex enhancer-binding protein MAD3\\nNFKBI',\n",
       "    'Gene Name': 'NFKBIA',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0021363|NF-kappa-B inhibitor alpha\\nMFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVP\\nRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVI\\nTNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATN\\nYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCG\\nADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTE\\nDELPYDDCVFGGQRLTL',\n",
       "    'Number of residues': '317',\n",
       "    'Molecular Weight': '35608.65',\n",
       "    'Theoretical pI': '4.31',\n",
       "    'GO Classification': 'Functionsenzyme binding / identical protein binding / NF-kappaB binding / nuclear localization sequence binding / transcription factor binding / ubiquitin protein ligase bindingProcessesapoptotic process / cellular response to cold / cytoplasmic sequestering of NF-kappaB / cytoplasmic sequestering of transcription factor / Fc-epsilon receptor signaling pathway / innate immune response / lipopolysaccharide-mediated signaling pathway / MyD88-dependent toll-like receptor signaling pathway / MyD88-independent toll-like receptor signaling pathway / negative regulation of apoptotic process / negative regulation of DNA binding / negative regulation of lipid storage / negative regulation of macrophage derived foam cell differentiation / negative regulation of myeloid cell differentiation / negative regulation of NF-kappaB transcription factor activity / negative regulation of Notch signaling pathway / neurotrophin TRK receptor signaling pathway / nucleotide-binding oligomerization domain containing 1 signaling pathway / nucleotide-binding oligomerization domain containing 2 signaling pathway / positive regulation of cellular protein metabolic process / positive regulation of cholesterol efflux / positive regulation of NF-kappaB transcription factor activity / positive regulation of transcription from RNA polymerase II promoter / positive regulation of type I interferon production / protein import into nucleus, translocation / regulation of cell proliferation / regulation of NF-kappaB import into nucleus / response to exogenous dsRNA / response to muramyl dipeptide / response to muscle stretch / stimulatory C-type lectin receptor signaling pathway / T cell receptor signaling pathway / toll-like receptor 10 signaling pathway / toll-like receptor 2 signaling pathway / toll-like receptor 3 signaling pathway / toll-like receptor 4 signaling pathway / toll-like receptor 5 signaling pathway / toll-like receptor 9 signaling pathway / toll-like receptor signaling pathway / toll-like receptor TLR1 / toll-like receptor TLR6 / TRIF-dependent toll-like receptor signaling pathway / viral processComponentscytoplasm / cytosol / I-kappaB/NF-kappaB complex / nucleus / plasma membrane',\n",
       "    'General Function': 'Ubiquitin protein ligase binding',\n",
       "    'Specific Function': 'Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.',\n",
       "    'Pfam Domain Function': 'Ank_2 (PF12796)\\nAnk_3 (PF13606)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0021364|NF-kappa-B inhibitor alpha (NFKBIA)\\nATGTTCCAGGCGGCCGAGCGCCCCCAGGAGTGGGCCATGGAGGGCCCCCGCGACGGGCTG\\nAAGAAGGAGCGGCTACTGGACGACCGCCACGACAGCGGCCTGGACTCCATGAAAGACGAG\\nGAGTACGAGCAGATGGTCAAGGAGCTGCAGGAGATCCGCCTCGAGCCGCAGGAGGTGCCG\\nCGCGGCTCGGAGCCCTGGAAGCAGCAGCTCACCGAGGACGGGGACTCGTTCCTGCACTTG\\nGCCATCATCCATGAAGAAAAGGCACTGACCATGGAAGTGATCCGCCAGGTGAAGGGAGAC\\nCTGGCCTTCCTCAACTTCCAGAACAACCTGCAGCAGACTCCACTCCACTTGGCTGTGATC\\nACCAACCAGCCAGAAATTGCTGAGGCACTTCTGGGAGCTGGCTGTGATCCTGAGCTCCGA\\nGACTTTCGAGGAAATACCCCCCTACACCTTGCCTGTGAGCAGGGCTGCCTGGCCAGCGTG\\nGGAGTCCTGACTCAGTCCTGCACCACCCCGCACCTCCACTCCATCCTGAAGGCTACCAAC\\nTACAATGGCCACACGTGTCTACACTTAGCCTCTATCCATGGCTACCTGGGCATCGTGGAG\\nCTTTTGGTGTCCTTGGGTGCTGATGTCAATGCTCAGGAGCCCTGTAATGGCCGGACTGCC\\nCTTCACCTCGCAGTGGACCTGCAAAATCCTGACCTGGTGTCACTCCTGTTGAAGTGTGGG\\nGCTGATGTCAACAGAGTTACCTACCAGGGCTATTCTCCCTACCAGCTCACCTGGGGCCGC\\nCCAAGCACCCGGATACAGCAGCAGCTGGGCCAGCTGACACTAGAAAACCTTCAGATGCTG\\nCCAGAGAGTGAGGATGAGGAGAGCTATGACACAGAGTCAGAGTTCACGGAGTTCACAGAG\\nGACGAGCTGCCCTATGATGACTGTGTGTTTGGAGGCCAGCGTCTGACGTTATGA',\n",
       "    'Chromosome Location': '14',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP25963UniProtKB Entry NameIKBA_HUMANGenBank Gene IDBC004983GenAtlas IDNFKBIAHGNC IDHGNC:7797',\n",
       "    'General References': \"Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD, Sampson-Johannes A, Mondal K, Ralph P, Baldwin AS Jr: Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell. 1991 Jun 28;65(7):1281-9. [Article] Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K, Kuppers R: Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000 Jan 17;191(2):395-402. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M, Barbe V, de Berardinis V, Ureta-Vidal A, Pelletier E, Vico V, Anthouard V, Rowen L, Madan A, Qin S, Sun H, Du H, Pepin K, Artiguenave F, Robert C, Cruaud C, Bruls T, Jaillon O, Friedlander L, Samson G, Brottier P, Cure S, Segurens B, Aniere F, Samain S, Crespeau H, Abbasi N, Aiach N, Boscus D, Dickhoff R, Dors M, Dubois I, Friedman C, Gouyvenoux M, James R, Madan A, Mairey-Estrada B, Mangenot S, Martins N, Menard M, Oztas S, Ratcliffe A, Shaffer T, Trask B, Vacherie B, Bellemere C, Belser C, Besnard-Gonnet M, Bartol-Mavel D, Boutard M, Briez-Silla S, Combette S, Dufosse-Laurent V, Ferron C, Lechaplais C, Louesse C, Muselet D, Magdelenat G, Pateau E, Petit E, Sirvain-Trukniewicz P, Trybou A, Vega-Czarny N, Bataille E, Bluet E, Bordelais I, Dubois M, Dumont C, Guerin T, Haffray S, Hammadi R, Muanga J, Pellouin V, Robert D, Wunderle E, Gauguet G, Roy A, Sainte-Marthe L, Verdier J, Verdier-Discala C, Hillier L, Fulton L, McPherson J, Matsuda F, Wilson R, Scarpelli C, Gyapay G, Wincker P, Saurin W, Quetier F, Waterston R, Hood L, Weissenbach J: The DNA sequence and analysis of human chromosome 14. Nature. 2003 Feb 6;421(6923):601-7. Epub 2003 Jan 1. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Ganchi PA, Sun SC, Greene WC, Ballard DW: I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol Cell. 1992 Dec;3(12):1339-52. [Article] Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW: Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11259-63. [Article] Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF: Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell. 1996 Sep 6;86(5):787-98. [Article] McElhinny JA, Trushin SA, Bren GD, Chester N, Paya CV: Casein kinase II phosphorylates I kappa B alpha at S-283, S-289, S-293, and T-291 and is required for its degradation. Mol Cell Biol. 1996 Mar;16(3):899-906. [Article] DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M: Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 1996 Apr;16(4):1295-304. [Article] Lin R, Beauparlant P, Makris C, Meloche S, Hiscott J: Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Mol Cell Biol. 1996 Apr;16(4):1401-9. [Article] Sachdev S, Hoffmann A, Hannink M: Nuclear localization of IkappaB alpha is mediated by the second ankyrin repeat: the IkappaB alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences. Mol Cell Biol. 1998 May;18(5):2524-34. [Article] Vuillard L, Nicholson J, Hay RT: A complex containing betaTrCP recruits Cdc34 to catalyse ubiquitination of IkappaBalpha. FEBS Lett. 1999 Jul 23;455(3):311-4. [Article] Gonen H, Bercovich B, Orian A, Carrano A, Takizawa C, Yamanaka K, Pagano M, Iwai K, Ciechanover A: Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha. J Biol Chem. 1999 May 21;274(21):14823-30. [Article] Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C, Brechot C, Israel A: Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol. 1999 Sep;19(9):6345-54. [Article] Peters RT, Liao SM, Maniatis T: IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell. 2000 Mar;5(3):513-22. [Article] Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, Kaneko Y, Nimura Y, Motoyama N, Ikeda K, Karin M, Nakanishi M: NAK is an IkappaB kinase-activating kinase. Nature. 2000 Apr 13;404(6779):778-82. [Article] Fenwick C, Na SY, Voll RE, Zhong H, Im SY, Lee JW, Ghosh S: A subclass of Ras proteins that regulate the degradation of IkappaB. Science. 2000 Feb 4;287(5454):869-73. [Article] Huang TT, Kudo N, Yoshida M, Miyamoto S: A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1014-9. [Article] Rodriguez MS, Dargemont C, Hay RT: SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001 Apr 20;276(16):12654-9. Epub 2000 Dec 21. [Article] Gambaryan S, Kobsar A, Rukoyatkina N, Herterich S, Geiger J, Smolenski A, Lohmann SM, Walter U: Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem. 2010 Jun 11;285(24):18352-63. doi: 10.1074/jbc.M109.077602. Epub 2010 Mar 31. [Article] Ganesh L, Yoshimoto T, Moorthy NC, Akahata W, Boehm M, Nabel EG, Nabel GJ: Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis. Mol Cell Biol. 2006 May;26(10):3864-74. [Article] Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, Pugh CW, Oldham NJ, Masson N, Schofield CJ, Ratcliffe PJ: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14767-72. Epub 2006 Sep 26. [Article] Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F, Arzt E: RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007 Oct 19;131(2):309-23. [Article] Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL, Gumucio DL, Shoham NG, Kastner DL: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008 Sep 1;112(5):1794-803. doi: 10.1182/blood-2008-01-134932. Epub 2008 Jun 24. [Article] Wu K, Kovacev J, Pan ZQ: Priming and extending: a UbcH5/Cdc34 E2 handoff mechanism for polyubiquitination on a SCF substrate. Mol Cell. 2010 Mar 26;37(6):784-96. doi: 10.1016/j.molcel.2010.02.025. [Article] Sun Z, Chen Z, Lawson SR, Fang Y: The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism functions. J Virol. 2010 Aug;84(15):7832-46. doi: 10.1128/JVI.00217-10. Epub 2010 May 26. [Article] Gerez J, Fuertes M, Tedesco L, Silberstein S, Sevlever G, Paez-Pereda M, Holsboer F, Turjanski AG, Arzt E: In silico structural and functional characterization of the RSUME splice variants. PLoS One. 2013;8(2):e57795. doi: 10.1371/journal.pone.0057795. Epub 2013 Feb 28. [Article] Jacobs MD, Harrison SC: Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998 Dec 11;95(6):749-58. [Article] Huxford T, Huang DB, Malek S, Ghosh G: The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell. 1998 Dec 11;95(6):759-70. [Article] Courtois G, Smahi A, Reichenbach J, Doffinger R, Cancrini C, Bonnet M, Puel A, Chable-Bessia C, Yamaoka S, Feinberg J, Dupuis-Girod S, Bodemer C, Livadiotti S, Novelli F, Rossi P, Fischer A, Israel A, Munnich A, Le Deist F, Casanova JL: A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest. 2003 Oct;112(7):1108-15. [Article] Lopez-Granados E, Keenan JE, Kinney MC, Leo H, Jain N, Ma CA, Quinones R, Gelfand EW, Jain A: A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency. Hum Mutat. 2008 Jun;29(6):861-8. doi: 10.1002/humu.20740. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB05983Bardoxolone methylinvestigationalunknownDetailsDB06543AstaxanthininvestigationalunknownDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetails'}},\n",
       "  {'Label': 'Tumor necrosis factor-inducible gene 6 protein',\n",
       "   'Detailed Info': {'Name': 'Tumor necrosis factor-inducible gene 6 protein',\n",
       "    'Synonyms': 'Hyaluronate-binding protein\\nTNF alpha-induced protein 6\\nTNF-stimulated gene 6 protein\\nTSG-6\\nTSG6\\nTumor necrosis factor alpha-induced protein 6',\n",
       "    'Gene Name': 'TNFAIP6',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0017573|Tumor necrosis factor-inducible gene 6 protein\\nMIILIYLFLLLWEDTQGWGFKDGIFHNSIWLERAAGVYHREARSGKYKLTYAEAKAVCEF\\nEGGHLATYKQLEAARKIGFHVCAAGWMAKGRVGYPIVKPGPNCGFGKTGIIDYGIRLNRS\\nERWDAYCYNPHAKECGGVFTDPKQIFKSPGFPNEYEDNQICYWHIRLKYGQRIHLSFLDF\\nDLEDDPGCLADYVEIYDSYDDVHGFVGRYCGDELPDDIISTGNVMTLKFLSDASVTAGGF\\nQIKYVAMDPVSKSSQGKNTSTTSTGNKNFLAGRFSHL',\n",
       "    'Number of residues': '277',\n",
       "    'Molecular Weight': '31203.09',\n",
       "    'Theoretical pI': 'Not Available',\n",
       "    'GO Classification': 'Functionshyaluronic acid bindingProcessescell adhesion / cell-cell signaling / inflammatory response / negative regulation of inflammatory response / signal transduction',\n",
       "    'General Function': 'Hyaluronic acid binding',\n",
       "    'Specific Function': 'Possibly involved in cell-cell and cell-matrix interactions during inflammation and tumorigenesis.',\n",
       "    'Pfam Domain Function': 'CUB (PF00431)\\nXlink (PF00193)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Not Available',\n",
       "    'Gene sequence': '>lcl|BSEQ0017574|Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)\\nATGATCATCTTAATTTACTTATTTCTCTTGCTATGGGAAGACACTCAAGGATGGGGATTC\\nAAGGATGGAATTTTTCATAACTCCATATGGCTTGAACGAGCAGCCGGTGTGTACCACAGA\\nGAAGCACGGTCTGGCAAATACAAGCTCACCTACGCAGAAGCTAAGGCGGTGTGTGAATTT\\nGAAGGCGGCCATCTCGCAACTTACAAGCAGCTAGAGGCAGCCAGAAAAATTGGATTTCAT\\nGTCTGTGCTGCTGGATGGATGGCTAAGGGCAGAGTTGGATACCCCATTGTGAAGCCAGGG\\nCCCAACTGTGGATTTGGAAAAACTGGCATTATTGATTATGGAATCCGTCTCAATAGGAGT\\nGAAAGATGGGATGCCTATTGCTACAACCCACACGCAAAGGAGTGTGGTGGCGTCTTTACA\\nGATCCAAAGCAAATTTTTAAATCTCCAGGCTTCCCAAATGAGTACGAAGATAACCAAATC\\nTGCTACTGGCACATTAGACTCAAGTATGGTCAGCGTATTCACCTGAGTTTTTTAGATTTT\\nGACCTTGAAGATGACCCAGGTTGCTTGGCTGATTATGTTGAAATATATGACAGTTACGAT\\nGATGTCCATGGCTTTGTGGGAAGATACTGTGGAGATGAGCTTCCAGATGACATCATCAGT\\nACAGGAAATGTCATGACCTTGAAGTTTCTAAGTGATGCTTCAGTGACAGCTGGAGGTTTC\\nCAAATCAAATATGTTGCAATGGATCCTGTATCCAAATCCAGTCAAGGAAAAAATACAAGT\\nACTACTTCTACTGGAAATAAAAACTTTTTAGCTGGAAGATTTAGCCACTTATAA',\n",
       "    'Chromosome Location': '2',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP98066UniProtKB Entry NameTSG6_HUMANHGNC IDHGNC:11898',\n",
       "    'General References': 'Lee TH, Wisniewski HG, Vilcek J: A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol. 1992 Jan;116(2):545-57. [Article] Nentwich HA, Mustafa Z, Rugg MS, Marsden BD, Cordell MR, Mahoney DJ, Jenkins SC, Dowling B, Fries E, Milner CM, Loughlin J, Day AJ: A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module. Chromosomal localization, frequency analysis, modeling, and expression. J Biol Chem. 2002 May 3;277(18):15354-62. Epub 2002 Feb 19. [Article] Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Wisniewski HG, Burgess WH, Oppenheim JD, Vilcek J: TSG-6, an arthritis-associated hyaluronan binding protein, forms a stable complex with the serum protein inter-alpha-inhibitor. Biochemistry. 1994 Jun 14;33(23):7423-9. [Article] Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki FM, Campbell ID, Day AJ: Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell. 1996 Sep 6;86(5):767-75. [Article]',\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB08818Hyaluronic acidapproved, vet_approvedunknownbinderDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitordownregulatorDetailsDB00843DonepezilapprovedunknowninhibitorDetails'}},\n",
       "  {'Label': 'Caspase-1',\n",
       "   'Detailed Info': {'Name': 'Caspase-1',\n",
       "    'Synonyms': '3.4.22.36\\nCASP-1\\nICE\\nIL-1 beta-converting enzyme\\nIL-1BC\\nIL1BC\\nIL1BCE\\nInterleukin-1 beta convertase\\nInterleukin-1 beta-converting enzyme\\np45',\n",
       "    'Gene Name': 'CASP1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0000885|Caspase-1\\nMADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDS\\nVIPKGAQACQICITYICEEDSYLAGTLGLSADQTSGNYLNMQDSQGVLSSFPAPQAVQDN\\nPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRT\\nGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIR\\nEGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKDSVG\\nVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEY\\nACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH',\n",
       "    'Number of residues': '404',\n",
       "    'Molecular Weight': '45158.215',\n",
       "    'Theoretical pI': '5.71',\n",
       "    'GO Classification': 'Functionscysteine-type endopeptidase activator activity involved in apoptotic process / cysteine-type endopeptidase activity / endopeptidase activityProcessesactivation of cysteine-type endopeptidase activity involved in apoptotic process / apoptotic process / cellular response to mechanical stimulus / cellular response to organic substance / innate immune response / interleukin-1 beta production / membrane hyperpolarization / mitochondrial depolarization / nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway / positive regulation of I-kappaB kinase/NF-kappaB signaling / positive regulation of interleukin-1 alpha secretion / positive regulation of interleukin-1 beta secretion / programmed necrotic cell death / proteolysis / pyroptosis / regulation of autophagy / regulation of inflammatory response / response to ATP / response to hypoxia / response to lipopolysaccharide / signal transduction / toxin transportComponentsAIM2 inflammasome complex / cytoplasm / cytosol / extracellular region / IPAF inflammasome complex / mitochondrion / NLRP1 inflammasome complex / NLRP3 inflammasome complex',\n",
       "    'General Function': 'Endopeptidase activity',\n",
       "    'Specific Function': 'Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis.',\n",
       "    'Pfam Domain Function': 'CARD (PF00619)\\nPeptidase_C14 (PF00656)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0020459|Caspase-1 (CASP1)\\nATGGCCGACAAGGTCCTGAAGGAGAAGAGAAAGCTGTTTATCCGTTCCATGGGTGAAGGT\\nACAATAAATGGCTTACTGGATGAATTATTACAGACAAGGGTGCTGAACAAGGAAGAGATG\\nGAGAAAGTAAAACGTGAAAATGCTACAGTTATGGATAAGACCCGAGCTTTGATTGACTCC\\nGTTATTCCGAAAGGGGCACAGGCATGCCAAATTTGCATCACATACATTTGTGAAGAAGAC\\nAGTTACCTGGCAGGGACGCTGGGACTCTCAGCAGCTCCTCAGGCAGTGCAGGACAACCCA\\nGCTATGCCCACATCCTCAGGCTCAGAAGGGAATGTCAAGCTTTGCTCCCTAGAAGAAGCT\\nCAAAGGATATGGAAACAAAAGTCGGCAGAGATTTATCCAATAATGGACAAGTCAAGCCGC\\nACACGTCTTGCTCTCATTATCTGCAATGAAGAATTTGACAGTATTCCTAGAAGAACTGGA\\nGCTGAGGTTGACATCACAGGCATGACAATGCTGCTACAAAATCTGGGGTACAGCGTAGAT\\nGTGAAAAAAAATCTCACTGCTTCGGACATGACTACAGAGCTGGAGGCATTTGCACACCGC\\nCCAGAGCACAAGACCTCTGACAGCACGTTCCTGGTGTTCATGTCTCATGGTATTCGGGAA\\nGGCATTTGTGGGAAGAAACACTCTGAGCAAGTCCCAGATATACTACAACTCAATGCAATC\\nTTTAACATGTTGAATACCAAGAACTGCCCAAGTTTGAAGGACAAACCGAAGGTGATCATC\\nATCCAGGCCTGCCGTGGTGACAGCCCTGGTGTGGTGTGGTTTAAAGATTCAGTAGGAGTT\\nTCTGGAAACCTATCTTTACCAACTACAGAAGAGTTTGAGGATGATGCTATTAAGAAAGCC\\nCACATAGAGAAGGATTTTATCGCTTTCTGCTCTTCCACACCAGATAATGTTTCTTGGAGA\\nCATCCCACAATGGGCTCTGTTTTTATTGGAAGACTCATTGAACATATGCAAGAATATGCC\\nTGTTCCTGTGATGTGGAGGAAATTTTCCGCAAGGTTCGATTTTCATTTGAGCAGCCAGAT\\nGGTAGAGCGCAGATGCCCACCACTGAAAGAGTGACTTTGACAAGATGTTTCTACCTCTTC\\nCCAGGACATTAA',\n",
       "    'Chromosome Location': '11',\n",
       "    'Locus': '11q23',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP29466UniProtKB Entry NameCASP1_HUMANGenBank Protein ID33793GenBank Gene IDX65019GenAtlas IDCASP1HGNC IDHGNC:1499',\n",
       "    'General References': \"Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al.: A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356(6372):768-74. [Article] Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, et al.: Molecular cloning of the interleukin-1 beta converting enzyme. Science. 1992 Apr 3;256(5053):97-100. [Article] Alnemri ES, Fernandes-Alnemri T, Litwack G: Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities. J Biol Chem. 1995 Mar 3;270(9):4312-7. [Article] Taylor TD, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, Dewar K, Lloyd C, Itoh T, Takeda T, Kim DW, She X, Barlow KF, Bloom T, Bruford E, Chang JL, Cuomo CA, Eichler E, FitzGerald MG, Jaffe DB, LaButti K, Nicol R, Park HS, Seaman C, Sougnez C, Yang X, Zimmer AR, Zody MC, Birren BW, Nusbaum C, Fujiyama A, Hattori M, Rogers J, Lander ES, Sakaki Y: Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006 Mar 23;440(7083):497-500. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Feng Q, Li P, Leung PC, Auersperg N: Caspase-1zeta, a new splice variant of the caspase-1 gene. Genomics. 2004 Sep;84(3):587-91. [Article] Kronheim SR, Mumma A, Greenstreet T, Glackin PJ, Van Ness K, March CJ, Black RA: Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor. Arch Biochem Biophys. 1992 Aug 1;296(2):698-703. [Article] Humke EW, Shriver SK, Starovasnik MA, Fairbrother WJ, Dixit VM: ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell. 2000 Sep 29;103(1):99-111. [Article] Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004 Mar;20(3):319-25. [Article] Lamkanfi M, Denecker G, Kalai M, D'hondt K, Meeus A, Declercq W, Saelens X, Vandenabeele P: INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem. 2004 Dec 10;279(50):51729-38. Epub 2004 Sep 21. [Article] Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7. Epub 2006 Jun 19. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Walker NP, Talanian RV, Brady KD, Dang LC, Bump NJ, Ferenz CR, Franklin S, Ghayur T, Hackett MC, Hammill LD, et al.: Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer. Cell. 1994 Jul 29;78(2):343-52. [Article] Rano TA, Timkey T, Peterson EP, Rotonda J, Nicholson DW, Becker JW, Chapman KT, Thornberry NA: A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). Chem Biol. 1997 Feb;4(2):149-55. [Article] Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y, Takeuchi M, Shibanuma T, Isomura Y: Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex. Chem Pharm Bull (Tokyo). 1999 Jan;47(1):11-21. [Article] Romanowski MJ, Scheer JM, O'Brien T, McDowell RS: Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding. Structure. 2004 Aug;12(8):1361-71. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB01017Minocyclineapproved, investigationalunknownnegative modulatorDetailsDB04875PralnacasaninvestigationalunknownDetailsDB05301LAX-101investigationalunknownDetailsDB05408EmricasaninvestigationalunknownDetailsDB05507VX-765investigationalunknownDetailsDB077331-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDEexperimentalunknownDetailsDB07744Z-Val-Ala-Asp fluoromethyl ketoneexperimentalunknownDetailsDB079163-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACIDexperimentalunknownDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitordownregulatorDetails'}},\n",
       "  {'Label': 'Caspase-3',\n",
       "   'Detailed Info': {'Name': 'Caspase-3',\n",
       "    'Synonyms': '3.4.22.56\\nApopain\\nCASP-3\\nCPP-32\\nCPP32\\nCysteine protease CPP32\\nProtein Yama\\nSCA-1\\nSREBP cleavage activity 1',\n",
       "    'Gene Name': 'CASP3',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0016333|Caspase-3\\nMENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTG\\nMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLS\\nHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDD\\nDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVN\\nRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH',\n",
       "    'Number of residues': '277',\n",
       "    'Molecular Weight': '31607.58',\n",
       "    'Theoretical pI': '6.51',\n",
       "    'GO Classification': 'Functionsaspartic-type endopeptidase activity / cyclin-dependent protein serine/threonine kinase inhibitor activity / cysteine-type endopeptidase activity / cysteine-type endopeptidase activity involved in apoptotic process / cysteine-type endopeptidase activity involved in execution phase of apoptosis / peptidase activity / phospholipase A2 activator activityProcessesactivation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c / apoptotic DNA fragmentation / apoptotic process / apoptotic signaling pathway / B cell homeostasis / cell fate commitment / cellular component disassembly involved in execution phase of apoptosis / cellular response to DNA damage stimulus / cellular response to organic cyclic compound / erythrocyte differentiation / execution phase of apoptosis / extracellular matrix disassembly / extracellular matrix organization / extrinsic apoptotic signaling pathway / extrinsic apoptotic signaling pathway in absence of ligand / glial cell apoptotic process / heart development / hippo signaling / hippocampus development / intrinsic apoptotic signaling pathway / keratinocyte differentiation / learning or memory / negative regulation of activated T cell proliferation / negative regulation of apoptotic process / negative regulation of B cell proliferation / negative regulation of cyclin-dependent protein serine/threonine kinase activity / neuron apoptotic process / neuron differentiation / neurotrophin TRK receptor signaling pathway / platelet formation / positive regulation of neuron apoptotic process / programmed cell death / proteolysis / regulation of cysteine-type endopeptidase activity involved in apoptotic process / response to amino acid / response to antibiotic / response to cobalt ion / response to drug / response to estradiol / response to glucocorticoid / response to glucose / response to hydrogen peroxide / response to hypoxia / response to lipopolysaccharide / response to nicotine / response to tumor necrosis factor / response to UV / response to X-ray / sensory perception of sound / T cell homeostasis / wound healingComponentscytosol / death-inducing signaling complex / membrane raft / nucleoplasm / nucleus / plasma membrane',\n",
       "    'General Function': 'Phospholipase a2 activator activity',\n",
       "    'Specific Function': \"Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage.\",\n",
       "    'Pfam Domain Function': 'Peptidase_C14 (PF00656)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0016334|Caspase-3 (CASP3)\\nATGGAGAACACTGAAAACTCAGTGGATTCAAAATCCATTAAAAATTTGGAACCAAAGATC\\nATACATGGAAGCGAATCAATGGACTCTGGAATATCCCTGGACAACAGTTATAAAATGGAT\\nTATCCTGAGATGGGTTTATGTATAATAATTAATAATAAGAATTTTCATAAAAGCACTGGA\\nATGACATCTCGGTCTGGTACAGATGTCGATGCAGCAAACCTCAGGGAAACATTCAGAAAC\\nTTGAAATATGAAGTCAGGAATAAAAATGATCTTACACGTGAAGAAATTGTGGAATTGATG\\nCGTGATGTTTCTAAAGAAGATCACAGCAAAAGGAGCAGTTTTGTTTGTGTGCTTCTGAGC\\nCATGGTGAAGAAGGAATAATTTTTGGAACAAATGGACCTGTTGACCTGAAAAAAATAACA\\nAACTTTTTCAGAGGGGATCGTTGTAGAAGTCTAACTGGAAAACCCAAACTTTTCATTATT\\nCAGGCCTGCCGTGGTACAGAACTGGACTGTGGCATTGAGACAGACAGTGGTGTTGATGAT\\nGACATGGCGTGTCATAAAATACCAGTGGAGGCCGACTTCTTGTATGCATACTCCACAGCA\\nCCTGGTTATTATTCTTGGCGAAATTCAAAGGATGGCTCCTGGTTCATCCAGTCGCTTTGT\\nGCCATGCTGAAACAGTATGCCGACAAGCTTGAATTTATGCACATTCTTACCCGGGTTAAC\\nCGAAAGGTGGCAACAGAATTTGAGTCCTTTTCCTTTGACGCTACTTTTCATGCAAAGAAA\\nCAGATTCCATGTATTGTTTCCATGCTCACAAAAGAACTCTATTTTTATCACTAA',\n",
       "    'Chromosome Location': '4',\n",
       "    'Locus': '4q34',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP42574UniProtKB Entry NameCASP3_HUMANGenBank Protein ID561666GenBank Gene IDU13737GenAtlas IDCASP3HGNC IDHGNC:1504',\n",
       "    'General References': \"Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994 Dec 9;269(49):30761-4. [Article] Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995 Jun 2;81(5):801-9. [Article] Pelletier M, Cartron PF, Delaval F, Meflah K, Vallette FM, Oliver L: Caspase 3 activation is controlled by a sequence located in the N-terminus of its large subunit. Biochem Biophys Res Commun. 2004 Mar 26;316(1):93-9. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al.: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul 6;376(6535):37-43. [Article] Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES: In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7464-9. [Article] Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR: Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. 1996 Aug;13(4):442-9. [Article] Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS: Fas-induced caspase denitrosylation. Science. 1999 Apr 23;284(5414):651-4. [Article] Bartke T, Pohl C, Pyrowolakis G, Jentsch S: Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol Cell. 2004 Jun 18;14(6):801-11. [Article] Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Cabrera JR, Bouzas-Rodriguez J, Tauszig-Delamasure S, Mehlen P: RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons. J Biol Chem. 2011 Apr 22;286(16):14628-38. doi: 10.1074/jbc.M110.195461. Epub 2011 Feb 28. [Article] Bienvenut WV, Sumpton D, Martinez A, Lilla S, Espagne C, Meinnel T, Giglione C: Comparative large scale characterization of plant versus mammal proteins reveals similar and idiosyncratic N-alpha-acetylation features. Mol Cell Proteomics. 2012 Jun;11(6):M111.015131. doi: 10.1074/mcp.M111.015131. Epub 2012 Jan 5. [Article] Rotonda J, Nicholson DW, Fazil KM, Gallant M, Gareau Y, Labelle M, Peterson EP, Rasper DM, Ruel R, Vaillancourt JP, Thornberry NA, Becker JW: The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat Struct Biol. 1996 Jul;3(7):619-25. [Article] Mittl PR, Di Marco S, Krebs JF, Bai X, Karanewsky DS, Priestle JP, Tomaselli KJ, Grutter MG: Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. J Biol Chem. 1997 Mar 7;272(10):6539-47. [Article] Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung CM, Debouck C, Richardson S, Levy MA, DeWolf WE Jr, Keller PM, Tomaszek T, Head MS, Ryan MD, Haltiwanger RC, Liang PH, Janson CA, McDevitt PJ, Johanson K, Concha NO, Chan W, Abdel-Meguid SS, Badger AM, Lark MW, Nadeau DP, Suva LJ, Gowen M, Nuttall ME: Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem. 2000 May 26;275(21):16007-14. [Article]\",\n",
       "    'Drug Relations': \"DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB01017Minocyclineapproved, investigationalunknownnegative modulatorDetailsDB031245-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic AcidexperimentalunknownDetailsDB05408EmricasaninvestigationalunknownDetailsDB068622-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACIDexperimentalunknownDetailsDB07696methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoateexperimentalunknownDetailsDB082131-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONEexperimentalunknownDetailsDB08229[N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acidexperimentalunknownDetailsDB082514-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACIDexperimentalunknownDetailsDB08497(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetateexperimentalunknownDetailsDB08498(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetateexperimentalunknownDetailsDB08499N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamideexperimentalunknownDetailsDB13751Glycyrrhizic acidapproved, experimentalyesantagonistDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitordownregulatorDetailsDB06255Incadronic acidexperimentalunknownactivatorDetailsDB00282Pamidronic acidapprovedunknownactivatorDetailsDB13048PAC-1investigationalyesactivatorDetailsDB12709TributyrininvestigationalunknownactivatorDetailsDB12843Oleandrinexperimental, investigationalunknownregulatorDetails\"}},\n",
       "  {'Label': 'Inhibitor of nuclear factor kappa-B kinase subunit beta',\n",
       "   'Detailed Info': {'Name': 'Inhibitor of nuclear factor kappa-B kinase subunit beta',\n",
       "    'Synonyms': '2.7.11.10\\nI-kappa-B kinase 2\\nI-kappa-B-kinase beta\\nIKK2\\nIKKB\\nNFKBIKB\\nNuclear factor NF-kappa-B inhibitor kinase beta',\n",
       "    'Gene Name': 'IKBKB',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0002295|Inhibitor of nuclear factor kappa-B kinase subunit beta\\nMSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCL\\nEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREG\\nAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCT\\nSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSE\\nVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCF\\nKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLA\\nLIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRN\\nLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLK\\nAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMAL\\nQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQS\\nFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKI\\nACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLE\\nNAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS',\n",
       "    'Number of residues': '756',\n",
       "    'Molecular Weight': '86563.245',\n",
       "    'Theoretical pI': '5.53',\n",
       "    'GO Classification': 'FunctionsATP binding / IkappaB kinase activity / protein heterodimerization activity / protein homodimerization activity / protein kinase activity / protein kinase binding / protein serine/threonine kinase activity / scaffold protein bindingProcessesB cell homeostasis / cell surface receptor signaling pathway / cellular response to tumor necrosis factor / cortical actin cytoskeleton organization / establishment of protein localization to plasma membrane / Fc-epsilon receptor signaling pathway / I-kappaB kinase/NF-kappaB signaling / I-kappaB phosphorylation / inflammatory response / innate immune response / interleukin-1-mediated signaling pathway / MyD88-dependent toll-like receptor signaling pathway / MyD88-independent toll-like receptor signaling pathway / negative regulation of apoptotic process / negative regulation of bicellular tight junction assembly / negative regulation of myosin-light-chain-phosphatase activity / neuron projection development / neurotrophin TRK receptor signaling pathway / nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway / nucleotide-binding oligomerization domain containing signaling pathway / positive regulation of cation channel activity / positive regulation of cell proliferation / positive regulation of I-kappaB kinase/NF-kappaB signaling / positive regulation of neuron death / positive regulation of NF-kappaB transcription factor activity / positive regulation of sodium ion transport / positive regulation of transcription from RNA polymerase II promoter / positive regulation of transcription, DNA-templated / positive regulation of type I interferon production / protein phosphorylation / regulation of establishment of endothelial barrier / regulation of phosphorylation / regulation of tumor necrosis factor-mediated signaling pathway / response to drug / response to fatty acid / response to toxic substance / response to virus / serine phosphorylation of STAT protein / skeletal muscle contraction / stimulatory C-type lectin receptor signaling pathway / stress-activated MAPK cascade / T cell receptor signaling pathway / toll-like receptor 10 signaling pathway / toll-like receptor 2 signaling pathway / toll-like receptor 3 signaling pathway / toll-like receptor 4 signaling pathway / toll-like receptor 5 signaling pathway / toll-like receptor 9 signaling pathway / toll-like receptor signaling pathway / toll-like receptor TLR1 / toll-like receptor TLR6 / TRIF-dependent toll-like receptor signaling pathway / tumor necrosis factor-mediated signaling pathwayComponentsCD40 receptor complex / cytoplasm / cytoplasmic side of plasma membrane / cytosol / IkappaB kinase complex / membrane raft / nucleus',\n",
       "    'General Function': 'Scaffold protein binding',\n",
       "    'Specific Function': 'Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.',\n",
       "    'Pfam Domain Function': 'Pkinase (PF00069)\\nIKKbetaNEMObind (PF12179)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0010805|Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)\\nATGTTTTCAGGGGGGTGTCATAGCCCCGGGTTTGGCCGCCCCAGCCCCGCCTTCCCCGCC\\nCCGGGGAGCCCGCCCCCTGCCCCGCGTCCCTGCCGACAGGAAACAGGTGAGCAGATTGCC\\nATCAAGCAGTGCCGGCAGGAGCTCAGCCCCCGGAACCGAGAGCGGTGGTGCCTGGAGATC\\nCAGATCATGAGAAGGCTGACCCACCCCAATGTGGTGGCTGCCCGAGATGTCCCTGAGGGG\\nATGCAGAACTTGGCGCCCAATGACCTGCCCCTGCTGGCCATGGAGTACTGCCAAGGAGGA\\nGATCTCCGGAAGTACCTGAACCAGTTTGAGAACTGCTGTGGTCTGCGGGAAGGTGCCATC\\nCTCACCTTGCTGAGTGACATTGCCTCTGCGCTTAGATACCTTCATGAAAACAGAATCATC\\nCATCGGGATCTAAAGCCAGAAAACATCGTCCTGCAGCAAGGAGAACAGAGGTTAATACAC\\nAAAATTATTGACCTAGGATATGCCAAGGAGCTGGATCAGGGCAGTCTTTGCACATCATTC\\nGTGGGGACCCTGCAGTACCTGGCCCCAGAGCTACTGGAGCAGCAGAAGTACACAGTGACC\\nGTCGACTACTGGAGCTTCGGCACCCTGGCCTTTGAGTGCATCACGGGCTTCCGGCCCTTC\\nCTCCCCAACTGGCAGCCCGTGCAGTGGCATTCAAAAGTGCGGCAGAAGAGTGAGGTGGAC\\nATTGTTGTTAGCGAAGACTTGAATGGAACGGTGAAGTTTTCAAGCTCTTTACCCTACCCC\\nAATAATCTTAACAGTGTCCTGGCTGAGCGACTGGAGAAGTGGCTGCAACTGATGCTGATG\\nTGGCACCCCCGACAGAGGGGCACGGATCCCACGTATGGGCCCAATGGCTGCTTCAAGGCC\\nCTGGATGACATCTTAAACTTAAAGCTGGTTCATATCTTGAACATGGTCACGGGCACCATC\\nCACACCTACCCTGTGACAGAGGATGAGAGTCTGCAGAGCTTGAAGGCCAGAATCCAACAG\\nGACACGGGCATCCCAGAGGAGGACCAGGAGCTGCTGCAGGAAGCGGGCCTGGCGTTGATC\\nCCCGATAAGCCTGCCACTCAGTGTATTTCAGACGGCAAGTTAAATGAGGGCCACACATTG\\nGACATGGATCTTGTTTTTCTCTTTGACAACAGTAAAATCACCTATGAGACTCAGATCTCC\\nCCACGGCCCCAACCTGAAAGTGTCAGCTGTATCCTTCAAGAGCCCAAGAGGAATCTCGCC\\nTTCTTCCAGCTGAGGAAGGTGTGGGGCCAGGTCTGGCACAGCATCCAGACCCTGAAGGAA\\nGATTGCAACCGGCTGCAGCAGGGACAGCGAGCCGCCATGATGAATCTCCTCCGAAACAAC\\nAGCTGCCTCTCCAAAATGAAGAATTCCATGGCTTCCATGTCTCAGCAGCTCAAGGCCAAG\\nTTGGATTTCTTCAAAACCAGCATCCAGATTGACCTGGAGAAGTACAGCGAGCAAACCGAG\\nTTTGGGATCACATCAGATAAACTGCTGCTGGCCTGGAGGGAAATGGAGCAGGCTGTGGAG\\nCTCTGTGGGCGGGAGAACGAAGTGAAACTCCTGGTAGAACGGATGATGGCTCTGCAGACC\\nGACATTGTGGACTTACAGAGGAGCCCCATGGGCCGGAAGCAGGGGGGAACGCTGGACGAC\\nCTAGAGGAGCAAGCAAGGGAGCTGTACAGGAGACTAAGGGAAAAACCTCGAGACCAGCGA\\nACTGAGGGTGACAGTCAGGAAATGGTACGGCTGCTGCTTCAGGCAATTCAGAGCTTCGAG\\nAAGAAAGTGCGAGTGATCTATACGCAGCTCAGTAAAACTGTGGTTTGCAAGCAGAAGGCG\\nCTGGAACTGTTGCCCAAGGTGGAAGAGGTGGTGAGCTTAATGAATGAGGATGAGAAGACT\\nGTTGTCCGGCTGCAGGAGAAGCGGCAGAAGGAGCTCTGGAATCTCCTGAAGATTGCTTGT\\nAGCAAGGTCCGTGGTCCTGTCAGTGGAAGCCCGGATAGCATGAATGCCTCTCGACTTAGC\\nCAGCCTGGGCAGCTGATGTCTCAGCCCTCCACGGCCTCCAACAGCTTACCTGAGCCAGCC\\nAAGAAGAGTGAAGAACTGGTGGCTGAAGCACATAACCTCTGCACCCTGCTAGAAAATGCC\\nATACAGGACACTGTGAGGGAACAAGACCAGAGTTTCACGGCCCTAGACTGGAGCTGGTTA\\nCAGACGGAAGAAGAAGAGCACAGCTGCCTGGAGCAGGCCTCATGA',\n",
       "    'Chromosome Location': '8',\n",
       "    'Locus': '8p11.2',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDO14920UniProtKB Entry NameIKKB_HUMANGenBank Protein ID2599558GenBank Gene IDAF029684GenAtlas IDIKBKBHGNC IDHGNC:5960',\n",
       "    'General References': \"Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A: IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997 Oct 31;278(5339):860-6. [Article] Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV: IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science. 1997 Oct 31;278(5339):866-9. [Article] Hu MC, Wang Y: IkappaB kinase-alpha and -beta genes are coexpressed in adult and embryonic tissues but localized to different human chromosomes. Gene. 1998 Nov 5;222(1):31-40. [Article] Shindo M, Nakano H, Sakon S, Yagita H, Mihara M, Okumura K: Assignment of IkappaB kinase beta (IKBKB) to human chromosome band 8p12-->p11 by in situ hybridization. Cytogenet Cell Genet. 1998;82(1-2):32-3. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Nusbaum C, Mikkelsen TS, Zody MC, Asakawa S, Taudien S, Garber M, Kodira CD, Schueler MG, Shimizu A, Whittaker CA, Chang JL, Cuomo CA, Dewar K, FitzGerald MG, Yang X, Allen NR, Anderson S, Asakawa T, Blechschmidt K, Bloom T, Borowsky ML, Butler J, Cook A, Corum B, DeArellano K, DeCaprio D, Dooley KT, Dorris L 3rd, Engels R, Glockner G, Hafez N, Hagopian DS, Hall JL, Ishikawa SK, Jaffe DB, Kamat A, Kudoh J, Lehmann R, Lokitsang T, Macdonald P, Major JE, Matthews CD, Mauceli E, Menzel U, Mihalev AH, Minoshima S, Murayama Y, Naylor JW, Nicol R, Nguyen C, O'Leary SB, O'Neill K, Parker SC, Polley A, Raymond CK, Reichwald K, Rodriguez J, Sasaki T, Schilhabel M, Siddiqui R, Smith CL, Sneddon TP, Talamas JA, Tenzin P, Topham K, Venkataraman V, Wen G, Yamazaki S, Young SK, Zeng Q, Zimmer AR, Rosenthal A, Birren BW, Platzer M, Shimizu N, Lander ES: DNA sequence and analysis of human chromosome 8. Nature. 2006 Jan 19;439(7074):331-5. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Mittal R, Peak-Chew SY, McMahon HT: Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18574-9. Epub 2006 Nov 20. [Article] Nemoto S, DiDonato JA, Lin A: Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase. Mol Cell Biol. 1998 Dec;18(12):7336-43. [Article] Cohen L, Henzel WJ, Baeuerle PA: IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):292-6. [Article] Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J: The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 1999 Jun 1;18(11):3044-53. [Article] Lallena MJ, Diaz-Meco MT, Bren G, Paya CV, Moscat J: Activation of IkappaB kinase beta by protein kinase C isoforms. Mol Cell Biol. 1999 Mar;19(3):2180-8. [Article] Delhase M, Hayakawa M, Chen Y, Karin M: Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science. 1999 Apr 9;284(5412):309-13. [Article] Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF: PKR stimulates NF-kappaB irrespective of its kinase function by interacting with the IkappaB kinase complex. Mol Cell Biol. 2000 Jul;20(13):4532-42. [Article] Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, Kaneko Y, Nimura Y, Motoyama N, Ikeda K, Karin M, Nakanishi M: NAK is an IkappaB kinase-activating kinase. Nature. 2000 Apr 13;404(6779):778-82. [Article] Salmeron A, Janzen J, Soneji Y, Bump N, Kamens J, Allen H, Ley SC: Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis. J Biol Chem. 2001 Jun 22;276(25):22215-22. Epub 2001 Apr 10. [Article] Chariot A, Leonardi A, Muller J, Bonif M, Brown K, Siebenlist U: Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J Biol Chem. 2002 Oct 4;277(40):37029-36. Epub 2002 Jul 19. [Article] Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW: Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol. 2002 May;22(10):3549-61. [Article] Tegethoff S, Behlke J, Scheidereit C: Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation. Mol Cell Biol. 2003 Mar;23(6):2029-41. [Article] Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 2004 Apr 16;117(2):225-37. [Article] Han KJ, Su X, Xu LG, Bin LH, Zhang J, Shu HB: Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem. 2004 Apr 9;279(15):15652-61. Epub 2004 Jan 22. [Article] Bruey JM, Bruey-Sedano N, Newman R, Chandler S, Stehlik C, Reed JC: PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages. J Biol Chem. 2004 Dec 10;279(50):51897-907. Epub 2004 Sep 28. [Article] Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ: beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8603-7. Epub 2004 Jun 1. [Article] Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EF, van der Vliet A, Janssen-Heininger YM: Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8945-50. Epub 2004 Jun 7. [Article] Hu WH, Pendergast JS, Mo XM, Brambilla R, Bracchi-Ricard V, Li F, Walters WM, Blits B, He L, Schaal SM, Bethea JR: NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation. J Biol Chem. 2005 Aug 12;280(32):29233-41. Epub 2005 Jun 10. [Article] Tanaka H, Fujita N, Tsuruo T: 3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J Biol Chem. 2005 Dec 9;280(49):40965-73. Epub 2005 Oct 5. [Article] Carter RS, Pennington KN, Arrate P, Oltz EM, Ballard DW: Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation. J Biol Chem. 2005 Dec 30;280(52):43272-9. Epub 2005 Nov 1. [Article] Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J: Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005 Oct 20;437(7062):1167-72. Epub 2005 Sep 21. [Article] Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18154-9. Epub 2006 Nov 17. [Article] Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, Orth K: Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science. 2006 May 26;312(5777):1211-4. [Article] Wu ZH, Shi Y, Tibbetts RS, Miyamoto S: Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 2006 Feb 24;311(5764):1141-6. [Article] Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C: Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem. 2007 Mar 30;282(13):10117-31. Epub 2007 Feb 6. [Article] Park MY, Moon JH, Lee KS, Choi HI, Chung J, Hong HJ, Kim E: FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly. J Biol Chem. 2007 Sep 21;282(38):27572-7. Epub 2007 Aug 7. [Article] Lobry C, Lopez T, Israel A, Weil R: Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):908-13. Epub 2007 Jan 9. [Article] Jobin C, Sartor RB: The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol. 2000 Mar;278(3):C451-62. [Article] Solt LA, May MJ: The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res. 2008;42(1-3):3-18. doi: 10.1007/s12026-008-8025-1. [Article] Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48. doi: 10.1016/j.molcel.2008.07.007. [Article] Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. doi: 10.1073/pnas.0805139105. Epub 2008 Jul 31. [Article] Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article] Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC: Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation. Biochem Biophys Res Commun. 2009 Nov 6;389(1):156-61. doi: 10.1016/j.bbrc.2009.08.127. Epub 2009 Aug 28. [Article] Sun W, Yu Y, Dotti G, Shen T, Tan X, Savoldo B, Pass AK, Chu M, Zhang D, Lu X, Fu S, Lin X, Yang J: PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. Cell Signal. 2009 Jan;21(1):95-102. doi: 10.1016/j.cellsig.2008.09.012. Epub 2008 Oct 1. [Article] Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H: Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics. 2009 Jul;8(7):1751-64. doi: 10.1074/mcp.M800588-MCP200. Epub 2009 Apr 15. [Article] Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46. doi: 10.1126/scisignal.2000007. [Article] Cui J, Zhu L, Xia X, Wang HY, Legras X, Hong J, Ji J, Shen P, Zheng S, Chen ZJ, Wang RF: NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell. 2010 Apr 30;141(3):483-96. doi: 10.1016/j.cell.2010.03.040. [Article] Wada K, Niida M, Tanaka M, Kamitani T: Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling. J Biochem. 2009 Dec;146(6):821-32. doi: 10.1093/jb/mvp127. Epub 2009 Aug 12. [Article] Yoboua F, Martel A, Duval A, Mukawera E, Grandvaux N: Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta. J Virol. 2010 Jul;84(14):7267-77. doi: 10.1128/JVI.00142-10. Epub 2010 Apr 21. [Article] Tsuchiya Y, Asano T, Nakayama K, Kato T Jr, Karin M, Kamata H: Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell. 2010 Aug 27;39(4):570-82. doi: 10.1016/j.molcel.2010.07.030. [Article] Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010 Jan 12;3(104):ra3. doi: 10.1126/scisignal.2000475. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P: Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. doi: 10.1042/BJ20101701. [Article] Wang W, Guo M, Hu L, Cai J, Zeng Y, Luo J, Shu Z, Li W, Huang Z: The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-kappaB signaling. J Biol Chem. 2012 Dec 14;287(51):42856-66. doi: 10.1074/jbc.M112.399923. Epub 2012 Oct 22. [Article] Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, Hahn WC: IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013 Mar 28;3(3):724-33. doi: 10.1016/j.celrep.2013.01.031. Epub 2013 Feb 28. [Article] Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M, Janda A, Hese K, Schlesier M, Holzmann K, Borte S, Laux C, Rump EM, Rosenberg A, Zelinski T, Schrezenmeier H, Wirth T, Ehl S, Schroeder ML, Schwarz K: Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med. 2013 Dec 26;369(26):2504-14. doi: 10.1056/NEJMoa1309199. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L, Bairoch A, Van Dorsselaer A, Carapito C: N-terminome analysis of the human mitochondrial proteome. Proteomics. 2015 Jul;15(14):2519-24. doi: 10.1002/pmic.201400617. Epub 2015 Jun 8. [Article] Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, Cuervo H, Berkowitz S, Zheng T, Guckian K, Pellegrini M, Lugovskoy A: Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure. 2008 May;16(5):798-808. doi: 10.1016/j.str.2008.02.012. [Article] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article] Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature. 2007 Mar 8;446(7132):153-8. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00995Auranofinapproved, investigationalyesinhibitorDetailsDB01169Arsenic trioxideapproved, investigationalyesinducerDetailsDB05183MLN0415investigationalunknownDetailsDB06521ErtiprotafibinvestigationalunknownDetailsDB00244MesalazineapprovedunknowninhibitorDetailsDB06151Acetylcysteineapproved, investigationalunknowninhibitorDetailsDB12010Fostamatinibapproved, investigationalunknowninhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownDetailsDB00795SulfasalazineapprovedyesinhibitorDetails'}},\n",
       "  {'Label': 'Extracellular signal-regulated kinase (ERK) (Protein Group)',\n",
       "   'Detailed Info': {'Name': 'Extracellular signal-regulated kinase (ERK)',\n",
       "    'Kind': 'protein group',\n",
       "    'Organism': 'Humans',\n",
       "    'Proteins': 'NameUniProt IDMitogen-activated protein kinase 1P28482DetailsMitogen-activated protein kinase 15Q8TD08DetailsMitogen-activated protein kinase 3P27361DetailsMitogen-activated protein kinase 4P31152DetailsMitogen-activated protein kinase 6Q16659DetailsMitogen-activated protein kinase 7Q13164Details',\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownDetailsDB02587Colforsinexperimental, investigationalunknownactivatorDetails'}},\n",
       "  {'Label': 'G1/S-specific cyclin-D1',\n",
       "   'Detailed Info': {'Name': 'G1/S-specific cyclin-D1',\n",
       "    'Synonyms': 'B-cell lymphoma 1 protein\\nBCL-1\\nBCL-1 oncogene\\nBCL1\\nPRAD1\\nPRAD1 oncogene',\n",
       "    'Gene Name': 'CCND1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0019051|G1/S-specific cyclin-D1\\nMEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIV\\nATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLT\\nAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRK\\nHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCD\\nPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI',\n",
       "    'Number of residues': '295',\n",
       "    'Molecular Weight': '33728.74',\n",
       "    'Theoretical pI': '4.68',\n",
       "    'GO Classification': 'Functionscyclin-dependent protein serine/threonine kinase regulator activity / enzyme binding / histone deacetylase binding / proline-rich region binding / protein kinase activity / protein kinase binding / transcription corepressor activity / transcription factor bindingProcessescanonical Wnt signaling pathway / cell division / cellular response to DNA damage stimulus / chromatin organization / endoplasmic reticulum unfolded protein response / fat cell differentiation / G1/S transition of mitotic cell cycle / lactation / Leydig cell differentiation / liver development / mammary gland alveolus development / mammary gland epithelial cell proliferation / mitotic cell cycle / mitotic G1 DNA damage checkpoint / negative regulation of cell cycle arrest / negative regulation of epithelial cell differentiation / negative regulation of transcription from RNA polymerase II promoter / negative regulation of Wnt signaling pathway / Notch signaling pathway / organ regeneration / positive regulation of cyclin-dependent protein serine/threonine kinase activity / positive regulation of G2/M transition of mitotic cell cycle / positive regulation of mammary gland epithelial cell proliferation / positive regulation of protein phosphorylation / re-entry into mitotic cell cycle / response to calcium ion / response to corticosterone / response to drug / response to estradiol / response to ethanol / response to iron ion / response to magnesium ion / response to organonitrogen compound / response to UV-A / response to vitamin E / response to X-ray / transcription, DNA-templatedComponentsbicellular tight junction / cyclin-dependent protein kinase holoenzyme complex / cytosol / intracellular / membrane / nucleoplasm / nucleus / transcriptional repressor complex',\n",
       "    'General Function': 'Transcription factor binding',\n",
       "    'Specific Function': 'Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.',\n",
       "    'Pfam Domain Function': 'Cyclin_C (PF02984)\\nCyclin_N (PF00134)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Nucleus',\n",
       "    'Gene sequence': '>lcl|BSEQ0019052|G1/S-specific cyclin-D1 (CCND1)\\nATGGAACACCAGCTCCTGTGCTGCGAAGTGGAAACCATCCGCCGCGCGTACCCCGATGCC\\nAACCTCCTCAACGACCGGGTGCTGCGGGCCATGCTGAAGGCGGAGGAGACCTGCGCGCCC\\nTCGGTGTCCTACTTCAAATGTGTGCAGAAGGAGGTCCTGCCGTCCATGCGGAAGATCGTC\\nGCCACCTGGATGCTGGAGGTCTGCGAGGAACAGAAGTGCGAGGAGGAGGTCTTCCCGCTG\\nGCCATGAACTACCTGGACCGCTTCCTGTCGCTGGAGCCCGTGAAAAAGAGCCGCCTGCAG\\nCTGCTGGGGGCCACTTGCATGTTCGTGGCCTCTAAGATGAAGGAGACCATCCCCCTGACG\\nGCCGAGAAGCTGTGCATCTACACCGACAACTCCATCCGGCCCGAGGAGCTGCTGCAAATG\\nGAGCTGCTCCTGGTGAACAAGCTCAAGTGGAACCTGGCCGCAATGACCCCGCACGATTTC\\nATTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCATCCGCAAA\\nCACGCGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAAGTTCATTTCCAATCCGCCC\\nTCCATGGTGGCAGCGGGGAGCGTGGTGGCCGCAGTGCAAGGCCTGAACCTGAGGAGCCCC\\nAACAACTTCCTGTCCTACTACCGCCTCACACGCTTCCTCTCCAGAGTGATCAAGTGTGAC\\nCCGGACTGCCTCCGGGCCTGCCAGGAGCAGATCGAAGCCCTGCTGGAGTCAAGCCTGCGC\\nCAGGCCCAGCAGAACATGGACCCCAAGGCCGCCGAGGAGGAGGAAGAGGAGGAGGAGGAG\\nGTGGACCTGGCTTGCACACCCACCGACGTGCGGGACGTGGACATCTGA',\n",
       "    'Chromosome Location': '11',\n",
       "    'Locus': '11q13',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP24385UniProtKB Entry NameCCND1_HUMANGenBank Protein ID35632GenBank Gene IDX59798GenAtlas IDCCND1HGNC IDHGNC:1582',\n",
       "    'General References': \"Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991 Apr 11;350(6318):512-5. [Article] Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell. 1991 Sep 20;66(6):1197-206. [Article] Xiong Y, Connolly T, Futcher B, Beach D: Human D-type cyclin. Cell. 1991 May 17;65(4):691-9. [Article] Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC: Characterization of a candidate bcl-1 gene. Mol Cell Biol. 1991 Oct;11(10):4846-53. [Article] Rimokh R, Berger F, Bastard C, Klein B, French M, Archimbaud E, Rouault JP, Santa Lucia B, Duret L, Vuillaume M, et al.: Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994 Jun 15;83(12):3689-96. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Motokura T, Arnold A: PRAD1/cyclin D1 proto-oncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer. 1993 Jun;7(2):89-95. [Article] Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene. 1994 Jan;9(1):71-9. [Article] Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996 Jul 15;88(2):674-81. [Article] LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1;11(7):847-62. [Article] Germain D, Russell A, Thompson A, Hendley J: Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem. 2000 Apr 21;275(16):12074-9. [Article] Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F: Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004 Jul 8;430(6996):226-31. [Article] Liu WD, Wang HW, Muguira M, Breslin MB, Lan MS: INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases. Biochem J. 2006 Jul 1;397(1):169-77. [Article] Wang HW, Muguira M, Liu WD, Zhang T, Chen C, Aucoin R, Breslin MB, Lan MS: Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription. J Endocrinol. 2008 Jul;198(1):29-39. doi: 10.1677/JOE-08-0001. Epub 2008 Apr 16. [Article] Zhang T, Liu WD, Saunee NA, Breslin MB, Lan MS: Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest. J Biol Chem. 2009 Feb 27;284(9):5574-81. doi: 10.1074/jbc.M808843200. Epub 2009 Jan 5. [Article] Shan J, Zhao W, Gu W: Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell. 2009 Nov 13;36(3):469-76. doi: 10.1016/j.molcel.2009.10.018. [Article] Santra MK, Wajapeyee N, Green MR: F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 2009 Jun 4;459(7247):722-5. doi: 10.1038/nature08011. Epub 2009 May 3. [Article] Mori T, Ikeda DD, Fukushima T, Takenoshita S, Kochi H: NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. Cell Cycle. 2011 Oct 1;10(19):3284-99. doi: 10.4161/cc.10.19.17176. Epub 2011 Oct 1. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, Holding FP, McMenamin RL, Yon J, Chopra R, Lengauer C, Jhoti H: Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4166-70. doi: 10.1073/pnas.0809645106. Epub 2009 Feb 23. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB01169Arsenic trioxideapproved, investigationalyesantagonistDetailsDB11718Encorafenibapproved, investigationalyesinhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowndownregulatorDetailsDB11752Bryostatin 1investigationalunknowninhibitorDetails'}},\n",
       "  {'Label': 'Myc proto-oncogene protein',\n",
       "   'Detailed Info': {'Name': 'Myc proto-oncogene protein',\n",
       "    'Synonyms': 'BHLHE39\\nClass E basic helix-loop-helix protein 39\\nProto-oncogene c-Myc\\nTranscription factor p64',\n",
       "    'Gene Name': 'MYC',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0008540|Myc proto-oncogene protein\\nMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPAPSEDIWKKFELLPTPP\\nLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPD\\nDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQD\\nLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPEPLVL\\nHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGGHSKPPHSPLVLKRC\\nHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRKCTSPRSSDTEENVKRRTHN\\nVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLL\\nRKRREQLKHKLEQLRNSCA',\n",
       "    'Number of residues': '439',\n",
       "    'Molecular Weight': '48803.55',\n",
       "    'Theoretical pI': 'Not Available',\n",
       "    'GO Classification': 'FunctionsDNA binding / E-box binding / protein complex binding / repressing transcription factor binding / RNA polymerase II core promoter proximal region sequence-specific DNA binding / transcription factor activity, sequence-specific DNA binding / transcription factor binding / transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingProcessesbranching involved in ureteric bud morphogenesis / canonical Wnt signaling pathway / cell cycle arrest / cellular iron ion homeostasis / cellular response to DNA damage stimulus / cellular response to drug / cellular response to UV / chromatin remodeling / chromosome organization / energy reserve metabolic process / fibroblast apoptotic process / gene expression / MAPK cascade / negative regulation of apoptotic process / negative regulation of cell division / negative regulation of fibroblast proliferation / negative regulation of monocyte differentiation / negative regulation of stress-activated MAPK cascade / negative regulation of transcription from RNA polymerase II promoter / Notch signaling pathway / oxygen transport / positive regulation of cell proliferation / positive regulation of cysteine-type endopeptidase activity involved in apoptotic process / positive regulation of DNA biosynthetic process / positive regulation of epithelial cell proliferation / positive regulation of fibroblast proliferation / positive regulation of mesenchymal cell proliferation / positive regulation of metanephric cap mesenchymal cell proliferation / positive regulation of response to DNA damage stimulus / positive regulation of transcription from RNA polymerase II promoter / positive regulation of transcription, DNA-templated / regulation of gene expression / regulation of telomere maintenance / response to drug / response to gamma radiation / response to growth factor / transcription initiation from RNA polymerase II promoter / transcription, DNA-templated / transforming growth factor beta receptor signaling pathwayComponentscytosol / nucleolus / nucleoplasm / nucleus / protein complex',\n",
       "    'General Function': 'Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding',\n",
       "    'Specific Function': \"Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.\",\n",
       "    'Pfam Domain Function': 'HLH (PF00010)\\nMyc-LZ (PF02344)\\nMyc_N (PF01056)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Nucleus',\n",
       "    'Gene sequence': '>lcl|BSEQ0013262|Myc proto-oncogene protein (MYC)\\nCTGGATTTTTTTCGGGTAGTGGAAAACCAGCAGCCTCCCGCGACGATGCCCCTCAACGTT\\nAGCTTCACCAACAGGAACTATGACCTCGACTACGACTCGGTGCAGCCGTATTTCTACTGC\\nGACGAGGAGGAGAACTTCTACCAGCAGCAGCAGCAGAGCGAGCTGCAGCCCCCGGCGCCC\\nAGCGAGGATATCTGGAAGAAATTCGAGCTGCTGCCCACCCCGCCCCTGTCCCCTAGCCGC\\nCGCTCCGGGCTCTGCTCGCCCTCCTACGTTGCGGTCACACCCTTCTCCCTTCGGGGAGAC\\nAACGACGGCGGTGGCGGGAGCTTCTCCACGGCCGACCAGCTGGAGATGGTGACCGAGCTG\\nCTGGGAGGAGACATGGTGAACCAGAGTTTCATCTGCGACCCGGACGACGAGACCTTCATC\\nAAAAACATCATCATCCAGGACTGTATGTGGAGCGGCTTCTCGGCCGCCGCCAAGCTCGTC\\nTCAGAGAAGCTGGCCTCCTACCAGGCTGCGCGCAAAGACAGCGGCAGCCCGAACCCCGCC\\nCGCGGCCACAGCGTCTGCTCCACCTCCAGCTTGTACCTGCAGGATCTGAGCGCCGCCGCC\\nTCAGAGTGCATCGACCCCTCGGTGGTCTTCCCCTACCCTCTCAACGACAGCAGCTCGCCC\\nAAGTCCTGCGCCTCGCAAGACTCCAGCGCCTTCTCTCCGTCCTCGGATTCTCTGCTCTCC\\nTCGACGGAGTCCTCCCCGCAGGGCAGCCCCGAGCCCCTGGTGCTCCATGAGGAGACACCG\\nCCCACCACCAGCAGCGACTCTGAGGAGGAACAAGAAGATGAGGAAGAAATCGATGTTGTT\\nTCTGTGGAAAAGAGGCAGGCTCCTGGCAAAAGGTCAGAGTCTGGATCACCTTCTGCTGGA\\nGGCCACAGCAAACCTCCTCACAGCCCACTGGTCCTCAAGAGGTGCCACGTCTCCACACAT\\nCAGCACAACTACGCAGCGCCTCCCTCCACTCGGAAGGACTATCCTGCTGCCAAGAGGGTC\\nAAGTTGGACAGTGTCAGAGTCCTGAGACAGATCAGCAACAACCGAAAATGCACCAGCCCC\\nAGGTCCTCGGACACCGAGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCCAG\\nAGGAGGAACGAGCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGATCCCGGAGTTGGAA\\nAACAATGAAAAGGCCCCCAAGGTAGTTATCCTTAAAAAAGCCACAGCATACATCCTGTCC\\nGTCCAAGCAGAGGAGCAAAAGCTCATTTCTGAAGAGGACTTGTTGCGGAAACGACGAGAA\\nCAGTTGAAACACAAACTTGAACAGCTACGGAACTCTTGTGCGTAA',\n",
       "    'Chromosome Location': '8',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP01106UniProtKB Entry NameMYC_HUMANHGNC IDHGNC:7553',\n",
       "    'General References': \"Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, Lenoir G, Leder P: The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell. 1983 Oct;34(3):779-87. [Article] Bernard O, Cory S, Gerondakis S, Webb E, Adams JM: Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J. 1983;2(12):2375-83. [Article] Colby WW, Chen EY, Smith DH, Levinson AD: Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29. Nature. 1983 Feb 24;301(5902):722-5. [Article] Watt R, Stanton LW, Marcu KB, Gallo RC, Croce CM, Rovera G: Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature. 1983 Jun 23-29;303(5919):725-8. [Article] Rabbitts TH, Hamlyn PH, Baer R: Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature. 1983 Dec 22-1984 Jan 4;306(5945):760-5. [Article] Watson DK, Psallidopoulos MC, Samuel KP, Dalla-Favera R, Papas TS: Nucleotide sequence analysis of human c-myc locus, chicken homologue, and myelocytomatosis virus MC29 transforming gene reveals a highly conserved gene product. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3642-5. [Article] Rabbitts TH, Forster A, Hamlyn P, Baer R: Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma. Nature. 1984 Jun 14-20;309(5969):592-7. [Article] Gazin C, Dupont de Dinechin S, Hampe A, Masson JM, Martin P, Stehelin D, Galibert F: Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J. 1984 Feb;3(2):383-7. [Article] Tachibana K, Takayama N, Matsuo K, Kato S, Yamamoto K, Ohyama K, Umezawa A, Takano T: Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc. Gene. 1993 Feb 28;124(2):231-7. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Nusbaum C, Mikkelsen TS, Zody MC, Asakawa S, Taudien S, Garber M, Kodira CD, Schueler MG, Shimizu A, Whittaker CA, Chang JL, Cuomo CA, Dewar K, FitzGerald MG, Yang X, Allen NR, Anderson S, Asakawa T, Blechschmidt K, Bloom T, Borowsky ML, Butler J, Cook A, Corum B, DeArellano K, DeCaprio D, Dooley KT, Dorris L 3rd, Engels R, Glockner G, Hafez N, Hagopian DS, Hall JL, Ishikawa SK, Jaffe DB, Kamat A, Kudoh J, Lehmann R, Lokitsang T, Macdonald P, Major JE, Matthews CD, Mauceli E, Menzel U, Mihalev AH, Minoshima S, Murayama Y, Naylor JW, Nicol R, Nguyen C, O'Leary SB, O'Neill K, Parker SC, Polley A, Raymond CK, Reichwald K, Rodriguez J, Sasaki T, Schilhabel M, Siddiqui R, Smith CL, Sneddon TP, Talamas JA, Tenzin P, Topham K, Venkataraman V, Wen G, Yamazaki S, Young SK, Zeng Q, Zimmer AR, Rosenthal A, Birren BW, Platzer M, Shimizu N, Lander ES: DNA sequence and analysis of human chromosome 8. Nature. 2006 Jan 19;439(7074):331-5. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Bentley DL, Groudine M: Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas. Mol Cell Biol. 1986 Oct;6(10):3481-9. [Article] Magrath I: The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990;55:133-270. [Article] Iijima S, Teraoka H, Date T, Tsukada K: DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein. Eur J Biochem. 1992 Jun 1;206(2):595-603. [Article] Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I: Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet. 1993 Sep;5(1):56-61. [Article] Gupta S, Seth A, Davis RJ: Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3216-20. [Article] Chou TY, Hart GW, Dang CV: c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem. 1995 Aug 11;270(32):18961-5. [Article] Alexandrov I, Shlyakhova L, Vartanian A, Zajac-Kaye M, Alexandrova N: c-Raf kinase binds to N-terminal domain of c-Myc. FEBS Lett. 1997 Sep 8;414(2):465-70. [Article] Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004 May 19;23(10):2116-25. Epub 2004 Apr 22. [Article] Zhang K, Faiola F, Martinez E: Six lysine residues on c-Myc are direct substrates for acetylation by p300. Biochem Biophys Res Commun. 2005 Oct 14;336(1):274-80. [Article] Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ: c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol. 2005 Mar;7(3):311-8. [Article] Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, Poreba E, Vervoorts J, Walsemann G, Grotzinger J, Kremmer E, Mehraein Y, Mertsching J, Kraft R, Austen M, Luscher-Firzlaff J, Luscher B: PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene. 2005 Mar 17;24(12):1982-93. [Article] Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48. [Article] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-72. [Article] Popov N, Herold S, Llamazares M, Schulein C, Eilers M: Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle. 2007 Oct 1;6(19):2327-31. Epub 2007 Jul 26. [Article] Secombe J, Li L, Carlos L, Eisenman RN: The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev. 2007 Mar 1;21(5):537-51. Epub 2007 Feb 20. [Article] Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, Tsuchiya E, Nakamura Y, Daigo Y: Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther. 2007 Feb;6(2):542-51. [Article] Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M: The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007 Jul;9(7):765-74. Epub 2007 Jun 10. [Article] Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. doi: 10.1073/pnas.0805139105. Epub 2008 Jul 31. [Article] Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article] Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16. [Article] Hydbring P, Larsson LG: Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res. 2010 Sep 1;70(17):6687-91. doi: 10.1158/0008-5472.CAN-10-1383. Epub 2010 Aug 16. [Article] Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, Sharifi HR, Lilischkis R, Hein N, Wu S, Vervoorts J, Henriksson M, Grandien A, Luscher B, Larsson LG: Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):58-63. doi: 10.1073/pnas.0900121106. Epub 2009 Dec 4. [Article] Choi SH, Wright JB, Gerber SA, Cole MD: Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev. 2010 Jun 15;24(12):1236-41. doi: 10.1101/gad.1920310. [Article] Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010 Jan 12;3(104):ra3. doi: 10.1126/scisignal.2000475. [Article] Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, Kassem M, Mann M, Olsen JV, Blagoev B: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal. 2011 Mar 15;4(164):rs3. doi: 10.1126/scisignal.2001570. [Article] Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, Yoshida K: DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest. 2012 Mar;122(3):859-72. doi: 10.1172/JCI60818. Epub 2012 Feb 6. [Article] Lavigne P, Crump MP, Gagne SM, Hodges RS, Kay CM, Sykes BD: Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper. J Mol Biol. 1998 Aug 7;281(1):165-81. [Article] Rimokh R, Rouault JP, Wahbi K, Gadoux M, Lafage M, Archimbaud E, Charrin C, Gentilhomme O, Germain D, Samarut J, et al.: A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 1991 Jan;3(1):24-36. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB08813Nadroparinapproved, investigationalunknowninhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowndownregulatorDetailsDB03756Doconexentapproved, investigationalunknowninhibitorDetailsDB01093Dimethyl sulfoxideapproved, vet_approvedunknowndownregulatorDetails'}},\n",
       "  {'Label': 'Proliferating cell nuclear antigen',\n",
       "   'Detailed Info': {'Name': 'Proliferating cell nuclear antigen',\n",
       "    'Synonyms': 'Cyclin\\nPCNA',\n",
       "    'Gene Name': 'PCNA',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0049803|Proliferating cell nuclear antigen\\nMFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTY\\nRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMD\\nLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNI\\nKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYK\\nIADMGHLKYYLAPKIEDEEGS',\n",
       "    'Number of residues': '261',\n",
       "    'Molecular Weight': '28768.48',\n",
       "    'Theoretical pI': 'Not Available',\n",
       "    'GO Classification': \"Functionschromatin binding / damaged DNA binding / dinucleotide insertion or deletion binding / DNA polymerase binding / DNA polymerase processivity factor activity / enzyme binding / estrogen receptor binding / histone acetyltransferase binding / identical protein binding / MutLalpha complex binding / purine-specific mismatch base pair DNA N-glycosylase activity / receptor tyrosine kinase bindingProcessescell proliferation / cellular response to hydrogen peroxide / cellular response to UV / DNA damage response, detection of DNA damage / DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest / DNA ligation / epithelial cell differentiation / error-free translesion synthesis / error-prone translesion synthesis / estrous cycle / G1/S transition of mitotic cell cycle / heart development / liver regeneration / mismatch repair / mitotic telomere maintenance via semi-conservative replication / nucleotide-excision repair, DNA gap filling / nucleotide-excision repair, DNA incision / nucleotide-excision repair, DNA incision, 5'-to lesion / positive regulation of deoxyribonuclease activity / positive regulation of DNA repair / positive regulation of DNA replication / protein sumoylation / regulation of transcription involved in G1/S transition of mitotic cell cycle / replication fork processing / response to cadmium ion / response to dexamethasone / response to estradiol / response to L-glutamate / telomere maintenance / telomere maintenance via recombination / transcription-coupled nucleotide-excision repair / translesion synthesisComponentscentrosome / DNA replication factor C complex / extracellular exosome / nuclear body / nuclear chromosome, telomeric region / nuclear replication fork / nucleoplasm / nucleus / PCNA complex / PCNA-p21 complex / replication fork / replisome\",\n",
       "    'General Function': \"Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways (PubMed:24939902). Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion.\",\n",
       "    'Specific Function': 'Chromatin binding',\n",
       "    'Pfam Domain Function': 'PCNA_C (PF02747)\\nPCNA_N (PF00705)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Nucleus',\n",
       "    'Gene sequence': '>lcl|BSEQ0049804|Proliferating cell nuclear antigen (PCNA)\\nATGTTCGAGGCGCGCCTGGTCCAGGGCTCCATCCTCAAGAAGGTGTTGGAGGCACTCAAG\\nGACCTCATCAACGAGGCCTGCTGGGATATTAGCTCCAGCGGTGTAAACCTGCAGAGCATG\\nGACTCGTCCCACGTCTCTTTGGTGCAGCTCACCCTGCGGTCTGAGGGCTTCGACACCTAC\\nCGCTGCGACCGCAACCTGGCCATGGGCGTGAACCTCACCAGTATGTCCAAAATACTAAAA\\nTGCGCCGGCAATGAAGATATCATTACACTAAGGGCCGAAGATAACGCGGATACCTTGGCG\\nCTAGTATTTGAAGCACCAAACCAGGAGAAAGTTTCAGACTATGAAATGAAGTTGATGGAT\\nTTAGATGTTGAACAACTTGGAATTCCAGAACAGGAGTACAGCTGTGTAGTAAAGATGCCT\\nTCTGGTGAATTTGCACGTATATGCCGAGATCTCAGCCATATTGGAGATGCTGTTGTAATT\\nTCCTGTGCAAAAGACGGAGTGAAATTTTCTGCAAGTGGAGAACTTGGAAATGGAAACATT\\nAAATTGTCACAGACAAGTAATGTCGATAAAGAGGAGGAAGCTGTTACCATAGAGATGAAT\\nGAACCAGTTCAACTAACTTTTGCACTGAGGTACCTGAACTTCTTTACAAAAGCCACTCCA\\nCTCTCTTCAACGGTGACACTCAGTATGTCTGCAGATGTACCCCTTGTTGTAGAGTATAAA\\nATTGCGGATATGGGACACTTAAAATACTACTTGGCTCCCAAGATCGAGGATGAAGAAGGA\\nTCTTAG',\n",
       "    'Chromosome Location': '20',\n",
       "    'Locus': '20p12.3',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP12004UniProtKB Entry NamePCNA_HUMANHGNC IDHGNC:8729',\n",
       "    'General References': \"Almendral JM, Huebsch D, Blundell PA, Macdonald-Bravo H, Bravo R: Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci U S A. 1987 Mar;84(6):1575-9. [Article] Travali S, Ku DH, Rizzo MG, Ottavio L, Baserga R, Calabretta B: Structure of the human gene for the proliferating cell nuclear antigen. J Biol Chem. 1989 May 5;264(13):7466-72. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Prelich G, Kostura M, Marshak DR, Mathews MB, Stillman B: The cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature. 1987 Apr 2-8;326(6112):471-5. [Article] Gary R, Ludwig DL, Cornelius HL, MacInnes MA, Park MS: The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21. J Biol Chem. 1997 Sep 26;272(39):24522-9. [Article] Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science. 1997 Sep 26;277(5334):1996-2000. [Article] Saha P, Chen J, Thome KC, Lawlis SJ, Hou ZH, Hendricks M, Parvin JD, Dutta A: Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase. Mol Cell Biol. 1998 May;18(5):2758-67. [Article] Ducoux M, Urbach S, Baldacci G, Hubscher U, Koundrioukoff S, Christensen J, Hughes P: Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA replication through a conserved p21(Cip1)-like PCNA-binding motif present in the third subunit of human DNA polymerase delta. J Biol Chem. 2001 Dec 28;276(52):49258-66. Epub 2001 Oct 10. [Article] Tsuchimoto D, Sakai Y, Sakumi K, Nishioka K, Sasaki M, Fujiwara T, Nakabeppu Y: Human APE2 protein is mostly localized in the nuclei and to some extent in the mitochondria, while nuclear APE2 is partly associated with proliferating cell nuclear antigen. Nucleic Acids Res. 2001 Jun 1;29(11):2349-60. [Article] Haracska L, Unk I, Johnson RE, Phillips BB, Hurwitz J, Prakash L, Prakash S: Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA. Mol Cell Biol. 2002 Feb;22(3):784-91. [Article] Fujita K, Shimazaki N, Ohta Y, Kubota T, Ibe S, Toji S, Tamai K, Fujisaki S, Hayano T, Koiwai O: Terminal deoxynucleotidyltransferase forms a ternary complex with a novel chromatin remodeling protein with 82 kDa and core histone. Genes Cells. 2003 Jun;8(6):559-71. [Article] Liu L, Rodriguez-Belmonte EM, Mazloum N, Xie B, Lee MY: Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen. J Biol Chem. 2003 Mar 21;278(12):10041-7. Epub 2003 Jan 9. [Article] Dzantiev L, Constantin N, Genschel J, Iyer RR, Burgers PM, Modrich P: A defined human system that supports bidirectional mismatch-provoked excision. Mol Cell. 2004 Jul 2;15(1):31-41. [Article] Kannouche PL, Wing J, Lehmann AR: Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol Cell. 2004 May 21;14(4):491-500. [Article] Poot RA, Bozhenok L, van den Berg DL, Steffensen S, Ferreira F, Grimaldi M, Gilbert N, Ferreira J, Varga-Weisz PD: The Williams syndrome transcription factor interacts with PCNA to target chromatin remodelling by ISWI to replication foci. Nat Cell Biol. 2004 Dec;6(12):1236-44. Epub 2004 Nov 14. [Article] Li H, Xie B, Zhou Y, Rahmeh A, Trusa S, Zhang S, Gao Y, Lee EY, Lee MY: Functional roles of p12, the fourth subunit of human DNA polymerase delta. J Biol Chem. 2006 May 26;281(21):14748-55. Epub 2006 Feb 28. [Article] Motegi A, Sood R, Moinova H, Markowitz SD, Liu PP, Myung K: Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J Cell Biol. 2006 Dec 4;175(5):703-8. Epub 2006 Nov 27. [Article] Jin J, Arias EE, Chen J, Harper JW, Walter JC: A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell. 2006 Sep 1;23(5):709-21. [Article] Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R, Hung MC: Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006 Dec;8(12):1359-68. Epub 2006 Nov 19. [Article] Unk I, Hajdu I, Fatyol K, Szakal B, Blastyak A, Bermudez V, Hurwitz J, Prakash L, Prakash S, Haracska L: Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18107-12. Epub 2006 Nov 15. [Article] Zhang S, Chea J, Meng X, Zhou Y, Lee EY, Lee MY: PCNA is ubiquitinated by RNF8. Cell Cycle. 2008 Nov 1;7(21):3399-404. [Article] Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, Dutta A: PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev. 2008 Sep 15;22(18):2496-506. doi: 10.1101/gad.1676108. [Article] Farina A, Shin JH, Kim DH, Bermudez VP, Kelman Z, Seo YS, Hurwitz J: Studies with the human cohesin establishment factor, ChlR1. Association of ChlR1 with Ctf18-RFC and Fen1. J Biol Chem. 2008 Jul 25;283(30):20925-36. doi: 10.1074/jbc.M802696200. Epub 2008 May 21. [Article] Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T: CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem. 2008 Oct 24;283(43):29045-52. doi: 10.1074/jbc.M806045200. Epub 2008 Aug 14. [Article] Burkovics P, Hajdu I, Szukacsov V, Unk I, Haracska L: Role of PCNA-dependent stimulation of 3'-phosphodiesterase and 3'-5' exonuclease activities of human Ape2 in repair of oxidative DNA damage. Nucleic Acids Res. 2009 Jul;37(13):4247-55. doi: 10.1093/nar/gkp357. Epub 2009 May 13. [Article] Unk I, Hajdu I, Fatyol K, Hurwitz J, Yoon JH, Prakash L, Prakash S, Haracska L: Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3768-73. doi: 10.1073/pnas.0800563105. Epub 2008 Mar 3. [Article] Motegi A, Liaw HJ, Lee KY, Roest HP, Maas A, Wu X, Moinova H, Markowitz SD, Ding H, Hoeijmakers JH, Myung K: Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12411-6. doi: 10.1073/pnas.0805685105. Epub 2008 Aug 21. [Article] Yu Y, Cai JP, Tu B, Wu L, Zhao Y, Liu X, Li L, McNutt MA, Feng J, He Q, Yang Y, Wang H, Sekiguchi M, Zhu WG: Proliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2. J Biol Chem. 2009 Jul 17;284(29):19310-20. doi: 10.1074/jbc.M109.015289. Epub 2009 May 6. [Article] Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16. [Article] Terai K, Abbas T, Jazaeri AA, Dutta A: CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell. 2010 Jan 15;37(1):143-9. doi: 10.1016/j.molcel.2009.12.018. [Article] Ogi T, Limsirichaikul S, Overmeer RM, Volker M, Takenaka K, Cloney R, Nakazawa Y, Niimi A, Miki Y, Jaspers NG, Mullenders LH, Yamashita S, Fousteri MI, Lehmann AR: Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell. 2010 Mar 12;37(5):714-27. doi: 10.1016/j.molcel.2010.02.009. [Article] Moldovan GL, Madhavan MV, Mirchandani KD, McCaffrey RM, Vinciguerra P, D'Andrea AD: DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol Cell Biol. 2010 Feb;30(4):1088-96. doi: 10.1128/MCB.01124-09. Epub 2009 Dec 7. [Article] De Haro LP, Wray J, Williamson EA, Durant ST, Corwin L, Gentry AC, Osheroff N, Lee SH, Hromas R, Nickoloff JA: Metnase promotes restart and repair of stalled and collapsed replication forks. Nucleic Acids Res. 2010 Sep;38(17):5681-91. doi: 10.1093/nar/gkq339. Epub 2010 May 10. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Rowbotham SP, Barki L, Neves-Costa A, Santos F, Dean W, Hawkes N, Choudhary P, Will WR, Webster J, Oxley D, Green CM, Varga-Weisz P, Mermoud JE: Maintenance of silent chromatin through replication requires SWI/SNF-like chromatin remodeler SMARCAD1. Mol Cell. 2011 May 6;42(3):285-96. doi: 10.1016/j.molcel.2011.02.036. [Article] Emanuele MJ, Ciccia A, Elia AE, Elledge SJ: Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9845-50. doi: 10.1073/pnas.1106136108. Epub 2011 May 31. [Article] Rahmeh AA, Zhou Y, Xie B, Li H, Lee EY, Lee MY: Phosphorylation of the p68 subunit of Pol delta acts as a molecular switch to regulate its interaction with PCNA. Biochemistry. 2012 Jan 10;51(1):416-24. doi: 10.1021/bi201638e. Epub 2011 Dec 20. [Article] Moldovan GL, Dejsuphong D, Petalcorin MI, Hofmann K, Takeda S, Boulton SJ, D'Andrea AD: Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell. 2012 Jan 13;45(1):75-86. doi: 10.1016/j.molcel.2011.11.010. Epub 2011 Dec 6. [Article] Centore RC, Yazinski SA, Tse A, Zou L: Spartan/C1orf124, a reader of PCNA ubiquitylation and a regulator of UV-induced DNA damage response. Mol Cell. 2012 Jun 8;46(5):625-35. doi: 10.1016/j.molcel.2012.05.020. [Article] Weston R, Peeters H, Ahel D: ZRANB3 is a structure-specific ATP-dependent endonuclease involved in replication stress response. Genes Dev. 2012 Jul 15;26(14):1558-72. doi: 10.1101/gad.193516.112. Epub 2012 Jul 3. [Article] Yuan J, Ghosal G, Chen J: The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and participates in cellular response to replication stress. Mol Cell. 2012 Aug 10;47(3):410-21. doi: 10.1016/j.molcel.2012.05.025. Epub 2012 Jun 14. [Article] Povlsen LK, Beli P, Wagner SA, Poulsen SL, Sylvestersen KB, Poulsen JW, Nielsen ML, Bekker-Jensen S, Mailand N, Choudhary C: Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol. 2012 Oct;14(10):1089-98. doi: 10.1038/ncb2579. Epub 2012 Sep 23. [Article] Ciccia A, Nimonkar AV, Hu Y, Hajdu I, Achar YJ, Izhar L, Petit SA, Adamson B, Yoon JC, Kowalczykowski SC, Livingston DM, Haracska L, Elledge SJ: Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol Cell. 2012 Aug 10;47(3):396-409. doi: 10.1016/j.molcel.2012.05.024. Epub 2012 Jun 14. [Article] Arboleda VA, Lee H, Parnaik R, Fleming A, Banerjee A, Ferraz-de-Souza B, Delot EC, Rodriguez-Fernandez IA, Braslavsky D, Bergada I, Dell'Angelica EC, Nelson SF, Martinez-Agosto JA, Achermann JC, Vilain E: Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet. 2012 May 27;44(7):788-92. doi: 10.1038/ng.2275. [Article] Menning M, Kufer TA: A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and Nod2-mediated inflammatory responses. FEBS Lett. 2013 Jul 11;587(14):2137-42. doi: 10.1016/j.febslet.2013.05.037. Epub 2013 May 24. [Article] Bacquin A, Pouvelle C, Siaud N, Perderiset M, Salome-Desnoulez S, Tellier-Lebegue C, Lopez B, Charbonnier JB, Kannouche PL: The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells. Nucleic Acids Res. 2013 Jul;41(13):6501-13. doi: 10.1093/nar/gkt397. Epub 2013 May 15. [Article] Vannier JB, Sandhu S, Petalcorin MI, Wu X, Nabi Z, Ding H, Boulton SJ: RTEL1 is a replisome-associated helicase that promotes telomere and genome-wide replication. Science. 2013 Oct 11;342(6155):239-42. doi: 10.1126/science.1241779. [Article] Baple EL, Chambers H, Cross HE, Fawcett H, Nakazawa Y, Chioza BA, Harlalka GV, Mansour S, Sreekantan-Nair A, Patton MA, Muggenthaler M, Rich P, Wagner K, Coblentz R, Stein CK, Last JI, Taylor AM, Jackson AP, Ogi T, Lehmann AR, Green CM, Crosby AH: Hypomorphic PCNA mutation underlies a human DNA repair disorder. J Clin Invest. 2014 Jul;124(7):3137-46. doi: 10.1172/JCI74593. Epub 2014 Jun 9. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Alabert C, Bukowski-Wills JC, Lee SB, Kustatscher G, Nakamura K, de Lima Alves F, Menard P, Mejlvang J, Rappsilber J, Groth A: Nascent chromatin capture proteomics determines chromatin dynamics during DNA replication and identifies unknown fork components. Nat Cell Biol. 2014 Mar;16(3):281-93. doi: 10.1038/ncb2918. Epub 2014 Feb 23. [Article] Cazzalini O, Sommatis S, Tillhon M, Dutto I, Bachi A, Rapp A, Nardo T, Scovassi AI, Necchi D, Cardoso MC, Stivala LA, Prosperi E: CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis. Nucleic Acids Res. 2014 Jul;42(13):8433-48. doi: 10.1093/nar/gku533. Epub 2014 Jun 17. [Article] Impens F, Radoshevich L, Cossart P, Ribet D: Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12432-7. doi: 10.1073/pnas.1413825111. Epub 2014 Aug 11. [Article] Perry JJ, Ballard GD, Albert AE, Dobrolecki LE, Malkas LH, Hoelz DJ: Human C6orf211 encodes Armt1, a protein carboxyl methyltransferase that targets PCNA and is linked to the DNA damage response. Cell Rep. 2015 Mar 3;10(8):1288-96. doi: 10.1016/j.celrep.2015.01.054. Epub 2015 Feb 26. [Article] Hendriks IA, Treffers LW, Verlaan-de Vries M, Olsen JV, Vertegaal AC: SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage. Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00179-5. doi: 10.1016/j.celrep.2015.02.033. [Article] Xiao Z, Chang JG, Hendriks IA, Sigurethsson JO, Olsen JV, Vertegaal AC: System-wide Analysis of SUMOylation Dynamics in Response to Replication Stress Reveals Novel Small Ubiquitin-like Modified Target Proteins and Acceptor Lysines Relevant for Genome Stability. Mol Cell Proteomics. 2015 May;14(5):1419-34. doi: 10.1074/mcp.O114.044792. Epub 2015 Mar 9. [Article] Vaca Jacome AS, Rabilloud T, Schaeffer-Reiss C, Rompais M, Ayoub D, Lane L, Bairoch A, Van Dorsselaer A, Carapito C: N-terminome analysis of the human mitochondrial proteome. Proteomics. 2015 Jul;15(14):2519-24. doi: 10.1002/pmic.201400617. Epub 2015 Jun 8. [Article] Gulbis JM, Kelman Z, Hurwitz J, O'Donnell M, Kuriyan J: Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell. 1996 Oct 18;87(2):297-306. [Article] Sakurai S, Kitano K, Yamaguchi H, Hamada K, Okada K, Fukuda K, Uchida M, Ohtsuka E, Morioka H, Hakoshima T: Structural basis for recruitment of human flap endonuclease 1 to PCNA. EMBO J. 2005 Feb 23;24(4):683-93. Epub 2004 Dec 16. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00279Liothyronineapproved, vet_approvedunknownantagonistDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowndownregulatorDetails'}},\n",
       "  {},\n",
       "  {'Label': 'Sialidase-1',\n",
       "   'Detailed Info': {'Name': 'Sialidase-1',\n",
       "    'Synonyms': '3.2.1.18\\nAcetylneuraminyl hydrolase\\nG9 sialidase\\nLysosomal sialidase\\nN-acetyl-alpha-neuraminidase 1\\nNANH',\n",
       "    'Gene Name': 'NEU1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0016250|Sialidase-1\\nMTGERPSTALPDRRWGPRILGFWGGCRVWVFAAIFLLLSLAASWSKAENDFGLVQPLVTM\\nEQLLWVSGRQIGSVDTFRIPLITATPRGTLLAFAEARKMSSSDEGAKFIALRRSMDQGST\\nWSPTAFIVNDGDVPDGLNLGAVVSDVETGVVFLFYSLCAHKAGCQVASTMLVWSKDDGVS\\nWSTPRNLSLDIGTEVFAPGPGSGIQKQREPRKGRLIVCGHGTLERDGVFCLLSDDHGASW\\nRYGSGVSGIPYGQPKQENDFNPDECQPYELPDGSVVINARNQNNYHCHCRIVLRSYDACD\\nTLRPRDVTFDPELVDPVVAAGAVVTSSGIVFFSNPAHPEFRVNLTLRWSFSNGTSWRKET\\nVQLWPGPSGYSSLATLEGSMDGEEQAPQLYVLYEKGRNHYTESISVAKISVYGTL',\n",
       "    'Number of residues': '415',\n",
       "    'Molecular Weight': '45466.96',\n",
       "    'Theoretical pI': '5.68',\n",
       "    'GO Classification': 'Functionsexo-alpha-(2->3)-sialidase activity / exo-alpha-(2->6)-sialidase activity / exo-alpha-(2->8)-sialidase activity / exo-alpha-sialidase activityProcessescellular protein metabolic process / dolichol-linked oligosaccharide biosynthetic process / ganglioside catabolic process / glycosphingolipid metabolic process / oligosaccharide catabolic process / positive regulation of neuron projection development / post-translational protein modification / protein N-linked glycosylation via asparagine / regulation of myoblast proliferation / small molecule metabolic process / sphingolipid metabolic processComponentscell junction / cell surface / cytoplasmic membrane-bounded vesicle / extracellular exosome / intracellular membrane-bounded organelle / lysosomal lumen / lysosomal membrane / lysosome / membrane / plasma membrane',\n",
       "    'General Function': 'Exo-alpha-sialidase activity',\n",
       "    'Specific Function': 'Catalyzes the removal of sialic acid (N-acetylneuraminic acid) moities from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex. Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl linkage.',\n",
       "    'Pfam Domain Function': 'BNR_2 (PF13088)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Lysosome membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0016251|Sialidase-1 (NEU1)\\nATGACTGGGGAGCGACCCAGCACGGCGCTCCCGGACAGACGCTGGGGGCCGCGGATTCTG\\nGGCTTCTGGGGAGGCTGTAGGGTTTGGGTGTTTGCCGCGATCTTCCTGCTGCTGTCTCTG\\nGCAGCCTCCTGGTCCAAGGCTGAGAACGACTTCGGTCTGGTGCAGCCGCTGGTGACCATG\\nGAGCAACTGCTGTGGGTGAGCGGGAGACAGATCGGCTCAGTGGACACCTTCCGCATCCCG\\nCTCATCACAGCCACTCCGCGGGGCACTCTTCTCGCCTTTGCTGAGGCGAGGAAAATGTCC\\nTCATCCGATGAGGGGGCCAAGTTCATCGCCCTGCGGAGGTCCATGGACCAGGGCAGCACA\\nTGGTCTCCTACAGCGTTCATTGTCAATGATGGGGATGTCCCCGATGGGCTGAACCTTGGG\\nGCAGTAGTGAGCGATGTTGAGACAGGAGTAGTATTTCTTTTCTACTCCCTTTGTGCTCAC\\nAAGGCCGGCTGCCAGGTGGCCTCTACCATGTTGGTATGGAGCAAGGATGATGGTGTTTCC\\nTGGAGCACACCCCGGAATCTCTCCCTGGATATTGGCACTGAAGTGTTTGCCCCTGGACCG\\nGGCTCTGGTATTCAGAAACAGCGGGAGCCACGGAAGGGCCGCCTCATCGTGTGTGGCCAT\\nGGGACGCTGGAGCGGGACGGAGTCTTCTGTCTCCTCAGCGATGATCATGGTGCCTCCTGG\\nCGCTACGGAAGTGGGGTCAGCGGCATCCCCTACGGTCAGCCCAAGCAGGAAAATGATTTC\\nAATCCTGATGAATGCCAGCCCTATGAGCTCCCAGATGGCTCAGTCGTCATCAATGCCCGA\\nAACCAGAACAACTACCACTGCCACTGCCGAATTGTCCTCCGCAGCTATGATGCCTGTGAT\\nACACTAAGGCCCCGTGATGTGACCTTCGACCCTGAGCTCGTGGACCCTGTGGTAGCTGCA\\nGGAGCTGTAGTCACCAGCTCCGGCATTGTCTTCTTCTCCAACCCAGCACATCCAGAGTTC\\nCGAGTGAACCTGACCCTGCGATGGAGCTTCAGCAATGGTACCTCATGGCGGAAAGAGACA\\nGTCCAGCTATGGCCAGGCCCCAGTGGCTATTCATCCCTGGCAACCCTGGAGGGCAGCATG\\nGATGGAGAGGAGCAGGCCCCCCAGCTCTACGTCCTGTATGAGAAAGGCCGGAACCACTAC\\nACAGAGAGCATCTCCGTGGCCAAAATCAGTGTCTATGGGACACTCTGA',\n",
       "    'Chromosome Location': '6',\n",
       "    'Locus': '6p21.3',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDQ99519UniProtKB Entry NameNEUR1_HUMANGenBank Protein ID2773339GenBank Gene IDAF040958GenAtlas IDNEU1HGNC IDHGNC:7758',\n",
       "    'General References': \"Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A: Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996 Dec 15;10(24):3156-69. [Article] Milner CM, Smith SV, Carrillo MB, Taylor GL, Hollinshead M, Campbell RD: Identification of a sialidase encoded in the human major histocompatibility complex. J Biol Chem. 1997 Feb 14;272(7):4549-58. [Article] Pshezhetsky AV, Richard C, Michaud L, Igdoura S, Wang S, Elsliger MA, Qu J, Leclerc D, Gravel R, Dallaire L, Potier M: Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet. 1997 Mar;15(3):316-20. [Article] Xie T, Rowen L, Aguado B, Ahearn ME, Madan A, Qin S, Campbell RD, Hood L: Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. Genome Res. 2003 Dec;13(12):2621-36. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Vinogradova MV, Michaud L, Mezentsev AV, Lukong KE, El-Alfy M, Morales CR, Potier M, Pshezhetsky AV: Molecular mechanism of lysosomal sialidase deficiency in galactosialidosis involves its rapid degradation. Biochem J. 1998 Mar 1;330 ( Pt 2):641-50. [Article] Lukong KE, Seyrantepe V, Landry K, Trudel S, Ahmad A, Gahl WA, Lefrancois S, Morales CR, Pshezhetsky AV: Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail. J Biol Chem. 2001 Dec 7;276(49):46172-81. Epub 2001 Sep 24. [Article] Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61. doi: 10.1021/pr8008012. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Lukong KE, Elsliger MA, Chang Y, Richard C, Thomas G, Carey W, Tylki-Szymanska A, Czartoryska B, Buchholz T, Criado GR, Palmeri S, Pshezhetsky AV: Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum Mol Genet. 2000 Apr 12;9(7):1075-85. [Article] Bonten EJ, Arts WF, Beck M, Covanis A, Donati MA, Parini R, Zammarchi E, d'Azzo A: Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet. 2000 Nov 1;9(18):2715-25. [Article] Naganawa Y, Itoh K, Shimmoto M, Takiguchi K, Doi H, Nishizawa Y, Kobayashi T, Kamei S, Lukong KE, Pshezhetsky AV, Sakuraba H: Molecular and structural studies of Japanese patients with sialidosis type 1. J Hum Genet. 2000;45(4):241-9. [Article] Lukong KE, Landry K, Elsliger MA, Chang Y, Lefrancois S, Morales CR, Pshezhetsky AV: Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex. J Biol Chem. 2001 May 18;276(20):17286-90. Epub 2001 Feb 20. [Article] Itoh K, Naganawa Y, Matsuzawa F, Aikawa S, Doi H, Sasagasako N, Yamada T, Kira J, Kobayashi T, Pshezhetsky AV, Sakuraba H: Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J Hum Genet. 2002;47(1):29-37. [Article] Pattison S, Pankarican M, Rupar CA, Graham FL, Igdoura SA: Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Hum Mutat. 2004 Jan;23(1):32-9. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00198OseltamivirapprovedunknowninhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB00482Celecoxibapproved, investigationalyesinhibitorDetails'}}],\n",
       " 'enzymes': [{'Label': 'Cytochrome P450 2C19',\n",
       "   'Detailed Info': {'Name': 'Cytochrome P450 2C19',\n",
       "    'Synonyms': '(R)-limonene 6-monooxygenase\\n(S)-limonene 6-monooxygenase\\n(S)-limonene 7-monooxygenase\\n1.14.13.-\\nCYPIIC17\\nCYPIIC19\\nCytochrome P450-11A\\nCytochrome P450-254C\\nMephenytoin 4-hydroxylase',\n",
       "    'Gene Name': 'CYP2C19',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0020694|Cytochrome P450 2C19\\nMDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI\\nYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW\\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\\nIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM\\nESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE\\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID\\nLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK\\nKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP\\nPFYQLCFIPV',\n",
       "    'Number of residues': '490',\n",
       "    'Molecular Weight': '55930.545',\n",
       "    'Theoretical pI': '7.42',\n",
       "    'GO Classification': 'Functions(R)-limonene 6-monooxygenase activity / (S)-limonene 6-monooxygenase activity / (S)-limonene 7-monooxygenase activity / arachidonic acid epoxygenase activity / enzyme binding / heme binding / iron ion binding / monooxygenase activity / oxidoreductase activity / oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen / oxygen binding / steroid hydroxylase activityProcessesarachidonic acid metabolic process / drug metabolic process / epoxygenase P450 pathway / exogenous drug catabolic process / heterocycle metabolic process / monoterpenoid metabolic process / omega-hydroxylase P450 pathway / oxidation-reduction process / small molecule metabolic process / steroid metabolic process / xenobiotic metabolic processComponentscytoplasm / endoplasmic reticulum membrane / intracellular membrane-bounded organelle',\n",
       "    'General Function': 'Steroid hydroxylase activity',\n",
       "    'Specific Function': 'Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.',\n",
       "    'Pfam Domain Function': 'p450 (PF00067)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Endoplasmic reticulum membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19)\\nATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG\\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\\nAATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC\\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT\\nGAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC\\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG\\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\\nGCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\\nATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA\\nTTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC\\nACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG\\nGAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT\\nCGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT\\nGAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG\\nACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\\nGCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG\\nGACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC\\nCTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC\\nATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA\\nTTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG\\nAAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG\\nGCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT\\nCTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG\\nCCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA',\n",
       "    'Chromosome Location': '10',\n",
       "    'Locus': '10q24.1-q24.3',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP33261UniProtKB Entry NameCP2CJ_HUMANGenBank Protein ID181344GenBank Gene IDM61854HGNC IDHGNC:2621',\n",
       "    'General References': \"Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry. 1991 Apr 2;30(13):3247-55. [Article] Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily. Biochemistry. 1993 Feb 9;32(5):1390. [Article] Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10. Nature. 2004 May 27;429(6990):375-81. [Article] Wrighton SA, Stevens JC, Becker GW, VandenBranden M: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys. 1993 Oct;306(1):240-5. [Article] Miyazawa M, Shindo M, Shimada T: Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab Dispos. 2002 May;30(5):602-7. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Reynald RL, Sansen S, Stout CD, Johnson EF: Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem. 2012 Dec 28;287(53):44581-91. doi: 10.1074/jbc.M112.424895. Epub 2012 Nov 1. [Article] de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22. [Article] De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 Oct;46(4):594-8. [Article] Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997 Apr;281(1):604-9. [Article] Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5. [Article] Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998 Apr;8(2):129-35. [Article] Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug;290(2):635-40. [Article] Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002 Dec;12(9):703-11. [Article] Morita J, Kobayashi K, Wanibuchi A, Kimura M, Irie S, Ishizaki T, Chiba K: A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8. [Article] Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 Oct;5(7):895-931. [Article] Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada J: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005 Aug;20(4):300-7. [Article]\",\n",
       "    'Drug Relations': \"DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00188Bortezomibapproved, investigationalnosubstrateinhibitorDetailsDB00213PantoprazoleapprovedunknownsubstrateinhibitorDetailsDB00215CitalopramapprovednosubstrateinhibitorDetailsDB00220NelfinavirapprovednosubstrateinducerDetailsDB00252Phenytoinapproved, vet_approvednosubstrateinducerDetailsDB00273TopiramateapprovedunknowninhibitorDetailsDB00328Indomethacinapproved, investigationalunknownsubstrateinhibitorDetailsDB00338Omeprazoleapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00349Clobazamapproved, illicitnosubstrateDetailsDB00395CarisoprodolapprovedunknownsubstrateDetailsDB00396Progesteroneapproved, vet_approvedunknownsubstrateinhibitorDetailsDB00420Promazineapproved, vet_approvedunknownsubstrateDetailsDB00444TeniposideapprovedunknownsubstrateDetailsDB00448Lansoprazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB00546AdinazolamexperimentalunknownsubstrateDetailsDB00582VoriconazoleapprovedunknownsubstrateinhibitorDetailsDB00665Nilutamideapproved, investigationalunknownsubstrateinhibitorDetailsDB00679Thioridazineapproved, withdrawnunknownsubstrateDetailsDB00736Esomeprazoleapproved, investigationalnosubstrateinhibitorDetailsDB00738Pentamidineapproved, investigationalunknownsubstrateDetailsDB00794Primidoneapproved, vet_approvedunknownsubstrateinducerDetailsDB00849MethylphenobarbitalapprovedunknownsubstrateDetailsDB00949FelbamateapprovedunknowninhibitorDetailsDB01018Guanfacineapproved, investigationalunknownsubstrateDetailsDB01104SertralineapprovedunknownsubstrateinhibitorDetailsDB01124Tolbutamideapproved, investigationalunknownsubstrateDetailsDB01129Rabeprazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB01131ProguanilapprovedunknownsubstrateDetailsDB01166Cilostazolapproved, investigationalunknownsubstrateDetailsDB01171Moclobemideapproved, investigationalunknownsubstrateinhibitorDetailsDB01174Phenobarbitalapproved, investigationalunknownsubstrateinducerDetailsDB01274Arformoterolapproved, investigationalunknownsubstrateDetailsDB01320Fosphenytoinapproved, investigationalunknownsubstrateDetailsDB01544Flunitrazepamapproved, illicitunknownsubstrateDetailsDB00176Fluvoxamineapproved, investigationalnoinhibitorDetailsDB00197Troglitazoneapproved, investigational, withdrawnunknowninhibitorDetailsDB00208TiclopidineapprovedunknownsubstrateinhibitorDetailsDB00321AmitriptylineapprovedunknownsubstrateinhibitorDetailsDB00343Diltiazemapproved, investigationalunknownsubstrateDetailsDB00455Loratadineapproved, investigationalnosubstrateinhibitorDetailsDB00458ImipramineapprovedunknownsubstrateinhibitorDetailsDB00503Ritonavirapproved, investigationalnoinducerDetailsDB00532Mephenytoinapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00586Diclofenacapproved, vet_approvedunknownsubstrateDetailsDB00622Nicardipineapproved, investigationalunknowninhibitorDetailsDB00625Efavirenzapproved, investigationalunknowninducerDetailsDB00745Modafinilapproved, investigationalunknowninhibitorDetailsDB00752Tranylcypromineapproved, investigationalunknowninhibitorDetailsDB00776OxcarbazepineapprovedunknowninhibitorDetailsDB01026Ketoconazoleapproved, investigationalunknowninhibitorDetailsDB01041Thalidomideapproved, investigational, withdrawnnosubstrateinhibitorDetailsDB01424Aminophenazoneapproved, withdrawnunknownsubstrateDetailsDB00333MethadoneapprovedunknownsubstrateDetailsDB06442AvasimibeinvestigationalunknowninhibitorDetailsDB01065Melatoninapproved, nutraceutical, vet_approvedunknownsubstrateDetailsDB01076AtorvastatinapprovednoinhibitorDetailsDB01095FluvastatinapprovedunknowninhibitorDetailsDB00196Fluconazoleapproved, investigationalunknowninhibitorDetailsDB00619ImatinibapprovednosubstrateDetailsDB00468QuinineapprovedunknownsubstrateinhibitorDetailsDB01142Doxepinapproved, investigationalnosubstrateDetailsDB01435Antipyrineapproved, investigationalunknownsubstrateDetailsDB00250Dapsoneapproved, investigationalunknownsubstrateDetailsDB00675TamoxifenapprovedunknownsubstrateDetailsDB05109Trabectedinapproved, investigationalunknownsubstrateDetailsDB01418Acenocoumarolapproved, investigationalunknownsubstrateDetailsDB00682WarfarinapprovedunknownsubstrateinhibitorDetailsDB00540NortriptylineapprovedunknownsubstrateDetailsDB00857Terbinafineapproved, investigational, vet_approvedunknownsubstrateDetailsDB00972AzelastineapprovedunknownsubstrateinhibitorDetailsDB01075Diphenhydramineapproved, investigationalunknownsubstrateDetailsDB00829Diazepamapproved, illicit, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00446Chloramphenicolapproved, vet_approved, withdrawnunknowninhibitorDetailsDB01242Clomipramineapproved, investigational, vet_approvedunknownsubstrateDetailsDB00758ClopidogrelapprovednosubstrateDetailsDB00531Cyclophosphamideapproved, investigationalunknownsubstrateDetailsDB01355HexobarbitalexperimentalunknownsubstrateDetailsDB00571Propranololapproved, investigationalunknownsubstrateDetailsDB00501Cimetidineapproved, investigationalunknowninhibitorDetailsDB00472Fluoxetineapproved, vet_approvedunknownsubstrateinhibitorDetailsDB06403Ambrisentanapproved, investigationalunknownsubstrateDetailsDB01175EscitalopramapprovednosubstrateDetailsDB06414EtravirineapprovedunknownsubstrateinhibitorDetailsDB01181IfosfamideapprovedunknownsubstrateDetailsDB05246MethsuximideapprovedunknownsubstrateinhibitorDetailsDB00726TrimipramineapprovedunknownsubstrateDetailsDB00357Aminoglutethimideapproved, investigationalunknowninducerDetailsDB00564Carbamazepineapproved, investigationalunknowninhibitorinducerDetailsDB01601LopinavirapprovedunknowninhibitorDetailsDB01045RifampicinapprovedunknowninducerDetailsDB06413Armodafinilapproved, investigationalunknowninhibitorDetailsDB00705DelavirdineapprovedunknowninhibitorDetailsDB01241GemfibrozilapprovedunknowninhibitorDetailsDB00951Isoniazidapproved, investigationalunknowninhibitorDetailsDB06268Sitaxentanapproved, investigational, withdrawnunknowninhibitorDetailsDB00216Eletriptanapproved, investigationalunknownsubstrateDetailsDB00363ClozapineapprovednosubstrateinhibitorDetailsDB00425ZolpidemapprovedunknownsubstrateDetailsDB01036Tolterodineapproved, investigationalunknownsubstrateDetailsDB01283Lumiracoxibapproved, investigationalunknownsubstrateDetailsDB00203Sildenafilapproved, investigationalunknownsubstrateinhibitorDetailsDB00672Chlorpropamideapproved, investigationalunknownsubstrateDetailsDB01120GliclazideapprovedunknownsubstrateDetailsDB01016GlyburideapprovedunknownsubstrateDetailsDB06739SeratrodastexperimentalunknownsubstrateDetailsDB06697ArtemetherapprovedunknownsubstrateinducerDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninducerDetailsDB01118Amiodaroneapproved, investigationalunknownsubstrateinhibitorDetailsDB00701Amprenavirapproved, investigationalunknowninhibitorDetailsDB00673Aprepitantapproved, investigationalunknownsubstrateinhibitorDetailsDB00289AtomoxetineapprovedunknownsubstrateDetailsDB01558Bromazepamapproved, illicit, investigationalunknownsubstrateDetailsDB00297Bupivacaineapproved, investigationalunknownsubstrateDetailsDB00921Buprenorphineapproved, illicit, investigational, vet_approvedunknowninhibitorDetailsDB00091Cyclosporineapproved, investigational, vet_approvedunknowninhibitorDetailsDB00604Cisaprideapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB06470ClomethiazoleinvestigationalunknownsubstrateDetailsDB01559Clotiazepamapproved, illicitunknownsubstrateDetailsDB01234Dexamethasoneapproved, investigational, vet_approvedunknowninducerDetailsDB00514DextromethorphanapprovedunknownsubstrateDetailsDB01093Dimethyl sulfoxideapproved, vet_approvedunknowninhibitorDetailsDB00590DoxazosinapprovedunknownsubstrateDetailsDB00783Estradiolapproved, investigational, vet_approvedunknownsubstrateDetailsDB00898EthanolapprovedunknowninhibitorDetailsDB01628Etoricoxibapproved, investigationalunknowninhibitorDetailsDB00502HaloperidolapprovedunknownsubstrateDetailsDB01050IbuprofenapprovedunknownsubstrateDetailsDB06738KetobemidoneinvestigationalunknownsubstrateDetailsDB00678LosartanapprovedunknowninhibitorDetailsDB01043Memantineapproved, investigationalunknowninhibitorDetailsDB01110Miconazoleapproved, investigational, vet_approvedunknowninhibitorDetailsDB00184NicotineapprovedunknownsubstrateDetailsDB06712Nilvadipineapproved, investigationalunknowninhibitorDetailsDB00717NorethisteroneapprovedunknownsubstrateinducerDetailsDB00334Olanzapineapproved, investigationalunknowninhibitorDetailsDB00312Pentobarbitalapproved, investigational, vet_approvedunknownsubstrateDetailsDB00850PerphenazineapprovedunknownsubstrateDetailsDB00454MeperidineapprovedunknownsubstrateDetailsDB03783PhenacetinwithdrawnunknownsubstrateDetailsDB00780PhenelzineapprovedunknowninhibitorDetailsDB01058Praziquantelapproved, investigational, vet_approvedunknownsubstrateDetailsDB00635Prednisoneapproved, vet_approvedunknowninducerDetailsDB00818Propofolapproved, investigational, vet_approvedunknownsubstrateDetailsDB01589Quazepamapproved, illicitnosubstrateDetailsDB01224QuetiapineapprovedunknownsubstrateDetailsDB01037Selegilineapproved, investigational, vet_approvedunknownsubstrateDetailsDB00966Telmisartanapproved, investigationalunknowninhibitorDetailsDB00624Testosteroneapproved, investigationalunknownsubstrateDetailsDB00763MethimazoleapprovedunknowninhibitorDetailsDB00373TimololapprovedunknownsubstrateDetailsDB01007TioconazoleapprovedunknowninhibitorDetailsDB00347TrimethadioneapprovedunknownsubstrateDetailsDB00313Valproic acidapproved, investigationalunknownsubstrateinhibitorDetailsDB00661VerapamilapprovedunknownsubstrateDetailsDB00549Zafirlukastapproved, investigationalunknowninhibitorDetailsDB00909Zonisamideapproved, investigationalunknownsubstrateinhibitorDetailsDB00398Sorafenibapproved, investigationalunknowninhibitorDetailsDB00932Tipranavirapproved, investigationalunknownsubstrateinhibitorDetailsDB00980Ramelteonapproved, investigationalunknownsubstrateDetailsDB01128BicalutamideapprovedunknowninhibitorDetailsDB01259Lapatinibapproved, investigationalunknownsubstrateDetailsDB01621Pipotiazineapproved, investigationalunknownsubstrateDetailsDB00918Almotriptanapproved, investigationalunknownsubstrateDetailsDB04920Clevidipineapproved, investigationalunknowninhibitorDetailsDB00109Enfuvirtideapproved, investigationalunknownsubstrateDetailsDB00239OxiconazoleapprovedunknownsubstrateDetailsDB06204TapentadolapprovedunknownsubstrateDetailsDB06209PrasugrelapprovednosubstrateDetailsDB04871Lorcaserinapproved, withdrawnnosubstrateDetailsDB08864RilpivirineapprovedunknownsubstrateinhibitorDetailsDB06605ApixabanapprovedunknownsubstrateDetailsDB06626Axitinibapproved, investigationalnosubstrateDetailsDB08828Vismodegibapproved, investigationalunknowninhibitorDetailsDB08899EnzalutamideapprovednoinducerDetailsDB08895Tofacitinibapproved, investigationalnosubstrateDetailsDB04938Ospemifeneapproved, investigationalunknownsubstrateDetailsDB00317Gefitinibapproved, investigationalunknowninhibitorDetailsDB08918Levomilnacipranapproved, investigationalunknownsubstrateDetailsDB08932MacitentanapprovednosubstrateDetailsDB08933LuliconazoleapprovednoinhibitorDetailsDB09049NaloxegolapprovedunknowninhibitorDetailsDB00951Isoniazidapproved, investigationalunknownDetailsDB09054IdelalisibapprovednoinhibitorDetailsDB09068Vortioxetineapproved, investigationalnosubstrateDetailsDB09280LumacaftorapprovednoinducerDetailsDB09570Ixazomibapproved, investigationalunknownsubstrateDetailsDB06176Romidepsinapproved, investigationalunknownsubstrateDetailsDB09119Eslicarbazepine acetateapprovednoinhibitorDetailsDB06789Hydroxyprogesterone caproateapproved, investigationalunknowninducerDetailsDB05812AbirateroneapprovedunknowninhibitorDetailsDB09118StiripentolapprovedunknownsubstrateinhibitorDetailsDB06595Midostaurinapproved, investigationalunknowninhibitorinducerDetailsDB05541Brivaracetamapproved, investigationalnosubstrateDetailsDB05351Dexlansoprazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB01685TopiroxostatexperimentalunknowninhibitorDetailsDB09120Zucapsaicinapproved, investigationalunknowninhibitorDetailsDB09198LobeglitazoneexperimentalnoinhibitorDetailsDB09167DosulepinapprovedunknowninhibitorDetailsDB09166EtizolamexperimentalunknownsubstrateDetailsDB11614RupatadineapprovednosubstrateDetailsDB12319Benzbromaroneinvestigational, withdrawnunknowninhibitorDetailsDB09238Manidipineapproved, investigationalunknowninhibitorDetailsDB13874Enasidenibapproved, investigationalunknownsubstrateinhibitorDetailsDB12070Letermovirapproved, investigationalnoinducerDetailsDB12332Rucaparibapproved, investigationalnoinhibitorDetailsDB09061Cannabidiolapproved, investigationalunknownsubstrateinhibitorDetailsDB13943Testosterone cypionateapprovedunknownsubstrateDetailsDB13944Testosterone enanthateapprovedunknownsubstrateDetailsDB13946Testosterone undecanoateapproved, investigationalunknownsubstrateDetailsDB13952Estradiol acetateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13953Estradiol benzoateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13954Estradiol cypionateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13955Estradiol dienanthateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13956Estradiol valerateapproved, investigational, vet_approvedunknownsubstrateDetailsDB11638Artenimolapproved, experimental, investigationalunknowninhibitorDetailsDB13941Piperaquineapproved, experimental, investigationalunknownsubstrateinhibitorDetailsDB11901Apalutamideapproved, investigationalnoinducerDetailsDB11633Isavuconazoleapproved, investigationalunknowninhibitorDetailsDB11586Asunaprevirapproved, investigational, withdrawnnosubstrateDetailsDB14011NabiximolsinvestigationalunknownsubstrateDetailsDB14009Medical Cannabisexperimental, investigationalunknownsubstrateinhibitorDetailsDB11632Opicaponeapproved, investigationalnoinducerDetailsDB13746Bioallethrinapproved, experimentalnosubstrateDetailsDB04948Lofexidineapproved, investigationalnosubstrateDetailsDB00598LabetalolapprovedunknownsubstrateDetailsDB11967Binimetinibapproved, investigationalnosubstrateDetailsDB11718Encorafenibapproved, investigationalnosubstrateDetailsDB12474Lynestrenolapproved, investigationalnosubstrateinhibitorDetailsDB00615Rifabutinapproved, investigationalnoinducerDetailsDB01201Rifapentineapproved, investigationalnoinducerDetailsDB01220Rifaximinapproved, investigationalnoinducerDetailsDB11753Rifamycinapproved, investigationalnoinhibitorDetailsDB01483BarbitalillicitnosubstrateinducerDetailsDB00418Secobarbitalapproved, vet_approvednoinducerDetailsDB00599Thiopentalapproved, vet_approvednosubstrateDetailsDB06654Safinamideapproved, investigationalunknowninhibitorDetailsDB09078Lenvatinibapproved, investigationalunknowninhibitorDetailsDB05928DovitinibinvestigationalunknowninhibitorDetailsDB08496(R)-warfarinexperimentalunknownsubstrateDetailsDB14055(S)-Warfarinexperimental, investigationalunknownsubstrateDetailsDB04911Oritavancinapproved, investigationalunknowninhibitorDetailsDB06218LacosamideapprovedunknownsubstrateDetailsDB13762DexrabeprazoleexperimentalunknownsubstrateDetailsDB12319Benzbromaroneinvestigational, withdrawnunknowninhibitorDetailsDB09213Dexibuprofenapproved, investigationalunknownsubstrateDetailsDB00518Albendazoleapproved, vet_approvednosubstrateDetailsDB14025ClinafloxacininvestigationalunknowninhibitorDetailsDB06731SeproxetineinvestigationalunknowninhibitorDetailsDB14575EslicarbazepineapprovedunknowninhibitorDetailsDB01323St. John's Wortapproved, investigational, nutraceuticalnosubstrateinducerDetailsDB12130Lorlatinibapproved, investigationalunknownsubstrateDetailsDB12245Triclabendazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB11823Esketamineapproved, investigationalunknownsubstrateDetailsDB06684VilazodoneapprovedunknownsubstrateDetailsDB12015Alpelisibapproved, investigationalunknowninhibitorDetailsDB00977EthinylestradiolapprovedunknowninhibitorDetailsDB06730GestodeneinvestigationalunknowninhibitorDetailsDB00641SimvastatinapprovedunknownsubstrateDetailsDB00227Lovastatinapproved, investigationalunknownsubstrateDetailsDB00715Paroxetineapproved, investigationalunknownsubstrateDetailsDB00956Hydrocodoneapproved, illicit, investigationalunknownsubstrateDetailsDB04861Nebivololapproved, investigationalunknownsubstrateDetailsDB12500Fedratinibapproved, investigationalunknownsubstrateDetailsDB08502CapravirineinvestigationalunknownsubstrateDetailsDB14635Curcumin sulfateexperimentalunknowninhibitorDetailsDB01039FenofibrateapprovedunknowninhibitorDetailsDB15444Elexacaftorapproved, investigationalnoinhibitorDetailsDB14975Voxelotorapproved, investigationalunknownsubstrateDetailsDB00741Hydrocortisoneapproved, vet_approvedunknowninducerDetailsDB06119Cenobamateapproved, investigationalunknownsubstrateinhibitorDetailsDB01222BudesonideapprovedunknowninducerDetailsDB00959Methylprednisoloneapproved, vet_approvedunknowninducerDetailsDB15328Ubrogepantapproved, investigationalunknowninhibitorDetailsDB00983Formoterolapproved, investigationalunknownsubstrateDetailsDB01006Letrozoleapproved, investigationalunknowninhibitorDetailsDB11837Osilodrostatapproved, investigationalunknowninhibitorDetailsDB00443Betamethasoneapproved, vet_approvedunknowninducerDetailsDB09241Methylene blueapproved, investigationalunknownsubstrateinhibitorDetailsDB11689Selumetinibapproved, investigationalnosubstrateDetailsDB14631Prednisolone phosphateapproved, vet_approvedunknowninducerDetailsDB14649Dexamethasone acetateapproved, investigational, vet_approvedunknowninducerDetailsDB00574Fenfluramineapproved, illicit, investigational, withdrawnunknownsubstrateDetailsDB14881Oliceridineapproved, investigationalunknownsubstrateDetailsDB12499Clascoteroneapproved, investigationalnoinhibitorDetailsDB15093Somapacitanapproved, investigationalunknowninhibitorDetailsDB06448Lonafarnibapproved, investigationalnosubstrateinhibitorDetailsDB04951Pirfenidoneapproved, investigationalunknownsubstrateinhibitorDetailsDB06137Tirbanibulinapproved, investigationalnoinhibitorDetailsDB00935Oxymetazolineapproved, investigationalnosubstrateDetailsDB08912Dabrafenibapproved, investigationalnosubstrateinhibitorinducerDetailsDB00170Menadioneapproved, nutraceuticalunknowninhibitorDetailsDB00476DuloxetineapprovedunknowninhibitorDetailsDB00052Somatotropinapproved, investigationalunknowninhibitorDetailsDB00330EthambutolapprovedunknowninhibitorDetailsDB14984Casimersenapproved, investigationalnoinhibitorDetailsDB01086Benzocaineapproved, investigationalunknownsubstrateDetailsDB08896RegorafenibapprovedunknowninhibitorDetailsDB00986Glycopyrroniumapproved, investigational, vet_approvedunknownsubstrateDetailsDB05271RotigotineapprovednoinhibitorDetailsDB01183Naloxoneapproved, vet_approvedunknownsubstrateDetailsDB12543Samidorphanapproved, investigationalnosubstrateDetailsDB12151Brincidofovirapproved, investigationalnoinhibitorDetailsDB16703Belumosudilapproved, investigationalnoinhibitorDetailsDB15463Belzutifanapproved, investigationalnosubstrateDetailsDB12265Fexinidazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB16220Lonapegsomatropinapproved, investigationalunknowninhibitorDetailsDB16349VicagrelinvestigationalunknownsubstrateDetailsDB12597Asciminibapproved, investigationalnoinhibitorDetailsDB04216Quercetinexperimental, investigationalnoinhibitorDetailsDB14973Abrocitinibapproved, investigationalnosubstrateDetailsDB05467Palovaroteneapproved, investigationalnosubstrateDetailsDB16236Mitapivatapproved, investigationalnoinducerDetailsDB12834SecnidazoleapprovedunknowninhibitorDetailsDB00470Dronabinolapproved, illicitnosubstrateinhibitorDetailsDB14737Cannabinolexperimental, investigationalunknownsubstrateDetailsDB11697Pacritinibapproved, investigationalnoinhibitorDetailsDB05087Ganaxoloneapproved, investigationalnosubstrateDetailsDB06016Cariprazineapproved, investigationalnoinhibitorDetailsDB14921Mavacamtenapproved, investigationalnosubstrateinducerDetailsDB12020Tecovirimatapproved, investigationalnoinhibitorDetailsDB06083Tapinarofapproved, investigationalnosubstrateDetailsDB00285VenlafaxineapprovednosubstrateDetailsDB12095Telotristat ethylapproved, investigationalnoinhibitorDetailsDB11739Vonoprazanapproved, investigationalunknownsubstrateinhibitorDetailsDB16267Olutasidenibapproved, investigationalnosubstrateDetailsDB02709ResveratrolinvestigationalnoinhibitorDetailsDB17472Pirtobrutinibapproved, investigationalunknowninhibitorinducerDetailsDB12548Sparsentanapproved, investigationalunknowninducerDetailsDB00381AmlodipineapprovednoinhibitorDetailsDB00862VardenafilapprovedunknowninhibitorDetailsDB11712Tezacaftorapproved, investigationalnoinhibitorDetailsDB15669Fezolinetantapproved, investigationalnosubstrateDetailsDB06700Desvenlafaxineapproved, investigationalnosubstrateDetailsDB11763Momelotinibapproved, investigationalunknownsubstrateDetailsDB14766EtrasimodapprovednosubstrateDetailsDB16826RepotrectinibinvestigationalnoinducerDetailsDB11679FruquintinibinvestigationalnosubstrateDetails\"}},\n",
       "  {'Label': 'Cytochrome P450 2C9',\n",
       "   'Detailed Info': {'Name': 'Cytochrome P450 2C9',\n",
       "    'Synonyms': '(R)-limonene 6-monooxygenase\\n(S)-limonene 6-monooxygenase\\n(S)-limonene 7-monooxygenase\\n1.14.13.-\\nCholesterol 25-hydroxylase\\nCYP2C10\\nCYPIIC9\\nCytochrome P-450MP\\nCytochrome P450 MP-4\\nCytochrome P450 MP-8\\nCytochrome P450 PB-1\\nS-mephenytoin 4-hydroxylase',\n",
       "    'Gene Name': 'CYP2C9',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0005471|Cytochrome P450 2C9\\nMDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV\\nYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW\\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\\nIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM\\nKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE\\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID\\nLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK\\nKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP\\nPFYQLCFIPV',\n",
       "    'Number of residues': '490',\n",
       "    'Molecular Weight': '55627.365',\n",
       "    'Theoretical pI': '7.99',\n",
       "    'GO Classification': 'Functions(R)-limonene 6-monooxygenase activity / (S)-limonene 6-monooxygenase activity / (S)-limonene 7-monooxygenase activity / arachidonic acid epoxygenase activity / aromatase activity / caffeine oxidase activity / drug binding / heme binding / iron ion binding / monooxygenase activity / oxidoreductase activity / oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen / oxygen binding / steroid hydroxylase activityProcessesarachidonic acid metabolic process / cellular amide metabolic process / drug catabolic process / drug metabolic process / epoxygenase P450 pathway / exogenous drug catabolic process / monocarboxylic acid metabolic process / monoterpenoid metabolic process / omega-hydroxylase P450 pathway / oxidation-reduction process / oxidative demethylation / small molecule metabolic process / steroid metabolic process / urea metabolic process / xenobiotic metabolic processComponentscytoplasm / endoplasmic reticulum membrane / intracellular membrane-bounded organelle',\n",
       "    'General Function': 'Steroid hydroxylase activity',\n",
       "    'Specific Function': 'Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.',\n",
       "    'Pfam Domain Function': 'p450 (PF00067)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Endoplasmic reticulum membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)\\nATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG\\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\\nAATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC\\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT\\nGAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC\\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG\\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\\nGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\\nATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG\\nTTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT\\nCCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG\\nAAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT\\nCAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT\\nGAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG\\nACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\\nGCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA\\nGACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC\\nCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC\\nATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA\\nTTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG\\nAAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG\\nGCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT\\nCTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG\\nCCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA',\n",
       "    'Chromosome Location': '10',\n",
       "    'Locus': '10q24',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP11712UniProtKB Entry NameCP2C9_HUMANGenBank Gene IDAY341248GenAtlas IDCYP2C9HGNC IDHGNC:2623',\n",
       "    'General References': \"Meehan RR, Gosden JR, Rout D, Hastie ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, et al.: Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet. 1988 Jan;42(1):26-37. [Article] Kimura S, Pastewka J, Gelboin HV, Gonzalez FJ: cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 1987 Dec 10;15(23):10053-4. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10. Nature. 2004 May 27;429(6990):375-81. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R: Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem. 1987 Nov;102(5):1075-82. [Article] Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FP: Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry. 1987 Feb 24;26(4):1094-9. [Article] Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP: Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry. 1988 Sep 6;27(18):6929-40. [Article] Ohgiya S, Komori M, Ohi H, Shiramatsu K, Shinriki N, Kamataki T: Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity. Biochem Int. 1992 Sep;27(6):1073-81. [Article] Shimada T, Misono KS, Guengerich FP: Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem. 1986 Jan 15;261(2):909-21. [Article] Komori M, Hashizume T, Ohi H, Miura T, Kitada M, Nagashima K, Kamataki T: Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. J Biochem. 1988 Dec;104(6):912-6. [Article] Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP: Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol. 1991 Jul;40(1):69-79. [Article] Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996 Sep 15;333(2):447-58. [Article] Sandhu P, Baba T, Guengerich FP: Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys. 1993 Nov 1;306(2):443-50. [Article] Miyazawa M, Shindo M, Shimada T: Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab Dispos. 2002 May;30(5):602-7. [Article] Honda A, Miyazaki T, Ikegami T, Iwamoto J, Maeda T, Hirayama T, Saito Y, Teramoto T, Matsuzaki Y: Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res. 2011 Aug;52(8):1509-16. doi: 10.1194/jlr.M014084. Epub 2011 May 16. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003 Jul 24;424(6947):464-8. Epub 2003 Jul 13. [Article] Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996 Oct;6(5):429-39. [Article] Bhasker CR, Miners JO, Coulter S, Birkett DJ: Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics. 1997 Feb;7(1):51-8. [Article] Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K, Higuchi S: Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics. 2000 Feb;10(1):85-9. [Article] Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. [Article] Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [Article] Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 Oct;5(7):895-931. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB03317Ferroheme CexperimentalunknownDetailsDB00196Fluconazoleapproved, investigationalunknowninhibitorDetailsDB00203Sildenafilapproved, investigationalunknownsubstrateinhibitorDetailsDB00222GlimepirideapprovedunknownsubstrateDetailsDB00250Dapsoneapproved, investigationalunknownsubstrateinducerDetailsDB00327Hydromorphoneapproved, illicitnosubstrateDetailsDB00469TenoxicamapprovedunknownsubstrateDetailsDB00470Dronabinolapproved, illicitnosubstrateinhibitorinducerDetailsDB00471MontelukastapprovedunknownsubstrateDetailsDB00472Fluoxetineapproved, vet_approvedunknownsubstrateinhibitorDetailsDB00482Celecoxibapproved, investigationalunknownsubstrateDetailsDB00549Zafirlukastapproved, investigationalunknownsubstrateinhibitorDetailsDB00559Bosentanapproved, investigationalunknownsubstrateinducerDetailsDB00580Valdecoxibapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00582VoriconazoleapprovedunknownsubstrateinhibitorDetailsDB00586Diclofenacapproved, vet_approvedunknownsubstrateDetailsDB00617ParamethadioneapprovedunknownsubstrateDetailsDB00675TamoxifenapprovedunknownsubstrateinhibitorDetailsDB00678LosartanapprovedunknownsubstrateDetailsDB00682WarfarinapprovedunknownsubstrateinducerDetailsDB00712Flurbiprofenapproved, investigationalunknownsubstrateDetailsDB00731Nateglinideapproved, investigationalunknownsubstrateDetailsDB00744Zileutonapproved, investigational, withdrawnunknownsubstrateDetailsDB00749Etodolacapproved, investigational, vet_approvedunknownsubstrateDetailsDB00784Mefenamic acidapprovedunknownsubstrateinhibitorDetailsDB00814Meloxicamapproved, vet_approvedunknownsubstrateDetailsDB00870Suprofenapproved, withdrawnunknownsubstrateinhibitorDetailsDB00916MetronidazoleapprovedunknowninhibitorDetailsDB00946Phenprocoumonapproved, investigationalunknownsubstrateDetailsDB01015SulfamethoxazoleapprovedunknownsubstrateinhibitorDetailsDB01029Irbesartanapproved, investigationalunknownsubstrateDetailsDB01050IbuprofenapprovedunknownsubstrateDetailsDB01067Glipizideapproved, investigationalunknownsubstrateDetailsDB01095FluvastatinapprovedunknownsubstrateinhibitorDetailsDB01104SertralineapprovedunknownsubstrateinhibitorDetailsDB01136Carvedilolapproved, investigationalunknownsubstrateDetailsDB01283Lumiracoxibapproved, investigationalunknownsubstrateDetailsDB00969Alosetronapproved, withdrawnnosubstrateDetailsDB00176Fluvoxamineapproved, investigationalnoinhibitorDetailsDB00214TorasemideapprovedunknownsubstrateinhibitorDetailsDB00252Phenytoinapproved, vet_approvednosubstrateinhibitorinducerDetailsDB00412Rosiglitazoneapproved, investigationalunknownsubstrateinhibitorDetailsDB00448Lansoprazoleapproved, investigationalunknowninhibitorinducerDetailsDB00503Ritonavirapproved, investigationalunknowninducerDetailsDB00532Mephenytoinapproved, investigational, withdrawnunknownsubstrateDetailsDB00673Aprepitantapproved, investigationalunknowninhibitorinducerDetailsDB00705DelavirdineapprovedunknowninhibitorDetailsDB01016GlyburideapprovedunknownsubstrateinhibitorDetailsDB01026Ketoconazoleapproved, investigationalunknowninhibitorDetailsDB01110Miconazoleapproved, investigational, vet_approvedunknowninhibitorDetailsDB01118Amiodaroneapproved, investigationalunknowninhibitorDetailsDB01124Tolbutamideapproved, investigationalunknownsubstrateDetailsDB01241GemfibrozilapprovedunknowninhibitorDetailsDB01381Ginkgo bilobaapproved, investigational, nutraceuticalunknowninhibitorDetailsDB01418Acenocoumarolapproved, investigationalunknownsubstrateDetailsDB04856DexloxiglumideinvestigationalunknownsubstrateinhibitorDetailsDB06442AvasimibeinvestigationalunknowninhibitorDetailsDB01098RosuvastatinapprovednosubstrateDetailsDB01065Melatoninapproved, nutraceutical, vet_approvedunknownsubstrateDetailsDB00796Candesartan cilexetilapprovedunknownsubstrateDetailsDB00641SimvastatinapprovedunknowninhibitorDetailsDB01076AtorvastatinapprovednoinhibitorDetailsDB00439Cerivastatinapproved, withdrawnunknowninhibitorDetailsDB01072Atazanavirapproved, investigationalnosubstrateinhibitorDetailsDB01181IfosfamideapprovedunknownsubstrateDetailsDB00619ImatinibapprovednosubstrateinhibitorDetailsDB00468QuinineapprovedunknownsubstrateDetailsDB01142Doxepinapproved, investigationalnosubstrateDetailsDB00321AmitriptylineapprovedunknownsubstrateDetailsDB04557Arachidonic AcidexperimentalunknownsubstrateDetailsDB01045RifampicinapprovedunknowninducerDetailsDB01174Phenobarbitalapproved, investigationalunknownsubstrateinducerDetailsDB00404Alprazolamapproved, illicit, investigationalunknownsubstrateDetailsDB00363ClozapineapprovednosubstrateDetailsDB00829Diazepamapproved, illicit, investigational, vet_approvedunknownsubstrateDetailsDB01357MestranolapprovedunknownsubstrateDetailsDB00788Naproxenapproved, vet_approvedunknownsubstrateDetailsDB00531Cyclophosphamideapproved, investigationalunknownsubstrateDetailsDB01355HexobarbitalexperimentalunknownsubstrateDetailsDB00396Progesteroneapproved, vet_approvedunknownsubstrateinhibitorDetailsDB00554Piroxicamapproved, investigationalunknownsubstrateDetailsDB00208TiclopidineapprovedunknowninhibitorDetailsDB00338Omeprazoleapproved, investigational, vet_approvedunknownsubstrateDetailsDB00715Paroxetineapproved, investigationalunknowninhibitorDetailsDB01435Antipyrineapproved, investigationalunknownsubstrateDetailsDB00177Valsartanapproved, investigationalunknownsubstrateDetailsDB00188Bortezomibapproved, investigationalnosubstrateinhibitorDetailsDB01041Thalidomideapproved, investigational, withdrawnnosubstrateDetailsDB05109Trabectedinapproved, investigationalunknownsubstrateDetailsDB00313Valproic acidapproved, investigationalunknownsubstrateinhibitorDetailsDB00857Terbinafineapproved, investigational, vet_approvedunknownsubstrateDetailsDB00238NevirapineapprovedunknowninducerDetailsDB06652VicrivirocinvestigationalunknownsubstrateDetailsDB00972AzelastineapprovedunknownsubstrateinhibitorDetailsDB00568Cinnarizineapproved, investigationalunknownsubstrateDetailsDB04841FlunarizineapprovedunknownsubstrateDetailsDB01075Diphenhydramineapproved, investigationalunknownsubstrateDetailsDB06725Lornoxicamapproved, investigationalunknownsubstrateDetailsDB01039FenofibrateapprovedunknowninhibitorDetailsDB00951Isoniazidapproved, investigationalunknowninhibitorDetailsDB00812Phenylbutazoneapproved, vet_approvedunknownsubstrateinhibitorDetailsDB06729SulfaphenazoleapprovedunknowninhibitorDetailsDB00444TeniposideapprovedunknowninhibitorDetailsDB06414EtravirineapprovedunknownsubstrateinhibitorDetailsDB01320Fosphenytoinapproved, investigationalunknownsubstrateinducerDetailsDB01221Ketamineapproved, vet_approvedunknownsubstrateDetailsDB00359Sulfadiazineapproved, investigational, vet_approvedunknowninhibitorDetailsDB01138SulfinpyrazoneapprovedunknowninhibitorDetailsDB00263Sulfisoxazoleapproved, vet_approvedunknowninhibitorDetailsDB01198ZopicloneapprovedunknownsubstrateDetailsDB00564Carbamazepineapproved, investigationalunknowninducerDetailsDB00794Primidoneapproved, vet_approvedunknownsubstrateinducerDetailsDB01201Rifapentineapproved, investigationalunknowninducerDetailsDB00418Secobarbitalapproved, vet_approvedunknowninducerDetailsDB00625Efavirenzapproved, investigationalunknowninhibitorDetailsDB01097Leflunomideapproved, investigationalunknownsubstrateinhibitorDetailsDB04868Nilotinibapproved, investigationalunknowninhibitorDetailsDB00398Sorafenibapproved, investigationalunknowninhibitorDetailsDB01101Capecitabineapproved, investigationalnodownregulatorDetailsDB00544FluorouracilapprovedunknowninhibitorDetailsDB06268Sitaxentanapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00752Tranylcypromineapproved, investigationalunknowninhibitorDetailsDB01424Aminophenazoneapproved, withdrawnunknownsubstrateDetailsDB00216Eletriptanapproved, investigationalunknownsubstrateDetailsDB00758ClopidogrelapprovednosubstrateinhibitorDetailsDB00843DonepezilapprovedunknownsubstrateDetailsDB00661VerapamilapprovedunknownsubstrateinhibitorDetailsDB00425ZolpidemapprovedunknownsubstrateDetailsDB01036Tolterodineapproved, investigationalunknownsubstrateDetailsDB00328Indomethacinapproved, investigationalunknownsubstrateDetailsDB00936Salicylic acidapproved, investigational, vet_approvedunknownsubstrateDetailsDB01628Etoricoxibapproved, investigationalunknownsubstrateinhibitorDetailsDB00921Buprenorphineapproved, illicit, investigational, vet_approvedunknownsubstrateDetailsDB00818Propofolapproved, investigational, vet_approvedunknownsubstrateDetailsDB00672Chlorpropamideapproved, investigationalunknownsubstrateDetailsDB01120GliclazideapprovedunknownsubstrateDetailsDB00201CaffeineapprovedunknownsubstrateDetailsDB00514DextromethorphanapprovedunknownsubstrateDetailsDB01009Ketoprofenapproved, vet_approvedunknownsubstrateinhibitorDetailsDB04725LicofeloneinvestigationalunknownsubstrateDetailsDB06737ZaltoprofenexperimentalunknownsubstrateDetailsDB06739SeratrodastexperimentalunknownsubstrateDetailsDB06738KetobemidoneinvestigationalunknownsubstrateDetailsDB06736Aceclofenacapproved, investigationalunknownsubstrateDetailsDB08798SulfamoxoleexperimentalunknowninhibitorDetailsDB06697ArtemetherapprovedunknownsubstrateDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownsubstrateDetailsDB00613Amodiaquineapproved, investigationalunknowninhibitorDetailsDB00701Amprenavirapproved, investigationalunknownsubstrateDetailsDB01117AtovaquoneapprovedunknowninhibitorDetailsDB01156BupropionapprovedunknownsubstrateDetailsDB00501Cimetidineapproved, investigationalunknowninhibitorDetailsDB00604Cisaprideapproved, investigational, withdrawnunknowninhibitorDetailsDB00257Clotrimazoleapproved, vet_approvedunknowninhibitorDetailsDB01176CyclizineapprovedunknowninhibitorDetailsDB00266DicoumarolapprovedunknownsubstrateDetailsDB00757Dolasetronapproved, investigationalunknownsubstrateDetailsDB00869DorzolamideapprovednosubstrateDetailsDB00668Epinephrineapproved, vet_approvedunknowninhibitorDetailsDB00783Estradiolapproved, investigational, vet_approvedunknownsubstrateDetailsDB00655EstroneapprovedunknownsubstrateDetailsDB00898EthanolapprovedunknowninhibitorDetailsDB01023Felodipineapproved, investigationalunknowninhibitorDetailsDB01195Flecainideapproved, withdrawnunknowninhibitorDetailsDB01544Flunitrazepamapproved, illicitunknownsubstrateDetailsDB00502HaloperidolapprovedunknownsubstrateDetailsDB01159Halothaneapproved, vet_approvedunknownsubstrateDetailsDB01177IdarubicinapprovedunknownsubstrateDetailsDB00281Lidocaineapproved, vet_approvedunknownsubstrateDetailsDB01601LopinavirapprovedunknowninhibitorinducerDetailsDB00603Medroxyprogesterone acetateapproved, investigationalunknowninhibitorDetailsDB00333MethadoneapprovedunknownsubstrateDetailsDB01028Methoxyfluraneapproved, investigational, vet_approved, withdrawnunknownsubstrateDetailsDB01171Moclobemideapproved, investigationalunknownsubstrateDetailsDB00745Modafinilapproved, investigationalunknowninhibitorinducerDetailsDB00184NicotineapprovedunknownsubstrateDetailsDB00904Ondansetronapproved, withdrawnunknownsubstrateDetailsDB00850PerphenazineapprovedunknownsubstrateDetailsDB03783PhenacetinwithdrawnunknownsubstrateDetailsDB01411PranlukastinvestigationalnoinhibitorDetailsDB01131ProguanilapprovedunknownsubstrateDetailsDB01069Promethazineapproved, investigationalunknowninhibitorDetailsDB01589Quazepamapproved, illicitnosubstrateDetailsDB00908Quinidineapproved, investigationalunknownsubstrateinhibitorDetailsDB00533Rofecoxibapproved, investigational, withdrawnunknownsubstrateDetailsDB01037Selegilineapproved, investigational, vet_approvedunknownsubstrateDetailsDB06150Sulfadimethoxineapproved, vet_approved, withdrawnunknowninhibitorDetailsDB00576Sulfamethizoleapproved, investigational, vet_approvedunknowninhibitorDetailsDB00891SulfapyridineapprovedunknowninhibitorDetailsDB00231Temazepamapproved, investigationalunknownsubstrateDetailsDB00624Testosteroneapproved, investigationalunknownsubstrateDetailsDB00763MethimazoleapprovedunknowninhibitorDetailsDB00323Tolcaponeapproved, withdrawnnoinhibitorDetailsDB00347TrimethadioneapprovedunknownsubstrateDetailsDB00726TrimipramineapprovedunknownsubstrateDetailsDB00197Troglitazoneapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB04898Ximelagatranapproved, investigational, withdrawnunknownsubstrateDetailsDB00495ZidovudineapprovedunknownsubstrateDetailsDB00755Tretinoinapproved, investigational, nutraceuticalunknownsubstrateDetailsDB01128BicalutamideapprovedunknowninhibitorDetailsDB01129Rabeprazoleapproved, investigationalunknowninhibitorDetailsDB01274Arformoterolapproved, investigationalunknownsubstrateDetailsDB04574Estrone sulfateapprovedunknownsubstrateinhibitorDetailsDB06413Armodafinilapproved, investigationalnoinhibitorDetailsDB00255Diethylstilbestrolapproved, investigational, withdrawnunknowninhibitorDetailsDB00420Promazineapproved, vet_approvedunknownsubstrateDetailsDB06594Agomelatineapproved, investigationalunknowninhibitorDetailsDB04831Tienilic acidwithdrawnunknowninhibitorDetailsDB06174Noscapineapproved, investigationalunknowninhibitorDetailsDB04920Clevidipineapproved, investigationalunknowninhibitorDetailsDB06370IndisulaminvestigationalunknownsubstrateDetailsDB06803Niclosamideapproved, investigational, vet_approvedunknownsubstrateDetailsDB00515CisplatinapprovedunknowninhibitorDetailsDB06820SulconazoleapprovedunknowninhibitorDetailsDB01154Thiamylalapproved, vet_approvedunknownsubstrateDetailsDB08828Vismodegibapproved, investigationalnosubstrateinhibitorDetailsDB00374Treprostinilapproved, investigationalunknownsubstrateDetailsDB06204TapentadolapprovedunknownsubstrateDetailsDB06209PrasugrelapprovednosubstrateDetailsDB08860PitavastatinapprovedunknownsubstrateDetailsDB08875Cabozantinibapproved, investigationalnosubstrateDetailsDB06605ApixabanapprovedunknownsubstrateDetailsDB08896RegorafenibapprovedunknowninhibitorDetailsDB08899EnzalutamideapprovednoinducerDetailsDB04938Ospemifeneapproved, investigationalunknownsubstrateDetailsDB00317Gefitinibapproved, investigationalunknowninhibitorDetailsDB06292DapagliflozinapprovednosubstrateDetailsDB09048Netupitantapproved, investigationalnosubstrateDetailsDB09080OlodaterolapprovednosubstrateDetailsDB09068Vortioxetineapproved, investigationalnosubstrateDetailsDB08439ParecoxibapprovedunknownsubstrateDetailsDB09280LumacaftorapprovednoinhibitorinducerDetailsDB09570Ixazomibapproved, investigationalunknownsubstrateDetailsDB11560Lesinuradapproved, investigationalnosubstrateDetailsDB05812AbirateroneapprovedunknowninhibitorDetailsDB08816TicagrelorapprovedunknowninhibitorinducerDetailsDB09063CeritinibapprovedunknowninhibitorDetailsDB00322FloxuridineapprovedunknowninhibitorDetailsDB05219Crisaboroleapproved, investigationalnoinhibitorDetailsDB06595Midostaurinapproved, investigationalunknowninhibitorinducerDetailsDB05015Belinostatapproved, investigationalunknowninhibitorDetailsDB05541Brivaracetamapproved, investigationalnosubstrateDetailsDB11611LifitegrastapprovednoinhibitorDetailsDB13174RheinexperimentalunknowninhibitorDetailsDB11994Diacereinapproved, investigationalunknowninhibitorDetailsDB03756Doconexentapproved, investigationalunknownsubstrateinhibitorDetailsDB11943Delafloxacinapproved, investigationalunknowninducerDetailsDB01685TopiroxostatexperimentalunknowninhibitorDetailsDB09120Zucapsaicinapproved, investigationalunknowninhibitorDetailsDB09118StiripentolapprovedunknowninhibitorDetailsDB09198LobeglitazoneexperimentalnoinhibitorDetailsDB09167DosulepinapprovedunknowninhibitorDetailsDB11614RupatadineapprovednosubstrateDetailsDB12319Benzbromaroneinvestigational, withdrawnunknowninhibitorDetailsDB09238Manidipineapproved, investigationalunknowninhibitorDetailsDB13874Enasidenibapproved, investigationalunknownsubstrateinhibitorDetailsDB13919CandesartanexperimentalunknownsubstrateinhibitorDetailsDB12070Letermovirapproved, investigationalnoinducerDetailsDB12332Rucaparibapproved, investigationalnoinhibitorDetailsDB09061Cannabidiolapproved, investigationalnosubstrateinhibitorDetailsDB13943Testosterone cypionateapprovedunknownsubstrateDetailsDB13944Testosterone enanthateapprovedunknownsubstrateDetailsDB13946Testosterone undecanoateapproved, investigationalunknownsubstrateDetailsDB13952Estradiol acetateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13953Estradiol benzoateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13954Estradiol cypionateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13955Estradiol dienanthateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13956Estradiol valerateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13941Piperaquineapproved, experimental, investigationalunknownsubstrateDetailsDB11901Apalutamideapproved, investigationalnoinducerDetailsDB11633Isavuconazoleapproved, investigationalunknowninhibitorinducerDetailsDB11586Asunaprevirapproved, investigational, withdrawnnosubstrateDetailsDB13975Black cohoshexperimentalnoinhibitorDetailsDB14011NabiximolsinvestigationalnosubstrateDetailsDB14009Medical Cannabisexperimental, investigationalnosubstrateinhibitorinducerDetailsDB13746Bioallethrinapproved, experimentalnosubstrateDetailsDB00486Nabiloneapproved, investigationalnosubstrateinhibitorDetailsDB14033Acetyl sulfisoxazoleapproved, vet_approvedunknowninhibitorDetailsDB11995Avatrombopagapproved, investigationalunknowninducerDetailsDB11672Curcuminapproved, investigationalnoinhibitorDetailsDB00949FelbamateapprovedunknowninhibitorDetailsDB13136Fluindioneapproved, investigationalunknownsubstrateDetailsDB14568Ivosidenibapproved, investigationalunknowninducerDetailsDB12474Lynestrenolapproved, investigationalnosubstrateDetailsDB00615Rifabutinapproved, investigationalnoinducerDetailsDB11753Rifamycinapproved, investigationalnoinhibitorinducerDetailsDB04818IproniazidwithdrawnunknowninhibitorDetailsDB01645GenisteininvestigationalunknowninhibitorDetailsDB09078Lenvatinibapproved, investigationalunknowninhibitorDetailsDB08881VemurafenibapprovedunknowninhibitorDetailsDB00839Tolazamideapproved, investigationalunknownsubstrateDetailsDB00414Acetohexamideapproved, investigational, withdrawnunknownsubstrateDetailsDB01251Gliquidoneapproved, investigationalunknownsubstrateDetailsDB01289GlisoxepideinvestigationalunknownsubstrateDetailsDB08962Glibornurideinvestigational, withdrawnunknownsubstrateDetailsDB13406CarbutamideexperimentalunknownsubstrateDetailsDB13675MetahexamideexperimentalunknownsubstrateDetailsDB08496(R)-warfarinexperimentalunknownsubstrateDetailsDB14055(S)-Warfarinexperimental, investigationalunknownsubstrateDetailsDB00022Peginterferon alfa-2bapprovedunknowninducerDetailsDB04911Oritavancinapproved, investigationalunknowninhibitorDetailsDB06717FosaprepitantapprovedunknowninducerDetailsDB09288PropacetamolexperimentalnosubstrateDetailsDB14635Curcumin sulfateexperimentalnoinhibitorDetailsDB01080VigabatrinapprovedunknowninducerDetailsDB06218LacosamideapprovednosubstrateDetailsDB09213Dexibuprofenapproved, investigationalnosubstrateDetailsDB08912Dabrafenibapproved, investigationalnosubstrateinhibitorinducerDetailsDB00834Mifepristoneapproved, investigationalnoinhibitorDetailsDB00980Ramelteonapproved, investigationalnosubstrateDetailsDB00440Trimethoprimapproved, vet_approvedunknownsubstrateDetailsDB04665CoumarinexperimentalnosubstrateDetailsDB14025ClinafloxacininvestigationalunknowninhibitorDetailsDB06731SeproxetineinvestigationalunknowninhibitorDetailsDB00621Oxandroloneapproved, investigationalunknowninhibitorDetailsDB11963Dacomitinibapproved, investigationalnosubstrateDetailsDB00220NelfinavirapprovednoinducerDetailsDB07615TranilastinvestigationalnosubstrateDetailsDB12245Triclabendazoleapproved, investigationalunknownsubstrateDetailsDB11823Esketamineapproved, investigationalunknownsubstrateDetailsDB00465KetorolacapprovedunknownsubstrateDetailsDB00304DesogestrelapprovednosubstrateDetailsDB00455Loratadineapproved, investigationalunknownsubstrateDetailsDB12371Siponimodapproved, investigationalunknownsubstrateDetailsDB00334Olanzapineapproved, investigationalnoinhibitorDetailsDB12147Erdafitinibapproved, investigationalnosubstrateDetailsDB00476DuloxetineapprovedunknownsubstrateDetailsDB00461NabumetoneapprovednosubstrateDetailsDB12015Alpelisibapproved, investigationalunknowninducerDetailsDB00590DoxazosinapprovedunknownsubstrateDetailsDB01032Probenecidapproved, investigationalunknowninhibitorDetailsDB12978Pexidartinibapproved, investigationalunknowninhibitorDetailsDB11757Istradefyllineapproved, investigationalunknownsubstrateDetailsDB00622Nicardipineapproved, investigationalnoinhibitorDetailsDB01137Levofloxacinapproved, investigationalnoinhibitorDetailsDB08502CapravirineinvestigationalunknownsubstrateDetailsDB01217Anastrozoleapproved, investigationalunknowninhibitorDetailsDB12808Trifaroteneapproved, investigationalunknownsubstrateDetailsDB12001Abemaciclibapproved, investigationalunknowninhibitorDetailsDB15444Elexacaftorapproved, investigationalnoinhibitorDetailsDB14975Voxelotorapproved, investigationalunknownsubstrateDetailsDB00635Prednisoneapproved, vet_approvedunknowninducerDetailsDB00741Hydrocortisoneapproved, vet_approvedunknowninducerDetailsDB01222BudesonideapprovedunknowninducerDetailsDB00959Methylprednisoloneapproved, vet_approvedunknowninducerDetailsDB15328Ubrogepantapproved, investigationalunknowninhibitorDetailsDB15233Avapritinibapproved, investigationalunknownsubstrateinhibitorDetailsDB00983Formoterolapproved, investigationalunknownsubstrateDetailsDB01115NifedipineapprovedunknowninhibitorinducerDetailsDB00957Norgestimateapproved, investigationalunknownsubstrateDetailsDB00977EthinylestradiolapprovedunknownsubstrateDetailsDB12457Rimegepantapproved, investigationalnosubstrateDetailsDB13609UmifenovirinvestigationalunknownsubstrateDetailsDB00443Betamethasoneapproved, vet_approvedunknowninducerDetailsDB09241Methylene blueapproved, investigationalunknowninhibitorDetailsDB11689Selumetinibapproved, investigationalnosubstrateDetailsDB14631Prednisolone phosphateapproved, vet_approvedunknowninducerDetailsDB00574Fenfluramineapproved, illicit, investigational, withdrawnunknownsubstrateDetailsDB14881Oliceridineapproved, investigationalunknownsubstrateDetailsDB12499Clascoteroneapproved, investigationalnoinhibitorDetailsDB15822Pralsetinibapproved, investigationalnoinhibitorinducerDetailsDB06448Lonafarnibapproved, investigationalnosubstrateDetailsDB04951Pirfenidoneapproved, investigationalunknownsubstrateinhibitorDetailsDB06137Tirbanibulinapproved, investigationalnoinhibitorDetailsDB11632Opicaponeapproved, investigationalnoinhibitorDetailsDB00170Menadioneapproved, nutraceuticalunknowninhibitorDetailsDB08864RilpivirineapprovedunknowninhibitorDetailsDB00330EthambutolapprovedunknowninhibitorDetailsDB14989Umbralisibapproved, investigational, withdrawnunknownsubstrateDetailsDB08877RuxolitinibapprovednosubstrateDetailsDB14984Casimersenapproved, investigationalnoinhibitorDetailsDB06237AvanafilapprovedunknownsubstrateDetailsDB04854FebuxostatapprovednosubstrateDetailsDB08995Diosminapproved, investigationalunknowninhibitorDetailsDB08822Azilsartan medoxomilapproved, investigationalnosubstrateDetailsDB00986Glycopyrroniumapproved, investigational, vet_approvedunknownDetailsDB15569Sotorasibapproved, investigationalunknowninducerDetailsDB12151Brincidofovirapproved, investigationalnoinhibitorDetailsDB15011Avacopanapproved, investigationalnoinhibitorDetailsDB12597Asciminibapproved, investigationalnoinhibitorDetailsDB08932MacitentanapprovednosubstrateDetailsDB04216Quercetinexperimental, investigationalnoinhibitorDetailsDB14973Abrocitinibapproved, investigationalnosubstrateDetailsDB16236Mitapivatapproved, investigationalnosubstrateinducerDetailsDB14737Cannabinolexperimental, investigationalunknownsubstrateinhibitorDetailsDB06016Cariprazineapproved, investigationalnoinhibitorDetailsDB14921Mavacamtenapproved, investigationalnosubstrateinducerDetailsDB06083Tapinarofapproved, investigationalnosubstrateDetailsDB15133Tepotinibapproved, investigationalnoinhibitorDetailsDB00285VenlafaxineapprovednosubstrateDetailsDB12095Telotristat ethylapproved, investigationalnoinhibitorDetailsDB15149Futibatinibapproved, investigationalnosubstrateDetailsDB17083LinzagolixapprovednosubstrateDetailsDB11739Vonoprazanapproved, investigationalunknownsubstrateDetailsDB16267Olutasidenibapproved, investigationalnosubstrateinducerDetailsDB02709ResveratrolinvestigationalunknowninhibitorDetailsDB15568Adagrasibapproved, investigationalunknownsubstrateinhibitorDetailsDB17449Anacaulaseapproved, investigationalunknowninhibitorDetailsDB17472Pirtobrutinibapproved, investigationalunknowninhibitorDetailsDB06374Elacestrantapproved, investigationalunknownsubstrateDetailsDB00349Clobazamapproved, illicitnoinhibitorDetailsDB12548Sparsentanapproved, investigationalunknowninducerDetailsDB00381AmlodipineapprovednoinhibitorDetailsDB00862VardenafilapprovedunknownsubstrateinhibitorDetailsDB08820IvacaftorapprovednoinhibitorDetailsDB11712Tezacaftorapproved, investigationalnoDetailsDB01194BrinzolamideapprovedunknownsubstrateDetailsDB15669Fezolinetantapproved, investigationalnosubstrateDetailsDB12255Vadadustatapproved, investigationalunknowninhibitorDetailsDB14924Ritlecitinibapproved, investigationalunknownsubstrateDetailsDB11763Momelotinibapproved, investigationalunknownsubstrateDetailsDB14766EtrasimodapprovednosubstrateDetailsDB11718Encorafenibapproved, investigationalnoinhibitorinducerDetailsDB16826RepotrectinibinvestigationalnoinducerDetailsDB11679FruquintinibinvestigationalnosubstrateDetails'}},\n",
       "  {'Label': 'UDP-glucuronosyltransferase 1-6',\n",
       "   'Detailed Info': {'Name': 'UDP-glucuronosyltransferase 1-6',\n",
       "    'Synonyms': '2.4.1.17\\nGNT1\\nPhenol-metabolizing UDP-glucuronosyltransferase\\nUDP-glucuronosyltransferase 1-F\\nUDP-glucuronosyltransferase 1A6\\nUDPGT 1-6\\nUGT-1F\\nUGT1\\nUGT1F',\n",
       "    'Gene Name': 'UGT1A6',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0008545|UDP-glucuronosyltransferase 1-6\\nMACLLRSFQRISAGVFFLALWGMVVGDKLLVVPQDGSHWLSMKDIVEVLSDRGHEIVVVV\\nPEVNLLLKESKYYTRKIYPVPYDQEELKNRYQSFGNNHFAERSFLTAPQTEYRNNMIVIG\\nLYFINCQSLLQDRDTLNFFKESKFDALFTDPALPCGVILAEYLGLPSVYLFRGFPCSLEH\\nTFSRSPDPVSYIPRCYTKFSDHMTFSQRVANFLVNLLEPYLFYCLFSKYEELASAVLKRD\\nVDIITLYQKVSVWLLRYDFVLEYPRPVMPNMVFIGGINCKKRKDLSQEFEAYINASGEHG\\nIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLL\\nGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSE\\nDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDL\\nTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH',\n",
       "    'Number of residues': '532',\n",
       "    'Molecular Weight': '60750.215',\n",
       "    'Theoretical pI': 'Not Available',\n",
       "    'GO Classification': 'Functionsenzyme binding / glucuronosyltransferase activity / protein heterodimerization activity / protein homodimerization activityProcessescellular glucuronidation / cellular response to hormone stimulus / flavonoid biosynthetic process / flavonoid glucuronidation / negative regulation of cellular glucuronidation / negative regulation of fatty acid metabolic process / negative regulation of glucuronosyltransferase activity / small molecule metabolic process / xenobiotic glucuronidation / xenobiotic metabolic processComponentsendoplasmic reticulum / endoplasmic reticulum membrane / extracellular exosome / integral component of membrane',\n",
       "    'General Function': 'Protein homodimerization activity',\n",
       "    'Specific Function': 'UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).',\n",
       "    'Pfam Domain Function': 'UDPGT (PF00201)',\n",
       "    'Transmembrane Regions': '490-506',\n",
       "    'Cellular Location': 'Microsome',\n",
       "    'Gene sequence': '>lcl|BSEQ0020785|UDP-glucuronosyltransferase 1-6 (UGT1A6)\\nATGGCCTGCCTCCTTCGCTCATTTCAGAGAATTTCTGCAGGGGTTTTCTTCTTAGCACTT\\nTGGGGCATGGTTGTAGGTGACAAGCTGCTGGTGGTCCCTCAGGACGGAAGCCACTGGCTT\\nAGTATGAAGGATATAGTTGAGGTTCTCAGTGACCGGGGTCATGAGATTGTAGTGGTGGTG\\nCCTGAAGTTAATTTGCTTTTGAAAGAATCCAAATACTACACAAGAAAAATCTATCCAGTG\\nCCGTATGACCAAGAAGAGCTGAAGAACCGTTACCAATCATTTGGAAACAATCACTTTGCT\\nGAGCGATCATTCCTAACTGCTCCTCAGACAGAGTACAGGAATAACATGATTGTTATTGGC\\nCTGTACTTCATCAACTGCCAGAGCCTCCTGCAGGACAGGGACACCCTGAACTTCTTTAAG\\nGAGAGCAAGTTTGATGCTCTTTTCACAGACCCAGCCTTACCCTGTGGGGTGATCCTGGCT\\nGAGTATTTGGGCCTACCATCTGTGTACCTCTTCAGGGGTTTTCCGTGTTCCCTGGAGCAT\\nACATTCAGCAGAAGCCCAGACCCTGTGTCCTACATTCCCAGGTGCTACACAAAGTTTTCA\\nGACCACATGACTTTTTCCCAACGAGTGGCCAACTTCCTTGTTAATTTGTTGGAGCCCTAT\\nCTATTTTATTGTCTGTTTTCAAAGTATGAAGAACTCGCATCAGCTGTCCTCAAGAGAGAT\\nGTGGATATAATCACCTTATATCAGAAGGTCTCTGTTTGGCTGTTAAGATATGACTTTGTG\\nCTTGAATATCCTAGGCCGGTCATGCCCAACATGGTCTTCATTGGAGGTATCAACTGTAAG\\nAAGAGGAAAGACTTGTCTCAGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGA\\nATTGTGGTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCA\\nATTGCTGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGA\\nCCATCGAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTT\\nGGTCACCCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGC\\nATATGCAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCA\\nAAGCGCATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAA\\nGATTTAGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATG\\nCGCCTCTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGG\\nGTGGAGTTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTC\\nACCTGGTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACA\\nGTGGCCTTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAA\\nGGGCGAGTTAAGAAAGCCCACAAATCCAAGACCCATTGA',\n",
       "    'Chromosome Location': '2',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP19224UniProtKB Entry NameUD16_HUMANHGNC IDHGNC:12538',\n",
       "    'General References': \"Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, Owens IS: A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem. 1992 Feb 15;267(5):3257-61. [Article] Harding D, Fournel-Gigleux S, Jackson MR, Burchell B: Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8381-5. [Article] Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, Popescu NC: Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001 Jun;11(4):357-68. [Article] Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Munzel PA, Lehmkoster T, Bruck M, Ritter JK, Bock KW: Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6. Arch Biochem Biophys. 1998 Feb 1;350(1):72-8. [Article] Girard H, Levesque E, Bellemare J, Journault K, Caillier B, Guillemette C: Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics. 2007 Dec;17(12):1077-89. [Article] Bellemare J, Rouleau M, Girard H, Harvey M, Guillemette C: Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro. Drug Metab Dispos. 2010 Oct;38(10):1785-9. doi: 10.1124/dmd.110.034835. Epub 2010 Jul 7. [Article] Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article] Ciotti M, Marrone A, Potter C, Owens IS: Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics. 1997 Dec;7(6):485-95. [Article] Nagar S, Zalatoris JJ, Blanchard RL: Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99. [Article] Menard V, Girard H, Harvey M, Perusse L, Guillemette C: Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat. 2009 Apr;30(4):677-87. doi: 10.1002/humu.20946. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00197Troglitazoneapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00688Mycophenolate mofetilapproved, investigationalunknownsubstrateDetailsDB00818Propofolapproved, investigational, vet_approvedunknownsubstrateDetailsDB01024Mycophenolic acidapproved, investigationalunknownsubstrateDetailsDB08826DeferiproneapprovedunknownsubstrateDetailsDB00316AcetaminophenapprovedunknownsubstrateDetailsDB00313Valproic acidapproved, investigationalunknownsubstrateDetailsDB01320Fosphenytoinapproved, investigationalnoinhibitorDetailsDB00252Phenytoinapproved, vet_approvednosubstrateinhibitorDetailsDB09288PropacetamolexperimentalnosubstrateDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownsubstrateDetailsDB00788Naproxenapproved, vet_approvedunknownsubstrateDetailsDB00564Carbamazepineapproved, investigationalunknowninducerDetailsDB15598Ferric maltolapprovedunknownsubstrateDetailsDB12243Edaravoneapproved, investigationalnosubstrateDetailsDB00349Clobazamapproved, illicitnoinhibitorDetailsDB00555Lamotrigineapproved, investigationalunknownsubstrateDetailsDB00503Ritonavirapproved, investigationalnoinducerDetailsDB14635Curcumin sulfateexperimentalunknowninhibitorDetailsDB00794Primidoneapproved, vet_approvedunknowninducerDetailsDB00783Estradiolapproved, investigational, vet_approvedunknownsubstrateinducerDetailsDB00714Apomorphineapproved, investigationalunknownsubstrateDetailsDB11796Fostemsavirapproved, investigationalunknownsubstrateDetailsDB00871TerbutalineapprovedunknownsubstrateDetailsDB00960Pindololapproved, investigationalunknownsubstrateDetailsDB12471Ibrexafungerpapproved, investigationalunknownsubstrateDetails'}},\n",
       "  {'Label': 'Arylamine N-acetyltransferase 2',\n",
       "   'Detailed Info': {'Name': 'Arylamine N-acetyltransferase 2',\n",
       "    'Synonyms': '2.3.1.5\\nAAC2\\nArylamide acetylase 2\\nN-acetyltransferase type 2\\nNAT-2\\nPNAT\\nPolymorphic arylamine N-acetyltransferase',\n",
       "    'Gene Name': 'NAT2',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0006940|Arylamine N-acetyltransferase 2\\nMDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMELGLEAIFDHIV\\nRRNRGGWCLQVNQLLYWALTTIGFQTTMLGGYFYIPPVNKYSTGMVHLLLQVTIDGRNYI\\nVDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHL\\nLPKKKHQKIYLFTLEPRTIEDFESMNTYLQTSPTSSFITTSFCSLQTPEGVYCLVGFILT\\nYRKFNYKDNTDLVEFKTLTEEEVEEVLKNIFKISLGRNLVPKPGDGSLTI',\n",
       "    'Number of residues': '290',\n",
       "    'Molecular Weight': '33542.235',\n",
       "    'Theoretical pI': '5.67',\n",
       "    'GO Classification': 'Functionsarylamine N-acetyltransferase activityProcessessmall molecule metabolic process / xenobiotic metabolic processComponentscytosol',\n",
       "    'General Function': 'Arylamine n-acetyltransferase activity',\n",
       "    'Specific Function': 'Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.',\n",
       "    'Pfam Domain Function': 'Acetyltransf_2 (PF00797)',\n",
       "    'Transmembrane Regions': 'Not Available',\n",
       "    'Cellular Location': 'Cytoplasm',\n",
       "    'Gene sequence': '>lcl|BSEQ0012509|Arylamine N-acetyltransferase 2 (NAT2)\\nATGGACATTGAAGCATATTTTGAAAGAATTGGCTATAAGAACTCTAGGAACAAATTGGAC\\nTTGGAAACATTAACTGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTGAGAACCTT\\nAACATGCATTGTGGGCAAGCCATGGAGTTGGGCTTAGAGGCTATTTTTGATCACATTGTA\\nAGAAGAAACCGGGGTGGGTGGTGTCTCCAGGTCAATCAACTTCTGTACTGGGCTCTGACC\\nACAATCGGTTTTCAGACCACAATGTTAGGAGGGTATTTTTACATCCCTCCAGTTAACAAA\\nTACAGCACTGGCATGGTTCACCTTCTCCTGCAGGTGACCATTGACGGCAGGAATTACATT\\nGTCGATGCTGGGTCTGGAAGCTCCTCCCAGATGTGGCAGCCTCTAGAATTAATTTCTGGG\\nAAGGATCAGCCTCAGGTGCCTTGCATTTTCTGCTTGACAGAAGAGAGAGGAATCTGGTAC\\nCTGGACCAAATCAGGAGAGAGCAGTATATTACAAACAAAGAATTTCTTAATTCTCATCTC\\nCTGCCAAAGAAGAAACACCAAAAAATATACTTATTTACGCTTGAACCTCGAACAATTGAA\\nGATTTTGAGTCTATGAATACATACCTGCAGACGTCTCCAACATCTTCATTTATAACCACA\\nTCATTTTGTTCCTTGCAGACCCCAGAAGGGGTTTACTGTTTGGTGGGCTTCATCCTCACC\\nTATAGAAAATTCAATTATAAAGACAATACAGATCTGGTCGAGTTTAAAACTCTCACTGAG\\nGAAGAGGTTGAAGAAGTGCTGAGAAATATATTTAAGATTTCCTTGGGGAGAAATCTCGTG\\nCCCAAACCTGGTGATGGATCCCTTACTATTTAG',\n",
       "    'Chromosome Location': '8',\n",
       "    'Locus': '8p22',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP11245UniProtKB Entry NameARY2_HUMANGenBank Protein ID219412GenBank Gene IDD90040HGNC IDHGNC:7646',\n",
       "    'General References': \"Grant DM, Blum M, Demierre A, Meyer UA: Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res. 1989 May 25;17(10):3978. [Article] Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990 Apr;9(3):193-203. [Article] Ohsako S, Deguchi T: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem. 1990 Mar 15;265(8):4630-4. [Article] Deguchi T: Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem. 1992 Sep 5;267(25):18140-7. [Article] Ferguson RJ, Doll MA, Rustan TD, Gray K, Hein DW: Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles. Drug Metab Dispos. 1994 May-Jun;22(3):371-6. [Article] Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, Behar DM, Semino O, Sakuntabhai A, Guiso N, Gicquel B, McElreavey K, Harding RM, Heyer E, Quintana-Murci L: Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet. 2006 Mar;78(3):423-36. Epub 2006 Jan 13. [Article] Nusbaum C, Mikkelsen TS, Zody MC, Asakawa S, Taudien S, Garber M, Kodira CD, Schueler MG, Shimizu A, Whittaker CA, Chang JL, Cuomo CA, Dewar K, FitzGerald MG, Yang X, Allen NR, Anderson S, Asakawa T, Blechschmidt K, Bloom T, Borowsky ML, Butler J, Cook A, Corum B, DeArellano K, DeCaprio D, Dooley KT, Dorris L 3rd, Engels R, Glockner G, Hafez N, Hagopian DS, Hall JL, Ishikawa SK, Jaffe DB, Kamat A, Kudoh J, Lehmann R, Lokitsang T, Macdonald P, Major JE, Matthews CD, Mauceli E, Menzel U, Mihalev AH, Minoshima S, Murayama Y, Naylor JW, Nicol R, Nguyen C, O'Leary SB, O'Neill K, Parker SC, Polley A, Raymond CK, Reichwald K, Rodriguez J, Sasaki T, Schilhabel M, Siddiqui R, Smith CL, Sneddon TP, Talamas JA, Tenzin P, Topham K, Venkataraman V, Wen G, Yamazaki S, Young SK, Zeng Q, Zimmer AR, Rosenthal A, Birren BW, Platzer M, Shimizu N, Lander ES: DNA sequence and analysis of human chromosome 8. Nature. 2006 Jan 19;439(7074):331-5. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Ebisawa T, Deguchi T: Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1252-7. [Article] Grant DM, Lottspeich F, Meyer UA: Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Lett. 1989 Feb 13;244(1):203-7. [Article] Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, Grant DM, Plotnikov AN: Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J Biol Chem. 2007 Oct 12;282(41):30189-97. Epub 2007 Jul 26. [Article] Vatsis KP, Martell KJ, Weber WW: Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6333-7. [Article] Abe M, Deguchi T, Suzuki T: The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun. 1993 Mar 31;191(3):811-6. [Article] Lin HJ, Han CY, Lin BK, Hardy S: Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994 Jun;4(3):125-34. [Article]\",\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00250Dapsoneapproved, investigationalunknownsubstrateDetailsDB01015SulfamethoxazoleapprovedunknownsubstrateDetailsDB00951Isoniazidapproved, investigationalunknownsubstrateDetailsDB04953Ezogabineapproved, investigationalunknownsubstrateDetailsDB00316AcetaminophenapprovedunknowninhibitorDetailsDB01068Clonazepamapproved, illicitunknownsubstrateDetailsDB11640Amifampridineapproved, investigationalnosubstrateDetailsDB09288PropacetamolexperimentalnoinhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownsubstrateDetailsDB12612Ozanimodapproved, investigationalunknownsubstrateDetails'}}],\n",
       " 'transporters': [{'Label': 'Solute carrier family 22 member 6',\n",
       "   'Detailed Info': {'Name': 'Solute carrier family 22 member 6',\n",
       "    'Synonyms': 'hOAT1\\nhPAHT\\nhROAT1\\nOAT1\\nOrganic anion transporter 1\\nPAH transporter\\nPAHT\\nRenal organic anion transporter 1',\n",
       "    'Gene Name': 'SLC22A6',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0037120|Solute carrier family 22 member 6\\nMAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN\\nGGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI\\nVTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA\\nFAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV\\nAYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE\\nGAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL\\nQGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS\\nIVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE\\nLYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT\\nRQQQEHQKYMVPLQASAQEKNGL',\n",
       "    'Number of residues': '563',\n",
       "    'Molecular Weight': '61815.78',\n",
       "    'Theoretical pI': '8.78',\n",
       "    'GO Classification': 'Functionschloride ion binding / inorganic anion exchanger activity / organic anion transmembrane transporter activity / sodium-independent organic anion transmembrane transporter activityProcessesalpha-ketoglutarate transport / anion transmembrane transport / organic anion transport / protein homooligomerization / renal tubular secretion / response to methotrexate / sodium-independent organic anion transport / transmembrane transportComponentsbasolateral plasma membrane / caveola / extracellular exosome / integral component of plasma membrane / plasma membrane / protein complex',\n",
       "    'General Function': 'Sodium-independent organic anion transmembrane transporter activity',\n",
       "    'Specific Function': \"Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.\",\n",
       "    'Pfam Domain Function': 'Sugar_tr (PF00083)',\n",
       "    'Transmembrane Regions': '10-30\\n136-156\\n165-187\\n191-213\\n225-245\\n249-269\\n338-358\\n369-389\\n396-416\\n426-446\\n456-475\\n485-505',\n",
       "    'Cellular Location': 'Cell membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)\\nATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG\\nGTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC\\nACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC\\nGGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC\\nTTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG\\nGCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC\\nGTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG\\nTACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC\\nCGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC\\nTTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT\\nGGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC\\nTGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG\\nGCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC\\nTTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG\\nCTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA\\nGGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC\\nAAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC\\nTGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG\\nCAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT\\nGCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT\\nGCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC\\nATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC\\nATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG\\nGGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG\\nCTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC\\nACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG\\nAGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG\\nCGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG\\nAATGGACTCTGA',\n",
       "    'Chromosome Location': '11',\n",
       "    'Locus': 'Not Available',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDQ4U2R8UniProtKB Entry NameS22A6_HUMANGenBank Protein ID3831566GenBank Gene IDAF057039GenAtlas IDhROAT1HGNC IDHGNC:10970',\n",
       "    'General References': 'Reid G, Wolff NA, Dautzenberg FM, Burckhardt G: Cloning of a human renal p-aminohippurate transporter, hROAT1. Kidney Blood Press Res. 1998;21(2-4):233-7. [Article] Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [Article] Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [Article] Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [Article] Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 Sep;56(3):570-80. [Article] Bahn A, Prawitt D, Buttler D, Reid G, Enklaar T, Wolff NA, Ebbinghaus C, Hillemann A, Schulten HJ, Gunawan B, Fuzesi L, Zabel B, Burckhardt G: Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. Biochem Biophys Res Commun. 2000 Aug 28;275(2):623-30. [Article] Taylor TD, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, Dewar K, Lloyd C, Itoh T, Takeda T, Kim DW, She X, Barlow KF, Bloom T, Bruford E, Chang JL, Cuomo CA, Eichler E, FitzGerald MG, Jaffe DB, LaButti K, Nicol R, Park HS, Seaman C, Sougnez C, Yang X, Zimmer AR, Zody MC, Birren BW, Nusbaum C, Fujiyama A, Hattori M, Rogers J, Lander ES, Sakaki Y: Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006 Mar 23;440(7083):497-500. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Groves CE, Munoz L, Bahn A, Burckhardt G, Wright SH: Interaction of cysteine conjugates with human and rabbit organic anion transporter 1. J Pharmacol Exp Ther. 2003 Feb;304(2):560-6. [Article] Tanaka K, Xu W, Zhou F, You G: Role of glycosylation in the organic anion transporter OAT1. J Biol Chem. 2004 Apr 9;279(15):14961-6. Epub 2004 Jan 28. [Article] Hong M, Zhou F, You G: Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1. J Biol Chem. 2004 Jul 23;279(30):31478-82. Epub 2004 May 15. [Article] Srimaroeng C, Chatsudthipong V, Aslamkhan AG, Pritchard JB: Transport of the natural sweetener stevioside and its aglycone steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8). J Pharmacol Exp Ther. 2005 May;313(2):621-8. Epub 2005 Jan 11. [Article] Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y: Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res. 2005 Apr;22(4):647-60. Epub 2005 Apr 7. [Article] Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB: A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J Biol Chem. 2006 Dec 8;281(49):38071-9. Epub 2006 Oct 11. [Article] Mizuno N, Takahashi T, Iwase Y, Kusuhara H, Niwa T, Sugiyama Y: Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34. Epub 2007 May 14. [Article] Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB: Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther. 2005 Aug;314(2):923-31. Epub 2005 May 24. [Article] Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 2005 Oct;68(4):1491-9. [Article]',\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00695Furosemideapproved, vet_approvedunknowninhibitorinducerDetailsDB00936Salicylic acidapproved, investigational, vet_approvedunknowninhibitorDetailsDB01032Probenecidapproved, investigationalunknownsubstrateinhibitorDetailsDB00345Aminohippuric acidapproved, investigationalunknownsubstrateinhibitorDetailsDB01009Ketoprofenapproved, vet_approvedunknowninhibitorDetailsDB03553Glutaric AcidexperimentalunknownsubstrateinhibitorDetailsDB00369CidofovirapprovedunknownsubstrateinhibitorDetailsDB01333CefradineapprovedunknowninhibitorDetailsDB00718Adefovir dipivoxilapproved, investigationalunknownsubstrateinhibitorDetailsDB00554Piroxicamapproved, investigationalunknowninhibitorDetailsDB03783PhenacetinwithdrawnunknowninhibitorDetailsDB00788Naproxenapproved, vet_approvedunknowninhibitorDetailsDB00328Indomethacinapproved, investigationalunknownsubstrateinhibitorDetailsDB01050IbuprofenapprovedunknowninhibitorDetailsDB00712Flurbiprofenapproved, investigationalunknowninhibitorDetailsDB00749Etodolacapproved, investigational, vet_approvedunknowninhibitorDetailsDB00861Diflunisalapproved, investigationalunknowninhibitorDetailsDB00586Diclofenacapproved, vet_approvedunknowninhibitorDetailsDB01597Cilastatinapproved, investigationalunknowninhibitorDetailsDB01053Benzylpenicillinapproved, vet_approvedunknowninhibitorDetailsDB04519Caprylic acidinvestigationalunknowninhibitorDetailsDB00501Cimetidineapproved, investigationalunknownsubstrateinhibitorDetailsDB00168Aspartameinvestigational, nutraceuticalunknowninhibitorDetailsDB00759Tetracyclineapproved, vet_approved, withdrawnunknowninhibitorDetailsDB00595Oxytetracyclineapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB01017Minocyclineapproved, investigationalunknowninhibitorDetailsDB00254Doxycyclineapproved, investigational, vet_approvedunknowninhibitorDetailsDB01004Ganciclovirapproved, investigationalunknowninhibitorDetailsDB00787AcyclovirapprovedunknownsubstrateinhibitorDetailsDB00917DinoprostoneapprovedunknownsubstrateinhibitorDetailsDB00456Cefalotinapproved, investigational, vet_approvedunknowninhibitorDetailsDB01212CeftriaxoneapprovedunknowninhibitorDetailsDB00493CefotaximeapprovedunknowninhibitorDetailsDB01329Cefoperazoneapproved, investigationalunknowninhibitorDetailsDB01327CefazolinapprovedunknownsubstrateinhibitorDetailsDB01326Cefamandoleapproved, experimentalunknowninhibitorDetailsDB01140Cefadroxilapproved, vet_approved, withdrawnunknowninhibitorDetailsDB00812Phenylbutazoneapproved, vet_approvedunknowninhibitorDetailsDB00563MethotrexateapprovedunknownsubstrateinhibitorDetailsDB00693FluoresceinapprovedunknownsubstrateinhibitorDetailsDB00678LosartanapprovedunknowninhibitorDetailsDB00999Hydrochlorothiazideapproved, vet_approvedunknownsubstrateinhibitorDetailsDB00887BumetanideapprovedunknownsubstrateinhibitorDetailsDB00175PravastatinapprovednoinhibitorDetailsDB00520CaspofunginapprovedunknowninhibitorDetailsDB00605Sulindacapproved, investigationalunknowninhibitorDetailsDB00140Riboflavinapproved, investigational, nutraceutical, vet_approvedunknowninhibitorDetailsDB00158Folic acidapproved, nutraceutical, vet_approvedunknowninhibitorDetailsDB00584Enalaprilapproved, vet_approvedunknowninhibitorDetailsDB00821Carprofenapproved, vet_approved, withdrawnunknowninhibitorDetailsDB01197CaptoprilapprovedunknownsubstrateinhibitorDetailsDB01124Tolbutamideapproved, investigationalunknowninhibitorDetailsDB01060Amoxicillinapproved, vet_approvedunknowninhibitorDetailsDB00567Cephalexinapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00313Valproic acidapproved, investigationalunknowninhibitorDetailsDB00779Nalidixic acidapproved, investigationalunknowninhibitorDetailsDB00903Etacrynic acidapproved, investigationalunknowninhibitorDetailsDB00091Cyclosporineapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00703MethazolamideapprovedunknowninhibitorDetailsDB00311EthoxzolamidewithdrawnunknowninhibitorDetailsDB00606CyclothiazideapprovedunknowninhibitorDetailsDB00880Chlorothiazideapproved, vet_approvedunknowninhibitorDetailsDB00819Acetazolamideapproved, vet_approvedunknowninhibitorDetailsDB02266Flufenamic acidapprovedunknowninhibitorDetailsDB00500TolmetinapprovedunknowninhibitorDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB01435Antipyrineapproved, investigationalunknowninhibitorDetailsDB03585Oxyphenbutazoneapproved, withdrawnunknowninhibitorDetailsDB00939Meclofenamic acidapproved, vet_approvedunknowninhibitorDetailsDB01424Aminophenazoneapproved, withdrawnunknowninhibitorDetailsDB00731Nateglinideapproved, investigationalunknowninhibitorDetailsDB00319PiperacillinapprovedunknowninhibitorDetailsDB01165OfloxacinapprovedunknowninhibitorDetailsDB01059NorfloxacinapprovedunknowninhibitorDetailsDB00607Nafcillinapproved, investigationalunknowninhibitorDetailsDB00827Cinoxacinapproved, investigational, withdrawnunknowninhibitorDetailsDB00446Chloramphenicolapproved, vet_approved, withdrawnunknowninhibitorDetailsDB00438CeftazidimeapprovedunknowninhibitorDetailsDB00578Carbenicillinapproved, investigationalunknowninhibitorDetailsDB00432Trifluridineapproved, investigationalunknownsubstrateinhibitorDetailsDB01016GlyburideapprovedunknowninhibitorDetailsDB04348Taurocholic acidapproved, experimentalunknownsubstrateinhibitorDetailsDB00529FoscarnetapprovedunknowninhibitorDetailsDB00672Chlorpropamideapproved, investigationalunknowninhibitorDetailsDB00229Cefotiamapproved, investigationalunknownsubstrateinhibitorDetailsDB01051Novobiocinapproved, investigational, vet_approved, withdrawnunknowninhibitorDetailsDB00286Conjugated estrogensapprovedunknownsubstrateDetailsDB02527Cyclic adenosine monophosphateexperimentalunknownsubstrateDetailsDB00709Lamivudineapproved, investigationalunknownsubstrateDetailsDB00365Grepafloxacinapproved, investigational, withdrawnunknownsubstrateDetailsDB00649Stavudineapproved, investigationalunknownsubstrateDetailsDB00943Zalcitabineapproved, investigationalunknownsubstrateDetailsDB00900DidanosineapprovedunknownsubstrateDetailsDB01032Probenecidapproved, investigationalyesinhibitorDetailsDB01237BromodiphenhydramineapprovedunknownDetailsDB01414Cefacetrileexperimental, vet_approvedunknownsubstrateinhibitorDetailsDB00654Latanoprostapproved, investigationalunknownsubstrateinhibitorDetailsDB00577Valaciclovirapproved, investigationalunknownDetailsDB08843GS 0573investigationalunknownDetailsDB00495ZidovudineapprovedunknownsubstrateDetailsDB02315Cyclic GMPexperimentalunknownDetailsDB08844Uric acidinvestigationalunknownDetailsDB01160Dinoprost tromethamineapproved, vet_approvedunknownDetailsDB06151Acetylcysteineapproved, investigationalunknownsubstrateDetailsDB08846Ellagic acidinvestigationalunknownsubstrateinhibitorDetailsDB04133Degraded CephaloridineexperimentalunknownDetailsDB00659Acamprosateapproved, investigationalunknownsubstrateDetailsDB08912Dabrafenibapproved, investigationalnoinhibitorDetailsDB00300Tenofovir disoproxilapproved, investigationalunknownsubstrateDetailsDB00493CefotaximeapprovedunknownDetailsDB01212CeftriaxoneapprovedunknownDetailsDB01685TopiroxostatexperimentalunknowninhibitorDetailsDB05016Atalurenapproved, investigationalnoinhibitorDetailsDB13874Enasidenibapproved, investigationalunknowninhibitorDetailsDB08930DolutegravirapprovednoinhibitorDetailsDB12332Rucaparibapproved, investigationalnoinhibitorDetailsDB11817Baricitinibapproved, investigationalunknowninhibitorDetailsDB00535CefdinirapprovedunknownsubstrateDetailsDB01415Ceftibutenapproved, investigationalunknownsubstrateDetailsDB01332Ceftizoximeapproved, withdrawnunknownsubstrateinhibitorDetailsDB09008Cefaloridineexperimental, withdrawnunknownsubstrateDetailsDB00155Citrullineinvestigational, nutraceuticalunknownsubstrateDetailsDB12243Edaravoneapproved, investigationalnosubstrateDetailsDB00770Alprostadilapproved, investigationalunknownsubstrateinhibitorDetailsDB09298Silibininexperimental, investigationalunknownsubstrateinhibitorDetailsDB09078Lenvatinibapproved, investigationalunknowninhibitorDetailsDB01606TazobactamapprovedunknownsubstrateinhibitorDetailsDB01045RifampicinapprovedunknowninhibitorDetailsDB11751Cabotegravirapproved, investigationalunknowninhibitorDetailsDB09213Dexibuprofenapproved, investigationalunknownDetailsDB09299Tenofovir alafenamideapprovednosubstrateDetailsDB14126Tenofovirexperimental, investigationalnosubstrateDetailsDB11757Istradefyllineapproved, investigationalunknowninhibitorDetailsDB15328Ubrogepantapproved, investigationalunknownsubstrateDetailsDB00927FamotidineapprovednosubstrateDetailsDB11644Tafamidisapproved, investigationalunknowninhibitorDetailsDB12466Favipiravirapproved, investigationalunknowninhibitorDetailsDB11837Osilodrostatapproved, investigationalunknowninhibitorDetailsDB00774Hydroflumethiazideapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB01324PolythiazideapprovedunknownsubstrateDetailsDB15822Pralsetinibapproved, investigationalnoinhibitorDetailsDB16628FosdenopterinapprovedunknowninhibitorDetailsDB00601Linezolidapproved, investigationalnoinhibitorDetailsDB12151Brincidofovirapproved, investigationalnoinhibitorDetailsDB12265Fexinidazoleapproved, investigationalunknowninhibitorDetailsDB16098Atogepantapproved, investigationalnosubstrateDetailsDB06176Romidepsinapproved, investigationalnoinhibitorDetailsDB15413Pafolacianineapproved, investigationalnosubstrateDetailsDB04847Roxadustatapproved, investigationalunknownsubstrateDetailsDB17083LinzagolixapprovednoinhibitorDetailsDB00642Pemetrexedapproved, investigationalnosubstrateDetailsDB11682Daprodustatapproved, investigationalnosubstrateDetailsDB01250OlsalazineapprovedunknownupregulatorDetailsDB12513Omaveloxoloneapproved, investigationalunknowninhibitorDetailsDB11712Tezacaftorapproved, investigationalnoinhibitorDetailsDB12255Vadadustatapproved, investigationalunknownsubstrateDetailsDB16704Durlobactamapproved, investigationalnosubstrateDetailsDB11718Encorafenibapproved, investigationalnoinhibitorDetails'}},\n",
       "  {'Label': 'P-glycoprotein 1',\n",
       "   'Detailed Info': {'Name': 'Multidrug resistance protein 1',\n",
       "    'Synonyms': '3.6.3.44\\nATP-binding cassette sub-family B member 1\\nMDR1\\nP-glycoprotein 1\\nPGY1',\n",
       "    'Gene Name': 'ABCB1',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0037114|Multidrug resistance protein 1\\nMDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII\\nHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG\\nIGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS\\nKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT\\nDKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG\\nAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG\\nAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG\\nQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF\\nATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA\\nIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG\\nFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS\\nSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII\\nNGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA\\nGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI\\nANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA\\nIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG\\nAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS\\nYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV\\nQLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV\\nSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD\\nEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL\\nLAQKGIYFSMVSVQAGTKRQ',\n",
       "    'Number of residues': '1280',\n",
       "    'Molecular Weight': '141477.255',\n",
       "    'Theoretical pI': '9.44',\n",
       "    'GO Classification': 'FunctionsATP binding / ATPase activity, coupled to transmembrane movement of substances / transporter activity / xenobiotic-transporting ATPase activityProcessesdrug transmembrane transport / G2/M transition of mitotic cell cycle / response to drug / small molecule metabolic process / stem cell proliferation / transmembrane transport / transportComponentscell surface / extracellular exosome / integral component of membrane / membrane / plasma membrane',\n",
       "    'General Function': 'Xenobiotic-transporting atpase activity',\n",
       "    'Specific Function': 'Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.',\n",
       "    'Pfam Domain Function': 'ABC_tran (PF00005)\\nABC_membrane (PF00664)',\n",
       "    'Transmembrane Regions': '45-67\\n117-137\\n187-208\\n216-236\\n293-316\\n331-352\\n712-732\\n757-777\\n833-853\\n855-874\\n935-957\\n974-995',\n",
       "    'Cellular Location': 'Cell membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)\\nATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC\\nAATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT\\nCGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC\\nCATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA\\nAATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT\\nACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA\\nATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT\\nGGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA\\nGGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC\\nAAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT\\nTTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC\\nATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT\\nGATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA\\nATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT\\nTTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT\\nGCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG\\nGTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT\\nGGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA\\nGCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG\\nAGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT\\nTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG\\nCAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG\\nCAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC\\nATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT\\nGCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT\\nGAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT\\nGACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC\\nATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC\\nTTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG\\nACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT\\nTTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC\\nATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA\\nGCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC\\nAGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA\\nAAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT\\nATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA\\nAATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA\\nAGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA\\nGCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT\\nGGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT\\nGTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT\\nGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA\\nGCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA\\nCTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT\\nGGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA\\nATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT\\nGCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT\\nACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA\\nGCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT\\nGTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA\\nGCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC\\nTACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT\\nGTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG\\nAAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC\\nCAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA\\nATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC\\nATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG\\nTCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA\\nCTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG\\nAAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT\\nGAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA\\nGCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA\\nGACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG\\nCTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG\\nTGA',\n",
       "    'Chromosome Location': '7',\n",
       "    'Locus': '7q21.1',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDP08183UniProtKB Entry NameMDR1_HUMANGenBank Protein ID307180GenBank Gene IDM14758GenAtlas IDABCB1HGNC IDHGNC:40',\n",
       "    'General References': \"Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381-9. [Article] Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990 Jan 5;265(1):506-14. [Article] Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C, Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997 Feb 28;272(9):5974-82. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64. [Article] Gekeler V, Weger S, Probst H: mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem Biophys Res Commun. 1990 Jun 15;169(2):796-802. [Article] Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K: P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun. 1989 Jul 14;162(1):224-31. [Article] Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001 Feb;2(1):51-64. [Article] Begley GS, Horvath AR, Taylor JC, Higgins CF: Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol. 2005 Jan;42(1):137-41. [Article] Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. doi: 10.1073/pnas.0805139105. Epub 2008 Jul 31. [Article] Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article] Katayama K, Yamaguchi M, Noguchi K, Sugimoto Y: Protein phosphatase complex PP5/PPP2R3C dephosphorylates P-glycoprotein/ABCB1 and down-regulates the expression and function. Cancer Lett. 2014 Apr 1;345(1):124-31. doi: 10.1016/j.canlet.2013.12.007. Epub 2013 Dec 11. [Article] Choi KH, Chen CJ, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 1988 May 20;53(4):519-29. [Article] Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998 Mar 1;91(5):1749-56. [Article] Decleves X, Chevillard S, Charpentier C, Vielh P, Laplanche JL: A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum Mutat. 2000 May;15(5):486. [Article] Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8. [Article] Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001 Mar;69(3):169-74. [Article] Honda T, Dan Y, Koyabu N, Ieiri I, Otsubo K, Higuchi S, Ohtani H, Sawada Y: Polymorphism of MDR1 gene in healthy japanese subjects: a novel SNP with an amino acid substitution (Glu108Lys). Drug Metab Pharmacokinet. 2002;17(5):479-81. [Article] Itoda M, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, Sawada J: Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab Pharmacokinet. 2002;17(6):566-71. [Article] Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet. 2002;47(1):38-50. [Article] Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003 Dec;73(6):1282-92. Epub 2003 Nov 7. [Article] Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7. [Article]\",\n",
       "    'Drug Relations': \"DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB00171ATPinvestigational, nutraceuticalunknownDetailsDB00778Roxithromycinapproved, investigational, withdrawnunknownDetailsDB04881ElacridarinvestigationalunknownDetailsDB04905TesmilifeneinvestigationalyesinducerDetailsDB05449FM-VP4investigationalunknownDetailsDB06240TariquidarinvestigationalunknownDetailsDB06191ZosuquidarinvestigationalyesinhibitorDetailsDB00661VerapamilapprovedunknownsubstrateinhibitorDetailsDB01232Saquinavirapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00220NelfinavirapprovednosubstrateinhibitorinducerDetailsDB00224IndinavirapprovedunknownsubstrateinhibitorinducerDetailsDB00701Amprenavirapproved, investigationalunknownsubstrateinducerDetailsDB01045RifampicinapprovedunknowninducerDetailsDB00206Reserpineapproved, investigational, withdrawnunknownsubstrateinhibitorinducerDetailsDB01115NifedipineapprovedunknownsubstrateinducerDetailsDB00834Mifepristoneapproved, investigationalunknowninhibitorinducerDetailsDB01234Dexamethasoneapproved, investigational, vet_approvedunknownsubstrateinhibitorinducerDetailsDB00257Clotrimazoleapproved, vet_approvedunknowninhibitorinducerDetailsDB00564Carbamazepineapproved, investigationalunknowninducerDetailsDB00656Trazodoneapproved, investigationalunknowninducerDetailsDB01149Nefazodoneapproved, withdrawnunknowninhibitorinducerDetailsDB00503Ritonavirapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00390DigoxinapprovedunknownsubstrateinhibitorinducerDetailsDB00279Liothyronineapproved, vet_approvedunknowninducerDetailsDB00451LevothyroxineapprovedunknowninducerDetailsDB00440Trimethoprimapproved, vet_approvedunknownsubstrateDetailsDB00396Progesteroneapproved, vet_approvedunknownsubstrateinhibitorinducerDetailsDB02261Platelet Activating FactorexperimentalunknownsubstrateinducerDetailsDB00091Cyclosporineapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00501Cimetidineapproved, investigationalunknownsubstrateinducerDetailsDB04630Aldosteroneexperimental, investigationalunknownsubstrateinducerDetailsDB00864Tacrolimusapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00877Sirolimusapproved, investigationalnosubstrateinhibitorinducerDetailsDB01174Phenobarbitalapproved, investigationalunknownsubstrateinducerDetailsDB00199Erythromycinapproved, investigational, vet_approvednosubstrateinhibitorDetailsDB01118Amiodaroneapproved, investigationalunknowninhibitorinducerDetailsDB01323St. John's Wortapproved, investigational, nutraceuticalunknowninducerDetailsDB00541Vincristineapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00570VinblastineapprovedunknownsubstrateinhibitorinducerDetailsDB02659Cholic AcidapprovedunknowninducerDetailsDB00675TamoxifenapprovedunknownsubstrateinhibitorinducerDetailsDB00428Streptozocinapproved, investigationalunknowninducerDetailsDB01204Mitoxantroneapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00997Doxorubicinapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB00694DaunorubicinapprovedunknownsubstrateinhibitorinducerDetailsDB00908Quinidineapproved, investigationalunknownsubstrateinhibitorDetailsDB01026Ketoconazoleapproved, investigationalunknowninhibitorDetailsDB01388Mibefradilinvestigational, withdrawnunknownsubstrateinhibitorDetailsDB04540Cholesterolapproved, investigationalunknowninhibitorDetailsDB00358Mefloquineapproved, investigationalunknownsubstrateinhibitorDetailsDB00622Nicardipineapproved, investigationalunknownsubstrateinhibitorDetailsDB00381AmlodipineapprovedunknownsubstrateinhibitorDetailsDB00972AzelastineapprovedunknowninhibitorDetailsDB00863Ranitidineapproved, withdrawnunknownsubstrateinhibitorDetailsDB00773EtoposideapprovedunknownsubstrateinhibitorDetailsDB00333MethadoneapprovedunknowninhibitorDetailsDB00641SimvastatinapprovedunknowninhibitorDetailsDB00227Lovastatinapproved, investigationalunknowninhibitorDetailsDB01076AtorvastatinapprovednosubstrateinhibitorDetailsDB01229Paclitaxelapproved, vet_approvedunknownsubstrateinhibitorDetailsDB00457PrazosinapprovedunknownsubstrateinhibitormodulatorDetailsDB01054Nitrendipineapproved, investigationalunknowninhibitorDetailsDB00975DipyridamoleapprovedunknownsubstrateinhibitorDetailsDB00343Diltiazemapproved, investigationalunknownsubstrateinhibitorDetailsDB01394ColchicineapprovedunknownsubstrateinducerDetailsDB01211ClarithromycinapprovedunknownsubstrateinhibitorDetailsDB00477Chlorpromazineapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00970Dactinomycinapproved, investigationalunknownsubstrateinhibitorDetailsDB13179TroleandomycinapprovedunknowninhibitorDetailsDB00831Trifluoperazineapproved, investigationalunknowninhibitorDetailsDB00342Terfenadineapproved, withdrawnunknowninhibitorDetailsDB00468QuinineapprovedunknownsubstrateinhibitorDetailsDB01167Itraconazoleapproved, investigationalunknowninhibitorDetailsDB00328Indomethacinapproved, investigationalunknownsubstrateinhibitorDetailsDB02587Colforsinexperimental, investigationalunknowninhibitorDetailsDB00623FluphenazineapprovedunknowninhibitorDetailsDB01023Felodipineapproved, investigationalunknowninhibitorDetailsDB01136Carvedilolapproved, investigationalunknowninhibitorDetailsDB00421SpironolactoneapprovedunknowninducerDetailsDB00281Lidocaineapproved, vet_approvedunknowninhibitorDetailsDB00537Ciprofloxacinapproved, investigationalunknownsubstrateDetailsDB00207AzithromycinapprovedunknownsubstrateinhibitorDetailsDB00316AcetaminophenapprovedunknownsubstrateinhibitorDetailsDB00196Fluconazoleapproved, investigationalunknowninhibitorDetailsDB00213PantoprazoleapprovedunknownsubstrateinhibitorDetailsDB00338Omeprazoleapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00448Lansoprazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB00678LosartanapprovedunknownsubstrateinhibitorDetailsDB00584Enalaprilapproved, vet_approvedunknowninhibitorDetailsDB00590DoxazosinapprovedunknowninhibitorDetailsDB01340CilazaprilapprovedunknowninhibitorDetailsDB01197CaptoprilapprovedunknowninhibitorDetailsDB00796Candesartan cilexetilapprovedunknowninhibitorDetailsDB01110Miconazoleapproved, investigational, vet_approvedunknowninhibitorDetailsDB00696ErgotamineapprovedunknowninhibitorDetailsDB01253ErgometrineapprovedunknowninhibitorDetailsDB00320Dihydroergotamineapproved, investigationalunknowninhibitorDetailsDB01200Bromocriptineapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00836LoperamideapprovedunknownsubstrateDetailsDB00813Fentanylapproved, illicit, investigational, vet_approvedunknowninhibitorDetailsDB00802Alfentanilapproved, illicitunknowninhibitorDetailsDB00401NisoldipineapprovedunknowninhibitorDetailsDB04832Zimelidineapproved, withdrawnunknowninhibitorDetailsDB00382Tacrineapproved, investigational, withdrawnunknownsubstrateDetailsDB00669Sumatriptanapproved, investigationalunknownsubstrateDetailsDB01037Selegilineapproved, investigational, vet_approvedunknowninhibitorDetailsDB00458ImipramineapprovedunknownsubstrateDetailsDB00502HaloperidolapprovedunknownsubstrateinhibitorDetailsDB00176Fluvoxamineapproved, investigationalunknowninhibitorDetailsDB00690Flurazepamapproved, illicit, investigationalunknowninhibitorDetailsDB00472Fluoxetineapproved, vet_approvedunknowninhibitorDetailsDB01142Doxepinapproved, investigationalunknownsubstrateDetailsDB01151Desipramineapproved, investigationalunknowninhibitorDetailsDB01242Clomipramineapproved, investigational, vet_approvedunknowninhibitorDetailsDB01239Chlorprothixeneapproved, experimental, investigational, withdrawnunknowninhibitorDetailsDB00490Buspironeapproved, investigationalunknowninhibitorDetailsDB01100PimozideapprovedunknowninhibitorDetailsDB00295Morphineapproved, investigationalnosubstrateDetailsDB00602Ivermectinapproved, investigational, vet_approvedunknownsubstrateinhibitorinducerDetailsDB00741Hydrocortisoneapproved, vet_approvedunknownsubstrateinducerDetailsDB00637Astemizoleapproved, withdrawnunknowninhibitorDetailsDB00508Triflupromazineapproved, vet_approvedunknowninhibitorDetailsDB00344ProtriptylineapprovedunknowninhibitorDetailsDB01069Promethazineapproved, investigationalunknowninhibitorDetailsDB01244Bepridilapproved, withdrawnunknowninhibitorDetailsDB00455Loratadineapproved, investigationalnosubstrateinhibitorDetailsDB00967Desloratadineapproved, investigationalunknowninhibitorDetailsDB00285VenlafaxineapprovedunknownsubstrateinhibitorDetailsDB01104SertralineapprovedunknowninhibitorDetailsDB00234Reboxetineapproved, experimentalunknowninhibitorDetailsDB00715Paroxetineapproved, investigationalunknowninhibitorDetailsDB00215CitalopramapprovedunknownsubstrateinhibitorDetailsDB01196Estramustineapproved, investigationalunknowninhibitorDetailsDB04348Taurocholic acidapproved, experimentalunknownsubstrateinhibitorDetailsDB00875Flupentixolapproved, investigational, withdrawnunknowninhibitorDetailsDB00351Megestrol acetateapproved, investigational, vet_approvedunknowninhibitorDetailsDB02010StaurosporineexperimentalunknowninhibitorDetailsDB01103QuinacrineinvestigationalunknowninhibitorDetailsDB01645GenisteininvestigationalunknowninhibitorDetailsDB04216Quercetinexperimental, investigationalunknowninhibitorDetailsDB01137Levofloxacinapproved, investigationalunknownsubstrateinhibitorDetailsDB03467NaringeninexperimentalunknowndownregulatorDetailsDB01016GlyburideapprovedunknowninhibitorDetailsDB00950Fexofenadineapproved, investigationalunknownsubstrateDetailsDB00726TrimipramineapprovedunknownsubstrateDetailsDB00571Propranololapproved, investigationalunknownsubstrateDetailsDB00635Prednisoneapproved, vet_approvedunknownsubstrateinducerDetailsDB00276Amsacrineapproved, investigationalunknowninhibitorDetailsDB00027Gramicidin DapprovedunknownsubstrateinhibitorDetailsDB01086Benzocaineapproved, investigationalunknowninhibitorDetailsDB01601LopinavirapprovedunknowninhibitorinducerDetailsDB00520CaspofunginapprovedunknowninhibitorDetailsDB00175PravastatinapprovednosubstrateDetailsDB00619ImatinibapprovednosubstrateinhibitorDetailsDB00398Sorafenibapproved, investigationalunknownsubstrateinhibitorDetailsDB01268Sunitinibapproved, investigationalunknowninhibitorDetailsDB01162TerazosinapprovedunknowninhibitorDetailsDB00470Dronabinolapproved, illicitunknowninhibitorDetailsDB00921Buprenorphineapproved, illicit, investigational, vet_approvedunknowninhibitorDetailsDB00966Telmisartanapproved, investigationalunknowninhibitorDetailsDB01254Dasatinibapproved, investigationalunknownsubstrateinhibitorDetailsDB00317Gefitinibapproved, investigationalunknownsubstrateinhibitorDetailsDB04868Nilotinibapproved, investigationalunknownsubstrateinhibitorDetailsDB00655EstroneapprovedunknownsubstrateinducerDetailsDB01259Lapatinibapproved, investigationalunknowninhibitorDetailsDB01263Posaconazoleapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00365Grepafloxacinapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB00829Diazepamapproved, illicit, investigational, vet_approvedunknownsubstrateDetailsDB01396Digitoxinapproved, investigationalunknownsubstrateDetailsDB01208Sparfloxacinapproved, investigational, withdrawnunknownsubstrateDetailsDB00959Methylprednisoloneapproved, vet_approvedunknownsubstrateinducerDetailsDB01224QuetiapineapprovedunknownsubstrateDetailsDB00334Olanzapineapproved, investigationalnosubstrateDetailsDB00363ClozapineapprovedunknownsubstrateDetailsDB01183Naloxoneapproved, vet_approvedunknownsubstrateDetailsDB04690CamptothecinexperimentalunknownsubstrateDetailsDB00860Prednisoloneapproved, vet_approvedunknownsubstrateDetailsDB01193Acebutololapproved, investigationalunknownsubstrateDetailsDB01050IbuprofenapprovedunknownsubstrateDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknownsubstrateinducermodulatorDetailsDB01184Domperidoneapproved, investigational, vet_approvedunknownsubstrateDetailsDB00443Betamethasoneapproved, vet_approvedunknownsubstrateDetailsDB00539Toremifeneapproved, investigationalunknownsubstrateDetailsDB00255Diethylstilbestrolapproved, investigational, withdrawnunknownsubstrateDetailsDB00882Clomifeneapproved, investigationalunknownsubstrateDetailsDB00783Estradiolapproved, investigational, vet_approvedunknownsubstratedownregulatorregulatorDetailsDB01248Docetaxelapproved, investigationalunknownsubstrateDetailsDB00563MethotrexateapprovedunknownsubstrateDetailsDB00373TimololapprovedunknownsubstrateDetailsDB01203NadololapprovedunknownsubstrateDetailsDB00523Alitretinoinapproved, investigationalunknownsubstrateDetailsDB01339Vecuroniumapproved, investigationalunknownsubstrateDetailsDB04840Debrisoquineapproved, investigationalunknownsubstrateDetailsDB00441GemcitabineapprovednosubstrateDetailsDB01030Topotecanapproved, investigationalunknownsubstrateDetailsDB02901Stanoloneillicit, investigationalunknownsubstrateDetailsDB00751Epinastineapproved, investigationalunknownsubstrateDetailsDB00717NorethisteroneapprovedunknowninhibitorDetailsDB04573Estriolapproved, investigational, vet_approvedunknownsubstrateinducerDetailsDB03203SphingosineexperimentalunknownsubstrateDetailsDB00439Cerivastatinapproved, withdrawnunknownsubstrateDetailsDB00286Conjugated estrogensapprovedunknownsubstrateDetailsDB01202LevetiracetamapprovedunknownsubstrateDetailsDB00252Phenytoinapproved, vet_approvedunknownsubstrateDetailsDB00585NizatidineapprovedunknownsubstrateDetailsDB00530Erlotinibapproved, investigationalunknownsubstrateinhibitorDetailsDB00555Lamotrigineapproved, investigationalunknownsubstrateinhibitorDetailsDB01261Sitagliptinapproved, investigationalunknownsubstrateDetailsDB01072Atazanavirapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB01169Arsenic trioxideapproved, investigationalunknowninhibitorDetailsDB06772CabazitaxelapprovedunknownsubstrateinhibitorDetailsDB01583LiotrixapprovedunknowninducerDetailsDB06287TemsirolimusapprovedunknownsubstrateinhibitorDetailsDB01587KetazolamapprovedunknownsubstrateDetailsDB04877VoacamineexperimentalunknowninhibitorDetailsDB00977EthinylestradiolapprovedunknownsubstrateDetailsDB01182PropafenoneapprovedunknowninhibitorDetailsDB00216Eletriptanapproved, investigationalunknownsubstrateDetailsDB04855DronedaroneapprovednoinhibitorDetailsDB06176Romidepsinapproved, investigationalunknownsubstrateDetailsDB06207SilodosinapprovedunknownsubstrateDetailsDB06414EtravirineapprovedunknowninhibitorDetailsDB06228RivaroxabanapprovedunknownsubstrateDetailsDB06695Dabigatran etexilateapprovedunknownsubstrateDetailsDB00973EzetimibeapprovedunknownsubstrateDetailsDB06702FesoterodineapprovedunknownsubstrateDetailsDB06212TolvaptanapprovednosubstrateinhibitorDetailsDB08860PitavastatinapprovedunknownsubstrateDetailsDB06589PazopanibapprovedunknownsubstrateDetailsDB08864RilpivirineapprovedunknowninhibitorDetailsDB08873Boceprevirapproved, withdrawnunknowninhibitorDetailsDB05521Telaprevirapproved, withdrawnunknownsubstrateinhibitorDetailsDB08874FidaxomicinapprovednosubstrateDetailsDB05039IndacaterolapprovedunknownsubstrateDetailsDB00349Clobazamapproved, illicitnosubstrateDetailsDB08882LinagliptinapprovedunknownsubstrateDetailsDB08827Lomitapideapproved, investigationalnoinhibitorDetailsDB08816TicagrelorapprovedunknownsubstrateinhibitorDetailsDB08865Crizotinibapproved, investigationalunknownsubstrateinhibitorDetailsDB06605ApixabanapprovedunknownsubstrateDetailsDB06626Axitinibapproved, investigationalnosubstrateinhibitorDetailsDB08828Vismodegibapproved, investigationalunknownsubstrateDetailsDB08889Carfilzomibapproved, investigationalunknownsubstrateinhibitorDetailsDB08893MirabegronapprovedunknownsubstrateinhibitorDetailsDB08896RegorafenibapprovedunknownsubstrateinhibitorDetailsDB08899EnzalutamideapprovednoinhibitorDetailsDB08820IvacaftorapprovednoinhibitorDetailsDB06616BosutinibapprovednosubstrateDetailsDB08901Ponatinibapproved, investigationalunknownsubstrateinhibitorDetailsDB08906Fluticasone furoateapprovednosubstrateinducerDetailsDB08907CanagliflozinapprovedunknownsubstrateinhibitorDetailsDB08910PomalidomideapprovedunknownsubstrateDetailsDB00480LenalidomideapprovednosubstrateDetailsDB08912Dabrafenibapproved, investigationalnosubstrateDetailsDB05773Trastuzumab emtansineapproved, investigationalunknownsubstrateDetailsDB00495ZidovudineapprovedunknownsubstrateDetailsDB00758ClopidogrelapprovednosubstrateDetailsDB08916AfatinibapprovedunknownsubstrateinhibitorDetailsDB00762Irinotecanapproved, investigationalunknownsubstrateDetailsDB00709Lamivudineapproved, investigationalunknownsubstrateDetailsDB00688Mycophenolate mofetilapproved, investigationalunknownsubstrateDetailsDB08918Levomilnacipranapproved, investigationalunknownsubstrateDetailsDB06290SimeprevirapprovedunknownsubstrateinhibitorDetailsDB08934SofosbuvirapprovednosubstrateDetailsDB06292DapagliflozinapprovedunknownsubstrateDetailsDB09076UmeclidiniumapprovednosubstrateDetailsDB09075EdoxabanapprovednosubstrateDetailsDB09063CeritinibapprovednosubstrateDetailsDB09078Lenvatinibapproved, investigationalnosubstrateinhibitorDetailsDB09079NintedanibapprovednosubstrateinhibitorDetailsDB09054IdelalisibapprovednosubstrateinhibitorDetailsDB09065CobicistatapprovedunknowninhibitorDetailsDB09291Rolapitantapproved, investigationalnoinhibitorDetailsDB09102Daclatasvirapproved, investigationalunknownsubstrateinhibitorDetailsDB06636Isavuconazoniumapproved, investigationalnoinhibitorDetailsDB06603Panobinostatapproved, investigationalnosubstrateDetailsDB09330OsimertinibapprovednosubstrateDetailsDB11362SelexipagapprovednosubstrateDetailsDB06403Ambrisentanapproved, investigationalunknownsubstrateDetailsDB09296Ombitasvirapproved, investigationalnosubstrateDetailsDB11574ElbasvirapprovednosubstrateinhibitorDetailsDB11575GrazoprevirapprovednosubstrateDetailsDB09161Technetium Tc-99m sestamibiapproved, investigationalnosubstrateDetailsDB11581Venetoclaxapproved, investigationalnosubstrateinhibitorDetailsDB05015Belinostatapproved, investigationalunknownsubstrateDetailsDB11613Velpatasvirapproved, investigationalnosubstrateinhibitorDetailsDB09027LedipasvirapprovednosubstratetransporterDetailsDB09198LobeglitazoneexperimentalnoDetailsDB09031Miltefosineapproved, investigationalunknownDetailsDB09280LumacaftorapprovednoinhibitorinducerDetailsDB11828Neratinibapproved, investigationalunknowninhibitorDetailsDB12026Voxilaprevirapproved, investigationalnosubstrateinhibitorDetailsDB13874Enasidenibapproved, investigationalunknownsubstrateinhibitorDetailsDB05889Inotuzumab ozogamicinapproved, investigationalunknownsubstrateDetailsDB13878Pibrentasvirapproved, investigationalunknownsubstrateinhibitorDetailsDB13879Glecaprevirapproved, investigationalunknownsubstrateinhibitorDetailsDB12483Copanlisibapproved, investigationalunknownsubstrateDetailsDB12001Abemaciclibapproved, investigationalunknownsubstrateinhibitorDetailsDB12364Betrixabanapproved, investigationalnosubstrateDetailsDB13919CandesartanexperimentalunknowninhibitorDetailsDB12070Letermovirapproved, investigationalnosubstrateinhibitorDetailsDB12332Rucaparibapproved, investigationalnosubstrateinhibitorDetailsDB09270Ubidecarenoneapproved, investigational, nutraceuticalnosubstrateDetailsDB11827Ertugliflozinapproved, investigationalnosubstrateDetailsDB13943Testosterone cypionateapprovedunknowninhibitorDetailsDB13944Testosterone enanthateapprovedunknowninhibitorDetailsDB13946Testosterone undecanoateapproved, investigationalunknowninhibitorDetailsDB09160Technetium Tc-99m tetrofosminapprovednobinderDetailsDB13951Stanolone acetateexperimentalunknownsubstrateDetailsDB13952Estradiol acetateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13953Estradiol benzoateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13954Estradiol cypionateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13955Estradiol dienanthateapproved, investigational, vet_approvedunknownsubstrateDetailsDB13956Estradiol valerateapproved, investigational, vet_approvedunknownsubstrateDetailsDB01420Testosterone propionateapproved, investigational, vet_approved, withdrawnnosubstrateDetailsDB11901Apalutamideapproved, investigationalunknowninducerDetailsDB11633Isavuconazoleapproved, investigationalunknowninhibitorDetailsDB11251Tocopherolapproved, investigationalnotransporterDetailsDB14003alpha-Tocopherol acetateapprovednosubstrateDetailsDB09099Somatostatinapproved, investigationalunknownsubstrateDetailsDB11635TocofersolanapprovedunknownantagonistDetailsDB11641Vinflunineapproved, investigationalnosubstrateDetailsDB11672Curcuminapproved, investigationalunknowninhibitorDetailsDB11995Avatrombopagapproved, investigationalunknownsubstrateDetailsDB09297Paritaprevirapproved, investigationalunknownsubstrateDetailsDB09183DasabuvirapprovedunknownsubstrateDetailsDB00813Fentanylapproved, illicit, investigational, vet_approvedunknownDetailsDB14062Concanamycin AexperimentalyesinhibitorDetailsDB14061HycanthoneexperimentalyesinhibitorDetailsDB14063DexverapamilexperimentalyesinhibitorDetailsDB14064EmopamilexperimentalyesinhibitorDetailsDB14065LomerizineexperimentalyesinhibitorDetailsDB14066TetrandrineexperimentalunknowninhibitorDetailsDB14067Dofequidarexperimental, investigationalunknowninhibitorDetailsDB14068DexniguldipineexperimentalunknowninhibitorDetailsDB14069ONT-093investigationalyesinhibitorDetailsDB14070HM-30181experimentalyesinhibitorDetailsDB14071DesmethylsertralineexperimentalunknowninhibitorDetailsDB14072Reversin 121experimentalyesinhibitorDetailsDB14146LoxicodegolinvestigationalunknownDetailsDB14538Hydrocortisone aceponateexperimental, vet_approvedunknownDetailsDB14539Hydrocortisone acetateapproved, vet_approvedunknownDetailsDB14540Hydrocortisone butyrateapproved, vet_approvedunknownDetailsDB14541Hydrocortisone cypionateapproved, investigational, vet_approvedunknownDetailsDB14542Hydrocortisone phosphateapproved, vet_approvedunknownDetailsDB14543Hydrocortisone probutateapproved, vet_approvedunknownDetailsDB14544Hydrocortisone valerateapproved, vet_approvedunknownDetailsDB14568Ivosidenibapproved, investigationalunknownsubstrateinhibitorDetailsDB11979Elagolixapproved, investigationalunknownsubstrateinhibitorDetailsDB13867Fluticasoneapproved, experimentalnosubstrateDetailsDB00608Chloroquineapproved, investigational, vet_approvedunknownsubstrateinhibitorDetailsDB00613Amodiaquineapproved, investigationalunknowninhibitorDetailsDB01087PrimaquineapprovedunknowninhibitorDetailsDB01611HydroxychloroquineapprovedunknowninhibitorDetailsDB01267PaliperidoneapprovedunknownsubstrateinhibitorDetailsDB05928DovitinibinvestigationalunknowninhibitorDetailsDB13125Lusutrombopagapproved, investigationalunknownsubstrateDetailsDB14635Curcumin sulfateexperimentalunknownDetailsDB14641Estriol tripropionateexperimentalunknownDetailsDB11952Duvelisibapproved, investigationalnosubstrateDetailsDB09213Dexibuprofenapproved, investigationalunknownDetailsDB11760Talazoparibapproved, investigationalunknownsubstrateDetailsDB12455Omadacyclineapproved, investigationalunknownsubstrateDetailsDB12836Grapiprantinvestigational, vet_approvednosubstrateDetailsDB12035Sarecyclineapproved, investigationalunknowninhibitorDetailsDB11753Rifamycinapproved, investigationalnosubstrateinhibitorDetailsDB11963Dacomitinibapproved, investigationalnosubstrateinhibitorDetailsDB11855Revefenacinapproved, investigationalnosubstrateDetailsDB12141Gilteritinibapproved, investigationalnosubstrateDetailsDB14126Tenofovirexperimental, investigationalnosubstrateDetailsDB00300Tenofovir disoproxilapproved, investigationalunknownsubstrateinhibitorDetailsDB09299Tenofovir alafenamideapprovedunknownsubstrateDetailsDB01264DarunavirapprovedunknownsubstrateinhibitorinducerDetailsDB00203Sildenafilapproved, investigationalunknownsubstrateinhibitorDetailsDB00862VardenafilapprovedunknownsubstrateinhibitorDetailsDB00776OxcarbazepineapprovedunknownsubstrateDetailsDB00248CabergolineapprovednosubstrateDetailsDB06480PrucaloprideapprovednosubstrateDetailsDB00734Risperidoneapproved, investigationalunknownsubstrateDetailsDB01117AtovaquoneapprovednoinhibitorDetailsDB00788Naproxenapproved, vet_approvednoinhibitorDetailsDB00615Rifabutinapproved, investigationalunknowninducerDetailsDB12582PiperineinvestigationalunknowninhibitorDetailsDB11978Glasdegibapproved, investigationalnosubstrateinhibitorDetailsDB09074OlaparibapprovednosubstrateinhibitorDetailsDB00243Ranolazineapproved, investigationalnosubstrateinhibitorDetailsDB00321AmitriptylineapprovedunknownsubstrateDetailsDB00341CetirizineapprovednosubstrateinhibitorDetailsDB09073Palbociclibapproved, investigationalnosubstrateinhibitorDetailsDB01079Tegaserodapproved, investigational, withdrawnunknownsubstrateDetailsDB13867Fluticasoneapproved, experimentalunknownsubstrateDetailsDB12147Erdafitinibapproved, investigationalnosubstrateinhibitorDetailsDB00736Esomeprazoleapproved, investigationalunknownsubstrateinhibitorDetailsDB00476DuloxetineapprovedunknowninhibitorDetailsDB00481Raloxifeneapproved, investigationalunknownsubstrateDetailsDB12015Alpelisibapproved, investigationalunknowninhibitorDetailsDB11712Tezacaftorapproved, investigationalnosubstrateinhibitorDetailsDB00768OlopatadineapprovednosubstrateDetailsDB00698Nitrofurantoinapproved, vet_approvedunknownsubstrateDetailsDB00451LevothyroxineapprovednoinducerDetailsDB00394Beclomethasone dipropionateapproved, investigationalunknownsubstrateinducerDetailsDB00612BisoprololapprovedunknownsubstrateinhibitorDetailsDB00916MetronidazoleapprovedunknowninhibitorDetailsDB00482Celecoxibapproved, investigationalunknownsubstrateDetailsDB11986Entrectinibapproved, investigationalunknownsubstrateinhibitorDetailsDB12500Fedratinibapproved, investigationalunknownsubstrateinhibitorDetailsDB12825Lefamulinapproved, investigationalunknownsubstrateDetailsDB01222BudesonideapprovednosubstrateDetailsDB11757Istradefyllineapproved, investigationalunknowninhibitorDetailsDB01233Metoclopramideapproved, investigationalunknownsubstrateDetailsDB01175EscitalopramapprovedunknownsubstrateDetailsDB00603Medroxyprogesterone acetateapproved, investigationalunknowninhibitorDetailsDB01217Anastrozoleapproved, investigationalunknownsubstrateDetailsDB01195Flecainideapproved, withdrawnunknownsubstrateDetailsDB01418Acenocoumarolapproved, investigationalunknownsubstrateDetailsDB05676Apremilastapproved, investigationalunknownsubstrateDetailsDB11732Lasmiditanapproved, investigationalunknownsubstrateinhibitorDetailsDB11586Asunaprevirapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB15444Elexacaftorapproved, investigationalnosubstrateinhibitorDetailsDB15566Prednisolone acetateapproved, vet_approvedunknownsubstrateDetailsDB15035Zanubrutinibapproved, investigationalnosubstrateDetailsDB00273TopiramateapprovedunknownsubstrateDetailsDB09237Levamlodipineapproved, investigationalunknownsubstrateDetailsDB14962Trastuzumab deruxtecanapproved, investigationalnosubstrateDetailsDB13007Enfortumab vedotinapproved, investigationalunknownsubstrateDetailsDB11951Lemborexantapproved, investigationalunknownsubstrateDetailsDB12941Darolutamideapproved, investigationalunknownsubstrateDetailsDB15091Upadacitinibapproved, investigationalnosubstrateinhibitorDetailsDB15328Ubrogepantapproved, investigationalunknownsubstrateDetailsDB15233Avapritinibapproved, investigationalunknowninhibitormodulatorDetailsDB00993AzathioprineapprovedunknownsubstrateDetailsDB00557HydroxyzineapprovedunknownsubstrateDetailsDB11077Polyethylene glycol 400approvedunknowninhibitorDetailsDB12887Tazemetostatapproved, investigationalunknownsubstrateDetailsDB01006Letrozoleapproved, investigationalunknownsubstrateDetailsDB00246ZiprasidoneapprovedunknownDetailsDB01190Clindamycinapproved, vet_approvedunknownsubstrateDetailsDB09287Polyethylene glycolapproved, vet_approvednoinhibitorDetailsDB00957Norgestimateapproved, investigationalunknowninhibitorDetailsDB11770TalinololinvestigationalunknownsubstrateDetailsDB04881ElacridarinvestigationalunknowninhibitorDetailsDB00932Tipranavirapproved, investigationalunknownsubstrateinhibitorinducerDetailsDB11869ValspodarinvestigationalunknowninhibitorDetailsDB00518Albendazoleapproved, vet_approvednosubstrateDetailsDB05239Cobimetinibapproved, investigationalnosubstrateDetailsDB06670OdanacatibinvestigationalunknownsubstrateDetailsDB04877VoacamineexperimentalnoinhibitorDetailsDB08930DolutegravirapprovednosubstrateDetailsDB00586Diclofenacapproved, vet_approvedunknowninducerDetailsDB11817Baricitinibapproved, investigationalunknownsubstrateDetailsDB11363Alectinibapproved, investigationalunknowninhibitorDetailsDB14723Larotrectinibapproved, investigationalunknownsubstrateDetailsDB00588Fluticasone propionateapprovedunknownsubstrateDetailsDB11430Monensinexperimental, vet_approvedunknownsubstrateDetailsDB03825Rhodamine 6GexperimentalunknownsubstrateDetailsDB09239NiguldipineexperimentalunknowninhibitorDetailsDB04851BiricodarinvestigationalunknowninhibitorDetailsDB06240TariquidarinvestigationalunknowninhibitorDetailsDB12799LaniquidarinvestigationalunknowninhibitorDetailsDB12923GallopamilinvestigationalunknowninhibitorDetailsDB06420AnnamycininvestigationalunknownDetailsDB00540NortriptylineapprovedunknownsubstrateDetailsDB00454MeperidineapprovedunknownsubstrateDetailsDB00652Pentazocineapproved, vet_approvedunknownsubstrateDetailsDB00818Propofolapproved, investigational, vet_approvedunknowninducerDetailsDB01590EverolimusapprovedunknownsubstrateinhibitorDetailsDB01212CeftriaxoneapprovedunknowninhibitorDetailsDB00872Conivaptanapproved, investigationalunknowninhibitorDetailsDB11544Salinomycinvet_approvedunknowninhibitorDetailsDB00909Zonisamideapproved, investigationalunknowninhibitorDetailsDB14057ValinomycinexperimentalunknownsubstrateinhibitorDetailsDB04908Flibanserinapproved, investigationalunknowninhibitorDetailsDB09039Eliglustatapproved, investigationalnosubstrateinhibitorDetailsDB01128BicalutamideapprovedunknowninhibitorDetailsDB00648MitotaneapprovedunknowninhibitorDetailsDB06448Lonafarnibapproved, investigationalnosubstrateinhibitorDetailsDB04960TipifarnibinvestigationalunknowninhibitorDetailsDB09048Netupitantapproved, investigationalunknowninhibitorDetailsDB09034Suvorexantapproved, investigationalunknownDetailsDB09030VorapaxarapprovedunknownDetailsDB05294VandetanibapprovedunknowninhibitorDetailsDB14062Concanamycin AexperimentalunknowninhibitorDetailsDB14061HycanthoneexperimentalunknowninhibitorDetailsDB08881VemurafenibapprovedunknownsubstrateinhibitorDetailsDB14063DexverapamilexperimentalunknowninhibitorDetailsDB14064EmopamilexperimentalunknowninhibitorDetailsDB14065LomerizineexperimentalunknowninhibitorDetailsDB14066TetrandrineexperimentalunknowninhibitorDetailsDB14069ONT-093investigationalunknowninhibitorDetailsDB14067Dofequidarexperimental, investigationalunknowninhibitorDetailsDB00603Medroxyprogesterone acetateapproved, investigationalunknowninhibitorDetailsDB12457Rimegepantapproved, investigationalunknownsubstrateDetailsDB12466Favipiravirapproved, investigationalunknowninhibitorDetailsDB00253MedrysoneapprovedunknownsubstrateDetailsDB09241Methylene blueapproved, investigationalunknownsubstrateinhibitorDetailsDB12612Ozanimodapproved, investigationalunknownsubstrateDetailsDB08868Fingolimodapproved, investigationalnoinhibitorDetailsDB07565Chloramphenicol succinateapprovedunknownsubstrateDetailsDB11689Selumetinibapproved, investigationalunknownsubstrateDetailsDB14631Prednisolone phosphateapproved, vet_approvedunknownsubstrateinducerDetailsDB11652Tucatinibapproved, investigationalunknownsubstrateDetailsDB15102Pemigatinibapproved, investigationalnosubstrateinhibitorDetailsDB00315Zolmitriptanapproved, investigationalnoDetailsDB14761Remdesivirapproved, investigationalunknownsubstrateDetailsDB11791Capmatinibapproved, investigationalunknownsubstrateinhibitorDetailsDB04845Ixabepiloneapproved, investigationalunknownsubstrateinhibitorDetailsDB15685Selpercatinibapproved, investigationalunknownsubstrateinhibitorDetailsDB14840RipretinibapprovedunknownsubstrateinhibitorDetailsDB00845Clofazimineapproved, investigationalunknownsubstrateinhibitorDetailsDB09038EmpagliflozinapprovedunknownsubstrateDetailsDB06419CethromycininvestigationalunknownsubstrateinhibitorDetailsDB00674GalantamineapprovednoinhibitorDetailsDB09026Aliskirenapproved, investigationalnosubstrateDetailsDB09274Artesunateapproved, investigationalunknownsubstrateDetailsDB00188Bortezomibapproved, investigationalnosubstrateDetailsDB14669Betamethasone phosphateapproved, vet_approvedunknownsubstrateinducerDetailsDB12674Lurbinectedinapproved, investigationalunknownsubstrateinhibitorDetailsDB14649Dexamethasone acetateapproved, investigational, vet_approvedunknownsubstrateinhibitorinducerDetailsDB00104Octreotideapproved, investigationalunknownsubstrateDetailsDB11796Fostemsavirapproved, investigationalunknownsubstrateDetailsDB15719Belantamab mafodotinapprovedunknownsubstrateDetailsDB15305Risdiplamapproved, investigationalunknownsubstrateDetailsDB15822Pralsetinibapproved, investigationalnosubstrateinhibitorDetailsDB14845Filgotinibapproved, investigationalunknownsubstrateDetailsDB15982BerotralstatapprovednosubstrateinhibitorDetailsDB11853Relugolixapproved, investigationalunknownsubstrateinhibitorDetailsDB14895Vibegronapproved, investigationalnosubstrateDetailsDB01380Cortisone acetateapproved, investigationalunknownsubstrateinducerDetailsDB11632Opicaponeapproved, investigationalnosubstrateDetailsDB15456Vericiguatapproved, investigationalunknownsubstrateDetailsDB11751Cabotegravirapproved, investigationalunknownsubstrateDetailsDB11693Voclosporinapproved, investigationalunknownsubstrateinhibitorDetailsDB15133Tepotinibapproved, investigationalnosubstrateinhibitorDetailsDB00052Somatotropinapproved, investigationalunknownsubstrateDetailsDB00346Alfuzosinapproved, investigationalunknownsubstrateDetailsDB15442Trilaciclibapproved, investigationalunknownsubstrateDetailsDB14989Umbralisibapproved, investigational, withdrawnunknowninhibitorDetailsDB00391Sulpirideapproved, investigationalunknownsubstrateDetailsDB00853Temozolomideapproved, investigationalnosubstrateDetailsDB06237AvanafilapprovedunknownsubstrateDetailsDB11800Tivozanibapproved, investigationalunknownsubstrateDetailsDB00080Daptomycinapproved, investigationalnosubstrateDetailsDB06288Amisulprideapproved, investigationalnosubstrateDetailsDB08995Diosminapproved, investigationalunknowninhibitorDetailsDB04876Vildagliptinapproved, investigationalnosubstrateDetailsDB08822Azilsartan medoxomilapproved, investigationalnoinhibitorDetailsDB00360Sapropterinapproved, investigationalunknowninhibitorDetailsDB05667Levoketoconazoleapproved, investigationalnoinhibitorDetailsDB16222Loncastuximab tesirineapproved, investigationalunknownsubstrateDetailsDB15569Sotorasibapproved, investigationalunknowninhibitorDetailsDB11886Infigratinibapproved, investigationalnosubstrateinhibitorDetailsDB12471Ibrexafungerpapproved, investigationalunknownsubstratetransporterDetailsDB16703Belumosudilapproved, investigationalnosubstrateinhibitorDetailsDB16261Odevixibatapproved, investigationalunknownsubstrateDetailsDB15463Belzutifanapproved, investigationalnosubstrateDetailsDB16220Lonapegsomatropinapproved, investigationalunknownsubstrateDetailsDB16390Mobocertinibapproved, investigationalunknownsubstrateinhibitorDetailsDB16732Tisotumab vedotinapprovednosubstrateDetailsDB16098Atogepantapproved, investigationalnosubstrateDetailsDB08931RiociguatapprovednosubstrateDetailsDB15011Avacopanapproved, investigationalnosubstrateDetailsDB12597Asciminibapproved, investigationalnosubstrateinhibitorDetailsDB06234Maribavirapproved, investigationalnoinhibitorDetailsDB16691Nirmatrelvirapproved, investigationalnosubstrateinhibitorDetailsDB12713Sotagliflozinapproved, investigationalnoinhibitorDetailsDB14973Abrocitinibapproved, investigationalunknowninhibitorDetailsDB16236Mitapivatapproved, investigationalnosubstrateinhibitorDetailsDB09061Cannabidiolapproved, investigationalnoinhibitorDetailsDB14737Cannabinolexperimental, investigationalunknowninhibitorDetailsDB14009Medical Cannabisexperimental, investigationalunknowninhibitorDetailsDB11697Pacritinibapproved, investigationalnoinhibitorDetailsDB06016Cariprazineapproved, investigationalunknowninhibitorDetailsDB16407AzvudineinvestigationalunknownactivatorregulatorDetailsDB12541SAR-405838investigationalnosubstrateDetailsDB00661VerapamilapprovedunknowninhibitorblockerDetailsDB09118StiripentolapprovedunknowninhibitorDetailsDB04951Pirfenidoneapproved, investigationalunknowninhibitorDetailsDB13997Baloxavir marboxilapproved, investigationalunknownsubstrateinhibitorDetailsDB15673Lenacapavirapproved, investigationalnosubstrateDetailsDB16650Deucravacitinibapproved, investigationalunknownsubstrateDetailsDB12095Telotristat ethylapproved, investigationalnosubstrateinhibitorDetailsDB15149Futibatinibapproved, investigationalnosubstrateinhibitorDetailsDB11739Vonoprazanapproved, investigationalunknowninhibitorDetailsDB11793Niraparibapproved, investigationalnosubstrateDetailsDB12489Mirvetuximab soravtansineapproved, investigationalnosubstrateDetailsDB16267Olutasidenibapproved, investigationalnoinhibitorDetailsDB12240Polatuzumab vedotinapproved, investigationalnosubstrateDetailsDB15568Adagrasibapproved, investigationalunknowninhibitorDetailsDB12236Bexagliflozinapproved, investigationalunknownsubstrateDetailsDB17472Pirtobrutinibapproved, investigationalunknownsubstrateinhibitorDetailsDB06374Elacestrantapproved, investigationalunknowninhibitorDetailsDB00683Midazolamapproved, illicitnosubstrateDetailsDB12548Sparsentanapproved, investigationalunknownsubstrateinhibitorDetailsDB15688Zavegepantapproved, investigationalunknownsubstrateDetailsDB16217Leniolisibapproved, investigationalnosubstrateDetailsDB01238Aripiprazoleapproved, investigationalunknowninhibitorDetailsDB09082VilanterolapprovednosubstrateDetailsDB12874Quizartinibapproved, investigationalnosubstrateinhibitorDetailsDB11763Momelotinibapproved, investigationalunknownsubstrateDetailsDB11718Encorafenibapproved, investigationalnosubstrateinhibitorDetailsDB15097Gefapixantapproved, investigationalnosubstrateDetailsDB11967Binimetinibapproved, investigationalnosubstrateDetailsDB16826RepotrectinibinvestigationalnosubstrateinhibitorDetails\"}},\n",
       "  {'Label': 'Solute carrier family 22 member 8',\n",
       "   'Detailed Info': {'Name': 'Solute carrier family 22 member 8',\n",
       "    'Synonyms': 'hOAT3\\nOAT3\\nOrganic anion transporter 3',\n",
       "    'Gene Name': 'SLC22A8',\n",
       "    'Organism': 'Humans',\n",
       "    'Amino acid sequence': '>lcl|BSEQ0007005|Solute carrier family 22 member 8\\nMTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPW\\nVLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNK\\nLKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFR\\nFLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQL\\nTVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLN\\nLQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQI\\nIFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKG\\nCLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGI\\nTALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLG\\nSS',\n",
       "    'Number of residues': '542',\n",
       "    'Molecular Weight': '59855.585',\n",
       "    'Theoretical pI': '9.05',\n",
       "    'GO Classification': 'Functionsinorganic anion exchanger activity / sodium-independent organic anion transmembrane transporter activityProcessesanion transmembrane transport / response to toxic substance / sodium-independent organic anion transport / transmembrane transportComponentsbasolateral plasma membrane / extracellular exosome / integral component of plasma membrane / plasma membrane',\n",
       "    'General Function': 'Sodium-independent organic anion transmembrane transporter activity',\n",
       "    'Specific Function': 'Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).',\n",
       "    'Pfam Domain Function': 'Sugar_tr (PF00083)',\n",
       "    'Transmembrane Regions': '10-30\\n124-144\\n155-175\\n177-197\\n213-233\\n237-257\\n328-348\\n355-375\\n387-407\\n412-432\\n472-492',\n",
       "    'Cellular Location': 'Basolateral cell membrane',\n",
       "    'Gene sequence': '>lcl|BSEQ0019450|Solute carrier family 22 member 8 (SLC22A8)\\nATGACCTTCTCGGAGATCCTGGACCGTGTGGGAAGCATGGGCCATTTCCAGTTCCTGCAT\\nGTAGCCATACTGGGCCTCCCGATCCTCAACATGGCCAACCACAACCTGCTGCAGATCTTC\\nACAGCCGCCACCCCTGTCCACCACTGTCGCCCGCCCCACAATGCCTCCACAGGGCCTTGG\\nGTGCTCCCCATGGGCCCAAATGGGAAGCCTGAGAGGTGCCTCCGTTTTGTACATCCGCCC\\nAATGCCAGCCTGCCCAATGACACCCAGAGGGCCATGGAGCCATGCCTGGATGGCTGGGTC\\nTACAACAGCACCAAGGACTCCATTGTGACAGAGTGGGACTTGGTGTGCAACTCCAACAAA\\nCTGAAGGAGATGGCCCAGTCTATCTTCATGGCAGGTATACTGATTGGAGGGCTCGTGCTT\\nGGAGACCTGTCTGACAGGTTTGGCCGCAGGCCCATCCTGACCTGCAGCTACCTGCTGCTG\\nGCAGCCAGCGGCTCCGGTGCAGCCTTCAGCCCCACCTTCCCCATCTACATGGTCTTCCGC\\nTTCCTGTGTGGCTTTGGCATCTCAGGCATTACCCTGAGCACCGTCATCTTGAATGTGGAA\\nTGGGTGCCTACCCGGATGCGGGCCATCATGTCGACAGCACTCGGGTACTGCTACACCTTT\\nGGCCAGTTCATTCTGCCCGGCCTGGCCTACGCCATCCCCCAGTGGCGTTGGCTGCAGTTA\\nACTGTGTCCATTCCCTTCTTCGTCTTCTTCCTATCATCCTGGTGGACACCAGAGTCCATA\\nCGCTGGTTGGTCTTGTCTGGAAAGTCCTCGAAGGCCCTGAAGATACTCCGGCGGGTGGCT\\nGTCTTCAATGGCAAGAAGGAAGAGGGAGAAAGGCTCAGCTTGGAGGAGCTCAAACTCAAC\\nCTGCAGAAGGAGATCTCCTTGGCCAAGGCCAAGTACACCGCAAGTGACCTGTTCCGGATA\\nCCCATGCTGCGCCGCATGACCTTCTGTCTTTCCCTGGCCTGGTTTGCTACCGGTTTTGCC\\nTACTATAGTTTGGCTATGGGTGTGGAAGAATTTGGAGTCAACCTCTACATCCTCCAGATC\\nATCTTTGGTGGGGTCGATGTCCCAGCCAAGTTCATCACCATCCTCTCCTTAAGCTACCTG\\nGGCCGGCATACCACTCAGGCCGCTGCCCTGCTCCTGGCAGGAGGGGCCATCTTGGCTCTC\\nACCTTTGTGCCCTTGGACTTGCAGACCGTGAGGACAGTATTGGCTGTGTTTGGGAAGGGA\\nTGCCTATCCAGCTCCTTCAGCTGCCTCTTCCTCTACACAAGTGAATTATACCCCACAGTC\\nATCAGGCAAACAGGTATGGGCGTAAGTAACCTGTGGACCCGCGTGGGAAGCATGGTGTCC\\nCCGCTGGTGAAAATCACGGGTGAGGTACAGCCCTTCATCCCCAATATCATCTACGGGATC\\nACCGCCCTCCTCGGGGGCAGTGCTGCCCTCTTCCTGCCTGAGACCCTGAATCAGCCCTTG\\nCCAGAGACTATCGAAGACCTGGAAAACTGGTCCCTGCGGGCAAAGAAGCCAAAGCAGGAG\\nCCAGAGGTGGAAAAGGCCTCCCAGAGGATCCCTCTACAGCCTCACGGACCAGGCCTGGGC\\nTCCAGCTGA',\n",
       "    'Chromosome Location': '11',\n",
       "    'Locus': '11q11',\n",
       "    'External Identifiers': 'ResourceLinkUniProtKB IDQ8TCC7UniProtKB Entry NameS22A8_HUMANGenBank Protein ID4378059GenBank Gene IDAF097491HGNC IDHGNC:10972',\n",
       "    'General References': 'Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [Article] Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21. [Article] Taylor TD, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, Dewar K, Lloyd C, Itoh T, Takeda T, Kim DW, She X, Barlow KF, Bloom T, Bruford E, Chang JL, Cuomo CA, Eichler E, FitzGerald MG, Jaffe DB, LaButti K, Nicol R, Park HS, Seaman C, Sougnez C, Yang X, Zimmer AR, Zody MC, Birren BW, Nusbaum C, Fujiyama A, Hattori M, Rogers J, Lander ES, Sakaki Y: Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006 Mar 23;440(7083):497-500. [Article] Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [Article] Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002 Apr;13(4):866-74. [Article] Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [Article] Srimaroeng C, Chatsudthipong V, Aslamkhan AG, Pritchard JB: Transport of the natural sweetener stevioside and its aglycone steviol by human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8). J Pharmacol Exp Ther. 2005 May;313(2):621-8. Epub 2005 Jan 11. [Article] Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y: Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res. 2005 Apr;22(4):647-60. Epub 2005 Apr 7. [Article] Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y: Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos. 2006 May;34(5):743-7. doi: 10.1124/dmd.105.008375. Epub 2006 Feb 2. [Article] Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 Jun;73(6):554-65. [Article] Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM: The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12. Epub 2005 Nov 15. [Article]',\n",
       "    'Drug Relations': 'DrugBank IDNameDrug groupPharmacological action?ActionsDetailsDB01032Probenecidapproved, investigationalyesinhibitorDetailsDB00624Testosteroneapproved, investigationalunknowninducerDetailsDB04348Taurocholic acidapproved, experimentalunknownsubstrateinhibitorDetailsDB00936Salicylic acidapproved, investigational, vet_approvedunknowninhibitorDetailsDB00908Quinidineapproved, investigationalunknowninhibitorDetailsDB01032Probenecidapproved, investigationalunknowninhibitorDetailsDB01053Benzylpenicillinapproved, vet_approvedunknownsubstrateinhibitorDetailsDB01092OuabainapprovedunknowninhibitorDetailsDB00328Indomethacinapproved, investigationalunknowninhibitorDetailsDB01050IbuprofenapprovedunknowninhibitorDetailsDB00536GuanidineapprovedunknowninhibitorDetailsDB03553Glutaric AcidexperimentalunknownsubstrateinhibitorDetailsDB00695Furosemideapproved, vet_approvedunknowninhibitorDetailsDB00586Diclofenacapproved, vet_approvedunknowninhibitorDetailsDB02659Cholic AcidapprovedunknownsubstrateinhibitorDetailsDB00887BumetanideapprovedunknowninhibitorDetailsDB01597Cilastatinapproved, investigationalunknowninhibitorDetailsDB00554Piroxicamapproved, investigationalunknowninhibitorDetailsDB00345Aminohippuric acidapproved, investigationalunknownsubstrateinhibitorDetailsDB04519Caprylic acidinvestigationalunknowninhibitorDetailsDB00501Cimetidineapproved, investigationalunknownsubstrateinhibitorDetailsDB00168Aspartameinvestigational, nutraceuticalunknowninhibitorDetailsDB00759Tetracyclineapproved, vet_approved, withdrawnunknownsubstrateinhibitorDetailsDB00595Oxytetracyclineapproved, investigational, vet_approvedunknownsubstrateDetailsDB01004Ganciclovirapproved, investigationalunknowninhibitorDetailsDB00787AcyclovirapprovedunknownsubstrateinhibitorDetailsDB00917DinoprostoneapprovedunknownsubstrateinhibitorDetailsDB00456Cefalotinapproved, investigational, vet_approvedunknowninhibitorDetailsDB01329Cefoperazoneapproved, investigationalunknowninhibitorDetailsDB01327CefazolinapprovedunknowninhibitorDetailsDB01326Cefamandoleapproved, experimentalunknowninhibitorDetailsDB01140Cefadroxilapproved, vet_approved, withdrawnunknowninhibitorDetailsDB01212CeftriaxoneapprovedunknowninhibitorDetailsDB00493CefotaximeapprovedunknowninhibitorDetailsDB00812Phenylbutazoneapproved, vet_approvedunknowninhibitorDetailsDB01009Ketoprofenapproved, vet_approvedunknowninhibitorDetailsDB00175PravastatinapprovednosubstrateinhibitorDetailsDB00927FamotidineapprovednosubstrateinhibitorDetailsDB00279Liothyronineapproved, vet_approvedunknowninhibitorDetailsDB00563MethotrexateapprovedunknownsubstrateinhibitorDetailsDB00286Conjugated estrogensapprovedunknownsubstrateinhibitorDetailsDB00469TenoxicamapprovedunknowninhibitorDetailsDB00584Enalaprilapproved, vet_approvedunknowninhibitorDetailsDB01650trans-2-hydroxycinnamic acidexperimentalunknowninhibitorDetailsDB00567Cephalexinapproved, investigational, vet_approvedunknowninhibitorDetailsDB00313Valproic acidapproved, investigationalunknownsubstrateinhibitorDetailsDB01065Melatoninapproved, nutraceutical, vet_approvedunknowninhibitorDetailsDB03793Benzoic acidapproved, investigationalunknowninhibitorDetailsDB01033MercaptopurineapprovedunknownsubstrateinhibitorDetailsDB01051Novobiocinapproved, investigational, vet_approved, withdrawnunknowninhibitorDetailsDB00213PantoprazoleapprovedunknowninhibitorDetailsDB00139Succinic acidapproved, nutraceuticalunknownsubstrateDetailsDB02527Cyclic adenosine monophosphateexperimentalunknownsubstrateDetailsDB00577Valaciclovirapproved, investigationalunknownsubstrateDetailsDB03902Oxalic AcidexperimentalunknownsubstrateDetailsDB00863Ranitidineapproved, withdrawnunknownsubstrateDetailsDB00583Levocarnitineapproved, investigationalunknownsubstrateDetailsDB00437AllopurinolapprovedunknownsubstrateDetailsDB00198OseltamivirapprovedunknownsubstrateDetailsDB01583LiotrixapprovedunknowninhibitorDetailsDB01414Cefacetrileexperimental, vet_approvedunknownsubstrateinhibitorDetailsDB06710MethyltestosteroneapprovedunknowninducerDetailsDB00495ZidovudineapprovedunknownsubstrateinhibitorDetailsDB08844Uric acidinvestigationalunknownDetailsDB00783Estradiolapproved, investigational, vet_approvedunknownsubstrateDetailsDB05804Prasterone sulfateinvestigationalunknownDetailsDB01160Dinoprost tromethamineapproved, vet_approvedunknownDetailsDB04133Degraded CephaloridineexperimentalunknownDetailsDB08837Tetraethylammoniumexperimental, investigationalunknownDetailsDB06335SaxagliptinapprovedunknownsubstrateDetailsDB08912Dabrafenibapproved, investigationalnoinhibitorDetailsDB00300Tenofovir disoproxilapproved, investigationalunknownsubstrateDetailsDB00493CefotaximeapprovedunknownDetailsDB01212CeftriaxoneapprovedunknownDetailsDB01053Benzylpenicillinapproved, vet_approvedunknownsubstrateinhibitorDetailsDB09272Eluxadolineapproved, investigationalunknownsubstrateDetailsDB09060AvibactamapprovednosubstrateDetailsDB01685TopiroxostatexperimentalunknowninhibitorDetailsDB05016Atalurenapproved, investigationalnoinhibitorDetailsDB13874Enasidenibapproved, investigationalunknowninhibitorDetailsDB12070Letermovirapproved, investigationalunknowninhibitorDetailsDB08930DolutegravirapprovednoinhibitorDetailsDB12332Rucaparibapproved, investigationalnoinhibitorDetailsDB11817Baricitinibapproved, investigationalunknownsubstrateinhibitorDetailsDB13943Testosterone cypionateapprovedunknowninducerDetailsDB13944Testosterone enanthateapprovedunknowninducerDetailsDB13946Testosterone undecanoateapproved, investigationalunknowninducerDetailsDB13952Estradiol acetateapproved, investigational, vet_approvedunknownDetailsDB13953Estradiol benzoateapproved, investigational, vet_approvedunknownDetailsDB13954Estradiol cypionateapproved, investigational, vet_approvedunknownDetailsDB13955Estradiol dienanthateapproved, investigational, vet_approvedunknownDetailsDB13956Estradiol valerateapproved, investigational, vet_approvedunknownDetailsDB11901Apalutamideapproved, investigationalnoinhibitorDetailsDB11995Avatrombopagapproved, investigationalunknowninhibitorDetailsDB00655EstroneapprovedunknownsubstrateDetailsDB00833CefaclorapprovedunknownsubstrateinhibitorDetailsDB00535CefdinirapprovedunknownsubstrateDetailsDB00229Cefotiamapproved, investigationalunknownsubstrateinhibitorDetailsDB01415Ceftibutenapproved, investigationalunknownsubstrateinhibitorDetailsDB01332Ceftizoximeapproved, withdrawnunknownsubstrateinhibitorDetailsDB09008Cefaloridineexperimental, withdrawnunknownsubstrateinhibitorDetailsDB00741Hydrocortisoneapproved, vet_approvedunknownsubstrateDetailsDB12243Edaravoneapproved, investigationalnosubstrateDetailsDB00950Fexofenadineapproved, investigationalunknownsubstrateDetailsDB00650LeucovorinapprovedunknownsubstrateinhibitorDetailsDB00881Quinaprilapproved, investigationalunknownsubstrateDetailsDB01098RosuvastatinapprovedunknownsubstrateinhibitorDetailsDB01261Sitagliptinapproved, investigationalunknownsubstrateDetailsDB14538Hydrocortisone aceponateexperimental, vet_approvedunknownDetailsDB14539Hydrocortisone acetateapproved, vet_approvedunknownDetailsDB14540Hydrocortisone butyrateapproved, vet_approvedunknownDetailsDB14541Hydrocortisone cypionateapproved, investigational, vet_approvedunknownDetailsDB14542Hydrocortisone phosphateapproved, vet_approvedunknownDetailsDB14543Hydrocortisone probutateapproved, vet_approvedunknownDetailsDB14544Hydrocortisone valerateapproved, vet_approvedunknownDetailsDB14568Ivosidenibapproved, investigationalunknowninhibitorDetailsDB09078Lenvatinibapproved, investigationalunknowninhibitorDetailsDB00319PiperacillinapprovedunknownsubstrateDetailsDB01606TazobactamapprovedunknownsubstrateinhibitorDetailsDB01045RifampicinapprovedunknowninhibitorDetailsDB11751Cabotegravirapproved, investigationalunknowninhibitorDetailsDB09213Dexibuprofenapproved, investigationalunknownDetailsDB12866PradigastatinvestigationalunknowninhibitorDetailsDB00642Pemetrexedapproved, investigationalnosubstrateDetailsDB00448Lansoprazoleapproved, investigationalunknowninhibitorDetailsDB06211Doripenemapproved, investigationalnosubstrateDetailsDB00945Acetylsalicylic acidapproved, vet_approvedunknowninhibitorDetailsDB00736Esomeprazoleapproved, investigationalunknowninhibitorDetailsDB09299Tenofovir alafenamideapprovednosubstrateDetailsDB14126Tenofovirexperimental, investigationalnosubstrateDetailsDB00788Naproxenapproved, vet_approvedunknownDetailsDB12377Relebactamapproved, investigationalunknownsubstrateDetailsDB05154PretomanidapprovedunknowninhibitorDetailsDB00654Latanoprostapproved, investigationalunknowninhibitorDetailsDB00999Hydrochlorothiazideapproved, vet_approvedunknownsubstrateDetailsDB01241GemfibrozilapprovedunknowninhibitorDetailsDB04855DronedaroneapprovedunknowninhibitorDetailsDB01222BudesonideapprovedunknownsubstrateDetailsDB01234Dexamethasoneapproved, investigational, vet_approvedunknownsubstrateDetailsDB11644Tafamidisapproved, investigationalunknowninhibitorDetailsDB12457Rimegepantapproved, investigationalunknowninhibitorDetailsDB12466Favipiravirapproved, investigationalunknowninhibitorDetailsDB11837Osilodrostatapproved, investigationalunknowninhibitorDetailsDB00253MedrysoneapprovedunknownsubstrateDetailsDB00774Hydroflumethiazideapproved, investigational, withdrawnunknownsubstrateinhibitorDetailsDB01324PolythiazideapprovedunknownsubstrateDetailsDB14631Prednisolone phosphateapproved, vet_approvedunknownsubstrateDetailsDB09038EmpagliflozinapprovedunknownsubstrateDetailsDB09274Artesunateapproved, investigationalunknowninhibitorDetailsDB14669Betamethasone phosphateapproved, vet_approvedunknownsubstrateDetailsDB14649Dexamethasone acetateapproved, investigational, vet_approvedunknownsubstrateDetailsDB01380Cortisone acetateapproved, investigationalunknownsubstrateDetailsDB00601Linezolidapproved, investigationalnoinhibitorDetailsDB01147Cloxacillinapproved, investigational, vet_approvednosubstrateinhibitorDetailsDB12151Brincidofovirapproved, investigationalnoinhibitorDetailsDB12265Fexinidazoleapproved, investigationalunknowninhibitorDetailsDB14973Abrocitinibapproved, investigationalunknownsubstrateDetailsDB04847Roxadustatapproved, investigationalunknownsubstrateDetailsDB17083LinzagolixapprovednosubstrateinhibitorDetailsDB16267Olutasidenibapproved, investigationalnoinhibitorDetailsDB11682Daprodustatapproved, investigationalnosubstrateDetailsDB01250OlsalazineapprovedunknownupregulatorDetailsDB12548Sparsentanapproved, investigationalunknowninhibitorDetailsDB11712Tezacaftorapproved, investigationalnoinhibitorDetailsDB12255Vadadustatapproved, investigationalunknownsubstrateinhibitorDetailsDB11718Encorafenibapproved, investigationalnoinhibitorDetailsDB12218CapivasertibinvestigationalnoinhibitorDetails'}}]}"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_additional_info_detailed(\"Aspirin\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_wikipedia_top_section(symptom):\n",
    "    \"\"\"\n",
    "    Get the top section content from a Wikipedia page\n",
    "    \"\"\"\n",
    "    base_url = \"https://en.wikipedia.org/wiki/\"\n",
    "    safe_symptom = '_'.join(symptom.split())  # Replace spaces with underscores for URL\n",
    "    response = requests.get(base_url + safe_symptom)\n",
    "    \n",
    "    if response.status_code != 200:\n",
    "        return None  # If the page does not exist or an error occurred\n",
    "    \n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    top_section = soup.find('p', class_=False)  # The first paragraph after the heading is usually the top section\n",
    "    return top_section.get_text() if top_section else None\n",
    "\n",
    "def get_symptoms_info(drug_info):\n",
    "    \"\"\"\n",
    "    Extract information about associated conditions from the 'Pharmacology' section\n",
    "    of the drug information and get the top section from the Wikipedia page for each symptom.\n",
    "    \"\"\"\n",
    "    symptoms_info = {}\n",
    "    try:\n",
    "        associated_info_str = drug_info['Pharmacology']['Associated Conditions']\n",
    "    except:\n",
    "        associated_info_str = drug_info['Pharmacology']['Associated Therapies']\n",
    "\n",
    "    if not associated_info_str:\n",
    "        return None\n",
    "    \n",
    "    symptoms = associated_info_str.split('\\n')\n",
    "\n",
    "    \n",
    "    for symptom in symptoms:\n",
    "        symptom_splitted = symptom.split(' ')\n",
    "        last_word = symptom_splitted[-1]\n",
    "        if '(' and ')' in last_word:\n",
    "            symptom = ' '.join(symptom_splitted[:-1])\n",
    "            \n",
    "        symptom_content = get_wikipedia_top_section(symptom.strip())\n",
    "        symptoms_info[symptom.strip()] = symptom_content\n",
    "    \n",
    "    return symptoms_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Acute Coronary Syndrome': 'Acute coronary syndrome (ACS) is a syndrome (a set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.[1] The most common symptom is centrally located pressure-like chest pain, often radiating to the left shoulder[2] or angle of the jaw, and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly women, older people, and people with diabetes mellitus.[3]\\n',\n",
       " 'Anxiety': 'Anxiety is an emotion which is characterized by an unpleasant state of inner turmoil and includes feelings of dread over anticipated events.[1][2][3] Anxiety is different from fear in that fear is defined as the emotional response to a real threat, whereas anxiety is the anticipation of a future threat.[4] It is often accompanied by nervous behavior such as pacing back and forth, somatic complaints, and rumination.[5]\\n',\n",
       " 'Atherothrombotic cerebral infarction': None,\n",
       " 'Cardiovascular Disease': 'Cardiovascular disease (CVD) is any disease involving the heart or blood vessels.[3] CVDs constitute a class of diseases that includes: coronary artery diseases (e.g. angina, heart attack), heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.[3][4]\\n',\n",
       " 'Cardiovascular Events': None,\n",
       " 'Cardiovascular Mortality': None,\n",
       " 'Colorectal Adenomas': None,\n",
       " 'Colorectal Cancer': \"Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine).[5] Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.[9] Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders.[2][3] Risk factors include diet, obesity, smoking, and lack of physical activity.[2] Dietary factors that increase the risk include red meat, processed meat, and alcohol.[2][4] Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis.[2] Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases.[2][3] It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous.[2]\\n\",\n",
       " 'Common Cold': 'The common cold or the cold is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx.[6][8] Signs and symptoms may appear fewer than two days after exposure to the virus.[6] These may include coughing, sore throat, runny nose, sneezing, headache, and fever.[3][4] People usually recover in seven to ten days,[3] but some symptoms may last up to three weeks.[7] Occasionally, those with other health problems may develop pneumonia.[3]\\n',\n",
       " 'Coronary artery reocclusion': None,\n",
       " 'Death': 'Death is the irreversible cessation of all biological functions that sustain an organism.[1] For organisms with a brain, death can also be defined as the irreversible cessation of functioning of the whole brain, including the brainstem. [2][3] Brain death is sometimes used as a legal definition of death.[4] The remains of a former organism normally begins to decompose shortly after death.[5] Death is an inevitable process that eventually occurs in all organisms. Some organisms, such as Turritopsis dohrnii, are biologically immortal. However, they can still die from means other than aging.[6]\\n',\n",
       " 'Dyspeptic signs and symptoms': None,\n",
       " 'Fever': \"Fever or pyrexia in humans is defined as having a body temperature above the normal range due to an increase in the body's temperature set point in the hypothalamus.[5][6][12][7] There is no single agreed-upon upper limit for normal temperature: sources use values ranging between 37.2 and 38.3\\xa0°C (99.0 and 100.9\\xa0°F) in humans.[1][7][8] The increase in set point triggers increased muscle contractions and causes a feeling of cold or chills.[2] This results in greater heat production and efforts to conserve heat.[3] When the set point temperature returns to normal, a person feels hot, becomes flushed, and may begin to sweat.[3] Rarely a fever may trigger a febrile seizure, with this being more common in young children.[4] Fevers do not typically go higher than 41 to 42\\xa0°C (106 to 108\\xa0°F).[6]\\n\",\n",
       " 'Flu caused by Influenza': None,\n",
       " 'Headache': 'Headache, also known as cephalalgia, is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache.[1][2] There is an increased risk of depression in those with severe headaches.[3]\\n',\n",
       " 'Heterozygous Familial Hypercholesterolemia': 'Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein cholesterol (LDL cholesterol), in the blood and early cardiovascular diseases. The most common mutations diminish the number of functional LDL receptors in the liver or produce abnormal LDL receptors that never go to the cell surface to function properly (abnormal trafficking).[citation needed] Since the underlying body biochemistry is slightly different in individuals with FH, their high cholesterol levels are less responsive to the kinds of cholesterol control methods which are usually more effective in people without FH (such as dietary modification and statin tablets). Nevertheless, treatment (including higher statin doses) is usually effective.\\n',\n",
       " 'Inflammation': 'Inflammation (from Latin: inflammatio) is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants,[1][2] and is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult[clarification needed] and the inflammatory process, and initiate tissue repair.\\n',\n",
       " 'Juvenile Idiopathic Arthritis': 'Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis (JRA),[1] is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children.[3] Juvenile, in this context, refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint.[4]\\n',\n",
       " 'Major Adverse Cardiovascular and Cerebrovascular Events': None,\n",
       " 'Menstrual Pain': None,\n",
       " 'Migraine': 'Migraine (UK: /ˈmiːɡreɪn/, US: /ˈmaɪ-/)[11][12] is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity.[1] Other characterizing symptoms may include nausea, vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature.[13] Up to one-third of migraine sufferers experience aura: a premonitory period of sensory disturbance widely accepted to be caused by cortical spreading depression at the onset of a migraine attack.[13] Although primarily considered to be a headache disorder, migraine is highly heterogenous in its clinical presentation and is better thought of as a spectrum disease rather than a distinct clinical entity.[14] Disease burden can range from episodic discrete attacks, consisting of as little as several lifetime attacks, to chronic disease.[14][15]\\n',\n",
       " 'Morbidity': 'A disease is a particular abnormal condition that adversely affects the structure or function of all or part of an organism and is not immediately due to any external injury.[1][2] Diseases are often known to be medical conditions that are associated with specific signs and symptoms. A disease may be caused by external factors such as pathogens or by internal dysfunctions. For example, internal dysfunctions of the immune system can produce a variety of different diseases, including various forms of immunodeficiency, hypersensitivity, allergies, and autoimmune disorders.\\n',\n",
       " 'Mucocutaneous Lymph Node Syndrome': None,\n",
       " 'Muscle Contraction': None,\n",
       " 'Myalgia': \"Myalgia (also called muscle pain and muscle ache in layman's terms) is the medical term for muscle pain.  Myalgia is a symptom of many diseases. The most common cause of acute myalgia is the overuse of a muscle or group of muscles; another likely cause is viral infection, especially when there has been no trauma.\\n\",\n",
       " 'Myocardial Infarction': 'A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction (tissue death) to the heart muscle.[1] The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw.[1] Often it occurs in the center or left side of the chest and lasts for more than a few minutes.[1] The discomfort may occasionally feel like heartburn.[1] Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat, feeling tired, and decreased level of consciousness.[1] About 30% of people have atypical symptoms.[8] Women more often present without chest pain and instead have neck pain, arm pain or feel tired.[11] Among those over 75 years old, about 5% have had an MI with little or no history of symptoms.[12] An MI may cause heart failure, an irregular heartbeat, cardiogenic shock or cardiac arrest.[3][4]\\n',\n",
       " 'Myocardial Infarction (MI), first occurrence': None,\n",
       " 'Neuropathic Pain': None,\n",
       " 'Pain': 'Pain is a distressing feeling often caused by intense or damaging stimuli. The International Association for the Study of Pain defines pain as \"an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.\"[1]\\n',\n",
       " 'Pain caused by Common Cold': None,\n",
       " 'Pain caused by Rheumatism': None,\n",
       " 'Pericarditis': 'Pericarditis is inflammation of the pericardium, the fibrous sac surrounding the heart.[8] Symptoms typically include sudden onset of sharp chest pain, which may also be felt in the shoulders, neck, or back.[1] The pain is typically less severe when sitting up and more severe when lying down or breathing deeply.[1] Other symptoms of pericarditis can include fever, weakness, palpitations, and shortness of breath.[1] The onset of symptoms can occasionally be gradual rather than sudden.[8]\\n',\n",
       " 'Polycythemia Vera': 'In oncology, polycythemia vera  is an uncommon myeloproliferative neoplasm (chronic leukemia) in which the bone marrow makes too many red blood cells.[1]\\n',\n",
       " 'Pre-Eclampsia': 'Pre-eclampsia is a multi-system disorder specific to pregnancy, characterized by the onset of high blood pressure and often a significant amount of protein in the urine.[1][8][9] When it arises, the condition begins after 20 weeks of pregnancy.[2][3] In severe cases of the disease there may be red blood cell breakdown, a low blood platelet count, impaired liver function, kidney dysfunction, swelling, shortness of breath due to fluid in the lungs, or visual disturbances.[2][3] Pre-eclampsia increases the risk of undesirable as well as lethal outcomes for both the mother and the fetus including preterm labor.[10][11][3] If left untreated, it may result in seizures at which point it is known as eclampsia.[2]\\n',\n",
       " 'Rheumatism': 'Rheumatism[2] or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue.[3] Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and  \"non-articular rheumatism\", also known as \"regional pain syndrome\" or \"soft tissue rheumatism\".[4][5] There is a close overlap between the term soft tissue disorder and rheumatism.[6] Sometimes the term \"soft tissue rheumatic disorders\" is used to describe these conditions.[7]\\n',\n",
       " 'Rheumatoid Arthritis': 'Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints.[1] It typically results in warm, swollen, and painful joints.[1] Pain and stiffness often worsen following rest.[1] Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body.[1] The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves and blood.[1] This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart.[1] Fever and low energy may also be present.[1] Often, symptoms come on gradually over weeks to months.[2]\\n',\n",
       " 'Rhino Sinusitis': None,\n",
       " 'Severe Pain': None,\n",
       " 'Spondyloarthropathies': 'Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such, it is a class or category of diseases rather than a single, specific entity. It differs from spondylopathy, which is a disease of the vertebra itself, but many conditions involve both spondylopathy and spondyloarthropathy.\\n',\n",
       " 'Stroke': 'Stroke (brain attack) is a medical condition in which poor blood flow to the brain causes cell death.[5] There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding.[5] Both cause parts of the brain to stop functioning properly.[5]\\n',\n",
       " 'Systemic Lupus Erythematosus': \"Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body.[1] Symptoms vary among people and may be mild to severe.[1] Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face.[1] Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.[1]\\n\",\n",
       " 'Tension Headache': 'Tension headache, also known as stress headache, or tension-type headache (TTH), is the most common type of primary headache. The pain can radiate from the lower back of the head, the neck, eyes or other muscle groups in the body typically affecting both sides of the head. Tension-type headaches account for nearly 90% of all headaches.\\n',\n",
       " 'Thromboembolism': 'Thrombosis (from Ancient Greek θρόμβωσις thrómbōsis \"clotting\") is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel (a vein or an artery) is injured, the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss.  Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot, or a piece of the clot, that breaks free and begins to travel around the body is known as an embolus.[1][2]\\n',\n",
       " 'Thrombosis': 'Thrombosis (from Ancient Greek θρόμβωσις thrómbōsis \"clotting\") is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. When a blood vessel (a vein or an artery) is injured, the body uses platelets (thrombocytes) and fibrin to form a blood clot to prevent blood loss.  Even when a blood vessel is not injured, blood clots may form in the body under certain conditions. A clot, or a piece of the clot, that breaks free and begins to travel around the body is known as an embolus.[1][2]\\n',\n",
       " 'Toothache': 'Toothache, also known as dental pain or tooth pain,[3] is pain in the teeth or their supporting structures, caused by dental diseases or pain referred to the teeth by non-dental diseases. When severe it may impact sleep, eating, and other daily activities.\\n',\n",
       " 'Transient Ischemic Attack': 'A transient ischemic attack (TIA), commonly known as a mini-stroke, is a minor stroke whose noticeable symptoms usually end in less than an hour.  TIA causes the same symptoms associated with strokes, such as weakness or numbness on one side of the body, sudden dimming or loss of vision, difficulty speaking or understanding language, slurred speech, or confusion.\\n',\n",
       " 'Vascular Death': None,\n",
       " 'Venous Thromboembolism': None,\n",
       " 'Acute Inflammation': None,\n",
       " 'Articular inflammation': None,\n",
       " 'Atherothrombotic events': None,\n",
       " 'Death caused by Myocardial Infarction': None,\n",
       " 'Fever or influenza-like illness': None,\n",
       " 'Moderate Pain': None,\n",
       " 'Recurrent Ischemic Stroke': None}"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "symptoms = get_symptoms_info(info)\n",
    "symptoms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_gene_info(gene_name):\n",
    "    \n",
    "    url = f\"https://www.genecards.org/cgi-bin/carddisp.pl?gene={gene_name}\"\n",
    "    headers = {\n",
    "    'User-Agent': 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/58.0.3029.110 Safari/537.3'\n",
    "}\n",
    "\n",
    "    response = requests.get(url, headers=headers)\n",
    "    \n",
    "    if response.status_code != 200:\n",
    "        print('failed 0')\n",
    "        return None  # If the page does not exist or an error occurred\n",
    "\n",
    "    soup = BeautifulSoup(response.text, 'html.parser')\n",
    "    summaries_section = soup.find('section', id='summaries')\n",
    "    \n",
    "    if not summaries_section:\n",
    "        print('failed 1')\n",
    "        return None  # If the summaries section is not found\n",
    "\n",
    "    summaries_dict = {}\n",
    "    subsections = summaries_section.find_all('div', class_='gc-subsection')\n",
    "    \n",
    "    for subsection in subsections:\n",
    "        # The header is often the text of the first 'h3' or 'h2' tag within the subsection\n",
    "        header_tag = subsection.find(['h2', 'h3'])\n",
    "        if not header_tag:\n",
    "            print('failed 2')\n",
    "            continue  # Skip if no header tag is found\n",
    "\n",
    "        header = header_tag.get_text().strip()\n",
    "\n",
    "        # The content is often within 'ul' tag within the subsection\n",
    "        content_tag = subsection.find('ul', class_='list-unstyled')\n",
    "        if not content_tag:\n",
    "            print('failed 3')\n",
    "            continue  # Skip if no content tag is found\n",
    "\n",
    "        content = content_tag.get_text(separator=\"\\n\").strip()\n",
    "\n",
    "        summaries_dict[header] = content\n",
    "\n",
    "    return summaries_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "failed 0\n"
     ]
    }
   ],
   "source": [
    "gene_info = get_gene_info(\"CYP3A4\")\n",
    "gene_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def scrape_drug_info(drug_name):\n",
    "    try:\n",
    "        drug_info = get_drug_info(drug_name)\n",
    "    except:\n",
    "        drug_info = None\n",
    "\n",
    "\n",
    "    try:\n",
    "        additional_info = get_additional_info_detailed(drug_name)\n",
    "    except:\n",
    "        try:\n",
    "            additional_info = get_additional_info(drug_name)\n",
    "        except:\n",
    "            additional_info = None\n",
    "\n",
    "            \n",
    "    try:\n",
    "        disease_info = get_symptoms_info(drug_info)\n",
    "    except:\n",
    "        disease_info = None\n",
    "    \n",
    "    return drug_info, additional_info, disease_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_json_dataset(csv_path, json_dir):\n",
    "    # Read the CSV file\n",
    "    df = pd.read_csv(csv_path)\n",
    "    \n",
    "    # Initialize the final result dictionary\n",
    "    result = {}\n",
    "\n",
    "    # Iterate over each row in the DataFrame\n",
    "    for _, row in df.iterrows():\n",
    "        drug_name = row['Drug Name']\n",
    "        # Initialize the dictionary for this drug\n",
    "        drug_dict = {}\n",
    "\n",
    "        # Add active ingredients and SMILES to the drug dictionary\n",
    "        active_ingredients = {\n",
    "            row[f'Active Ingredient {i}']: row[f'SMILES {i}']\n",
    "            for i in range(13) if pd.notna(row[f'Active Ingredient {i}'])\n",
    "        }\n",
    "        drug_dict.update(active_ingredients)\n",
    "\n",
    "        # Get detailed drug information using the scrape_drug_info function\n",
    "        drug_info, additional_info, disease_info = scrape_drug_info(drug_name)\n",
    "        drug_dict.update({\n",
    "            'Drug Information': drug_info,\n",
    "            'Additional Information': additional_info,\n",
    "            'Disease Information': disease_info\n",
    "        })\n",
    "\n",
    "        # Add the drug dictionary to the result under the drug name key\n",
    "        result[drug_name] = drug_dict\n",
    "\n",
    "    # Define the JSON file path\n",
    "    json_file_path = os.path.join(json_dir, 'drug_info.json')\n",
    "\n",
    "    # Write the result dictionary to a JSON file\n",
    "    with open(json_file_path, 'w', encoding='utf-8') as json_file:\n",
    "        json.dump(result, json_file, ensure_ascii=False, indent=4)\n",
    "\n",
    "    print(f\"JSON file created at {json_file_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "JSON file created at data/drug_info.json\n"
     ]
    }
   ],
   "source": [
    "create_json_dataset('data/mini_drug_activities.csv', 'data/')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "my-rdkit-env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
